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Summary 
The work presented in herein focuses on the optimisation and use of established animal 
models to study behavioural, pharmacological, histological and molecular correlates of the 
debilitating motor side effects of current and future treatments for Parkinson’s disease, namely 
L-DOPA induced dyskinesia (LID) and graft induced dyskinesia (GID).  
Chapter 3 optimises the 6-OHDA lesion model in mice, from surgical approaches to 
behavioural assessment of motor function.  The neurotoxin was injected at three different 
regions along the nigrostriatal tract to produce unique patterns of dopaminergic cell death in 
the midbrain. The resulting cell loss was correlated to behavioural deficits identified through 
an extensive battery of motor hand tests.  
Fully lesioned mice from each of the three models were chosen for chronic L-DOPA 
treatment, described in Chapter 4, where doses were increased every 1-2 weeks. Behaviour 
was assessed and correlated to deficits on motor hand tests prior to L-DOPA treatment, cell 
loss within sub regions of the midbrain, serotonergic density levels and upregulations in 
∆FosB and striatal TH cell populations.  
Chapter 5 uses knowledge gained in previous chapters to use the most appropriate 6-OHDA 
mouse model of LID for the examination of changes in the Regulators of G-protein Signalling 
(RGS) following an acute and chronic L-DOPA treatment. RGS2 was the only one to increase 
significantly following either treatment regime. 
In Chapter 6 a well established rat model of GID (the induction of dyskinesia in the 
transplanted 6-OHDA lesioned rat through the administration of amphetamine) was used to 
assess the use of pharmacological agents known to reduce LID.  Changes in locomotor 
function and abnormal inhibitory movements (AIMs) could be assessed giving an insight into 
the mechanism and receptors involved.  
To further the understanding of GID, Chapter 7 examines dopamine receptor levels, RGS 
transcript expression, and the proportions of dopamine and serotonin cells in the transplanted, 
6-OHDA lesioned rodent brain. The aim was to determine any correlation between these 
parameters and amphetamine induced dyskinesia. Only the number of dopaminergic and 
serotonin cells could be correlated to dyskinesia and not the proportion of serotonin cells. 
As no previous mouse model of GID has been established, Chapter 8 demonstrates that 
transplantation of E12 ventral mesencephalon (VM) grafts can be optimised in the lesioned 
mouse of C57/Bl6 and CD1 strains to give functional recovery, and amphetamine induced 
dyskinesia.  Both strains were also used to demonstrate that transplants were also able to 
reduce LID. 
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1. Introduction 
1.1 Parkinson’s Disease (PD) 
 
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder that was first 
characterised in 1817, by George Parkinson in his ‘Essay on the Shaking Palsy’ (Parkinson, 
1817). PD is recognised clinically by characteristic motor abnormalities which include tremor, 
rigidity, changes in gait, akinesia (absence of movement), bradykinesia (slowness of 
movement), hypokinesia (reduced amplitude of movement), postural instability, dysphagia and 
micrographia (reviewed in (Yanagisawa et al., 1989, Lichter et al., 1988). Patients typically 
have different profiles of parkinsonian symptoms that may depend on age of onset 
(Wickremaratchi et al., 2011). Changes in rapid eye movement (REM) sleep, procedural 
memory loss, delayed reactions, hallucination and changes in autonomic responses and 
perception have also been reported, (reviewed in (Lichter et al., 1988). It affects up to 1% of 
individuals over the age of 70 in Europe and a smaller proportion develop a young onset form 
of the disease which is commonly defined as being when the patient is still of working age. 
Individuals that have a younger PD onset have an overall worse quality of life than those with 
late stage development (Knipe et al., 2011). Following diagnosis approximately 80% of 
patients die within 10 years (von Campenhausen et al., 2005, Ishihara et al., 2007). In the U.K. 
alone it is estimated that 120,000 people are currently living with PD (Parkinsons.org.uk), 
resulting in a significant socioeconomic burden, that is predicted to increase in future years. A 
cross-sectional analysis of over 300 late stage PD patients has shown that each person requires 
approximately £25,000 - £62,000 worth of medical help per annum, the majority of which is 
spent on health care professionals (Findley et al., 2011) and only 7% spent on direct medical 
intervention. As well as the emotional hardship suffered by the individual and family 
members, an appropriate treatment of PD is much needed to relieve the economic burden in 
the U.K.  
 
The most effective anti-parkinsonian treatment to date is oral L-3,4-dihydroxyphenylalanine 
(L-DOPA) medication, used for its efficiency to treat bradykinetic and akinetic motor side 
effects at relatively low cost. However, long-term use of this treatment usually gives rise to 
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debilitating abnormal movements, termed dyskinesia (Encarnacion and Hauser, 2008). 
Interventions that can be used to treat dyskinesia by correcting electrophysiological 
dysregulation (deep brain stimulation) are costly (Shan et al., 2011), and other transplantation 
and gene therapy approaches are only at pre-clinical and early clinical trial phases of 
development (Lindvall and Bjorklund, 2004, Manfredsson et al., 2009). Promising 
transplantation approaches are hindered, in part, by the development of dyskinetic side effects 
in some patients that are directly related to the grafted tissue (Freed et al., 2001) and (reviewed 
in Lane and Smith, 2010). 
 
The defining pathological features of PD are the specific cell death of dopaminergic neurons 
within the substantia nigra pas compacta (SNc), accompanied by the accumulation of the 
protein α-synuclein into large spheroid inclusions named Lewy bodies (Bethlem and den, 
1960, Bethlem and Den Hartog Jager, 1960, Spillantini et al., 1997). Dystrophic Lewy neurites 
can also be found within the same region post-mortem (Bethlem and den, 1960, Bethlem and 
Den Hartog Jager, 1960, Spillantini et al., 1997). The Braak hypothesis is sometimes referred 
to in PD and proposes that Lewy body pathology might spread from one region to another 
(Braak and Braak, 1990, Braak et al., 2003, Steiner et al., 2011). Although protein aggregation 
and neuropathology can be correlated (reviewed in (Hawkes et al., 2010), it remains unclear 
whether aggregates cause cell death, are a consequence of cellular dysfunction, or have a 
protective role. Much has been learnt from the genetic variants of the disease. Mutations in the 
genes encoding alpha–synuclein, ubiquitin carboxyl-terminal esterase L1 (UCHL1), PTEN-
induced putative kinase 1 (PINK1) and Parkin have been linked to familial PD (reviewed in 
(Morris, 2005) and it is thought that genes such as Leucine-rich repeat kinase 2 (LRRK2) and 
others, may predispose a subsection of the population to an increased risk of idiopathic disease 
development (Paisan-Ruiz et al., 2005, Shiba et al., 2009) and (reviewed in (Morris, 2007). 
 
PD is commonly idiopathic, although there are also genetic variants that contribute to 
approximately 5% of cases. The idiopathic form is thought to originate from exposure to 
environmental risk factors such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -like 
chemicals, heavy metals and pesticides through farming (Berger, 2000, Richardson et al., 
2005), although no single cause has been identified. Explanations for dopamine neuron loss 
suggest that alternative shifts in energy metabolism within the mitochondria following 
exposure to substances which inhibit mitochondrial function may cause apoptosis. Chemicals 
such as MPTP or paraquat reduce nicotinamide adenine dinucleotide dehydrogenase (NADH) 
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and co-enzyme Q1 reductase activity (Richardson et al., 2005), which points to environmental 
influences in the disease process. Furthermore, changes in dopamine production have also 
been found to increase free radical production and oxidative stress. However, elevated 
scavenger activity has also been noted and these changes may occur following the induction of 
apoptotic signals by another mechanism (Miyazaki et al., 2007). There is evidence to support 
each of these mechanisms but which is the leading factor remains undetermined. A significant 
lack of understanding of the pathogenesis of PD is in part due to uncertainty as to the cause, 
and without a defined trigger, identifying mechanism is difficult.  
 
1.2. The Basal Ganglia 
1.2.1. The normal brain 
Parkinsonian symptoms in PD arise through dysregulation of the basal ganglia, resulting in 
altered signalling to the cortex and hence disadvantageous execution of motor function. Under 
normal conditions the SNc projects to the caudate nucleus and putamen (collectively known as 
the striatum), where dopamine mediated signals are relayed to the other output nuclei of the 
basal ganglia. Striatal neurons are electrically quiescent under normal circumstances, with 
activity generated by cortical stimulation (Gerfen, 1992). The two main outputs of the striatum 
are GABAergic and make up the direct and indirect pathways, controlling other output nuclei, 
namely the substantia nigra pars reticulata (SNr), the internal globus pallidus (GPi,) and the 
subthalamic nucleus (STN). Specifically neurons within the direct monosynaptic pathway 
project to the GPi and SNr and cause an inhibitory effect on postsynaptic signals to the 
thalamus. This results in the disinhibition (enhancement) of thalamo-cortical networks and 
movement (Mink and Thatch 1991a,b,c, Boraud et al., 2000). Cells within the indirect 
pathway project to the GPi and SNr, via polysynaptic connections in the GPe and STN, 
causing an excitatory action on the thalamus. The balance of direct and indirect signalling, as 
shown in Fig. 1.1, allows for the excitation of the thalamus and the blockade of irrelevant 
motor commands for normal motor function through the cortex (DeLong et al., 1986, 
Alexander et al., 1986). Once movements are initiated in the cortex, signals are fed back to the 
thalamus, where they are relayed back to premotor and motor areas to control fine movements 
(Obeso et al., 2000a). In addition to the STN, the glutamatergic cortico-striatal pathway 
provides another major input to the striatum. The bi-directional modulation of the spiking rates 
of the GPi and the SNr by GABAergic neurons is only possible because of the autonomous 
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pacemaker properties of the GPe, GPi, STN and SNr (reviewed in (Gerfen and Surmeier, 
2011).  
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Fig. 1.1. A depiction of the circuitry within the basal ganglia of a healthy human. Dopamine 
projections (yellow) run from the SN to the caudate nucleus and putamen. GABA neurons 
(red) in the indirect pathway connect to the GPe and STN while the direct pathway exerts an 
effect on the GPi. The pedunculopontine nucleus (PNN), spinal cord (SC) and thalamus also 
receive an excitatory glutamatergic input. Glutamatergic signals (blue) connect the thalamus to 
the cortex, cortex to the STN and the cortex to the GP.  
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The model of motor function in the basal ganglia, although largely accurate can be seen as 
over-simplistic as there are other factors influencing this tightly regulated system. The 
importance of the pedunculopontine nucleus (PPN) is often not considered, yet receives inputs 
from output nuclei and influencing pallidal outputs and subthalamic inputs. Further, afferents 
from the PPN provide glutamatergic regulation of various nuclei and a cholinergic feedback 
loop provides input to and from the spinal cord (Pahapill and Lozano, 2000). Serotonergic and 
noradrenergic projections originating from the dorsal raphé and locus coeruleus (LC) 
respectively, influence striatal outputs (Moore and Bloom, 1979). L-DOPA induced 
dyskinesia (LID: a set of uncontrolled inhibitory movements) reflects a second 
neuropathological state of the basal ganglia (See 1.4.1).  
 
The γ-Aminobutyric acid (GABA) releasing medium spiny neurons (MSNs) of the striatum, 
controlling direct (striatonigral) and indirect (striatopallidal) pathway, express D1 or D2 
dopamine receptors respectively and are often distinguished by specific biomarkers other than 
the receptors themselves (see Table 1.1). 90-95% of the neuronal population in the striatum 
consists of the projection MSNs, whereas the remaining 5-10% of cells comprised a mixed 
population of interneurons (DiFiglia et al., 1976). Interneurons can be subclassified into 4 
types (Table 1.2). Broadly, interneurons intergrate and modulate feedbackward and 
feedforward information, between the SNc, thalamus, cortex and GPe and the MSNs of the 
striatum (Kawaguchi, 1993) and (reviewed in (Kawaguchi et al., 1995). 
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Table 1.1. The distinction between two populations of MSNs in the striatum. 
1
 Prodynorphin (PDyn), Preproenkephalin (PPE) 
 
2Table based off information in (Matamales et al., 2009).  
 
 
 
 
Table 1.2. Types of interneurons in the striatum.  
 
 
 
 
 
 
 
 
 
1
Nitric oxide synthase (NOS), nicotinamide adenine dinucleotide phosphate diaphorase. Dopamine and cAMP-
regulated phosphoprotien. 
2
Table based off information in (Kawaguchi, 1993) and (reviewed in (Kawaguchi et al., 1995). 
 
 Subtypes of medium spiny neurons
2
 
Pathway Direct Indirect 
Markers  PDyn
1
 PPE
1
 
 Substance P A2a  
Receptors D1 D2 
Neuro-anatomy Rat/mouse – entopeduncular nucleus Rat/mouse – Globus Pallidus  
 
Size (nuclus) 
Monkey / human – GPi 
10–11 µm 
Monkey/ human – GPe 
10–11 µm 
 Subtypes of interneurons
2
    
Type GABAergic 1 GABAergic 2 GABAergic 2 Cholinergic 
Markers Parvalbumin Calretinin Samatostatin ChAT 
   Neuropeptide Y DARPP-32
1
 
   NOS
1
  
   NADPH
1
  
Receptors D2  D1 D1 & D2 
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In addition to the basic control of movement by the projection definitions above, neurons of 
the striatum can be compartmentalised into patch (or ‘striosome’) and matrix neuro-
anatomical arrangements that differently control output nuclei. The patch/striosomes division 
in the striatum are defined by µ-opiate receptor binding and low acetylcholinesterase staining 
(present in cats and monkeys, but not apparent in the adult rodent) and matrix regions that 
additionally stain for calbindin and samatostatin. The matrix occupies the majority of the 
space and receives inputs predominantly from the neocortical and sensorimotor cortex, 
whereas the striosomes occupy labyrinths within the matrix and receive more limbic 
allocortical inputs (Gerfen et al., 1985, Gerfen, 1985). This is not exclusive, however, with 
functional connections from either cortical areas in the patch/ matrix (Gerfen, 1989). There are 
also discrepancies with the regional cortical connections, as the patch/ matrix are uniform 
throughout the dorsal and ventral tiers. However, the limbic cortex projects to the ventral area 
and the neocortex to the dorsal area (Haber and McFarland, 1999). Therefore, although this 
model has proved invaluable for evaluating connectivity in the basal ganglia, it may be 
perceived as over-simplified. In addition, striatal outputs from both patch and matrix 
compartments connect to the GPi and SNr, but only those of the patch project to the SNc.  
 
It is important to note that the SNc can also be compartmentalised into regions of patch and 
matrix, defined by calbindin staining of neuropil, showing calbindin-poor ‘nigrosomes’ within 
a calbindin-rich matrix (Gerfen, 1992) of which approximately 60% of the SNc cell bodies 
reside (Damier et al., 1999a). Cell bodies that in the ventral tier of the SNc project to the 
striatal patch compartment, however cell bodies originating in medial SNc, project to the 
matrix (Gerfen, 1992). The ventral tier of the SNc further receives inputs from the patch 
compartment of the striatum.  
 
1.2.2. PD Neuropathology 
Dopamine neuron loss and the presence of Lewy bodies reflect the two main 
pathophysiological hallmarks of PD. Thus, patients with idiopathic PD exhibit deficits in 
striatal dopamine signalling and dopamine terminal loss within the striatum accompanied by 
loss of cells within the SNc (Mitchell et al., 1989, Crossman, 1989); which underlies the 
characteristic akinetic and bradykinetic motor symptoms characteristic of PD. These cannot be 
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detected until cell losses have been reached 50 - 60%, with even higher losses needed in 
dopaminergic fibres, as the result of their extensive branching in the striatum (Bernheimer et 
al., 1973). In terms of patch/matrix compartmentalisation it is evident that projections from the 
dorsal SNc are largely spared, with the majority of cell loss in the ventrolateral area (Damier 
et al., 1999b) and hence denervation of terminals within the putamen. A reduction of tyrosine 
hydroxylase (TH) and L-aromatic amino acid decarboxylase (AADC) provide pathological 
markers of dopamine cell loss (Hornykiewicz, 1982). By contrast, other dopaminergic nigro-
pallidal and nigro-subthalamic projections are less affected in PD (Lavoie et al., 1989, Whone 
et al., 2003), although dopamine levels in the GP have been found to be reduced in PD (Fahn 
et al., 1971). In the dopamine-depleted striatum a subset of interneurons also appear to be 
dopaminergic, co-expressing TH, the dopamine transporter (DAT), and glutamic acid 
decarboxylase (GAD) needed for the synthesis of GABA (Huot and Parent, 2007). Their 
functions in PD remain unclear.  
 
Cell loss in the SNc is a major contributing factor to loss of motor function. However, 
degeneration is not restricted to this region, with cell loss also evident in the ventral tegmental 
area (VTA) and corresponding mesocorticolimbic projection areas in the nucleus accumbens 
(NAcc), the prefrontal cortex and the amygdala. These components form part of the limbic 
system which is responsible for emotion, memory and reward-based behaviour, such that 
neuropathological changes in this system are likely to contribute to the non-motor symptoms 
of PD (Fahn et al., 1971, Jellinger, 1991). There is also evidence that the disease originates in 
the brainstem, affecting dorsal motor nuclei before the pathological spreading of the disease to 
the forebrain regions, which can be used to characterise disease stage (Backlund et al., 1985, 
Braak et al., 2003). Neuropathological changes also occur in the LC and raphé nucleus, 
reducing noradrenergic and serotonin (5-HT) input, respectively, to the striatum and cortex 
(Braak and Braak, 2000, Braak et al., 2000).  
 
The presence of Lewy bodies has provided a pathological hallmark of PD since the early years 
of the 20
th
 century, long before the discovery of dopamine as a transmitter in the late 1950s. 
Lewy bodies are spherical cytoplasmic inclusions located in cell bodies, although filamentous 
proteins in the perikaryal cytoplasm termed ‘Lewy neurites’ are also present and located 
largely in dopaminergic axons. Lewy bodies are now known to be composed of aggregated α-
synuclein, but also contain ubiquitinated proteins and various cytoskeleton components 
(Spillantini et al., 1997, Kuzuhara et al., 1988). In PD, Lewy bodies are located predominantly 
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in the ventral tier of the SNc, also the main site of degeneration (Wakabayashi et al., 1990, 
Wakabayashi, 1989). Degeneration in this region causes electrophysiological circuitry changes 
(Bardinet et al., 2009), resulting from the lack of dopamine signalling in the striatum. 
 
There is a defined set of circuitry changes (Fig. 1.2) that contribute to the cardinal motor 
symptoms of PD (Albin et al., 1989). However, as stated above, neuropathology is not 
restricted to these primary areas. Activation of the D1 receptors is largely attenuated and there 
is a reduction in D2 activation, causing a reduction in the inhibitory control of the GPi and SNr 
and that of the indirect pathway, to cause an increasing in firing of the STN. Therefore the fine 
balance of signalling is disrupted by the lack of dopamine signal and excessive glutamate 
signal causes an over-inhibition of thalamo-cortical projections, resulting in less movement 
(reviewed in (Calabresi et al., 2000b, Sealfon and Olanow, 2000). 
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Fig. 1.2. A depiction of the neuropathological changes to the circuitry of the basal ganglia of a 
PD patient. Dopamine projections (yellow) run from the SNc to the putamen. GABA neurons 
(red) in the indirect pathway connect to the GPe and STN, while the direct pathway exerts an 
effect on the GPi. The pedunculopontine nucleus (PPN), spinal cord (SC) and thalamus also 
receive excitatory glutamatergic input. Glutamatergic signals (blue) connect the thalamus to 
the cortex, cortex to the STN and the cortex to the GP. A reduction in input is signified by the 
dashed line and an enhancement of signal signified by the dotted line. (Based on (Albin et al., 
1989). 
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The degeneration of dopaminergic neurons causes profound changes in the neuro-peptide 
markers used to distinguish between direct and indirect signalling pathways. Late stage PD 
patients have decreases in intra-cellular protein levels of substance P and enkephalin in the 
putamen (Tenovuo et al., 1984, Sivam, 1991), yet levels of preprotachykinin are maintained 
(Nisbet et al., 1995). In contrast the precursors to enkephalin and dynorphin, 
(preproenkephalin and prodynorphin) were found to be increased (Levy et al., 1995). Caution 
should be taken when analysing the results from post-mortem, as variations in disease stage, 
tissue fixation processes, time of fixation from death, and prior treatment with dopamine 
agonists or L-DOPA may all confound results. The MPTP-treated primate model of PD has 
therefore been used to determine further pathological mechanisms. In accordance MPTP 
treated primates, that were mildly symptomatic, have an up-regulation of TH and DAT 
transporter levels whereas those of a severe phenotype show losses similar to that of the PD 
patient (reviewed in (Jenner, 2009, Jenner, 2003). Dopamine and 5-HT turnover is likely 
increased in the model, following the observation of increased TH and 5-HT fibre thickness in 
the caudate and putamen, as the result of enlarged neurotransmitter carrying varicosities (Zeng 
et al., 2010, Song and Haber, 2000). Specific in-depth investigation has been carried out in 
rodent models of PD concerning receptor and/or intra-cellular changes in relation to 
experimental dopamine depletion and L-DOPA treatment (discussed in sections 1.6 and 1.7). 
  
1.3. Treatment Strategies in PD 
Surgical, pharmacological, and deep brain stimulation (DBS) interventions provide a high 
degree of symptomatic relief to many PD patients, however none of these strategies prevent or 
slow disease progression. Given that the main drug treatment for PD causes dyskinetic side 
effects, as well as the emergence of ‘on’ and ‘off’ phases throughout the day, there is an 
urgent need for alternative approaches. Consequently, restorative and neuroprotective 
interventions by cell transplantation and other gene therapeutic approaches for the treatment of 
PD are being keenly explored.  
 
1.3.1. Historical Surgical Interventions 
There are a number of surgical strategies involving the ablation of areas within the basal 
ganglia that have been used historically for the treatment of PD. Initial procedures involved 
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the obliteration of the caudate nucleus, this caused some elevation of tremor and rigidity 
(Meyers, 1951, Meyers, 1942). The stereotaxic pedunculotomy and encephalotomy can 
elevate tremor and thalamotomy has had positive effects on bradykinesia and resting tremor 
(Narabayashi et al., 1997, Narabayashi et al., 1987, Walker, 1952). Pallidotomy and 
subthalamotomy can also be used to alleviate bradykinesia and rigidity (reviewed in 
(Zesiewicz and Hauser, 2001). These crude surgical strategies have mainly been used to treat 
motor abnormalities up until the introduction of L-DOPA in the 1960’s and thereafter open 
neuro-surgery largely went out of favour as the preferred choice because of complications 
such as haemorrhage and infection, until the modern era of more selective, targeted and 
rationally based stereotaxic techniques (see 1.3.5).  
 
1.3.2. Pharmacological Treatments 
There are a number of pharmacological treatment strategies for patients displaying 
parkinsonian motor symptoms. Historically anticholinergics were used as the primary 
treatment for PD (Kapp, 1992). These are useful as the neurodegeneration associated with PD 
causes the depletion of acetylcholine as well as dopamine, and were found to be partially 
useful for treating tremor (Marjama-Lyons and Koller, 2000). Anticholinergics are no-longer 
preferred as they have been associated with cognitive impairments, and give a number of side 
effects such as dry mouth, gut problems and blurred vision (Perry et al., 2003). The first 
dopamine based therapy for the treatment of PD was L-3,4-dihydroxyphenylalanine (L-
DOPA). Indeed the discovery of dopamine as a neurotransmitter and its role in Parkinson’s 
disease was integrally tied up with the pharmacological reversal of motor symptoms by L-
DOPA in Carlsson’s classic studies using reserpine model to deplete brain catecholamines 
(Carlsson, 1959, Carlsson and Hillarp, 1958, Carlsson et al., 1957). 
 
Currently L-DOPA therapy is the most wildly used treatment of PD (reviewed in (Espay, 
2010, Tan, 2003, Poewe et al., 2010), and is a derivative found naturally in Mucuna Pruriens 
(velvet bean). It exerts a therapeutic effect by ameliorating the pathological decreases in 
dopamine levels, enhancing dopamine synthesis, stimulating dopamine receptors and thus 
restoring postsynaptic activity in striatal neurons. L-DOPA is a precursor to dopamine that can 
cross the blood brain barrier (BBB) where it is converted into dopamine. Oral L-DOPA 
medication is absorbed in the gut by specific amino acid transporters, where an excess of 99% 
is metabolised, before entering the blood (Sasahara et al., 1981). The biosynthesis of 
dopamine from this precursor and biodegradation routes is illustrated in Fig. 1.3. Early clinical 
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trials with L-DOPA failed, due both to peripherally induced side effects and limited central 
action, until it was recognised that it had to be administered with a peripheral amino acid 
decarboxylase (AADC) inhibitor to prevent the conversion to dopamine before entering the 
brain (Nutt et al., 1987), thus increasing the ‘therapeutic window’ of L-DOPA, causing a 
greater time in ‘on’ (Brooks and Sagar, 2003).  
 
 
 
 
Fig. 1.3. The biosynthesis of dopamine from its precursor L-DOPA from the conversion of L-
tyrosine (from the diet) by TH and its subsequent conversion into noradrenaline (NA) and 
adrenaline catecholamines (in the presence of Dopamine β-hydroxylase and 
Phenylethanolamine N-methyltransferase). Conversely, these catecholamines can be degraded 
to non active forms 3,4-Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) 
by the degredation enzymes: monoamine oxidase (MAO) and catechol-o-methyl transferase 
(COMT), indicated by the red arrow. 
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Once in the brain, L-DOPA is further metabolised in dopaminergic neuron terminals, 
interneurons and epithelial tissue, resulting in a short plasma half life of 4 hours. Limiting the 
metabolism of dopamine in pre-synaptic terminals to HVA and DOPAC may therefore be 
advantageous to maintain extracellular dopamine levels of the caudate-putamen. Monoamine 
oxidase B (MAO-B) inhibitors such as rasagiline have been found have to positive clinical 
effects disease progression and on motor complications when given in the early stage, 
reducing the degradation of dopamine (Schapira, 2010). Catechol-o-methyl transferase 
(COMT) inhibitors such as entacapone can also be used in combination with L-DOPA to 
increase the plasma half life (Nissinen et al., 2009).  
 
Appropriate dopamine agonist treatments are the current focus to manage early stage PD; the 
most commonly used are D2 receptor agonists including: pramipexole, bromocriptine, piribedil 
and cabergoline (Espay, 2010, Tan, 2003, Poewe et al., 2010). Investigators involved in the 
CALM-PD study found the use of pramipexole in early PD gives an additional 
neuroprotective effect and a means to control bradykinetic/akinetic movements without 
dyskinesia, in contrast to L-DOPA (CALM-investigators, 2009). Clinicians currently also 
favour the use of dopamine agonist drugs to prolong the time before L-DOPA needs to be 
given for approximately 5 years (Adler et al., 1997). The dopamine agonist action of 
apomorphine is also exploited in some instances, although usually only in patients with other 
complications, as it requires daily injection (Stocchi et al., 2001).  
 
The use of D1 mediated agonism is not currently used in the treatment of PD. However, 
administration of either SKF-82958 or A-77636 in the MPTP primate model of PD has been 
found to have anti-parkinsonian actions, although long term use may cause debilitative 
involuntary side effects (Blanchet et al., 1996).  
 
1.3.4. Deep Brain Stimulation 
Deep brain stimulation (DBS) has emerged in the last 15 years for the treatment of PD, and is 
now an established technique to control movement. DBS involves the control of the electrical 
output of the basal ganglia by the implantation and fine adjustment of electrodes within 
specific output nuclei. The technology was developed from early electrical activity modulating 
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experiments in the 1980s (Benabid et al., 1987). Currently the main target for DBS to 
eliminate bradykinesia, postural instability and tremor is the STN, where stimulation is often 
bilateral and targeted to the dorsolateral motor regions (Herzog et al., 2004). Long-term 
improvements for tremor and bradykinesia have also been noted with GPi-DBS and ventral 
nucleus of the thalamus-DBS (Zahodne et al., 2009b). Alternative STN and GPi-DBS targets 
have been compared in randomised double blind clinical trials, but as yet no clear differences 
between target sites have been observed, with significant improvement of parkinsonian 
symptoms based on the unified Parkinson’s disease rating scale (UPDRS) using both (Follett 
et al., 2010).  
 
Outcome measures of DBS on symptoms such as gait, speech and cognition are often difficult 
to interpret (reviewed in (Bronstein et al., 2011). However an improvement of depression has 
been noted with GPi-DBS in contrast to STN-DBS where a worsening was observed (Follett et 
al., 2010). The latter target has also been associated with cognitive decline one year post-
procedure (Mikos et al., 2010, Zahodne et al., 2009a). Although clearly effective, DBS has 
significant long term costs, not only in the cost of the stimulators themselves and their 
maintenance, but also the cost of specialist physiologists (Shan et al., 2011) and (reviewed in 
(Groiss et al., 2009). 
  
1.3.3. Future Cell Replacement Strategies 
Current strategies only treat motor symptoms and do not stop disease progression or reverse 
the damage, which are the two main goals of future cell therapies for PD. As so many cells 
have been lost in advanced stages of PD, resulting in long-term changes in the circuitry of the 
basal ganglia, one approach has been to directly replace the lost dopamine neurons by the 
implantation of replacement dopaminergic neurons. In the 1980’s the transplantation of 
adrenal cells into the denervated striatum in animal models of PD produced a degree of motor 
function recovery mediated by the release of catecholamines (Freed et al., 1983, Freed et al., 
1981, Backlund et al., 1985). This led to the first implantation of autologous adrenal medulla 
cells in PD patients in the early 1980s (Backlund et al., 1985, Lindvall et al., 1988, Lindvall et 
al., 1989, Madrazo et al., 1988). In spite of initial claims of dramatic alleviation of symptoms 
by an open surgical approach in two patients (Madrazo et al 1987), this could not be replicated 
and a series of more careful studies, in particular in the USA, led to the recognition of poor 
survival of adult medullary cells, limited acute and no sustained functional benefits, and the 
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surgery itself was associated with significant complications in elderly frail patients, with 
unacceptable levels of morbidity and occasional mortality (Quinn, 1990). This adrenal 
medulla approach rapidly fell out of favour. However, animal studies suggested more reliable 
results in experimental animals by transplantation of allogenic dopaminergic cells from the 
embryonic ventral mesencephalon (VM) (Freed, 1983, Dunnett et al., 1981, Bjorklund et al., 
1981, Brundin et al., 1986). The first transplants of VM of 6-9 week human embryos donated 
from elective surgical terminations into PD patients yielded good graft survival as visualised 
by F-dopa PET imaging, and clearcut functional benefits (Lindvall 1990). Long term follow 
up studies of these first patients continues to show good clinical benefit in at least some 
patients, sustained over 10-15 years (reviewed in (Dunnett et al., 2001). Typically 1.5- 4.9 
embryos were used per putamen. Initial preclinical studies used solid tissue pieces that were 
subsequently demonstrated to have functional effects on the behaviour of animal models when 
implanted into cortex and ventricles (Bjorklund and Stenevi, 1979, Stenevi et al., 1976). 
However it was quickly shown that increased improvement of the motor phenotype in models, 
could be achieved using single cell suspensions with topographic placement in the striatum 
(Dunnett et al., 1983b, Dunnett et al., 1983a, Schmidt et al., 1981), used for all subsequent 
clinical trials.  
 
The positive outcome from both the small trials of the 1980’s and pre-clinical research enabled 
the implementation of two large National Institutes of Health (NIH) double-blind, placebo 
controlled studies (Freed et al., 1990, Olanow et al., 2003). The result of these however was 
more disappointing than expected (Freed et al., 2001, Olanow et al., 2009a, Olanow et al., 
2009b). Ongoing open label trials of 26 patients however has lead to symptomatic 
improvements based on the UPDRS, 6-24 months post-transplantation (Hagell et al., 1999) 
and (reviewed in  (Dunnett et al., 2001). In some patients transplantation enabled a reduction 
in medication, a reduced time in ‘off’ and in others L-DOPA could be removed altogether 
(Freed et al., 2001, Hagell et al., 1999). Evidence from position emission topography (PET) 
scans in patients has shown the transplanted tissue is able to survive over time and reinnervate 
the dopamine-depleted striatum, leading to an improvement in clinical tests such as the 
UPDRS (Cochen et al., 2003, Freeman et al., 1995). Long-term follow up studies have shown 
that symptomatic improvement goes beyond dopamine replacement and transplantation causes 
a degree of functional integration, demonstrated by task-driven cortical activation 18 months 
post-surgery (Piccini et al., 2000). The high variability between individuals (Olanow et al., 
2003, Freed et al., 2001) and a large placebo effect in some individuals under controlled 
30 
 
conditions (Goetz et al., 2008), produced some concern regarding the reliability of the 
technique.  
 
Grafts have also had mixed success in altering abnormal movements caused by L-DOPA. 
Whilst it has been reported in some trials that the grafts can reduce time in ‘on’ dyskinesia, in 
others only marginal improvements or even a worsening effect was seen in patients (Freed et 
al., 2001, Freed, 2004, Olanow et al., 2003, Olanow et al., 2009b). A number of studies also 
reported the occurrence of ‘runaway dyskinesia’, i.e. abnormal movement profile that 
continues even with the withdrawal of L-DOPA treatment (Freed et al., 2001, Hagell et al., 
2002), and which has subsequently been termed graft induced dyskinesia (GID), as detailed in 
section 1.5.  
 
1.3.5. Future Gene Therapy 
An emerging novel surgical treatment for the cardinal symptoms of PD is the delivery of 
genomic transcripts or recombinant proteins into dopamine-depleted areas. infusion of Glial 
cell-derived neurotrophic factor (GDNF) into the putamen by low basal and pulsed delivery in 
10 PD patients caused initial motor improvements, although the benefits appeared to be lost 9 
months after treatment withdrawal (Slevin et al., 2006). However, it has been proposed that 
the significance levels in this study were based on misleading power calculations, even though 
re-evaluation of the statistics has justified the beneficial outcome (Matcham et al., 2007). 
Nevertheless the delivery system by chronic infusion is not ideal, and is associated by 
significant technical complications and side effects. Therefore the use of viral vectors has been 
explored as an alternative technology for sustained bio-delivery. An adeno-associated viral 
(AAV) mediated gene transfer of neurturin (CERE-120), a structural and functional homolog 
of GDNF, can cause the partial tyrosine hydroxylase (TH)-induction in patients and can reach 
approximately 15% of putamen (Marks et al., 2008). However, the neuroprotective outcome 
was not as successful as previous primate studies (Herzog et al., 2007), most likely due to 
there being less retrograde transport to the SN in the human studies (Marks et al., 2008) and 
(reviewed in (Bartus et al., 2011).  
 
Pre-clinical evidence suggests that growth factor expression in the SN can significantly save a 
proportion of dying cells (Choi-Lundberg et al., 1997), reflecting new surgical targets that 
could be exploited in the clinic. Although deemed suitable in for use in humans by a safety 
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study, the clinical outcome has so far been disappointing (reviewed in (Manfredsson et al., 
2009). The AAV mediated GAD over-expression into the STN has proved to be safe and 
efficacious in a double-bind, randomised, sham-controlled clinical trial, causing improvements 
on the UPDRS 6-months post injection (LeWitt et al., 2011). The use of tyrosine hydroxylase 
(TH) and GTP cyclohydrolase-1 viral vectors can cause a reversal in certain sensory-motor 
problems in rodent models of PD, negating bradykinesia and akinesia like deficits (Bjorklund 
et al., 2010, Kirik et al., 2002) and is now very close to being tested at clinical trial.  
 
A third gene therapy approach that is likely to be exploited in the future is combined TH, 
AADC and GCH1 transfer to enhance dopamine synthesis in striatal neurons themselves, 
although ratios will need to be carefully controlled in vivo (Duan et al., 2005). Moreover the 
mechanism by which dopamine synthesised within striatal neurons (which do not have the 
machinery for vesicular packaging, storage and release of the transmitter) can provide a 
regulated action at receptors located on the outside of the cells, remains to be explained. 
 
In summary, the invasive nature of gene therapy, along with the significant regulatory 
concerns surrounding gene manipulation and therapy will mean that it will not be suitable for 
everyone. Moreover, significant technical advances are also required to optimise the surgical 
technique and to deduce appropriate concentrations for stable diffusion of the transcripts 
throughout the caudate-putamen and/or SN. 
 
1.4. L-DOPA Induced Dyskinesia (LID) 
 
1.4.1. Development and Causes 
At later stages of the disease, fluctuations in extracellular dopamine concentration from oral L-
DOPA treatment give rise to debilitating dyskinesia (a set of abnormal involuntary movements 
(AIMs) present in the limbs, trunk and face). This is the result of a short L-DOPA half life and 
hence shorter duration of action, causing the wearing off of the beneficial motor effect before 
the next dose is given. Adequate symptomatic control may last approximately 10 hours after 
reaching the brain in the early stage of the disease, but may last as little as two in advanced PD 
(reviewed in (Schapira et al., 2009). It is usual for dyskinetic symptoms to manifest 5-10 years 
following initiation of L-DOPA therapy (reviewed in (Encarnacion and Hauser, 2008), this 
form of dyskinesia is commonly biphasic or may only occur at times of peak dose (‘on’ phase) 
or as a wearing off affect (‘off’ phase) as the result of fluctuations in circulating plasma L-
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DOPA levels (Cubo et al., 2001). Under normal circumstances extracellular dopamine levels 
are stable, causing the low level continuous stimulation of dopamine receptiors in the caudate 
and putamen, this balance is disrupted by L-DOPA in PD patients and post synaptic receptors 
are under stimulated when L-DOPA has been utilised and overstimulated at peak dose 
(reviewed in Stocchi et al., 2009). However if this is controlled aduaquately dyskinesia can be 
much reduced, clinictials often favour the use of apomorphine or duodernum pumps so that 
dyskinesias may be managed (see section 1.4.2).  The pulsate nature of L-DOPA treatment 
leads to permanent post-synaptic changes that sensitise receptors and lead to signalling 
abnormalities, discussed in section 1.8.  
 
Dopamine level fluctuations and post-synaptic changes result in a second pathological state of 
the basal ganglia circuitry (Fig. 1.3). It is generally accepted that excess dopamine produced 
by the action of L-DOPA causes an abnormal decrease in the firing of neurons within the GPi 
and an excessive dis-inhibition of thalamo-cortical signalling, resulting an increased cortical 
output (Obeso et al., 2000b). In short, there is a disproportionate signalling of the D1 mediated 
direct pathway. The changes to the direct pathway caused by L-DOPA are fundamental to the 
development of dyskinesia. Lesions of the STN and pharmacological reduction of signalling 
by GABA receptor agonists can both induce dyskinesia in the absence of L-DOPA (Burbaud 
et al., 1998, Hamada and DeLong, 1992). In agreement, the agonist action of apomorphine on 
D1 and D2 receptors decreases the activity in the STN and increases firing in the GPe 
(reviewed in (Lozano et al., 2000). This general model of dyskinesia however is often 
considered to be over-simplified as indicated by other experiments (reviewed in (Obeso et al., 
2000a). Unexpectedly, dyskinesia is enhanced by GPe lesions and reduced by GPi lesions 
(Blanchet et al., 1994, Marsden and Obeso, 1994). Thus, evidence suggests that following L-
DOPA the basal ganglia undergoes a number of neuro-plastic changes over time, resulting in 
an alteration of neuronal firing (reviewed in (Cenci and Konradi, 2010).  
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Fig. 1.3. A representative diagram showing the circuitry of the basal ganglia in Parkinson’s 
disease patients, following L-DOPA treatment. Dopaminergic neurons (yellow) project from 
the SN to the putamen. GABA neurons (red) in the indirect pathway connect to the GPe and 
STN while the direct pathway exerts an effect on the GPi. The pedunculopontine nucleus 
(PPN), spinal cord (SC) and thalamus also receive an excitatory glutamatergic input. 
Glutamatergic signals (blue) connect the thalamus to the cortex, cortex to the STN and the 
cortex to the GP. A reduction in input is signified by the dashed line and an enhancement of 
signal signified by the dotted line.  
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It is emerging that dyskinesia in PD is not solely the result of continued dopamine 
denervation, long term post-synaptic changes and consequent firing patterns of the basal 
ganglia, but may also be dependent on the interplay of the glutamatergic and serotonergic 
systems (Cenci and Konradi, 2010). The change in the glutamate controlled cortico-striatal 
pathway is now found to be critically important in emergence of LID. Dyskinetic PD animal 
models lack the ability to reverse experimentally-induced long term potentiation (LTP) and 
have synaptic storage information deficits within the cortex (Cenci and Konradi, 2010, 
Dunnett, 2003, Picconi et al., 2003, Calabresi et al., 2000a). The manifestation of LID arises 
though the inability to erase unneeded motor information, termed synaptic depotentiation. In 
addition, 5-HT neurons have the ability to convert L-DOPA into dopamine and may also 
contribute to dyskinesia; sufficient autoregulation of dopamine release is prohibited, as 5-HT 
terminals lack D2 receptors, thereby providing dysregulated dopamine release into the 
denervated striatum (reviewed in (Carta et al., 2010a, Carta et al., 2008c). Although the 
relationship between the 5-HT fibres and dyskinetic movements has been established in 
animal models, there is a lack of post mortem data to confirm this in PD patients. 
 
1.4.2. Treatment Strategies for LID 
There are currently no effective treatments for the prevention or amelioration of dyskinesia in 
response to L-DOPA therapy that do not compromise lifestyle and anti-parkinsonian effects in 
humans and non-human primates. Historically, pallidotomies were used for their anti-
hyperkinetic effect on highly dyskinetic patients (Meyers et al., 1959). However, open brain 
surgery is no longer preferred. There has been a drive to achieve constant levels of L-DOPA 
within the striatum, thereby avoiding dopamine fluctuations and dyskinesia and this has been 
demonstrated by slow infusion into the gastrointestinal tract (Odin et al., 2008). This is not 
ideal, however, and requires a permanent attachment of an often cumbersome bag to the 
abdomen, and requires careful monitoring of the dietary habits of the individual. The bag may 
also present a potential source of infection (Devos, 2009). Therefore an alternative co-
treatment strategy using compounds that alter signalling within the basal ganglia are often 
adopted by clinicians. Subcutaneous apomorphine pumps can also be used to control LID and 
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where the drug is administered continuously over 6 months, both a reduction in AIMs and 
‘off’ phase could be observed (Katzenschlager et al., 2005). 
 
Dopamine receptor antagonists are not used for the treatment of LID, as therapeutic doses will 
simply result in the worsening of parkinsonism. Similarly reducing L-DOPA without replacing 
it alleviates LID, but the consequence is a worsening of the bradykinetic symptoms. 
Amantadine has NMDA antagonistic and anticholinergic properties and has shown to be the 
most effective for reducing AIMs in L-DOPA treated PD patients; however only 50% of 
patients have shown an improvement with this combination approach, and severity is only 
mildly reduced for a short period of time (da Silva-Junior et al., 2005, Godwin-Austen et al., 
1970).  
 
Several other compounds have been trialled but are not available as ‘on-label’ drugs for the 
treatment of dyskinesia. Furthermore, there are new putative compounds but many fail to go 
beyond the clinical trial stage. The D2 and α-adrenergic receptor antagonistic and partial 5-
HT1A agonist properties of buspirone are able to reduce severe dyskinesia in some patients 
(Bonifati et al., 1994). Of late, an open labelled clinical trial testing low doses of aripiprazole 
on LID has shown that even in patients that were not responsive to amantadine, a reduction in 
the severity and frequency of dyskinesia resulted although in some cases may have also 
worsened general movement as scored on the UPDRS (Meco et al., 2009). This novel 
antipsychotic acts by a partial agonism at the D2 and 5-HT1A receptors and antagonism of the 
5-HT2A receptor (Meco et al., 2009). Cannabinoid agonists have also been shown to reduce 
dyskinesia clinically in some L-DOPA treated patients, from their proposed action on 
receptors on the GPi (Sieradzan et al., 2001), although cannabis itself had no effect on 
dyskinesia in a double blind placebo controlled study (Carroll et al., 2004). Non-specific 
opioid receptor and specific δ-opioid antagonism with naloxone or naltrindole, respectively, 
resulted in a small yet significant reduction in LID in two small scale studies (Manson et al., 
2001, Fox et al., 2004). Overall, the pharmacological approach to the adverse effects of L-
DOPA treatment has had limited success at clinical trial stages, although there are a number of 
other agents that have shown a greater efficacy in experimental models of PD (Dekundy et al., 
2007, Lundblad et al., 2002). 
 
In animal models of PD L-DOPA is used to induce abnormal movements that closely mimic 
LID in patients, allowing specific systems and receptors to be targeted with pre-existing or 
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novel compounds, hence validating the model (Dekundy et al., 2007, Lundblad et al., 2002). 
Dopamine antagonists such as haloperidol can reduce dyskinesia by 99% in rodents (Johnston 
et al., 2005, Monville et al., 2005, Lundblad et al., 2005), but they completely suppress all 
voluntary motor function at effective doses. Noradrenergic and opioid modulators such as 
propanolol, clonidine, naloxone and yohimbine show some anti-dyskinestic effects in hemi-
parkinsonian rodents (Dekundy et al., 2007, Lundblad et al., 2002). Responses to opioid 
receptor modulation in particular are not uniform between studies, as both agonism of κ-opioid 
receptors and antagonism of µ- and δ-opioid receptors may result in a reduction in 
experimental LID (Henry et al., 2001, Ikeda et al., 2009). 5-HT1A and 5-HT1B receptor 
agonists and 5-HT2C receptor antagonists have also shown some efficacy to minimise 
dyskinesia in rodents and primates (Dekundy et al., 2007, Munoz et al., 2008b, Carta et al., 
2008d, Carta et al., 2008a). Cannabinoid agonists targeting cannabinoid receptor-1 (CB1 
receptors) such as WIN55,212-2 can also reduce dyskinesia experimentally (Morgese et al., 
2009). Cholinergic modulators however have had no effect (Dekundy et al., 2007). Glutamate 
modulating drugs including amantadine have had the most promising effect on experimental 
dyskinesia; however, many of the compounds also influence the functionalities of other 
systems (Dekundy et al., 2007, Lundblad et al., 2002). Specifically, mGluR5 antagonists have 
been shown to reduce AIMs in rodent models, whereas mGluR1 antagonists exhibit more 
limited effect (Dekundy et al., 2006). The ability of two mGluR5 receptor antagonists, MPEP 
and MTEP, to reduced LID has also been shown in non-human primates (Morin et al., 2010). 
AMPA receptor antagonist drugs can also reduce dyskinesia by up to 75% (Kobylecki et al., 
2010). LID can be prevented by NR1 and NR2b specific NMDA antagonists when given 
simultaneously to L-DOPA through treatment in non human primates (Ouattara et al., 2009). 
However, both pre-clinical research and clinical trials have shown that co-treatments are not 
ideal as they generally have little efficiency in targeting AIMs over general motor function and 
therefore other strategies are now sought to control LID. 
 
The application of high frequency DBS directly into the GPi has shown marked improvements 
of hyperkinetic symptoms in patients (Kumar et al., 2000). However, complications using this 
technique include the difficult fine adjustment of frequencies necessary to gain maximal 
possible reduction in hyperkinesia without worsening bradykinesia, and a ‘wearing off’ effect 
seen in some patients a year or more post-surgery. Recently, GPi-DBS has be used to treat the 
most severe forms of dyskinesia; however, this is often compromised in favour of reduction in 
medication and STN stimulation to improve motor function (reviewed in (Groiss et al., 2009).  
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1.5. Graft Induced Dyskinesia (GID) 
 
1.5.1. Development and Possible Causes 
The development of AIMs, 6-12 months after the transplantation of VM derived tissue, was 
first noted by Freed et al. and retrospective analysis has found this debilitating side effect to 
occur in the absence of L-DOPA (Freed et al., 2001, Freed et al., 2003, Ma et al., 2002). These 
abnormal movements have subsequently been termed ‘run away’ or graft-induced dyskinesia 
(GID). The development of dyskinesia was initially seen in a small number of patients (Freed 
et al., 2001), manifesting through what was subsequently described as a combination of 
hyperkinesia and dystonia symptoms, highlighted in (Olanow et al., 2009b, Olanow et al., 
2009a, Olanow et al., 2003). These have been phenotypically described as ‘repetitive 
stereotypic alternating contractions of flexor and extensor muscles’ (Olanow et al., 2003), 
found in the face and limbs or generalised across the whole body (Freed et al., 2001). In some 
grafted patients, hyperkinetic movements required DBS therapy of the GPi or STN to decrease 
their severity (Freed et al., 2001). Table 1.3 describes the occurrence, onset and severity of 
GID in the three large scale clinical trials. AIMs were analysised in follow up studies or by 
retrospective analysis: - 
 
Study Reported  Patients 
affected 
Time of 
development 
AIM description Treatment 
Denver Freed et al. 
2001 
15 % 1 year post 
transplantation 
Severe debilitating 
dyskinesia 
Amantadine 
and DBS 
(all) 
Tampa Olanow et 
al., 2003 
56.5% 6-12 months 
post 
transplantation 
Mild stereotypic 
movements of the 
lower extremities 
DBS (small 
%) 
Lund Hagall et 
al., 2002 
Not 
determined 
40 months post 
transplantation 
Mild to moderate 
choreiform 
movements 
none 
Table 1.3. Observations of GID in the three documented clinical trials of primary 
dopaminergic tissue transplantation. 
 
GID is not causally linked with L-DOPA administration as AIM persist following the 
withdrawal of L-DOPA therapy post-operatively (Hagell et al., 2002, Winkler et al., 2005) and 
(reviewed in (Lindvall and Bjorklund, 2004). Patients that have diurnal dyskinesia in response 
to L-DOPA preoperatively however may have a worsened ‘off’ phase dyskinesia and 
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improved ‘on’ phase dyskinesia postoperatively (Freed et al., 2001, Hagell et al., 2002, 
Olanow et al., 2009a). It is now considered that GID, develops a year or more following 
transplantation, and is not correlated with anti-parkinsonian effects (Hagell et al., 2002, Nova 
et al., 2004). In contrast other studies noted GID development in the first 12 months (Freed et 
al., 2001, Olanow et al., 2003). Timing of GID development may be important, as it seemingly 
occurs when a beneficial effect was noted, indicating that graft functionality or the withdrawal 
of immuno-suppression may be a risk factor for GID development (reviewed in (Lane and 
Smith, 2010). 
 
GID has led to the questioning of the future of transplantation as a viable treatment strategy 
for the field of PD. This has prompted much experimental research on the mechanistic cause 
of this phenomenon (detailed in section 1.9.) so that it may be reduced/ avoided in future 
clinical trials. In large GID is rare and although most patients exhibiting these AIMs find the 
side effects inconvenient they would not voluntarily forego the greater benefit of the graft for 
the elimination of the side effect. 
 
1.5.2. Strategies for GID 
Few pharmacological strategies have been used to negate dyskinetic side effects associated 
with cell transplantation in humans, not least because the phenomenon has only become 
apparent in the last decade and the number of patients affected is small. This better 
pharmachological management of this problem however may overcome political hurdles, to 
enable further clinical trials. Amantadine had limited success in reducing GID (reviewed in 
(Lane et al., 2010), buspirone has shown some symptomatic relief in two grafted PD patients, 
associated with its 5HT1A agonist properties (Politis et al., 2010, Politis et al., 2011a). D1 and 
D2 specific antagonists have been shown to reduce GID in the grafted rodent model of PD 
(Lane et al., 2009a). GID can also be reduced experimentally using 5-HT1A and 5-HT1B 
receptor agonists singly and to a greater extent in combination, although the exact mechanism 
of which is unclear (Lane et al., 2009a, Carta et al., 2010b). It is not known whether other anti-
dyskinetic agents used for the treatment for LID (see section 1.4.2), will have any beneficial 
effect on the hyperkinesia caused by dopamine cell replacement strategies. 
 
Although the precise electrophysiological consequences that cause abnormal movements 
following a dopamine rich transplant have yet to be elucidated both GPi and STN-DBS 
treatment strategies have been shown to cause improvements in some cases (Freed et al., 2004, 
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Herzog et al., 2008, Ma et al., 2002). However, transient benefits or no improvements have 
been recorded in some individuals using these measures, and thus experimental research is 
needed before the efficiency of DBS in transplanted patients is equal to that seen for the 
treatment of LID. 
 
1.6. Animal models of PD 
1.6.1. Pharmacological  
The alkaloid reserpine was used to create the first animal model of PD (Carlsson et al., 1957, 
Carlsson et al., 1991). Reserpine causes the blockade of the vesicular monoamine transporter, 
preventing the reuptake of the neurotransmitter into vesicles of released or newly synthesised 
monoamines. It was the observation of the akinetic effects of reserpine on experimental rabbits 
and rats by Carlsson (1957) that first suggested that dopamine was a neurotransmitter in its 
own right (rather than just a precursor for noradrenaline). Further, in view of similarities to 
akinetic symptoms, it was first proposed that PD may involve a reduction in dopamine 
transmission within the basal ganglia (Carlsson et al., 1957). These symptoms prevail for 2-3 
days before the replenishing of stores is enabled, allowing behavioural and neuro-chemical 
recovery. Carlsson et al. (1957) also observed that rigidity and akinesia in reserpine-treated 
rabbits could be alleviated by L-DOPA.  
 
Methamphetamine is a lesser used pharmacological model of PD, which can deplete dopamine 
permanently, to cause a mild parkinsonian syndrome in the animals when off the drug. 
Administration of 2.5mg/kg, twice daily over 4 days reduces dopamine and 5-HT in the 
striatum, potentiated by pargyline (Jarvis and Wagner, 1985), and causes a loss of nigral 
dopaminergic neurons (Sonsalla et al., 1996), leading to the a permanent PD motor phenotype. 
Although this model is less commonly used due to side effects of thermal-dysregulation, and 
adverse psychological behaviours, ubiquitin and α-synuclein positive inclusions have been 
reported (Fornai et al., 2004). To mimic more closely the links of idiopathic PD to the farming 
and agricultural sector, rotenone and paraquat used as herbicides and pesticides, are seen to 
cause dopaminergic cell death in animal models, an effect believed to be mediated by an 
increase in free oxygen species (Anderson et al., 2007, Bove et al., 2005, Corasaniti et al., 
1998, Greenamyre et al., 2003, Richardson et al., 2005). Although Lewy body-like inclusions 
have been reported in the brains of animals treated experimentally using these chemicals, non-
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specific cell death, procedural difficulties in administration, inconsistency of lesions, and high 
death rates reduce the practical utility of these toxin models, which are consequently not 
commonly used in experimental PD research (reviewed in (Greenamyre et al., 2003, 
Corasaniti et al., 1998).  
 
Although models mentioned above have been used in the assessment of PD and analysis of the 
pathways of the basal ganglia, MPTP and 6-OHDA models are often preferred as they are well 
characterised, can mimic late stage PD, cause long-term maladaptive changes and dopamine 
depletion is stable (Jenner et al., 1984, Langston and Ballard, 1983, Ungerstedt, 1968) and 
(reviewed in (Cenci et al., 2009, Jenner, 2009).  
 
1.6.2. MPTP 
The ability of MPTP to cause a fast severe parkinsonian phenotype in humans (Langston and 
Ballard, 1983), by promoting cell death within the SN, has lead to its use in animal models to 
recapitulate the pathology and motor features of idiopathic human PD (Anichtchik et al., 2004, 
Boyce et al., 1984, Braungart et al., 2004, Jenner, 2003, Jenner et al., 1984). MPTP is a 
lipophilic by-product of the synthesis of mepethidine, it can cross the BBB with relative ease 
where it is then metabolised into MPP+ by MAO-B in non-neural cells. MPP+ is the active 
toxic metabolite which is taken up into neurons through the dopamine transporter (DAT). Cell 
death is induced by inhibition of complex I of the mitochondrial respiratory chain increasing 
the presence of free oxygen species (Nicklas et al., 1985). MPTP administration to mice and 
non-human primates selectively damages dopaminergic neurons of the midbrain, although 
there is evidence that other monoamine systems may also be affected (Luchtman et al., 2009, 
Perez-Otano et al., 1991). MPTP produces a rapid pattern of PD like cell death in mammals, 
and a stable lesion develops after a few weeks corresponding to the time at which behavioural 
deficits similar to clinical PD are observed (Jenner et al., 1984). In non human primates, the 
variation in the motor phenotype can be assessed with rating scales that are similar to that used 
to characterise PD in the clinic. Although typical inclusion body formation is not seen 
following MPTP toxicity (Fornai et al., 2005), aged primates and mice show an up-regulation 
in the expression of soluble α-synuclein (Halliday et al., 2009). MPTP has also been used to 
disrupt usual patterns of movement in caenorhabditis elegans (C. elegans) and zebrafish 
(Braungart et al., 2004, Anichtchik et al., 2004). Since primates are expensive to house and 
maintain, rodent based studies are often preferred. MPTP has species specific effects being 
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less potent in mice than in monkeys; and rats are even less susceptible to its neurotoxic effect 
(Boyce et al., 1984).  
 
1.6.3. 6-OHDA 
The catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) is able to destroy 
dopaminergic terminals and cell bodies by inhibiting mitochondrial complexes I and IV as 
well as producing hydroxyl free radical species by auto-oxidation (Ben-Shachar et al., 1995, 
Glinka and Youdim, 1995, Ungerstedt, 1968). Motor behavioural deficits manifest in 
conjuction with cell loss in the SNc, beginning in the second week post-injection, and 
gradulaly progressing until a stable plauteau is reached at day 28 (Blandini et al., 2007b). The 
unilateral 6-OHDA lesioned rat model of PD was developed by Ungerstedt in 1968 and has 
had a diverse use in the assessment of motor, cognitive and therapeutic aspects of Parkinson’s 
disease (Perese et al., 1989, Kirik et al., 1998). To establish this model the neurotoxin can be 
injected stereotaxically into either the striatum, median forebrain bundle (MFB) or SN regions 
of the nigrostriatal pathway. The selectivity of 6-OHDA on the dopaminergic system is 
currently unclear and there is evidence that the neurotoxin can disrupt seratonergic and 
adrenergic systems, although this may be dependent on cannula type, species, 6-OHDA 
concentration and infusion rate of the neurotoxin (Fulceri et al., 2006, Bishop et al., 2009).  
 
The hemi-parkinsonian rodent model, produced by the injection of 6-OHDA into one 
hemisphere, has been used widely to assess the role of the nigrostriatal pathway in motor 
function, to determine the degree of functional recovery following the transplantation of 
primary dopamine releasing cells (Torres et al., 2008, Mendez et al., 1996, Ishida et al., 1990, 
Mandel et al., 1990, Olsson et al., 1995, Dowd and Dunnett, 2004, Klein et al., 2009) and 
increasingly being utilised to explore the mechanisms underlying LID (Jankovic and Aguilar, 
2008, Jankovic, 2008, Bordet and Destee, 1992, Kirik et al., 1998, Cenci et al., 1998), or GID 
(Carlsson et al., 2006b, Lane et al., 2009a, Lane et al., 2009b, Lane et al., 2006b, Steece-
Collier et al., 2003). Although 6-OHDA is predominantly used in the rodent, other more basic 
models such as zebra fish, C. elegans and salamanders can also be used to assess the 
sensitivity to the drug and the testing of neuroprotective compounds (Anichtchik et al., 2004, 
Marvanova and Nichols, 2007, Nass et al., 2002, Parish et al., 2007). Interestingly, the 
salamander has a more progressive parkinsonian phenotype, similar in nature to that seen in 
the patient, yet deficits are not stable or long lasting. Overall the 6-OHDA lesion model is 
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non-selective among catecholamines, dopaminergic, noradrenergic and adrenergic pathways 
being equally susceptible to its toxic action. Nevertheless, two different strategies can be 
adopted, separately or together, to yield more selective dopaminergic cell death. First, 
stereotaxic techniques can permit selective placement of the toxin into a discrete area of the 
brain where only one principle pathway is present, such as targeting the coerulocortical 
noradrenergic pathway by injection into the dorsal noradrenergic bundle caudal and dorsal to 
the substantia nigra (McGaughy et al., 1997). The ascending forebrain dopamine fibres from 
the ventral mesencephalon course together with noradrenergic fibres of the median forebrain 
bundle, so this strategy is not feasible at this level. However, the striatum itself receives a 
relatively sparse noradrenergic innervation, so that 6-OHDA injections placed directly into 
striatal terminal areas can yield relatively selective dopamine depletion (Debeir et al., 2005). A 
second strategy involves pretreatment with pharmacological inhibitors of catecholamine 
transport that block reuptake into some pathways but not others. Thus, administration of 
desipramine hydrochloride during stereotaxic surgery can be used to block uptake into 
noradrenaline (NA) neurons, thereby increasing selectivity of toxicity to dopamine pathways 
(Fink and Smith, 1980, Fulceri et al., 2006, Jeste and Smith, 1980). However this does not 
control for 5-HT uptake and physical damage caused by the cannula during the lesioning 
process but 5-HT neurons are less sensitive than catecholaminergic ones to 6-OHDA, and such 
cross-toxicity can be minimised by use of lower concentrations and slower delivery of the 
toxin (Fulceri et al., 2006). So relative selective can be achieved by judicious combination of 
toxin dose, site of delivery and pharmacological pretreatment, the parameters for which are 
best established empirically. However, the 6-OHDA model still differs in another way from 
dopamine loss in idiopathic disease, in that toxicity is essentially acute, and it does not allow 
for the progression of the disease with aging and typical regional spreading, as described by 
(Braak and Braak, 1990).  
 
Behavioural tests are able to determine, with relative accurracy, the extent of dopaminergic 
neuron denervation in the unilateral 6-OHDA lesioned rat, though it is considered that the 
unlesioned side can overcompensate for unilateral motor deficits to some degree (Barneoud et 
al., 2000, Costall et al., 1976b, Costall et al., 1976c, Dowd et al., 2005b, Dunnett et al., 1981, 
Dunnett et al., 1988a, Kirik et al., 1998, Metz et al., 2005, Olds et al., 2006, Olsson et al., 
1995, Perese et al., 1989, Schwarting and Huston, 1996, Woodlee et al., 2005), the bilateral 
model is less common, as loss of appetite and thirst is common (Pioli et al., 2008, Paille et al., 
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2007, Sakai and Gash, 1994) and (reviewed in (Zigmond and Stricker, 1989), which give rise 
to significant issues of maintaining good health and welfare of the experimental animals. 
 
The standardisation of lesioning techniques and in depth behavioural analysis of the unilateral 
rat 6-OHDA model has led to its preference in the experimental PD field, and the size of the 
lesion is often assessed robustly with the use of amphetamine and apomorphine induced 
rotation (continued circling of mice through 360
o
). In unilateral models amphetamine causes 
dopamine release and subsequent stimulation of the dopamine receptors on the intact side, 
driving rotation in the ipsilateral (same side to the lesion) direction (Ungerstedt, 1971b) and 
apomorphine acts on the lesion-induced supersensitive receptors to induce rotation toward the 
contralateral (opposite to the lesion) direction (Ungerstedt, 1971a). Dopamine losses of 90% 
have been found to cause 5/7 turns per minute following an amphetamine (0.63-2.5mg/kg) or 
apomorphine (0.015-0.1mg/kg) challenge (Costall et al., 1976a, Costall et al., 1976b, Schmidt 
and Westermann, 1980). It was later found that dopamine losses in rats with partial lesions 
could be correlated to amphetamine, apomorphine and L-DOPA rotation (Hefti et al., 1980). 
 
Simple motor behaviour in the unilateral model can also be assessed by a variety of hand tests 
that can indicate the extent of the lesion pre-mortem, useful where drug naive animals are 
needed. Commonly, motor deficits on the contralateral side are often compared to the 
ipsilateral side to the lesion, serving as an internal control. The cylinder test, first described by 
(Schallert et al., 2000) assesses the laterality of forelimb use in a novel environment, where 
MFB rat models typically express a 70% or higher usage of the ipsilateral limb. A similar bias 
is also seen in the corridor test, in which unilateral lesioned rats show lateralised differences, 
preferentially retrieving pellets located on the ipsilateral of the head, nose and snout, 
neglecting pellets positioned on the contralateral side (Dowd et al., 2005a, Dowd et al., 
2005b). Sensorimotor dysfunction is also often tested using whisker simulation leading to 
placing and grasping reactions (Woodlee et al., 2005). Deficits in the contralateral limb, with 
an overcompensation response in the ipsilateral paw, can be seen when using the skilled 
reaching test (staircase), when dopamine depletion is at 80% or more (Montoya et al., 1990, 
Montoya et al., 1991, Pagnussat Ade et al., 2009). The grip strength meter highlights clasping 
and forelimb movement deficits in rats with MFB lesions (Dunnett et al., 1998) and forelimb 
akinesia is also noted when conducting other stepping tests (Blume et al., 2009, Olsson et al., 
1995) and gait analysis (Klein et al., 2009). The majority of these tests are essential to 
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determine a baseline on which to apply new therapies, yet have only been efficiently 
characterised in rats. 
 
The effectiveness of some of the above mentioned tests has previously been reported in the 6-
OHDA mouse (Iancu et al., 2005, Grealish et al., 2010b), however many have not been fully 
characterised for use this species. In mice a 31.5 fold increase in apomorphine rotation is seen 
following a dopamine depleting lesion and both amphetamine and apomorphine rotation is 
found to correlate with cell loss (Mandel and Randall, 1985). The skilled paw reaching 
‘staircase’ test has also limited success when translated for use in the unilateral 6-OHDA 
mouse (Baird et al., 2001). The 70-75% usage of the ipsilateral limb in the cylinder and 
corridor test correlating to near complete destruction of dopaminergic neurons has also been 
shown in mice (Grealish et al., 2010b, Iancu et al., 2005), although strain and lesion type 
comparisons have not yet been established. General motor co-ordination and balance deficits 
in lesioned mice were also observed by means of the rotarod test (Iancu et al., 2005). 
 
The optimisation of the hemi-parkinsonian mouse model is much needed as it will enable 
‘proof of principle’ type experiments emphasising findings across species, and greatly 
facilitate testing of novel stem cell and genetic therapies. There are also a number of non-
behavioural issues that need to be addressed for the optimisation of the 6-OHDA mouse. The 
success of the lesion may be dependent on the concentration and volume of 6-OHDA and the 
accuracy of the stereotaxic co-ordinates. This has varied extensively between previous mouse 
studies, the majority of which use striatal lesions owing to the ease of targeting the largest area 
in the nigro-striatal tract, see Table 1.4. Another important issue to resolve is improving 
survival post-surgery, since mortality rates over 80% have been reported previously (Lundblad 
et al., 2004b). The best target area along the nigrostriatal pathway must be balanced with the 
mortality caused by the lesion and the degree of interference with other systems such as 
forebrain 5-HT pathways which, like dopamine, have rich projections to the striatum.  
45 
 
 
 
 
Conc 
1 
Volume Stereotaxic Co-ordinates (mm) 
2 
Strain Sex Reference 
16 µg/µl 4 µl n/r n/r M (Von Voigtlander and 
Moore, 1973) 
4 µg/µl 4µl AP= +5 (to occipital structure),  
ML= -2.2, DV= -3.5 
Swiss M (Torello et al., 1983) 
4 µg/µl 4µl AP= +0.5, ML= -2.4, DV= -3.1 C57Bl/6 M/F (Randall, 1984) 
3.32 µg/l 4µl AP= +4.8 (Lambda), ML= -1.7,  
DV= -3.0 and -2.7 (dura) 
MNRI M (Brundin et al., 1986) 
4 µg/µl 4µl AP= +3 (to occipital structure),  
ML= -2.2, DV= -3.5 
Swiss M (Thermos et al., 1987) 
4 µg/µl 4µl AP= +0.5, ML= -2.4, DV= -3.1 C57Bl/6 M (Mandel and Randall, 
1990) 
2 µg/µl 2µl AP= +0.4, ML= -1.8, DV= -3.5 C57Bl/6 M (Bensadoun et al., 
2000) 
3 µg/µl 2x2 µl (i) AP= +1.0, ML= -2.1, DV = -2.9 
(ii) AP= +0.3, ML= -2.3, DV = -2.9 
C57Bl/6 M (Lundblad et al., 2004b) 
3 µg/µl 2x 2µl (i) AP= +1.0, ML= -2.1, DV = -2.9 
(ii) AP= +0.3, ML= -2.3, DV = -2.9 
C57Bl/6 M (Lundblad et al., 2004b) 
3 µg/µl 2x 2µl (i) AP= +1.0, ML= -2.1, DV = -2.9 
(ii) AP= +0.3, ML= -2.3, DV = -2.9 
C57Bl/6 M (Lundblad et al., 2005) 
6 µg n/r AP = +0.8, ML= -1.0, DV= -2.5 A/J M/F (Liang et al., 2005) 
 
3 µg/µl 
 
3.9 µg or 
5.4 µg 
AP= -1.2, ML= ±1.1, DV= -5.0,  
with incisor bar set at ±0.0 
CBA F (Iancu et al., 2005) 
2.5 µg/µl 2x 2µl AP= +0.5, ML= +2.4, DV -4.0 and -3.0 
(dura) 
C57BL/6J / 
OlaHsd 
M (Pavon et al., 2006a) 
3 µg/µl 2x 2µl (i) AP= +1.0, ML= - 2.1, DV= -3.2 
(ii) AP= +0.3,
 
ML= - 2.3, DV= -3.2 
C57Bl/7 M (Santini et al., 2007) 
2 µg/µl 2µl AP= + 0.4, ML= - 1.8, DV= - 3.5 C57Bl/6 M (Alvarez-Fischer et al., 
2007) 
4 µg/µl 2µl AP= + 0.8, ML= -1.9, DV= - 2.6 C57Bl/6 M (Richter et al., 2008) 
2 µg/µl 1µl AP= + 0.4, ML= - 1.8, DV= - 3.5 C57Bl/6 /  
SWISS / 
sv129 
M (Alvarez-Fischer et al., 
2008) 
Table 1.4. Parameters of mouse 6-OHDA lesions in published studies of the unilateral striatal 
lesion model. Concentration is based on free base 6-OHDA.HBr (1) and co-ordinates are 
calculated relative to Bregma, unless otherwise stated (2). Abbreviations: AP, anterior-
posterior; ML, medial-lateral; DV, dorsal-ventral; M, male; F, female; n/r, Not reported. 
Published in Contemporary Models of Movement Disorders (Smith and Heuer, 2011). 
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1.6.4. Transgenic 
PD is predominantly idiopathic. However, the use of genetic models highlights the 
mechanisms by which rare autosomal recessive and dominant mutations can cause the familial 
forms of the disease. The first gene mutation associated with PD was identified in a Greek 
family cohort (the ‘Contorsi’ kindred), within SNCA, the gene encoding for α-synuclein 
(Polymeropoulos et al., 1997). Since then, the aggregated protein has been found in various 
mutated forms in familial PD (Tong and Shen, 2009) and identified as a constituent protein in 
Lewy bodies (Spillantini et al., 1997). It is generally thought therefore that the protein plays a 
role in disease pathology, and hence a number of transgenic mice have been created with 
mutations in this gene to model PD. The first transgenic mouse made to mimic the 
synucleinopathy family of diseases was produced from the incision of human wild type 
α-synuclein under the PDGFβ pan neural promoter (Masliah et al., 2000). Inclusion formation 
in these mice was seen in the cortex, hippocampus, olfactory bulb and occasionally in the SN. 
The stereotaxic injection of wild type or mutant α-synuclein into neurons, via a viral vector, 
leads to a progress loss of dopaminergic neurons in rodents and non-human primates 
(Eslamboli et al., 2007, Kirik et al., 2003). However, the development of these inclusions does 
not resemble the human form as the presence of α-synuclein fibrils is not seen, nor do they 
form the large spherical globular cytoplasmic structures, characteristic of Lewy bodies 
themselves.  
 
LRRK2 is another gene in which mutations are associated with familial PD, and moderate 
overexpression of the human unmutated gene in mice causes an increase of striatal dopamine 
levels, inducing hyperactivity and enhanced performance in behavioural tests but, again, no 
overt Lewy body formation (Li et al., 2010). By knocking in human mutant LRRK2 into the 
same mice, the changes in motor function were ameliorated (Tong and Shen, 2009), yet 
deficits in dopamine handling detected including reduced striatal dopamine content, reduced 
vesicle release and a decrease in dopamine uptake. Other mice have been established to 
overexpress known heritable PD mutations in UCHL1 and PINK1 (Dawson et al., 2010, 
Setsuie et al., 2007, Zhou et al., 2007), to further models with changes in dopamine handling 
and inclusion bodies. 
 
 In all genetically modified mouse lines, cell death is typically less extensive than observed 
with 6-OHDA or MPTP neurotoxins and provide interesting models of early PD. However 
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they are not sufficient to bring about a robust motor deficit for the testing of novel treatments. 
The mechanistic similarity between genetic and idiopathic forms of the human disease is also 
currently unknown. 
 
1.7. Dyskinesia Models 
LID is a common motor side effect of current PD pharmacotherapy and causes debilitating 
AIMs. Effective animal models of LID therefore are essential to test new co-treatments that 
may reduce AIMs or to trial future interventions in a previously L-DOPA treated brain, 
mimicking that of the patient. 
 
1.7.1. LID and GID in Primates 
The first established animal model of LID was in the MPTP treated primate (Jolkkonen et al., 
1995, Paxinos, 2001, Pearce et al., 1995). On first administration in akinetic monkeys, L-
DOPA produced a marked anti-akinetic effect and greatly improved postural instability and 
gait (Jolkkonen et al., 1995). In these initial experiments oral L-DOPA was then given to 
common marmosets for three weeks and the recipients developed dystonic and choric AIMs 
seven days after the initiation of daily treatments, mimicking the rapid development of LIDs in 
advanced patients first given L-DOPA treatment, for example in the rare cases of MPTP 
toxicity in the case of the frozen addicts (Langston and Palfreman, 1995), or the introduction 
of L-DOPA soon after its discovery to postencephalitic patients (Sacks, 1973). Dyskinesias 
were found to be mimicked by dopamine receptor agonists after long-term treatment (Pearce 
et al., 1995) and related to doses of L-DOPA and peripheral COMT inhibitor entacapone given 
in combination (Paxinos, 2001). Furthermore, L-DOPA was found to restore levels of 
substance P depleted following MPTP, linking anti-parkinsonian effects of L-DOPA to 
physiological changes (Jolkkonen et al., 1995).  
 
Models of LID are now predominantly rodent based as non-human primates are costly and 
stringently controlled by the Home Office in the UK. Moreover, GID has not been found in 
non-human primates and, notably, spontaneous AIMs have so far only been observed in 
humans. Thus GID is normally induced in grafted rodent, previously and chronically treated 
with L-DOPA, using amphetamine, at a dose where no AIMs or stereotypy is seen in either 
non-grafted 6-OHDA rats, nor in grafted rats not pretreated with L-DOPA.  
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1.7.1. LID in Rodents 
A more recent model sprung from the recognition and acceptance that, following L-DOPA 
treatment, hemi-parkinsonian rats also exhibit AIMs which can be quantified (Cenci and 
Lundblad, 2007, Winkler et al., 2002b) and can be correlated physiological hallmarks within 
the striatum (Cenci et al., 1998, Andersson et al., 1999, Andersson et al., 2001, Andersson et 
al., 2003). In the rodent, dyskinesia can be induced by approximately 6mg/kg of L-DOPA, 
when less than 20% of dopamine remains in the lesioned striatum. Surprisingly, in all studies, 
a small proportion (typically 10-25%) of animals with equivalent dopamine depletion will 
remain non-dyskinetic (Lundblad et al., 2004b, Cenci et al., 1998). Where less dopamine 
denervation is observed, abnormal movements can only be initiated by a higher dose 
(Lundblad et al., 2004b, Winkler et al., 2002b). However the proportion of non-dyskinetic 
animals remains at a similar rate, and so is not primarily a dose related phenomenon. Specific 
AIM-physiological hallmark correlations and a definitive dose response curve of chronic L-
DOPA treatment in mice, of different 6-OHDA lesion types, have not yet been defined to the 
same degree as the rat. 
 
LID rating scales for 6-OHDA-lesioned rat and mice have been based on scoring individual 
components of the AIMs (including: body axis, forelimbs, hindlimbs and orolingual types) for 
their duration and severity (Cenci et al., 1998, Lundblad et al., 2004a, Winkler et al., 2002a). 
The scores from each component are then summed to give an overall severity rating. To 
examine AIMs, animals are placed singly in transparent rotometer bowls or cages following an 
injection with L-DOPA. Typically, behaviours are scored over one minute, every 20 or 30 
mins for approximately 3 hours; as detailed further in Chapter 2. Animals within the same 
cohort will generally have varying levels of AIMs and those with scores that fall below a pre-
determined threshold are considered ‘non-dyskinetic’ (Cenci and Lundblad, 2007). 
Assessment and induction of AIMs can be subject to interpretation by individuals and to the 
environmental conditions. It has also recently been found that the induction and severity of the 
abnormal movements can be modified by conditioned exposure to environmental cues and 
context, such that AIMs can even be triggered by paired association by saline alone (Lane et 
al., 2011). Consequently, the use of blind ratings in a standardised environment is important 
for consistent results. 
 
The various behavioural components of dyskinesia are thought to arise through the stimulation 
of different anatomical parts of the denervated striatum. Whilst the administration of 
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amphetamine into the ventrolateral area specifically induces orofacial stereotypies (Kelley et 
al., 1988) forelimb, hindlimb and axial positional movements are more closely related to 
highly innervated dorsolateral areas (Brown and Sharp, 1995).  
 
Although the 6-OHDA lesioned rodent has been invaluable to discovering mechanisms of L-
DOPA action and to test new pharmacological co-treatment strategies, it does not completely 
model the full range of side effects observed following chronic treatment in man. There is 
disparity in the manifestation, pretreatment with agonists, presence of non-dyskinetics and 
time course of dyskinesia between humans and animal models. For example, it is usual for 
dyskinetic symptoms to manifest 5-10 years following L-DOPA therapy as the result of 
aberrant plasticity (Encarnacion and Hauser, 2008), while in the 6-OHDA lesioned rat AIMs 
are triggered several days after the initiation of L-DOPA, as lesions are near to complete. In 
the case for advanced degeneration in humans and subsequent L-DOPA treatment LID may 
too develop quickly (Langston and Palfreman, 1995, Sacks, 1973). Further, there may be 
species differences in the manifestation and severity of LID and, although similar, AIMs with 
different characteristics have been induced in the 6-OHDA lesioned mouse model previously 
(Lundblad et al., 2004b, Lundblad et al., 2005). A large scale comparison between all three 
lesion groups with correlations to histological measures has yet to be undertaken.  
 
1.7.2. GID in Rodents 
Embryonic VM grafts transplanted into the denervated striatum of rodents following unilateral 
6-OHDA lesions standard models used to assess cell replacement in PD, and have been 
extensively optimised (Abrous et al., 1993, Arbuthnott et al., 1985, Bjorklund et al., 1981, 
Dunnett et al., 1983b, Dunnett et al., 1983a, Dunnett et al., 1988a, Dunnett et al., 1988b). 
Significant numbers of surviving primary dopaminergic cells in the lesioned striatum will 
cause a reduction of ipsilateral rotation to amphetamine, or an over compensation toward the 
contralateral direction (Bjorklund et al., 1980, Dunnett et al., 1988a). Psychostimulant-induced 
rotation has also been noted in mice (Thompson et al., 2009, Veng et al., 2002, Zhou et al., 
1993, Shimizu et al., 1990, Brundin et al., 1989, Shimizu et al., 1988). Turning to 
amphetamine is usually a biphasic response with an initial high level of circling behaviour 
from the rapid release of dopamine from the graft, before a slower bell-shaped response (Fig 
1.4), until a complete cession of turning 6 hours post injection (Torres and Dunnett, 2007). A 
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proportion of the cohort will also develop AIMs in response to amphetamine, this group is 
now used to model GID (Carlsson et al., 2006b, Lane et al., 2006b).  
 
 
 
Fig. 1.4. Predicted time courses of amphetamine-induced rotation and AIMs in lesion only rats 
and those with additional dopaminergic transplants (Lane and Smith, 2010). 
 
 
Spontaneous dyskinesia in transplanted 6-OHDA lesioned rats have been reported in two 
studies, although AIMs are transient in expression, sporadic and mild in severity (Vinuela et 
al., 2008, Lane et al., 2006b), therefore lacking the ability to be used as a GID model. Further, 
no spontaneous AIMs were seen without pharmacological stimulation when animals were 
subject to mild stress (Carlsson et al., 2006a). In the absence of a model in which GID is 
spontaneous, the reproducibility of amphetamine driven AIMs in the transplanted rat has 
enabled mechanistic insights into GID development, discussed in section 1.9. 
 
The methodology of model production and the scoring of subsequent AIMs have now been 
standardised. Prior to transplantation, 6-OHDA lesioned rodents are primed with L-DOPA for 
4 weeks to elicit LID as described by Winkler et al., (2002), thus causing long term changes in 
the denervated striatum; an important step in model development (Cenci and Konradi, 2010, 
Cenci et al., 2009, Picconi et al., 2003, Winkler et al., 2002b, Lane et al., 2006b). There is a 
greater tendency for amphetamine mediated AIMs in animals primed (by long-term L-DOPA 
treatment) for LID, although a proportion of the primed experimental cohort will still not 
develop dyskinesia; these animals are termed ‘non-dyskinetic’ (Lane et al., 2009a). AIMs in 
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grafted rodents vary in appearance yet on the whole look phenotypically similar to LID and 
are scored on the same rating scale as LID first devised by (Cenci and Lundblad, 2007, 
Winkler et al., 2002b). Typically LID is reduced by a graft (Garcia et al., 2011, Lee et al., 
2000) and when L-DOPA is applied post-transplantation development of AIMs is restricted 
(Steece-Collier et al., 2009). It has also been reported that novel stereotypic behaviours can 
develop in L-DOPA treated animals following transplantation (Steece-Collier et al., 2003).  
 
1.8. Mechanisms of LID 
1.8.1. Circuitry and receptor Changes 
A number of factors have been considered to effect the emergence and severity of LID in 
humans and animal models of PD; these predominantly include altered dopamine and 
glutamatergic inputs, dysregulation of dopamine release by the 5-HT system, vascular 
changes, neurogenesis and phenotypic shift of existing cells in the basal ganglia (Bishop et al., 
2009, Darmopil et al., 2008, Dawson et al., 1991, Faucheux et al., 1999, Gil et al., 2010, Paille 
et al., 2004, Tande et al., 2006, Westin et al., 2006). Changes in direct and indirect pathway 
signalling are thought to be in part due to changes in G-protein coupled receptor (GPCR) 
levels that have been looked at in PD patients and hence extensively studied in the 6-OHDA 
lesioned rodent model. 
 
Initially changes were identified at the receptor level, for example D1 receptor levels were 
found to be elevated in the brains of PD patients regardless of L-DOPA treatment, whereas D2 
receptor increases were only seen in patients receiving no treatment (Seeman et al., 1987). 
These findings prompted much experimental work. 6-OHDA alone (in the absence of L-
DOPA) caused a 37% and 35% increase in D1 binding within the striatum and SN 
respectively, in comparison to the intact side and a 54% increase of D2 binding in the striatum 
(Dawson et al., 1991). Changes of this nature were found within dorsomedial, dorsolateral, 
ventromedial and ventrolateral quadrants of the striatum (Gagnon et al., 1991). Similar lesion 
induced D2 receptor changes have also been reported (Blunt et al., 1992, Savasta et al., 1992). 
In contrast, no increases in the expression of D1 receptors were apparent in the lesioned brain 
compared to control animals (Savasta et al., 1992). Further analysis has shown that the density 
of D1 receptors is reduced in the dorsolateral and ventrolateral medial striatum (Blunt et al., 
1992). There have also been mixed reports on the change in receptor levels in response to L-
DOPA treatment. It has been shown that no further changes in receptor levels were found with 
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L-DOPA treatment (Blunt et al., 1992). However, increases in D1 and D2 have been reported 
in another experiment for both chronic and acute treatment regimes (Rioux et al., 1993). 
Although receptor levels are disputed in the L-DOPA treated 6-OHDA lesioned brain, it is 
clear that receptors become supersensitive to the pulsatile delivery of dopamine agonists, and 
complex signalling cascade dysfunction arises (Section 1.8.2). Thus, an imbalance of the D1 
and D2 mediated signalling of the direct and indirect pathway respectively is thought to be a 
major driver of dyskinesia.  
 
Rodent studies have demonstrated that partial nigrostriatal dopamine depletion reduces the 
ability of corticostriatal neurons to undergo LTP, through changes in NMDA receptor subunit 
composition and acute L-DOPA treatment is able to rescue this dysregulation (Paille et al., 
2010). Chronic administration nevertheless is sufficient to cause LID and this occurrence is 
associated with impaired synaptic depotentiation, a phenomenon which reduces the plasticity 
promoting mechanism LTP (Picconi et al., 2003, Picconi et al., 2008). Fast glutamate 
transmission in the striatum from cortical inputs is mediated by metabotropic glutamate 
receptors and antagonism of the mGlu5 receptor subtype reduces LID (Yamamoto and 
Soghomonian, 2009, Mela et al., 2007). There is also an apparent change in the ratio NR2A 
and NR2B NMDA subunit expression (by increase of the NR2B) on the post synaptic neurons 
of the striatum with L-DOPA treatment (Ouattara et al., 2009). Where this pattern of 
expression was disrupted, by altering membrane associated guanylate kinase protein levels, 
AIMs could be induced in non-dyskinetic rodents (Gardoni et al., 2006). In addition, AMPA 
receptors are thought to change in response to L-DOPA treatment (Calon et al., 2002, Ouattara 
et al., 2010), yet other studies have found no such change (Silverdale et al., 2002). The 
antagonism of AMPA receptors can also reduce the severity of AIMs in an L-DOPA treated 
models of PD (Konitsiotis et al., 2000). 
 
It has been proposed that negative correlation exists between 5-HT and DA levels within the 
denvervated striatum. Animals with LID have significantly higher 5-HT innervations in the 
ipsilateral striatum than non-dyskinetic groups (Gil et al., 2010). The sensitised contralateral 
rotational response to L-DOPA can be desensitised by intrastriatal infusion, only occurring 
where there was destruction of 5-HT projections within the striatum, indicating the importance 
of 5-HT in the rotational response to L-DOPA (Kaariainen et al., 2009). A substantial 
reduction of LID can also be caused by 5-HT1A and 5-HT1B agonist drugs (Munoz et al. 2008) 
and microinfusions of 8-OH-DPAT directly into the intact dorsal raphé can attenuate the 
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expression of LID (Bishop et al., 2009, Jaunarajs et al., 2009, Tomiyama et al., 2005, Dupre et 
al., 2008, Munoz et al., 2008a, Eskow et al., 2009). In addition, dopamine depletion may also 
cause serotonergic sprouting (Zhou et al., 1991b). Although other neurotransmitter systems are 
unlikely to have a causal role in LID, they may have a secondary effect in controlling 
dyskinesia expression. Pharmacological evidence has shown that if L-DOPA is given in 
combination with µ and δ receptors/ α2-adrenergic receptor/ CB1 receptor antagonist 
treatments then a reduction of abnormal movement occurs (Morgese et al., 2009, Dekundy et 
al., 2007, Lundblad et al., 2002), as discussed in section 1.3.2. This indirect modulation is 
likely as many of these receptors co-localise with dopamine, 5-HT and glutamatergic receptors 
on the same neuron and they therefore share common intracellular signalling pathways, 
partially negating the pathological molecular changes causing dyskinesia. It has also been 
found that receptors may not just be co-localised but form physical hetro-oligomer, 
influencing signalling further (Juhasz et al., 2008). 
 
Post-mortem examination of PD patients that have previously received L-DOPA revealed 
notable micro-vascular remodelling, proposed to be caused by the synthesis of new endothelial 
cells, corresponding to the observed increase expression of endothelial growth factors 
(Faucheux et al., 1999, Yasuda et al., 2007). Newly formed neurons could be co-labelled with 
the proliferation marker BrdU, and markers of mature neurons, glia and endothelia could be 
found in striatum, GP, entopeduncular nucleus and SNr of L-DOPA treated rats (Westin et al., 
2006). Proliferation to a lesser degree can also be found in the SNr of saline treated rats. The 
majority of newly formed cells reside within microvasculature and this is associated with an 
increase in vessel length. Further, dyskinetic rats have an increased albumin leakage, a sign of 
hyper-permeability, an integral component of angiogenesis, found within all areas of the basal 
ganglia (Westin et al., 2006). This suggests that long-term L-DOPA treatment causes vascular 
remodelling which is detrimental to beneficial effects of L-DOPA and newly proliferating 
endothelial cells are positively correlated with dyskinesia.  
 
There is now growing interest in the emergence of TH positive cells first identified in the 
striatum of MPTP-treated primates (Jollivet et al., 2004). BrdU studies have shown that these 
are not formed by neurogenesis but rather represent cells already present in the striatum that 
have changed phenotype (Darmopil et al., 2008). Unilateral 6-OHDA lesioned mice also show 
this phenotypic shift of GABAergic striatal neurons towards a dopaminergic phenotype 
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(Francardo et al., 2011,(Darmopil et al., 2008, Mazloom and Smith, 2006, Tande et al., 2006), 
but it remains unclear how this occurrence may relate to dopamine depletion in different areas 
of the nigrostriatal tract or the effect of L-DOPA treatment.  These cells have a number of 
characteristics, namely, they are large, generally aspiny, stain positive for glutamic acid 
decarboxylase (GAD) and GABA without co-expression of calbindin, neuropeptide Y or 
parvalbimin, and they are thought to be GABAergic interneurons (Tande et al., 2006). TH 
positive cells can be colocalised with enkephalin and dynorphin and therefore there may be a 
subgroup of MSNs that have begin to express TH (Darmopil et al., 2008). 
 
1.8.2. Regulators of G-protein Signalling (RGS) Dysfunction 
G-protein coupled receptors (GPCRs) are localised to the plasma membrane of all neuronal 
cells and control synaptic and chemical detection, altering transduction with the basal ganglia 
(Schoneberg et al., 2007). GPCRs including dopamine receptors can be visualised by X-ray 
crystallography and have been found to have 6-7 trans-membrane domains that are structurally 
and functionally conserved between species (Palczewski et al., 2000). The α subunit of the G-
protein initiates signal transduction from stimulation of the GPCR via its dissociation from β 
and γ subunits (Gether et al., 2002). Conformational changes of the α subunit from an active to 
an inactive form is rate limited by the hydrolysis of GTP to GDP (Milligan et al., 1990). There 
are two large families of GTP binding proteins; large G-proteins namely the Gi, Go and Gq 
subtypes and small G-proteins such as rap, ras, rho and rab. G-proteins have a variety of 
functions in the mammalian brain modulating all GPCRs and Ca
2+
 ion channels and 
consequently activating protein kinase C (PKC) or adenyl cyclase- protein kinase A (PKA) 
pathways (Dolphin, 1990, Palczewski et al., 2000), ultimately leading to the activation of ERK 
and transcriptional dysregulation (Section 1.8.3). 
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Fig. 1.5. The G-protein coupled receptor transduction following the stimulation of dopamine 
receptors of the D1 and D2 type. Dopamine receptors are differently modulated by regulators 
of G-proteins. 
 
 
RGS proteins are powerful negative modulators of GPCRs that accelerate the inactivation of 
the alpha subunits. There are subtypes of RGS that are specific to GPCR, cell type and or 
location in the brain, shown in Fig 1.5, these regulators are transcribed from separate genes 
and are not produced by alternate splicing. RGS levels are differentially activated following 
dopamine denervation by 6-OHDA in the striatum, part of the post-synaptic compensatory 
mechanism for the reduction in dopamine levels. RGS2, RGS5 and RGS8 transcripts increase 
and RGS9-2 and RGS4 decrease following a lesion, in comparison to the intact control side 
(Geurts et al., 2003). In contrast, mRNA levels of RGS3, RGS6, RGS7, RGS11 and RGS12 
were unchanged. Following prolonged reserpine treatment mRNA levels of RGS2, RGS4, 
RGS5, RGS8, RGS9 and RGS10 were found to be significantly decreased. Conversely, 
Taymans et al. (2002) did not detect such a change in RGS2.  
 
There have been many studies which implicate the involvement of RGS dysregulation with 
movement abnormalities. RGS4 is highly abundant and expressed ubiquitously throughout the 
cortex, striatum and hippocampus. A significant change in movement induced by opioids was 
produced in RGS4 knockout mice (Grillet et al., 2005). RGS4 polymorphisms are also 
implicated in the development of Schizophrenia and RGS9-2 in dyskinesia associated with 
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anti-psychotic treatment (Guo et al., 2006, Seeman et al., 2007, Liou et al., 2009) and LID 
(Gold et al., 2007). RGS9-2 is specific to the striatum and when this gene is knocked out in 
vivo motor coordination defects and changes in working/episodic memory manifest (Kovoor et 
al., 2005, Blundell et al., 2008). Viral-mediated overexpression of RGS9 may cause D1 and D2 
signalling to function in equilibrium; thereby reducing LID (Gold et al., 2007).  
  
Selective dopamine antagonists and agonists such as L-DOPA cause an unusual pattern of 
RGS transcription which is currently disputed between groups. RGS2 up regulation is seen 20 
minutes after an L-DOPA injection of 50mg/kg in 6-OHDA lesioned rats, with no change 
observed in RGS2, RGS4, RGS8 or RGS9-2 transcripts (Geurts et al., 2002). In agreement, 
microarray work has highlighted that acute L-DOPA (single injection: 50mg/kg) is able to 
increase RGS2 two hours post injection (El Atifi-Borel et al., 2009). Interestingly, no change 
in RGS was seen in when rats were treated daily for a number of weeks. Unfortunately the 
development of AIMs in response to L-DOPA was not characterised in this study and 
therefore correlations between LID and RGS could not be made. Conversely, another group 
has shown that a single injection of L-DOPA is able to increase RGS2, RGS4 RGS9-2 
transcripts in the striatum of 6-OHDA lesioned rats (Ko et al., 2008, unpublished poster, PD 
U.K. York, Nov 3-4). It still remains to be found whether RGS transcript expression can be 
correlated to the severity of AIMs or whether the apparent upregulation differs depending on 
acute and chronic L-DOPA treatment, in either the ‘off’ or ‘on’ states with more standard 
doses of L-DOPA. 
 
Therefore clarity into these basic transcription patterns is much needed in animal models to 
better understand LID. Clues into RGS mediated expression have been found, however, using 
selective antagonism of dopamine receptors, in intact rats (Taymans et al., 2004), see Table 
1.5. Dopamine receptor agonists and antagonists dramatically changed the expression of RGS2 
and RGS4 yet failed to alter the expression of RGS8, RGS9 and RGS10 (Taymans et al., 2003). 
mRNA expression was measured by autoradiographic in situ-hybridisation, and perhaps other 
methods such as qPCR might increase the sensitivity to be able to detect subtle differences. 
From investigations carried out by Taymans et al. (2004) it can be suggested that L-DOPA 
will also alter the expression of RGS2 and RGS4 to a greater extent than other RGS transcripts. 
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Dopamine 
receptor 
modulating drug 
Action RGS transcript Expression Response time 
(hours)  
SKF82958 D1 agonist 2 ↑↑ transient 0.5 
SKF82958 D1 agonist 4 nd
1
 nd
1
 
Haloperidol D2 antagonist 2 ↑↑ transient 0.5 
Haloperidol D2 antagonist 4 ↓↓ transient 8 
Quinpirole D2 agonist 2 ↓↓ transient 1-2 
Quinpirole D2 agonist 4 ↑↑ transient 2-4 
SCH23390 D1 antagonist 2 ↓↓ transient 1-2 
SCH23390 D1 antagonist 4 ↑↑ transient 2-4 
1
Not determined (nd) 
Table 1.5. Specific dopamine receptor modulation by agonists and antagonists differently 
modulate the expression of RGS2 and RGS4. Table was created by observations discussed and 
quantified from (Taymans et al., 2004).  
 
 
 
1.8.3. Intracellular Signalling 
L-DOPA is associated with large scale neuroplastic changes, including changes in receptor 
levels, signalling throughout the basal ganglia and the proliferation of new cells. However, it 
is also essential to study the intracellular signalling changes to fully understand the origins of 
dyskinesia associated with L-DOPA.  
 
The stimulation of the D1 receptor induces a transcriptional upregulation of PDyn, while the 
stimulation of the D2 receptor can block PPE transcription. In accordance, decreased 
expression of PDyn and an increase in PPE levels is a hallmark of PD (Sivam et al., 1986b, 
Sivam et al., 1986a, Young et al., 1986, Cenci et al., 1993), although L-DOPA cannot reverse 
the changes evoked in these biological markers. Instead L-DOPA induces a number of 
transcriptional changes via the mitogen-activated protein kinase (MAPK) signalling cascade 
(Pavon et al., 2006a, Santini et al., 2007, Wang et al., 1997). Stimulation of dopamine 
receptors causes the phosphorylation and subsequent activation of extracellular-signal-
regulated kinases 1/2 (ERK), 20 minutes after L-DOPA injection, causing transcription by 
translocation of the protein into the nucleus (Wang et al., 1997, Impey et al., 1999, Pavon et 
al., 2006a). It should be noted however that the supersensitisation of dopamine receptors is a 
requirement of ERK dysregulation and is tightly controlled by a number of interacting proteins 
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downstream of the receptor itself. ERK activation causes short term transcriptional changes 
and long term changes in plasticity. 
 
ERK activation causes the intra-nuclear phosphorylation of cAMP response element-binding 
(CREB) that acts on CRE and AP-1 promoter elements on a vast array of genes acting both 
immediately and over many weeks and months. High-throughput microarray screens suggest 
that these genes are involved in intracellular signalling, phosphorylation, secretion, translation, 
transcription, exocytosis and synaptic transmission (El Atifi-Borel et al., 2009). Chronic L-
DOPA treatment is associated with a transcriptional and translational increase in PDyn within 
the striatum mediated by an upregulation of the FosB/∆FosB transcription factor (Cao et al., 
2010, Lane et al., 2009b, Pavon et al., 2006b, Westin et al., 2001, Rodriguez et al., 2001, 
Doucet et al., 1996, Konradi et al., 2004). This expression of FosB/∆FosB is highly selective 
to areas without dopaminergic fibre innervation and is often most prounouced in the lateral 
striatum of 6-OHDA lesion models (Andersson et al., 1999, Andersson et al., 2003). 
FosB/∆FosB mediated transcription acts immediately and plays a causative role in dyskinesia, 
supported by the demonstration that viral mediated over expression of this gene induce AIMs 
in animal models (Cao et al., 2010, Andersson et al., 1999). Other immediate early genes 
(IEGs) are differently regulated by L-DOPA. JunD does not increase in response to chronic 
treatment (Valastro et al., 2007), Zif -268 expression increases only in striatonigral neurons 
and c-fos increases in the STN (Cao et al., 2010, Andersson et al., 1999, Valastro et al., 2007, 
Carta et al., 2008b).  
 
In general ERK signalling is involved in several forms of synaptic plasticity (Thomas and 
Huganir, 2004). Many studies have so far focused on the role of ERK for memory 
consolidation in the hippocampus, although it is thought that ERK has a similar function 
within the basal ganglia. Plasticity in the form of LTP can be caused by the high frequency 
stimulation of post synaptic neurons by activation of glutamate receptors (Thomas and 
Huganir, 2004). Plasticity by ERK causes an increased activation and expression of AMPA 
receptors, leading to both structural and signalling changes (Patterson et al., 2010, Toyoda et 
al., 2009). It is also understood that ERK signalling can control long term depression (LTD), 
which is a neuro-plastic change caused by pre-synaptic low frequency stimulation acting on 
post synaptic NMDA and mGlu receptors (Thomas and Huganir, 2004). Evidence for the 
emergence of striatonigral plasticity has been found by the transcriptional induction of 
activity-regulated cytoskeleton-associated protein (ARC), an associated cytoskeleton protein 
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used for structural changes (Sgambato-Faure et al., 2005). Subsequently, gene screens have 
confirmed such changes and up-regulated genes involved in growth, synaptogenesis, 
neurogenesis and cell proliferation result from long term L-DOPA treatment (El Atifi-Borel et 
al., 2009, Konradi et al., 2004).  
 
1.9. Mechanisms of GID 
 
1.9.1. Causes of GID 
GID does not have a single well-defined cause, and it is currently thought that this 
phenomenon may arise from an interaction of several factors. The first hypothesis put forward 
following the original report of GID by Freed et al (2001a) was that GID was caused by 
excessive dopamine from the transplant. Subsequently however, 
18
F-DOPA PET analysis on 
GID patients found that striatal dopamine was not excessive, but rather that dopamine was 
unevenly distributed with ‘hotspots’ in parts of the striatum, interspersed by widespread areas 
of denervation (Ma et al., 2002). Conversely, other clinical trial groups failed to find evidence 
of dopamine hotspots within the striatum of grafted patients (Hagell et al., 2002, Olanow et al., 
2009a, Piccini et al., 2005). It has also been noticed that dyskinesia in some cases resembles 
‘end-of-dose’ LID which occurs during sub-optimal levels of dopamine stimulation, indicating 
partial reinnervation of the striatum may be responsible for GID (Olanow et al., 2003). The 
experimental models of GID (described in section 1.7.2.) show there has been no correlation 
found between the number of transplanted cells or the size of the graft and the expression of 
amphetamine-induced AIMs (Lane et al., 2009b, Lane et al., 2006b). The location of the graft 
within the denervated striatum may also play a role in the development of amphetamine-
induced AIMs; more caudally placed grafts show the greatest risk, yet have the most 
functional efficacy (Carlsson et al., 2006b). LID triggered in grafted rodent models is much 
reduced where a more even pattern of innervation is seen (Steece-Collier et al., 2003). 
Nevertheless, rare cases of spontaneous experimental GID have sporadically been reported, 
but only with highly focal grafts (Maries et al., 2006).  
 
There have been a number of indicators to suggest that graft rejection may trigger AIMs 
(Soderstrom et al., 2008). The provision of immunosuppression was quite different in each of 
the 3 clinical trials reporting GID. In the Lund transplantation study, an immunosuppressive 
regime was applied for at least 2 years post surgery (Hagell et al., 1999), the withdrawal of 
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which coincided with the development of GID or worsening in some patients (Hagell et al., 
2002). In the Tampa-Mt Sinai clinical trial there was also an association between peak 
development of GID at 6-12 months post-transplantation and the end of the 6 month 
immunosuppression period (Olanow et al., 2003, Olanow et al., 2009a). It is not clear whether 
this is coincidental, since in the grafted hemi-parkinsonian rat model the inflammation 
response caused by the introduction of interleukin-2 does not change the severity of AIMs 
(Lane et al., 2008). In agreement the incidence of GID was reported in the Denver-Colombia 
trial, where no immune suppression was used (Freed et al., 2001). Immunological aspects of 
transplantation therefore warrant further investigation. 
 
The aberrant release of L-DOPA-derived dopamine from 5-HT terminals in the striatum is 
thought to be a major contributing factor to LID (Bishop et al., 2009, Dupre et al., 2008, 
Eskow et al., 2009, Gil et al., 2010). However, the contribution of this system to GID is poorly 
understood. The dissection of the VM from the developing embryo often contains a proportion 
of developing 5-HT neurons that are consequently transplanted, with the amount dependent on 
dissection technique. In the absence of dopaminergic neurons, transplants of 5-HT cells 
increase unregulated dopamine release, exacerbating LID experimentally (Carlsson et al., 
2008). Furthermore, the proportion of dopamine to 5-HT neurons may be critical to achieve an 
optimal functional benefit of the graft and to reduce LID, but may not have a causal role in 
GID (Carlsson et al., 2008, Garcia et al., 2011). Generally, amphetamine-induced AIMs in 
rodent models may not be greatly influenced by the quantity of 5-HT neurons in the transplant 
or host 5-HT innervations (Carlsson et al., 2009, Carlsson et al., 2007, Garcia et al., 2011, 
Lane et al., 2009a). The contribution of 5-HT neurons may contribute to some cases to GID. In 
two select patients in vivo imaging techniques have shown excessive 5-HT innervation in the 
denervated striatum and when treated with 5-HT receptor agonists off medication dyskinesias 
were much reduced (Politis et al., 2010, Politis et al., 2011b).  
 
Other factors including the stage of disease progression, neuronal loss and the severity of LID 
prior to transplantation may contribute to GID. In patients with preoperative dopamine loss 
restricted to the putamen there was a trend towards improved outcome, including lower ‘off 
medication’ abnormal movements (Piccini et al., 2005). This is backed by evidence that rodent 
models show a clear relationship between levels of LID pre-transplant and the development of 
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amphetamine-induced AIMs at the post-graft stage (Lane et al., 2006a). Specifically, L-DOPA 
priming causes an increase in GID severity in grafted rodents (Lane et al., 2009b).  
 
As no single factor has been highlighted as the most likely cause of GID, it appears most 
likely that AIMs arise from several factors working synergistically. It is hoped that GID will 
be reduced in future clinical trials by the optimisation of the surgical procedure, precise 
dissection techniques and the appropriate appointment of PD patients. 
 
1.9.2. Circuitry and receptor changes 
Although there are multiple factors that may contribute to GID development, there is still a 
limited understanding of the precise system and intercellular mechanisms that underlie the 
expression of these abnormal movements. Also, there has not yet been any post mortem 
receptor analysis of the brains from GID sufferers. Indeed, the only experimental model 
available, by which the mechanisms of this side effect can by studied, is the amphetamine-
induced, L-DOPA primed and grafted rodent. To date, studies have broadly shown that 
transplantation normalises both lesion and L-DOPA-induced D1 and D2 receptor expression 
within the reinnervated areas of the striatum (Blunt et al., 1992, Dawson et al., 1991, Gagnon 
et al., 1991, Lu et al., 1991, Rioux et al., 1993, Rioux et al., 1991, Savasta et al., 1992), 
although changes vary significantly between studies and there has not yet been a correlation of 
receptors and AIMs. 
 
Electrophysiological changes leading to GID development have not yet been elucidated, yet 
evidence has been provided by transplanted patients that have subsequently undergone DBS. 
Two individuals from the Lund clinical trial received DBS treatment directed at either the GPi 
or STN, yet only GPi-DBS was successful at reducing off medication dyskinesia (Herzog et 
al., 2008), suggesting direct pathway involvement in GID. However, evidence from other 
trials suggests that the pathway is more complex. A small group of patients from the Denver-
Colombia study received DBS directed at the GPi with apparent success (Freed, 2004, Ma et 
al., 2002), although only transient benefits were seen when the same area was targeted in the 
Tampa-Mt Sinai study (Cho et al., 2005). DBS to the STN was also found to be beneficial in a 
further 3 cases of GID from the latter study (Cho et al., 2005). From these case studies 
conclusions cannot be drawn as to the precise changes in basal ganglia function that 
contributes to GID. Again, both better models and a rational theoretical framework are 
required before appropriate treatment measures can be instigated with any confidence. 
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1.9.3. Transcriptional Changes 
The post-receptor signalling changes in grafted rodents or humans that lead to GID remain 
poorly understood. A number of key studies show that IEG and regular striatal gene 
expression levels are altered by the dopamine released from newly transplanted cells, but these 
have not yet been related to AIMs. c-fos expression within an intact animal is increased by 
cocaine and amphetamine, and this phenomenon is blocked by a dopamine depleting lesion, 
but restored following grafting (Rodriguez et al., 1999). Furthermore, grafting alone can 
decrease basal FosB/∆FosB and PPE protein levels to pre-lesion levels (Maries et al., 2006, 
Vinuela et al., 2008, Carlsson et al., 2009). Transcript levels of PPE, D2 and the GABA 
synthesising enzyme glutamic acid decarboxylase 67 (GAD 67) were also normalised by a VM 
derived graft, although the lesion-induced down regulation of mRNAs coding for neuropeptide 
precursor preprotachykinin was unchanged (Winkler et al., 2003). In grafted rats the L-DOPA 
mediated increase in FosB/∆FosB is inhibited in the lateral striatal area, but the transplant does 
not negate the L-DOPA mediated increase in c-fos (Lane et al., 2009b). Overall however there 
was no association with abnormal movements and IEG expression in grafted rat model of GID 
and since FosB/∆FosB is known to play a causative role in LID, an alternate mechanism for 
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1.10. Aims of this Thesis 
L-DOPA treatment and neural transplantation are viable methods for treating the motor 
symptoms of PD, although both the current pharmacological and potential transplantation 
approaches carry the risk of dyskinesia induction. These debilitating side effects are a 
significant problem in the current pharmacological treatment of PD, and this has jeopardised 
the futures of both primary embryonic and stem cell transplantation as therapeutic strategies. 
An understanding of the mechanisms of LID and GID are essential to either prevent or 
ameliorate these AIMs. The first process in gaining meaningful information is the optimisation 
and study in animal models of both conditions, starting with a well characterised model of PD. 
 
This thesis has three main goals: 
Firstly as the 6-OHDA lesioned mouse model of PD is poorly understood, inconsistently used, 
and weakly characterised in terms of motor deficits, LID expression and response to 
transplantation, I aimed to optimise all these aspects. Secondly, as the rat model of GID has 
previously been well established, this was utilised to explore the pharmacological 
responsiveness and potential underlying mechanisms of GID. Thirdly, further mechanistic 
insights into GID and LID were investigated by the measurements of RGS transcripts and 
proteins, with the aim of finding a new biological marker or ‘biomarker’ of dyskinesia.  
 
Thus, the overall aims of the thesis were:  
1) To characterise the 6-OHDA lesion mouse model of PD in terms of behavioural 
deficits and response to L-DOPA (Chapters 3 and 4). 
2) To map the expression of RGS in response to L-DOPA challenge and the development 
of dyskinesia in mice (Chapter 5). 
3) To establish the mechanisms of GID using pharmacological co-treatments in rats, with 
the aim of reducing it (Chapter 6). 
4) To examine RGS and dopamine receptor expression in response to transplantation and 
GID in the rat (Chapter 7). 
5) To characterise a mouse model of GID (Chapter 8). 
6) To discuss the future of L-DOPA and transplantation treatment strategies (Chapter 9). 
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2. Methods  
2.1 Animal Husbandry and Legislation 
Adult male C57/Bl6 and CD1 mice and were housed 1-6 per cage and female Sprague-Dawley 
(SD) rats were house 1-4 per cage. Environmental conditions in holding rooms were 
monitored daily, in compliance with Home Office rules and regulations. Home cage 
dimensions are: L45cm, W28cm, D13cm (mouse) L54cm, W37cm, D21cm (rat). Standard 
living conditions were maintained at a 12 hour light /12 hour dark cycle, with hygienic animal 
bedding (Lignocel), nutritionally balanced maintenance diet of 14% protein (Harlan), water 
and environmental enrichment by cardboard tubing, present in the cage. All experiments were 
undertaken under a project 30/2498 and personal licence 30/8321 issued on behalf of the 
Secretary of State as part of the 1986 Animal Scientific Procedures Act (ASPA),. 
 
2.2 Surgery Techniques 
2.2.1 General Surgery considerations 
Anaesthesia was induced with isoflurane carried by O2 at a concentration of 5% (rat) and 4% 
(mouse) and placed in stereotaxic frame (KOPF). Anaesthetic maintenance was achieved with 
isoflurane at 2-3% (rat) and 3-0.5% (mouse) in constant NO2 and O2 at a ratio of 2:1. Co-
ordinates were measured from bregma so that a hole could be drilled through the cranium 
using a stereotaxic drill (Foredom), at the desired location. A 30-gauge cannula was then 
positioned above the opening on an additional stereotaxic arm. 6-OHDA hydrobromide 
(Sigma) was calculated as the free base weight and dissolved in a solution of 0.2 mg/ml 
ascorbic acid in 0.9% sterile saline (Animal Care Limited). The neurotoxin was mechanically 
infused into the site at rate of 1µl/min using a 10µl Hamilton syringe driven by a compact 
infusion pump (975, Harvard), set at 1µl/min. The cannula was left in place for three minutes 
after which it was slowly removed and animals sutured with Vicryl (Ethicon). An aseptic 
technique was used throughout and animals were monitored continuously for appropriate 
respiration. Animals were left to recovery in a 30
o
C incubator until they were able to right 
themselves. Analgesic medication was given s.c at the time of surgery (Metacam) and post 
operative care carried out for 5 days. Mice received additional post-operative care for 2 weeks, 
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this included: mashed food, glucose saline (4 % glucose, 0.18 % saline, Animal Care Limited) 
s.c injections and health/ weight checks. 
 
2.2.2 6-OHDA Lesions in Rats 
A single 3µl injection of 6 µg/µl (freebase concentration) of 6-OHDA hydrobromide (Sigma) 
was used to lesion all rats using the procedure detailed in Section 2.2.1. In rats stereotaxic co-
ordinates were used to target the MFB relative to bregma and the dura surface (mm): AP= -
3.9, ML= -0.9, DV= -6.9, nose-bar = -4.5; these were optimised for an increased lesion 
success rate by (Torres et al., 2011).  
 
2.2.3 6-OHDA lesions in mice 
The same equipment was used in mice and rats, with the exchange of ergonomically designed 
ear bars and mouth-piece for the mouse. Unilateral lesions were carried out by single or 
double injections of 6 µg/µl (freebase concentration) of 6-OHDA hydrobromide (Sigma) into 
the right MFB (1 µl) striatum (2x1.5 µl) or SN (1.5 µl) using the same delivery system as with 
the rat. The stereotaxic co-ordinates for mice were determined using the mouse brain atlas of 
(Paxinos, 2001) and expressed in mm relative to bregma. The efficiency of coordinates varies 
depending on strain, age, weight and sex as these factors denote brain size. MFB co-ordinates 
used for the C57/ Bl6 strain were optimised using the standard surgery procedure using 
cannulae loaded with trypan blue. 1µl of the dye was injected into the MFB, using a number of 
co-ordinates, to stain the end point of the cannula entry (Successful entry points are indicated 
in Fig. 2.1). Although all the co-ordinates chosen were able to hit the MFB, co-ordinate 3 was 
able to hit a more caudal location where the region was its largest point and was subsequently 
chosen for experiments in this thesis. The SN and striatal co-ordinates were already optimised 
by the Lund University group (Lundblad et al., 2004b) and used respectively for this strain 
(mm) Str: (i) AP = +1.0, L = −2.1, DV = −2.9; (ii) AP = +0.3, L = −2.3, DV = −2.9, MFB: 
Bregma AP = −1.2, L = −1.2, DV = −4.75 (co-ordinate 3) and SNc: AP= -3.0, ML= -1.2, 
DV=-4.5, with the nose bar set at 0 mm relative to the interaural line.  
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Figure 2.1. Optimisation of MFB lesion co-ordinates by the injection of 1µl of trypan blue. 
Co-ordinate 1: -AP: -0.7, ML: -1.2, DV: -4.75, co-ordinate 2: AP: -0.7, ML: -1, DV: -4.75 and 
co-ordinate 3: AP = −1.2, L = −1.2, DV = −4.75. 
 
2.2.4 Grafting of primary dopamine tissue in Rats 
Pregnant female SD rats were purchased from Charles River, where they were time mated to 
be carrying E13 aged embryos at the day of arrival, where E0 is considered the day after 
pairing overnight. Adult rats were killed at E14 by terminal anaesthesia using an intra-
peritoneal (i.p) injection of Euthatal (Park vet Group, U.K sodium pentobarbital, 50mg/ml, 
1ml/kg) and cervical dislocation so that the intact uterus containing the embryos could be 
harvested. Embryos were then carefully removed from the uterine horns into Hanks Balanced 
Saline Solution (HBSS, Invitrogen, U.K). Ventral VM was dissected and prepared by methods 
described in Neural Transplantation (Dunnett, 1992), seen in Fig. 2.2.  
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Fig. 2.2 Adapted from Dunnett and Björklund (1992). The spinal cord is severed and an initial 
cut is made to dissociate developing brain with the rest of the body. B) The skin is removed 
and the brain dissociated with the rest of the body. C) The VM is removed by three cuts; using 
iridectomy scissors. The first is a vertical cut toward the developing tectum, the second toward 
the dorsal thalamus and the third horizontally as an estimation of the VM area from the two 
vertical cuts. The meninges are then removed from dissociated VM and tissue pieces are 
pooled. 
 
 
After three washes in HBSS, the VM tissue pieces were trypsinised (400µl (10µg/ml; Lorne 
Laboratories, U.K) and incubated for ten minutes at 37
o
C. Tissue pieces were allowed to settle 
and as much Trypsin as possible removed (200µl), without disturbing the tissue. Any 
remaining trypsin was inhibited (Sigma, U.K) for 20 minutes at 37
o
C. 200µl of the supernatant 
was then removed and 200µl of DNase was added, before further 5 minute incubation at 37
o
C. 
The supernatant was removed and fresh DNase was used to create a cell suspension that 
contained single cells and cellular aggregates, at a volume of 1VM/ 2µl. 2µl of sample was 
taken and mixed with 8µl of trypan blue solution (0.4% Sigma, U.K), for the viability and an 
estimation of total cells in suspension, by means of a haemocytometer. 
 
2.2.5 Grafting of primary dopamine tissue in mice 
Time mated pregnant female, C57/ Bl6 and CD1 mice were ordered in from Harlan to be E13 
on the day of surgery. Lesioned mice were anaesthetised and restrained according standard 
surgery protocols (Section 2.2.2.). The dissection and cell suspension was carried out in 
accordance with the rat protocol (Dunnett, 1992), with the time in trypsin reduced to 5 minutes 
and the suspension adjusted to a concentration of 150,000 cells/µl. 1µl of the crude single cell 
suspension was injected into the lesioned striatum of mice with a Hamilton syringe at AP 
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+0.8mm: ML -1.7mm: DV-3.0mm relative to bregma, with the tooth bar set to 0mm relative to 
the interaural line. A further deposit of 1µl was placed at DV -2.8mm. Post-operative care and 
analgesia was provided for 5 days. Cell suspensions were kept at room temperature and mixed 
with a pipette before grafting into each animal.  
 
2.3 Behavioural Techniques 
2.3.1 General Behavioural Considerations 
Behavioural tasks that could not be scored in real time were recorded with a 24x optical zoom 
digital video recorder (NVGSIS, Panasonic) and digital video-cassettes (TDK DV digital 
standard – 60minutes). Video recording was required where stated in this chapter and footage 
was replayed in slow-play mode, to ensure adequate frame-by frame post hoc analysis (Gaspar 
et al.). The testing environment was kept constant with respect to temperature, humidity, 
background noise level and smell. When possible, bias was avoided and all behavioural testing 
was conducted in a manner in which the investigator was blind to the treatment group. 
Specifically, animals in different treatment groups were mixed in cages and the investigator 
has no knowledge of which animals belong to which groups before the tests were complete. In 
the case of the pharmachological testing of drugs, an investigator blind Latin square paradigm 
was adopted remove the bias that previous high or low dosing may cause. 
 
Precision sugar pellets of 20mg (Sandown Scientific) were used as a reward to motivate 
animals to perform the given task. Mice were required to be food restricted to 85% of their 
free feeding weight prior to the corridor and staircase tests. A sample of the sugar pellets was 
provided in the home cage to prevent neophobia during the test. Animals were also housed in 
small groups for the duration of feeding to prevent bulling that may result in unequal food 
consumption. 
 
2.3.2 Drug Induced Rotation in the Rat 
0.05mg/kg Apomorphine hydrochloride (Sigma) and 0.25-2.5mg/kg Methamphetamine 
(Sigma), given via the sub-cutaneous (s.c) and i.p routes respectively, were used to measure 
net rotational asymmetry in grafted rats. Doses were made based on free base weight and 
made in 0.9% saline (Animal care Limited, York). Rats were placed in computerised clear 
plastic rotometers (med Associates); dimensions: D: 35cm R:17.5cm. Software (Rotorat, Med 
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Associates) was adjusted to record rotations for 6 hours; parameters: full counts 360
o
, partial 
counts 90
o
, retrace 45
o
 and time 5 min time bins. A minimum 3 day interval was introduced 
between amphetamine challenges for all experiments. 
 
 
2.3.3 Spontaneous and Drug Induced Rotation in the Mouse 
Spontaneous (non-pharmacologically induced) rotation in a novel environment in mice was 
previously reported by observations in an open field environment (Cenci and Lundblad, 2007), 
where dopamine released by exploring new surroundings causes turning toward the ipsilateral 
direction. Each mouse was placed in standard lab beakers (H:14cm, D:11.5cm) and allowed to 
explore the novel environment for 10 minutes. The video recorder was set up above the 
beakers to record the number of full rotations in each direction. These recordings were then 
analyzed post hoc and full rotations counted using fast-forward video playback reporting net 
rotations over the period (# clockwise - # anticlockwise).  
 
Hemi-parkinsonian mice were also injected with 0.05mg/kg apomorphine (s.c.) or 2.5mg/kg 
methamphetamine (i.p.) dissolved into 0.9% saline (Animal care Limited, York) and placed 
back into the beaker to initiate a robust turning response in either the contralateral or 
ipsilateral direction respectively (See Figure 2.3). Both drugs were injected at a volume of 
2ml/kg. Apomorphine is dissolved with the addition of 0.2% ascorbate and kept on ice and 
before use. The video recorder was set up above the beakers to record peak rotation; over 20 
minutes, immediately following apomorphine injection or 20 minutes after methamphetamine 
injection. Drug induced rotation was only carried out after spontaneous rotation and a duration 
of 2 weeks separated amphetamine and apomorphine injections. 
 
2.3.4 Automated Locomotor Activity 
Animal activity was assessed using automated Med Associate hardware and MED-PC (IV) 
software over a 2 hour period. Fifteen animals were housed in individual plastic cages with 
three infrared beams crossing the base of each box; dimensions: L42cm; W26cm; D19cm. 
Animals were allowed to acclimatise to the cages 10 minutes before the start of the 
experiment. Beam breaks recorded from each crossing were totalled for each of the animals, to 
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2.3.5 Cylinder 
As described previously in the 6-OHDA lesioned rat (Schallert et al., 2000), forelimb 
asymmetry was assessed by noting the paw used for each of the first 20 weight bearing rears 
made on the side of a class cylinder measuring (H:14cm, D:11.5cm) in diameter (See Figure 
2.3). In mice 2 mirrors were placed directly behind the cylinder so that a 360
o
 view was seen 
by the observer. The session was videotaped and scored by detailed freeze frame analysis at a 
later date by an observer blind to the lesion status of the animals. Animals that failed to reach 
20 touches were removed from the cylinder after ten minutes. Simultaneous ipsilateral and 
contralateral forelimb touches were excluded from the count. Since a novel spherical 
environment was needed for both spontaneous rotation and cylinder tests, these were carried 
out simultaneously. 
 
2.3.6 Elevated Beam Test 
In the rat, beam walking has been used to successfully show unilateral deficits following a 6-
OHDA lesion (See Figure 2.3). The elevated beam test for mice was adapted from the rat 
based test (Allbutt and Henderson, 2007) and analyses the motor co-ordination and dexterity 
of right and left hindlimbs and forelimbs, where foot slips are recorded on ipsilateral and 
contralateral sides with respect to the lesion. Mice were made to transverse along an inclined 
ledge of decreasing width (80cm), before they were allowed to enter an enclosed (escape box) 
platform at the top. A foot slip was defined as paw misplacement where all digits entirely miss 
or slip off the narrow ledge of the beam, causing a noticeable imbalance in the body posture of 
the mouse. 
 
On the first training day the elevated beam was placed on a bench top, such that the 
investigator could walk around the apparatus and see both sides. Mice were then placed facing 
outward, on the end of the elevated beam so they have to balance and turn inward. Mice were 
also placed in the enclosed space at the top of the beam and allowed to explore it for 5 
minutes. On training day 2 each mouse was required to balance on the inner ledge to traverse 
the beam to the half way point three times, and on day 3 mice walked the whole beam to reach 
the platform once. On the test day, a video recorder was set up on one side of the beam so foot 
slips on this side could be scored post hoc. The investigator was positioned on the opposite 
side of the elevated beam, to count foot slips on that side (3 runs per mouse) in real time and 
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to record the time to transverse the beam.. For analysis, the two quickest times and 
corresponding foot slips averaged (outcome measure: foot slips count = # ipsilateral - # 
contralateral). 
 
2.3.7. Corridor Test  
The corridor test assesses lateralised sensory-motor integration, proprioception and neglect. A 
scaled down version of the rat apparatus was built, dimensions 2x: 60 cm x 4 cm x 15 cm. 10 
pairs of adjacent 1cm pots containing 6 (20mg) sugar pellets (Sandown Scientific) were 
equally spaced at 5-cm intervals along the length of the corridor. Mice were habituated to the 
apparatus, on two days before testing; by the placement of sugar pellets randomly along the 
corridor floor and mice were free to explore for 20 min. Mice were food-restricted throughout 
(Section 2.3.1). The number of successful retrievals out of a total of 20 were recorded (= # 
ipsilateral - # contralateral), as defined by (Dowd et al., 2005a, Grealish et al., 2010b). The 
mouse was removed prior to twenty retrievals if 5 minutes had elapsed. 
 
 
 
Figure 2.3. Photography of behavioural hand tests adapted from (Smith and Heuer, 2011) of 
the Cylinder (A), Apomorphine Rotation (B) and balance beam (C). 
 
2.3.8. Staircase test 
The staircase test (Campden Instruments, Loughborough, UK) for mice is an objective test of 
skilled forelimb use, described previously (Baird et al., 2001) and illustrated in (Smith and 
Heuer, 2011). In brief, the apparatus consists of start box with an adjoined testing section, 
fitted with a central plinth, onto which the mouse can climb so that there may be a narrow gap 
on either side. In these spaces are situated two staircases with eight steps of equal height, to 
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which two precision sugar pellets (20mg, Sandown Scientific) were place in shallow wells. 
The apparatus is configured such that the mouse can only retrieve pellets from each staircase 
with the corresponding forepaw on that side. Therefore the total number of pellets removed 
provides a measure of reaching success and skilled forelimb use, for both ipsilateral and 
contralateral sides to the lesion. 
The success of this test depends on food restriction to 85% of their free feeding body weight 
(mentioned above) and pre-training prior to the lesion. On the first day of training, mice were 
placed in the staircase apparatus for 20 min to explore and sugar pellets scattered on the plinth 
of the platform, and in the wells at each step of the staircases. All mice were then tested for 30 
min daily until they reached a stable level of performance. The last three days of training were 
then averaged for use as a baseline (pre-lesion) performance measure. Post lesion data is 
similarly averaged over a 3-day block. For statistical analysis, reaching deficits are expressed 
in terms of the number pellets retrieved contralateral to lesion as a percentage of the number 
retrieved on the ipsilateral side. 
2.3.9. Rotarod 
The rotarod apparatus (Ugo Basile, Varese, Italy) was used to provide an overall assessment of 
motor coordination and balance (Alvarez-Fischer et al., 2008, Monville et al., 2006a, Ogura et 
al., 2005, Schallert et al., 2000). Mice received two training days of 3 trials at 12 rpm and 22 
rpm, respectively. Trials lasted 300 s in total and were separated by at least one hour. On 
training days, mice that fell off the rotating beam were placed back on until the time had 
elapsed. On the test day, an accelerating protocol was used for each of the three trials (speed: 4 
to 44 rpm over 300 s). The latency to fall was recorded as the outcome measure by the average 
of the two best trials (highest latencies). 
2.3.10. Stepping test 
The stepping test previously used for MPTP treated mice (Blume et al., 2009), was conducted 
using a modified protocol. The test was initiated by the placement of the mouse on a flat table 
where it was left to explore for 3 s. Subsequently the hind legs were elevated from the surface 
by the investigator with a grip at the base of its tail and gently pulling it backwards over a 
distance of 50 cm for 5 s. The test was recorded using a video camera and scored using frame-
by-frame playback to count the number of adjusting steps the mouse made in total. All mice 
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were tested three times and the average number of adjusting steps for each side was expressed 
as bias score (# ipsilateral - # contralateral).  
 2.3.11. Gait analysis 
Gait was analysed using the footprint method, used previously in rodents, where the fore paws 
and hind-paws were differently coloured using red and blue non-toxic water-based paint (de 
Medinaceli et al., 1982, Richter et al., 2008). Testing was conducted in the corridor apparatus, 
to encourage the mice to move in a straight and continuous line, with white absorbent paper 
secured to the floor that was cut to fit the entire length. The distance covered by three 
consecutive strides was recorded for each mouse.  
2.3.12. Inverted Grid test 
The inverted grid test is a measure of the grip strength of the forelimbs and hindlimbs of the 
mouse. To start the trial animals were placed onto the centre of a metal grid (home cage lid) 
with a rim of 4cm on which they were prohibited from climbing, allowing access to a 
rectangle of approximately 20 x 21 cm, as detailed in previous studies (Brooks and Dunnett, 
2009, Brooks et al., 2004a, Dunnett et al., 1998). The grid was then slowly inverted and in a 
position 30 cm above the work bench. To dampen any falls, towels were placed directly 
below. The time the mouse spent grasping the grid without falling off was recorded, with a 
maximum cut off point of 300 s. Each mouse was tested three times with one hour gap 
between testing sessions. The average of the two best times for each mouse were used as the 
outcome measure.  
 
2.4 Dyskinesia Assessment 
L-DOPA methyl ester HCl and the peripheral DOPA decarboxylase inhibitor, benserazide HCl 
(Sigma) were dissolved in 0.9% saline immediately before use. The drugs were administered 
at the volume of 10ml/kg (rats) 2ml/kg (mice) in a single daily i.p. injection. AIMs were 
scored simultaneously to rotation in rats and simultaneously to locomotor activity in mice. All 
animals were scored once every 20 minutes for 3 hours. AIMs in grafted rats were scored with 
2.5mg/kg of amphetamine for the same duration. 
  
The AIMs scoring criteria is based on the specific rating scales (Cenci and Lundblad, 2007, 
Winkler et al., 2002b) as follows: Duration score (time out of one minute); 0= absent, 1= 
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present less than half the time, 2= present for over half the time, 3= present for the whole time 
but interruptible by an external stimulus (i.e. tapping sound), 4= present throughout but 
uninterruptible by external stimuli. Amplitude score (severity in one minute); orolingual; 1= 
repetitive chewing movements, 2= with tongue protrusions, axial; 1= consistent deviation of 
the head and neck to ~30
o
, 2= deviation of the neck and head to between 30
o
 and 60
o
, 3= 
deviation of head, neck and upper trunk of 60
o
 to 90
o
, 4= consistent deviation to 90
o
 with loss 
of balance; limb 1= small oscillatory movements of paw and distal forelimb, 2= low amplitude 
circular movements of the forelimb, 3= extension of the forelimb including displacement of 
the shoulder, 4= maximal amplitude movements of shoulder and limb. Duration and amplitude 
scores are the sum of all forelimb, hindlimb, orolingual and axial AIMs at all time points in 
the respective category. These are then in turn multiplied together to give a total integrated 
AIM score. Mice were classified as dyskinetic if they consistently displayed all categories of 
AIMs, between severity scores 2-4, when challenged with 2.5mg/kg of methamphetamine 
(Sigma). Animals were defined as non-dyskinetic exhibited either no or occasional AIMs of 
minimal severity, and scored no more than 2 at any given time, for any category for the 
duration of the testing session. 
 
 
2.5 Molecular and Histological Techniques 
2.5.1 General Technical Considerations 
Techniques detailed below have been optimised within our group and variations for species 
are indicated. For the chemical and equipment suppliers see Appendix (II) and for the 
chemical composition of the solutions see Appendix (III). 
 
 
2.5.2 Perfusion 
Animals are terminally anaesthetised with sodium pentobarbital (200mg/ml) (Euthetal, Merial) 
until total loss of reflex. The heart was exposed through cuts from below the sternum up to 
dorsal parts of the rib cage. Phosphate buffered saline (PBS) was trans-cardinally perfused into 
the left ventricle for 2mins and the right aorta was severed immediately after the start. 
Perfusion was then switched to 1.5% paraformaldehyde (PFA, Cal Biochem) in 0.1M PBS and 
allowed to perfuse for 3-6 minutes. Flow rates for pre-wash and fixative were 20ml/min 
(mouse) and 60ml/min (rat). Extra precautions for rats were undertaken for a fast efficient 
75 
 
perfusion; these include clamping the descending aorta and initiating perfusion in the 
ascending aorta. The whole brain was dissected and then post fixed in 4% PFA (Cal Biochem) 
in 0.1M PBS for 3 hours. The brains were then transferred to 25% sucrose (Fisher Scientific) 
in PBS until they were no longer afloat and the tissue was then stored at +4
o
C until further 
processing.  
 
2.5.3 Snap freezing 
Animals were killed by cervical dislocation and the whole brain dissected from the skull. The 
brain was placed in iso-pentane (methyl –2-butane 2 methylbutane isopentane, Fisher 
Scientific) on dry ice for 30 seconds and tissue was then stored at -80
o
C. 
 
2.5.4 Immunohistochemistry 
Perfused tissue (see tissue preparation) was cut at 40µm on a sliding sledge freezing 
microtome and collected into 96 well plates (Sero–Wel) flooded in TRIS buffered saline 
(TBS) with sodium azide (0.02%) at pH 7.4 to be stored at 4
0
C until required. A 1 in 6 series 
of sections was selected from the plates, put into a single pot and washed with TBS. 
Endogenous peroxidise activity was quenched by 10% H2O2 (VWR) in methanol (Fisher 
Scientific) before further washes in TBS. Non specific binding sites were blocked by 3% horse 
serum in TBS for 1 h. Tissue sections were then incubated in primary antibody for 16 h at 
room temperature with 3% serum at concentrations of 1:1000, TH (raised in rabbit, 
Chemicon), 1:15,000, 5-HT (raised in rabbit, Immunostar Inc) and 1:500 FosB (raised in 
rabbit, Santa Cruz) before a wash in PBS. Sections were incubated in biotinylated secondary 
antibody (anti-rabbit antibody raised in horse for TH, 1:200 for all stains). Sections were 
washed again in TBS and left in a Biotin-Streptavidin mixture, from a DAKO ABC kit (5µl A 
and 5µl B), for biotinylation. Prior to staining tissue was washed in TRIS non-saline (TNS) 
solution for equilibration. We visualised the tissue-bound antibody using a standard 
peroxidase-based method using the chromogen, 3-3′-diaminobenzadine (DAB kit, Vector 
Laboratories) in a 0.5mg/ml reaction (1:5 concentration) in TNS initiated by a 0.25% addition 
of hydrogen peroxide (H2O2). The reaction was stopped by submersion in TBS and sections 
were mounting on slides (Thermo scientific) coated in gelatine. Slides were air dried before 
dehydration in alcohol steps from 75-100% (Fisher Scientific) and xylene (VWR). Coverslips 
were then added with distyrene plasticizer and xylene (DPX). Routinely, some of the sections 
were processed excluding the primary antibody serving as a control for the stain. 
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Peroxidase based immunohistochemistry (ICH) was also carried out on fresh snap-frozen 
tissue. Sections were cut to a 30µm thickness on the cryostat and mounted directly onto super 
frost slides to be stored -80
0
C. The immunohistochemistry protocol remained the same but 
required an initial fixation step in 4% PFA before being left to air-dry overnight. A 20 min 
permeabilisation step in acetone and full evaporation of the solvent was also required before 
starting ICH. 
 
Fluorescence ICH was undertaking in the same way as the peroxidase-based staining 
procedure, with the absence of the quench and DAB colour reaction steps. A 1 in 6 series of 
tissue sections were incubated in primary antibodies for 16 h at room temperature with 3% 
serum at concentrations of 1:1000, TH (raised in mouse, Chemicon) and 1:2000, GABA 
(raised in rabbit, Abcam), before a wash in TBS. Hoechst nuclear stain 1:10,000 was then 
added to the free floating sections and left for 10 minutes, before another wash in TBS. 
Sections were incubated in fluorescent secondary antibodies added together: anti-rabbit 
antibody (Green, Molecular probes); and anti-mouse antibody (red, Molecular probes), both at 
1:200. 
 
2.5.5 In-situ hybridisation - Probe synthesis 
Oligonucleotides were designed using genetic sequences obtained from Ensemble online 
genomic database (ensemble.org) specific for that gene and species (See Appendix I). Forward 
and reverse primers were optimised for the following parameters: Primer length 20b +/- 2; 
primer Tm 55°C +/- 5; primer GC% 50 +/- 5; product length 300-800b. The specificity of the 
design was verified using an online Basic Local Alignment Search Tool (BLAST) against 
online nucleotide collections from the National Centre for Biotechnology Information (NCBI) 
(ncbi.nlm.nih.gov). Primers were manufactured by MWG Operon. 
 
cDNA was made from fresh, adult murine tissue (See, 2.3.1- cDNA manufacture). This was 
then used in a polymerase chain reaction (PCR) reaction with the manufactured primers to 
create copies of the genetic sequence. The oligonucleotides were then chemically incorporated 
into a PCR II TOPO cloning vector (Fig. 2.4.) using a salt solution provided with the kit 
(Invitrogen).  
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Figure 2.4. A base and enzyme map of the PCR II TOPO cloning vector. PCR insert sites and 
T7 and Sp6 promoter sites are indicated. 
 
 
The PCR II TOPO cloning vector (Invitrogen) and PCR product was then transformed by heat 
shock at 42
o
C into Escherichia-coli (E-coli), one shot TOPO10 chemically competent cells, 
(Invitrogen) and plated on agar (Difco) - plates. Ampicillin (150mg/ml) was added to the agar 
before solidifying at a 1:1000 concentration. Several colonies were selected on the basis of 
antibiotic resistance and were grown through stages of S.O.B and LB media, with Ampicillin 
at the same concentration and were left at 37
o
C overnight. DNA was extracted from bacteria 
using the QIAprep high speed plasma min kit (QIGEN). Vectors were cut enzymatically using 
Apa I and Hind III (New England Biolabs) and run on a 1% agarose gel to screen for vectors 
that contain inserts, according to size in comparison to the PCR II TOPO cloning vector 
(Invitrogen) without an insert. Validation of vectors with correct PCR inserts, based on the 
nucleotide chain, was by sequencing from the T7 promoter region (DNA Sequencing Core, 
Molecular Biology Unit at Cardiff University, UK). 
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DNA vectors that contain inserts were cut enzymatically with either Kpn I or Xho I enzymes 
(New England Bio-Labs) in corresponding buffers over 2 hours at 37
0
C. Vectors were then 
checked for linearisation by separation with a circular plasmid on a 0.5% agarose gel. RNA 
was transcribed from the cut template from either Sp6 or T7 promoter regions using Sp6 or T7 
polymerases (Boehringer) in the following reaction mixture: DIGNTPs (Boehringer), RNAse 
inhibitor (Boehringer), 10x transcription buffer (Boehringer) and RNA free water (Ambion), 
for 2hours at 37
0
C. Following this DNA was digested with DNase I (Boehringer). The 
precipitation of RNA was then achieved by the addition of sodium carbonate at 60
0
C and then 
ammonium acetate on ice. Precipitates were collected by centrifugation at 6000rpm in a 
micro-centrifuge (5415R Eppendorf). RNA is finally washed in 100% ethanol and 
resuspended in a TE and formamide solution (1:1). 
 
The efficiency of the DIG RNA oligonucleotide probe to detect complementary RNA was 
checked using 5 different probe concentrations, made by serial dilution of the concentrated 
stock into RNase free water (Ambion). These were then hybridised onto a nylon membrane 
blotted with RNA using a U.V. transillumination light box (UVP). The intensity of the stain 
was thus decided prior to starting In-situ hybridisation. 
 
2.5.6 In situ hybridisation - Optimising 
Whole brains were embedded in Cryo embedding compound (Bright) and 30µm thick serial 
sections were taken from these using a cryostat (Bright, microtome 5030) and directly 
mounted onto superfrost slides (Thermo Scientific). Temperature was maintained at the 
following: cutting chamber –35
0
C, mounting stage 30
0
C. The tissue was then permeabilised by 
digestion with protein kinase (PK, Roche) and fixed with 4% PFA (Cal Biochem). Time taken 
for these steps was adjusted to gain maximum clarity for visualisation at the end stage. Sp6 
and T7 polymerised strands of RNA then acted as sense and anti-sense controls; these can 
differ with each manufactured probe, as the orientation of the insert in the DNA construct is 
unknown until optimisation. 
 
2.5.7 In-situ hybridisation - Procedure 
The fixed tissue sections were washed in PBS before carboxylation in 0.1% 
diethylpyrocarbonate (DEPC). Slides are washed again in PBS and 2x Sodium chloride- 
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sodium citrate (SSC) buffer. Sides were placed in staining tray flooded with formamide and 
5xSSC solution (1:1) and 0.5mls of pre-hybridisation buffer were added to each slide for 
3hours at 56°C. The probe was placed in hybridisation buffer and heated to 95°C for 
linearisation, before being added to the sections. The sections were covered with Nesco film 
and the tray left at 56°C overnight. 
 
Excess probe was washed off the sections through a series of washes: 5xSSC, 2xSSC, 
0.2xSSC, formamide with 0.2xSSC (1:1), and Tris Buffered Saline – Tween (TBS-T). The 
tissue is then blocked using 1% whole milk in TBS-T for 1hour before the addition of 0.5mls 
of anti-DIG antibody (Roche) in 1% whole milk (1:5000) to each slide. Excess antibody was 
then washed off through a series of washes in TBS-T before equilibration in 1x alkaline 
phosphatise (AP) with MgCl2 (1M) before development in 100mg/ml of 4-Nitro blue 
tetrazolium chloride solution (NBT, Roche), and 50mg/ml 5-Bromo-4-chloro-3-indolyl-
phosphate 4-toluidine salt solution (BCIP, Roche) in 1xAP. The reaction was left until an 
appropriate colour change occurred, in a staining tray flooded with 1xAP. The reaction was 
stopped in 1x Tris-Ethylenediaminetetraacetic acid (EDTA) solution (TE).  
 
2.5.8 qPCR 
The recording of the exponential amplification of specified DNA sequences in real time was 
achieved using a double stranded DNA fluorescent DYAMO SYBR green kit (Finnzymes). A 
standard PCR protocol was adopted and 10µl of the dye (containing a set concentration of 
dNTPs and MgCl2) was added per well, with 1µl of cDNA and 0.5µl of each primer, in a 
translucent 96 well plate. Primers were made specifically for qPCR with a Tm of 60
o
C (See 
Appendix 1). The hot start Taq polymerase within the SYBR green was initiated by 95
o
C for 
15 minutes in the machine. Amplification conditions used were 40 cycles of 95
o
C followed by 
60
o
C for 30 seconds and 72
o
C for 30 seconds. Melt curves were generated from readings every 
0.5
o
C between 53
o
C and 95
o
C. qPCR data was analysed by Opticon monitor 3 software and 
samples were always normalised to GAPDH levels in the same sample by the ∆∆C(t) method. 
Differential expression of mRNA is presented in terms of fold change (FC) to the initial 
variable always set at 1.  
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The ∆∆Ct method is used for relative quantification to a calibrator (the sample used to 
compare all other samples to). The sample RGS gene and GAPDH reference gene are 
normalised against variation in sample quality and quantity by the following: - 
 
• ∆C(t)sample = C(t)target- C(t)reference 
• ∆C(t)calibrator = C(t)target- C(t)reference 
 
∆∆C(t) is then calculated from the results from above : - 
 
• ∆∆C(t) = ∆C(t)sample - ∆C(t)calibrator 
 
Expression of the target gene is normalised to the reference gene, remaining relative to the 
calibrator: 2
-∆∆C(t)
.
 
 
qPCR primers were tested by their capacity to display known changes of RGS expression in 
striatal tissue by apomorphine (1mg/kg) and methamphetamine (2.5mg/kg) in mice (See Fig. 
2.5). Striata were dissected 30 minutes following the challenge and compared to striatal tissue 
taken from a mouse 30 minutes after a saline injection. In accordance with previous work 
apomorphine does not elicit a change in RGS2, RGS4, RGS8 or RGS9-2 at this time, as 
changes occur with complete wearing off of the drug up to 24 hours later (Hooks et al., 2008, 
Psifogeorgou et al., 2007, Garzon et al., 2005). In addition, increases in RGS2 (3 fold), RGS8 
(0.5 fold) and RGS4 (0.5 fold) expression and decreases in RGS9-2 (1.5 fold) expression in 
the striatum and nucleus accumbens of rodents, as seen when using these optimised primers, 
have been reported in response to a single challenge of amphetamine previously (Burchett et 
al., 1999, Burchett et al., 1998, Schwendt et al., 2006). These changes in RGS gene expression 
following amphetamine and lack of change following injections of apomorphine in intact 
animals are in agreement with previous work and provide strong evidence that the primers are 
working efficiently. 
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Figure 2.5. The testing of qPCR primers in tissue samples from intact mice, 30 minutes after a 
challenge of 1mg/kg of apomorphine or 2.5mg/kg of amphetamine. 
 
2.5.9 Western Blotting- Protein Extraction 
Proteins from the cytosolic fraction were isolated from dissected whole striata stored at -80
o
C. 
300µl of lysis buffer (stored at 4
o
C) was used to homogenise the tissue. The lysate was then 
transferred immediately to the centrifuge to be spun for 10 mins at 6500 rpm at +4 C°. Up to 
150µl of supernatant was then transferred a new Eppendorf (on ice) and an equal volume of 2x 
Laemmli (LB) buffer with 2-mercaptoethanol was added and mixed. The denaturation of 
proteins was achieved by boiling for 5mins at 95°C before replacing on ice. Denatured 
proteins were stored at -20°C until future use. 
 
2.5.10 Western Blotting- Procedure 
Prior to running proteins on SDS-PAGE, protein levels were normalised to ensure comparable 
levels of total protein were assessed. Total protein concentration was measured using a 
commercial protein assay kit (BioRad), based on the Bradford procedure (Bradford 1976). 
Homogenized protein samples were passed through a two layer polyacrylamide gel, consisting 
of a 6% upper “stacking gel” layer, followed by a higher concentration “resolving gel”, 
typically 10-20% acrylamide. The percentage of polyacrylamide contained in the resolving gel 
was altered according to the weight of proteins being assessed. Normalised levels of protein 
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were loaded into the stacking gel wells. Prestained protein weight marker ladder (Fermentas 
PageRuler Plus) was added to an additional well. Voltage and length of run time varied 
depending on the molecular weight of the protein being assessed. 
 Following electrophoresis, proteins were transferred from the polyacrylamide resolving gel to 
a PVDF membrane. Membranes were blocked in a solution of 3% non-fat milk (Marvel) in 
TBS-T for one hour. Blocking solution was removed and the membrane incubated in primary 
antibodies (RGS2: raised in rabbit from Abcam; RGS4: raised in goat from Santa Cruz; 
RGS9-2: raised in goat from Santa Cruz; TH: raised in rabbit from Chemicon) in 3% non-fat 
milk (Marvel) in TBS-T for overnight at +4
o
C. Primary antibody solution was removed and 
the membrane washed thoroughly in TBS-T. Samples were then incubated with anti-rabbit, 
anti-mouse or anti-goat secondary HRP conjugated antibodies (Amersham) for 1-2 hours. 
Protein bands were then imaged using the ECL or ECL+ chemi-luminescent detection systems 
in accordance with the manufacturers instructions (Amersham). Band intensities were 
analysed using AlphaImager 2200 analysis software. Following analysis, membranes were 
washed with TBS-T to remove ECL/ECL+. Membranes were reblocked and probed with 
antibody against β-actin (Abcam). Relative concentrations of test protein in samples were 
calculated by normalising band intensities against intensities of β-actin. 
 
2.5.11 Tritiated Ligand binding Assays 
Sections for radioligand binding were cut on the cryostat directly onto superfrost slides, from 
fresh frozen whole brains. Sections were allowed to air dry at room temperature, overnight 
before use. [
3
H]SCH23390 (Perkin Elmer) was used to assess D1 receptor binding, based on 
the protocol of (Dewar and Reader, 1989). Sections were incubated in radioligand buffer 1 
(See Appendix III) twice for 8 minutes at room temperature. 4.25µL of 0.5nM [
3
H]SCH23390 
was mixed with radioligand buffer 1 for specific D1 receptor binding and was mixed with 
radioligand buffer 1 and 10µM cis-flupenthixol (5mg/l) for non specific binding. Sections 
were left for 90 minutes at room temperature, washed in TRIS and deionised water for 2 
minutes each and dried overnight. 
 
[
3
H] Raclopride (Perkin Elmer) was used to assess D2 receptor binding, based on the protocol 
of (Dewar and Reader, 1989). Sections were twice pre-incubated in radioligand buffer 2 (See 
Appendix III) for 8 minutes at room temperature. Specific binding was then initiated in the 
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same buffer with 100nM (100ul per 100ml) of ketanserin stock solution (5mg/ml stock in 
H2O) and 2nM of [
3
H] Raclopride (17.4µl/100ml). [
3
H] Raclopride in radioligand buffer 2 was 
mixed with 10µM Sulpiride (3mg/l) for non-specific binding on adjacent sides with 
corresponding serial sections. All sections were left for 120 minutes at room temperature and 
washed in TRIS and deionised water for 2 minutes each and left to dry overnight. 
 
For development and calibration slides were arranged in cassettes with the addition of two 
autradiographic [
3
H] micro-scales (GE Healthcare) containing known high and low 
radioactivity levels. The high concentration strip emits radioactivity at 113.22- 4070Bq/mg 
and the low concentration strip at 3.774- 580.9 Bq/mg; each strip is split into 8 known 
radioactivity sections within theses ranges. Amersham photographic Hyperfilm MP (GE 
Healthcare) was laid on the slides in darkness and cassettes were left for 3 months at 4
o
C. 
Radioactivity was then detected using a compact X4 imaging system (Xograph) with 
development and fixing solutions (Champion Photochemistry). 
 
2.7 Quantification and Microscopy 
2.7.1 General quantification and statistics 
The statistical analysis used for each experiment is detailed in corresponding experimental 
chapters. SPSS (version 16) was used to deduce statistical significance for all Pearson’s 
correlations, partial correlations, 1-3 way analysis of variance (ANOVA) and T-tests, and 
where appropriate post-hoc tests (as described in each chapter) were also implemented to 
specify significance to 95%*(P<0.05), 99%**(P<0.01) and 99.9%***(P<0.001). Information 
on any relevant interactions, the total and error sum of square values, and stat value are also 
provided for each test. 
 
Scores on behavioural tests and TH positive cell counts are expressed as a percentage of the 
intact side. Cell bodies were counted under a Leica light microscope in the VTA and SNc at 
the level of the medial terminal nucleus of the accessory nucleus of the optic tract interception 
as described by (Dowd and Dunnett, 2004). TH immuno-reactive cells within the striatum 
were counted in all sections from a 1 in 6 series through the mouse brain and corrected 
formulaically to deduce cell numbers in whole striatum. The quantification of RGS positive 
cells at different regions within the striatum and immunological staining of proteins within 
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cells was quantified by counting under a DMBRE Leica light microscope within a 600µm2 
field, at 10x magnification. Half brains were visualised using a free standing Wild Makrozom 
M420 microscope (Switzerland). Images were taken by an Optronics camera and processed 
using Magnafire (2.1) software. Before quantification the investigator was blind as to which 
series of stained sections belong to which group. In addition groups were randomised in the 
blinding process. Upon completeion of cell counting/ density analysis the investagtor was 
informed of the blinding for analysis, thereby removing experimenter bias during 
quantification. 
 
2.7.2 Determining Statistical Power 
Group sizes for the experiments were determined by previous literature that has yielding 
significant results, for that particular kind of experiment: behavioural (Iancu et al., 2005), 
dyskinesia (Lundblad et al., 2005) and grafting/ histology (Lane et al., 2006). In addition we 
can calculate group sizes that will have enough power to show a statistically significant affect 
with a 1 tailed (i.e LID always expected to increase with big lesions and GID with large grafts) 
a prioir power analysis test. The following have been calculated by the GPower statistical 
software (Erdfelder et al., 2006). 
 
• Motor behavioural assessments: a total of 102 (critical t 100=1.66) would have an 80% 
power to yield a statistically significant result, for a medium effect size (0.5) at the 
alpha level of 0.05.  
 
• Dyskinesia, molecular and biochemical analysis: a total sample size of 42 mice 
(critical t 40=1.68) would have an 80% power to yield a statistically significant result, 
for a predicted large effect size (0.8) at the alpha level of 0.05.  
 
2.7.3 Quantification and Density Analysis with ImageJ 
We assessed the density of TH- and 5-HT-immunopositive neurons in the dorsal and ventral 
striatum from images of every 6th section (taken with Leica DFC420 camera and Leica 
application V3.6 software) on ImageJ software (Version 1.42, National Institutes of Health, 
USA). A formula was used to convert default grey scale measurements into arbitrary optical 
density (O.D) values. Density was normalised to background levels of the corpus callosum 
and photographic sheet variances normalised to each other using a correction factor for the 
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difference in density based of the autoradiographic [3H] micro-scales (GE Healthcare). 
Control slides that have undergone the same procedure with the addition of competitive 
antagonists of corresponding receptors were measured and subtracted from test slide values. 
Equally for western blot analysis relative intensities of each band was quantified using density 
analysis software provided by ImageJ, and normalised corresponding GAPDH bands.  
 
The low levels of background found within the striatum after a FosB stain allowed for 
automatic quantification of cell numbers using the ImageJ software. Photos for all regions and 
animals were taken the same day under DMBRE Leica light microscope without adjusting 
light levels at 10x magnification. The formula on ImageJ was adjusted to detect the maximum 
number of cells for their shape and size. 
 
2.7.4 Analysis of Dopaminergic Grafts 
Dopamine cell bodies densely stained with TH/5-HT by ICH or RGS DIG labelled 
oligonucleotide probes were counted in every sixth 40µm coronal brain section at a 200x 
magnification. The number from each section was then combined to give the total amount of 
dopamine neurons / RGS stained cells for each brain. The diameter of TH positive cells / RGS 
positive nuclei was deduced from by measuring at least 50 random positively stained cells 
under an Olympus BX50 microscope and Olympus C.A.S.T grid system. The total number of 
cells present in the graft was calculated using the Abercrombie correction formula 
(Abercrombie, 1946): - 
 
T = F x A x M/ (D/M) 
T = total number of cells 
F = frequency of sections 
A = total counts for one animal 
M = section thickness 
D = average cell/nucleus area. 
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3. A Comprehensive Behavioural Assessment of 
the 6-OHDA lesioned mouse model of 
Parkinson’s disease 
 
Summary 
The 6-OHDA lesioned rat is still the most commonly used model of PD, however due to the 
increasing availability of transgenic mice, mouse based tests and mouse derived cells, there 
has been much interest in a mouse version of the model. The comprehensive histological and 
behavioural assessments available for the rat are not as defined as those described for the 
mouse. This study examines the consequences of injecting 6-OHDA at three sites along the 
nigrostriatal tract (SN, MFB and striatum). This process caused distinct patterns of neuron 
depletion in the SNc, VTA and the denervation of dopaminergic fibre terminals in the 
striatum. Intense animal husbandry procedures ensured that the mortality rates remained high 
post lesion, a significant problem for some other studies. A large battery of motor hand tests 
evaluated behavioural deficits in all three models in comparison with intact control animals. 
Each of the lesion groups displayed marked behavioural deficits which correlated with 
histological measures to different degrees. The cylinder, corridor test, inverted cage lid, 
balance beam, rotarod, psycho-stimulant rotation (amphetamine and apomorphine) and 
spontaneous rotation correlated the most closely with cell loss within the SNc, and partial 
correlation analysis has shown the majority are dependent on SNc cell loss rather than that of 
the VTA. 
 
 
 
Chapter 3 - Declaration 
The experiments in this chapter were carried out in collaboration with PhD student Andreas 
Heuer (AH). Specifically he carried out the Staircase test, the inverted cage lid test, gait 
analysis, the rotarod, the stepping test and part of the histology. These tests were included in 
this thesis chapter with all others in order to allow completeness of the presentiation and to be 
able to compare them in the discussion, but are indicated in the results section with the 
abbreviation AH. 
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3.1. Introduction 
The in-depth behavioural analysis of the 6-OHDA lesioned model in the rat has led to a 
preference for its use in the experimental PD field. However, with the increased use of 
transgenics to explore different pathologies, the utility of a mouse model is clearly apparent. A 
limited number of studies have been carried out in the 6-OHDA lesioned mouse but at the time 
of starting this thesis there was little consistency between the surgical procedures, and 
behavioural assessments in conjunction with a worryingly low survival rate. The two 
predominant studies that have aimed to validate up to 4 behavioural hand tests to determine 
lesion extent and thus select animals for further study, used pre-selections by evaluating 
amphetamine-induced rotation (Iancu et al., 2005, Grealish et al., 2010b). Furthermore, it is 
unclear whether select psychostimulant induced rotation or drug free behavioural measures 
will show the most promising results when compared to each other (Mandel and Randall, 
1985, Iancu et al., 2005). New motor and sensory-motor behavioural indicators of nigrostriatal 
damage and greater optimisation of the model to enhance survival, are necessary to make it a 
more robust and useable model of PD.  
 
Rotational asymmetry remains the gold standard for the evaluation of the 6-OHDA lesion in 
the rat. Dopamine losses of 95% or more in the rat relate to a peak rotation rate of 7-15 turns 
per minute following an amphetamine (0.63-2.5mg/kg)/ apomorphine (0.015-0.1mg/kg) 
challenge (Costall et al., 1976a, Costall et al., 1976b, Schmidt and Westermann, 1980) and 
there are widely accepted relationships between dose and the extent of denervation (Hefti et 
al., 1980). This makes for highly predictive testing. Although up to a 31.5 fold change in 
directional bias has also been found in the mouse following an apomorphine challenge 
(Mandel and Randall, 1985), the reports of the rotational behaviour of the mouse model are 
highly variable, both in terms of outcome and technique (Francardo et al., 2011b, Grealish et 
al., 2010b, Iancu et al., 2005). The cylinder test, first described by (Schallert et al., 2000) 
assesses the laterality of forelimb use in a novel environment, and typically, rats with 
unilateral dopamine depletion will preferentially use the ipsilateral limb 70-90% of the time. 
Thus far reports are mixed as to the validity of this test in the mouse (Francardo et al., 2011b, 
Grealish et al., 2010b, Iancu et al., 2005). The corridor is used to discriminate lateralised 
differences of sensory-motor neglect. Rats show an ipsilateral bias of 75% following near 
complete neuronal degeneration of the striatum and SNc (Dowd et al., 2005b, Dowd et al., 
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2005a), retrieving sugar pellets predominantly when placed on their ipsilateral side, ignoring 
those on the contralateral. When recently adapted for mice, similar levels of predictability for 
dopamine depletion were observed (Grealish et al., 2010b).  
 
In the 6-OHDA rat model, deficits in the contralateral paw and a 10% overcompensation of 
the ipsilateral paw also manifest in the staircase test, when dopamine depletion is at 80% or 
more (Montoya et al., 1991, Montoya et al., 1990, Pagnussat Ade et al., 2009). The success of 
the staircase task, first devised for the Sprague-Dawley strain, has led to its adaptation for 
other strains of rat (Pagnussat Ade et al., 2009), mice (Baird et al., 2001) and models of other 
neurodegenerative diseases e.g. Huntington’s disease and Stroke (Fricker et al., 1996, Peeling 
et al., 2001, Klein et al., 2007, Galtrey and Fawcett, 2007, Dowd et al., 2005b). Other 
behavioural assessments such as grip strength and adjusted stepping have consistently defined 
unilateral denervation through functional forelimb differences (Dowd et al., 2005b, Dunnett et 
al., 1998, Olsson et al., 1995, Paille et al., 2007), but these are not well adapted for use in the 
mouse.  
 
Overall motor coordination and locomotion deficits can be assessed in hemi-parkinsonian 
rodents in open field, rotarod and beam walking paradigms (Koob et al., 1981, Fink and 
Smith, 1980, Fornaguera and Schwarting, 2002, Allbutt and Henderson, 2007, Iancu et al., 
2005, Monville et al., 2006a, Ogura et al., 2005). In particular the latency to fall off the 
accelerating rotarod can correlate with 60% or greater loss of dopaminergic cells in mice 
(Iancu et al., 2005), however in the rat this test remains more discriminative to the extent of 
the lesion (Monville et al., 2006b).  
 
This chapter focuses on clarifying the use of these various behavioural assessments in the 
mouse model of Parkinson’s disease. Motor deficits were evaluated in three different lesion 
models to determine which may offer accurate predictors of 25- 90% unilateral dopamine 
depletion and to optimise some of the less frequently used behavioural tasks described 
previously in 6-OHDA rats and mice, and some which have not been used previously.  
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3.2. Experimental Design 
A cohort of 105 male C57/Bl6 mice (Charles River, UK) was divided into 4 experimental 
groups. One group (n=15) served as untreated experimental controls whereas the other three 
groups (n = 30 in each) were designated for stereotaxic surgery. The staircase test required 
extensive pre-training (see Chapter 2) before surgery, which was carried out over 14 days, 
under a food restriction regime, where mice were maintained to 85% of their free feeding body 
weight. Mice were subject to unilateral lesions to the dopaminergic system, aimed at the SN, 
the MFB, or the striatum with co-ordinates optimised from trypan blue injections, confirming 
accuracy at the target site (see Chapter 2). An intensive daily animal husbandry regime was 
undertaken to ensure the full recovery of the mice. Six weeks post-lesion, mice were food-
restricted to 90% of their free feeding weight and tested on the staircase and corridor test. 
Mice were allowed ad libitum access to food for all other behavioural hand tests that were 
carried out in the following order: staircase, corridor, balance beam, spontaneous rotatrion, 
cylinder, rotarod, inverted cagelid, locomotor activity and separate amphetamine- and 
apomorphine-induced rotation sessions. At the end of testing, mice were used for a separate 
dyskinesia experiment (see Chapter 3) then were perfused transcardially with 1.5% 
paraformaldehyde, before were brains were removed, post-fixed and stored in sucrose before 
processing. Brains were cut into coronal sections of 40 micrometers and a 1 in 6 series from 
each mouse was used to stain for TH, where density and cell counts in the SNc and VTA were 
quantified, detailed histological methods and modes of quantification as detailed in Chapter 2. 
The behavioural data were analysed using 1-way ANOVA, and Dunnett’s post-hoc tests, using 
intact control groups as baseline. When appropriate a bias score was calculated as 100 x 
(ipsilateral paw or side/ contralateral paw or side). Behavioural results were used for bivariate 
correlation analysis with the histological measures of cell loss, using Pearson correlation 
coefficients (one-tailed). Finally, in select analysis co-correlation between SNc /VTA 
depletion was factored out using partial correlation analysis for each of the behavioural 
assessments. 
 
3.3. Results 
3.3.1. Mortality Rates and Weight 
The insensitive husbandry regime achieved a low mortality rate for all groups, where death 
was evident within the first 10 days post-lesion and none were lost after this time (see Fig 
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3.1A). Survival rates depended upon lesion type where: Striatal >95%; MFB >80%; SNc 
>90%. All mice were given a highly palatable diet in an attempt to maintain body weight and 
therefore control mice put on weight over the two weeks of intensive animal husbandry, this 
was not seen in mice lesioned to the striatum and SNc where weight remained stable (Fig 
3.1B). The MFB group had a reduced weight compared to all other groups for 10 days post 
surgery and compared to the baseline level (Fig 3.1B). 
 
 
 
 
Fig. 3.1. Survival (A) and body weight (B) measures for 14 consecutive days post lesion 
plotted per group, where the baseline day was recorded at the day of surgery. Values are 
expressed as means ± SEM.
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3.3.2. Histological analysis of the lesions 
6-OHDA reduced the numbers of TH positive neurons in the SNc (F3,90 = 13.33, p<0.001) in 
all three lesion groups (Fig. 3.2A-B) and in the corresponding TH-fibre density in the dorsal 
striatum (F3,89 = 17.57, p<0.001), significant reductions were observed for each type compared 
to intact controls (Striatum and MFB groups p<0.001; SN p<0.01). There was also significant 
cell loss in the VTA (F3,90 = 9.05, p <0.001) and TH fibre density depletion in the ventral 
striatum (F3,90 = 12.67, p <0.001), however only MFB and Striatal groups differed 
significantly from control (p<0.01 and p<0.001 respectively).  
 
20-50% of the animals in all groups had near to compete lesions (>90% depletion), while a 
smaller number of animals in both the MFB and SN lesion groups had very small lesions 
(<25% depletion). The lesion success was highest in the Striatum lesion group where the 
majority of mice exhibited at least partial lesions (between from 25% up to >90% depletion). 
The variability of the lesions is considered further with subsequent correlation analysis against 
behavioural deficits. Mice with near to complete lesions were chosen from each group for use 
in another study, detailed in Chapter 4, where it is evident that group deficits are more 
pronounced (see section 4.3.1).  
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Fig. 3.2. Bright-field photomicrographs of representative sections for successful lesions of the 
Striatum (St) medial forebrain bundle (MFB) and substantia nigra (SN) groups compared to 
the intact controls. Sections were cut in the coronal plane and stained for TH. Sections were 
taken at the approximate levels: (St Level 1) +1.0mm, (St Level 2) -0.2mm, (St Level 3) -
1.3mm, and (SN Level) -5.2mm from Bregma. Scale bar represents 1mm for all levels. Cell 
counts were expressed as percent of contralateral for SNc (A) and VTA (B). Striatal density 
measures of TH positive fibres are expressed as percent of contralateral for the dorsal striatum 
(C) and ventral striatum (D). Graphs are annotated at the p<0.05*, p<0.01** and p<0.001*** 
level of significance. Values are expressed as means ± SEM. 
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3.3.3. Group effects on motor deficits 
There were a number of tests that showed no differences between lesion groups and non-
operated controls (Fig 3.3.), including staircase (Group, F3,91 = 0.58, p =ns) and adjusting 
stepping tests (F3,85 = 1.63, p =ns), undertaken by AH, and horizontal locomotor activity (F3,91 
= 1.51, p =ns). A trend was noted for group effects of lesion-induced deficits on the balance 
beam test (Fig. 3.3C; F3,90 = 2.65, p =0.054), and when the MFB group is directly compared to 
unlesioned controls a significant performance deficit was found (p<0.05). Performance on the 
corridor test was impaired in mice with MFB or striatal lesions (Fig. 3.3B; F3,91 = 4.62, 
p<0.01, post hoc p<0.01 for both groups). The striatal group showed specific deficits in the 
cylinder test (Fig. 3.3D; F3,91 = 4.25, p<0.01, post hoc p<0.05). The inverted cage lid test, 
performed by AH, was used as a measure of grip strength was able to detect lesion deficits 
compared to the intact control group (Fig. 3.3H; Group, F3,91 = 3.59, p<0.05), however post 
hoc analysis showed this only to be true for the Striatum lesion group (p<0.05). The latency to 
fall from the rotating rod was significantly different between the other lesion groups and the 
from the control group (Fig. 3.3E; Group, F3,91 = 3.76, p<0.05), where all lesion groups 
reached significance to varying degrees (SN and Striatum, p<0.05 MFB, p<0.01).  
Rotational deficits proved to be one of the most robust measures to determine group lesion 
effects. Significant differences were noted between lesioned mice with methamphetamine 
induced rotation (Fig. 3.3K; F3,90 = 4.33, p<0.01), apomorphine induced rotation (Fig. 3.3L; 
Group, F3,85 = 6.09, p<0.05) and by spontaneous rotation (Fig. 3.3J, F3,91 = 10.59, p<0.001). 
Methamphetamine was able to induce ipsilateral rotation in all groups (Striatal, p<0.01; MFB, 
p<0.001; SN, p<0.05), where as apomorphine-induced rotational differences were only seen in 
Striatal (p<0.05) and MFB (p<0.01) groups. Significant spontaneous total net ipsilateral 
rotation was seen exclusively in mice with an MFB lesions, where p<0.01. 
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Fig. 3.3. Effects by group on select behavioural hand tests compared to unlesioned controls. 
Graphical representations of the following are shown: pellets retrieved on the staircase (A), 
pellets retrieved on the corridor (B), foot slips on the balance beams (C), paw preference on 
the cylinder (D), Latency to fall on the rotarod (E), stepping test (F), stride length (G), grip 
strength by the grip test (H), locomotor activity (I), percentage of spontaneous turns (J), 
percentage of turns from 2.5mg/kg of methamphetamine (K) and percentage of turns from 
0.05mg/kg of apomorphine (L). Significant differences determined by a 1-way ANOVA are 
indicated by p<0.05*, p<0.01** and p<0.001***. Values are expressed as means ± SEM. 
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3.3.4. Correlation of Motor Deficits and Lesion Extent in the SNc 
Without pre-selection of animals by rotation, group effects may have been masked by the 
presence of mice with partial and failed lesions, therefore a comprehensive correlation 
analysis was performed to determine the relationship between cell loss in the VTA and SNc 
and all of the behavioural hand tests performed (Table 3.1 and Table 3.2 respectively).  
The proportion of dopaminergic cell bodies remaining in the SNc in the lesioned side could be 
correlated to total spontaneous rotation (r= -0.485, p<0.01), total amphetamine rotation (r= -
0.694, p<0.01), total apomorphine rotation (r= 0.548, p<0.01), the cylinder test (r= -0.581, 
p<0.01) and the corridor test (r= -0.557, p<0.01) (Table 3.1). The percentage of cells 
remaining in the SNc was weakly correlated to the stepping test (r= -0.254, p<0.01) and gait 
analysis (r= 0.184, p<0.05), undertaken by AH. The staircase, inverted cage lid, and basal 
locomotor activity did not correlate with the percentage of TH positive cells in the SNc on the 
ipsilateral side. Although a high proportion of the hand tests undertaken could be correlated to 
the percentage of TH positive cells remaining on the ipsilateral side, few reached significance 
when each group was considered separately. Nevertheless the cylinder and amphetamine tests 
could be robustly correlated to the percentage of TH positive cells remaining in the SNc, in all 
lesion groups (Table 3.1). In contrast, the total number of spontaneous rotations and 
performance on the corridor test was only correlated to the cells counts in the SN and MFB 
lesion groups.  
Partial correlation analysis uses the percentage of cells remaining in the VTA as a covariate, 
so that it may be excluded as a confounding factor in the evaluation of correlation with SNc 
cell loss. With this statistical analysis the overall deficits correlated significantly with SNc cell 
loss on the balance beam (Fig. 3.4A; r= -0.186, p<0.05), the corridor test (Fig 3.4B; r= 0.440, 
p<0.001), the rotarod (Fig. 3.4C; r= 0.175, p=0.05), the cylinder test (r= -0.385, p<0.001), 
total spontaneous rotation (r= 0.356, p<0.001), total amphetamine induced rotation (r=0.630, 
p<0.001), and total apomorphine induced rotation (r= -0.200, p<0.05). Assessment by partial 
correlation has also shown that significant trends, found with standard bivariate Pearson’s 
correlations, also remain for individual groups, therefore reinforcing the sensitivity of these 
tests to specific losses of neurons in the SNc. 
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Table 3.1. Pearson’s correlation coefficients between percentage of cells remaining in the SNc 
of mice lesioned to the striatum, MFB and SNc and deficits on a battery of motor hand tests. 
Significance is indicated by p<0.05* and p<0.01**.Values are expressed as means ± SEM. 
 
Hand test/ Group Overall  Striatum  MFB  SN  
Rotarod 0.304 ** 0.036  0.215  0.309  
Cage lid 0.171  0.027  -0.132  0.052  
Amphetamine Rot (total) −0.698 ** −0.623 ** −0.810 ** -0.619 ** 
Apomorphine Rot (total)  0.548 ** 0.359 * 0.665 ** 0.476 ** 
Spontaneous Rot (total)  -0.485 ** -0.153  -0.671 ** -0.630 ** 
% Balance Beam -0.399 ** -0.104  -0.283  -0.778  
% Cylinder -0.581 ** -0.336 * -0.751 ** -0.442 * 
% Corridor 0.557 ** 0.317  0.529 ** 0.734 ** 
% Staircase -0.076  -0.202  -0.009  -0.015  
% Stepping Bias -0.254 ** 0.223  -0.205  -0.269  
Gait (stride length left) 0.184 * 0.087  -0.009  0.248  
Activity Perseverative 0.136  -0.009  0.258  0.110  
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Fig. 3.4. Pearson’s correlations between 
percentage of cells remaining in the SNc 
of mice lesioned to the striatum, MFB 
and SNc and deficits on the balance 
beam (A), corridor (B) and rotarod (C). 
Significance is indicated by *, p<0.05 
or  **, p<0.01.  
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3.3.5. Correlation of Motor Deficits and Lesion Extent in the VTA 
The correlations between the percentage of dopaminergic cell bodies preserved in the VTA 
and performance on each of the behavioural tests are indicated in Table 3.2. The proportion of 
remaining cells in the VTA for all groups correlated robustly with performance on the cylinder 
test (r= -0.516, p<0.01). Moderate to weak correlations were also evident between the VTA 
cell counts and deficits incurred on the balance beam test (r= -0.425, p<0.01), the stepping test 
(r= 0.400, p<0.01), total amphetamine-induced rotations (r= -0.698, p<0.01), the corridor test 
(r= 0.383, p<0.01), total spontaneous rotations (r= -0.485, p<0.01), total apomorphine-
induced rotations (r= 0.450, p<0.01) and performance on the rotarod (r= 0.275, p<0.01). All 
other tests did not reach significance. When assessing each group individually, the percentage 
of remaining VTA cells correlated significantly with behaviour on the corridor and balance 
beam tests for the MFB and SN lesion group. Conversely the cylinder test correlated 
significantly with VTA dopamine depletion in the Striatal and MFB lesion groups. Total 
amphetamine mediated turns and the stepping tests were exclusively correlated to the Striatal 
lesion group and spontaneous rotation only with the MFB group. 
When controlling for the remaining percentage of SNc cell counts with partial correlation 
analysis, overall correlations between cells remaining in the VTA with the performance on the 
cylinder test (r= -0.238, p<0.05) and balance beam (r= -0.244, p<0.05) remained significant, 
whereas all other tests that had previously been deemed significant by Pearson’s correlation 
analysis (Table 3.2), failed to reach significance in the present analysis.  
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Table 3.2. Pearson’s correlation coefficients between percentage of cells remaining in the 
VTA of mice lesioned to the striatum, MFB and SN with deficits on a battery of motor hand 
tests. Significance is indicated by p<0.05* and p<0.01**.Values are expressed as means ± 
SEM. 
 
 
 
 
 
 
Hand test/ Group Overall  Striatum  MFB  SN  
Rotarod 0.275 ** 0.018  0.296  0.171  
Cage lid 0.080  -0.325 * -0.254  0.368 * 
Amphetamine Rot (total) -0.698 ** -0.623 ** -0.810 ** -0.619 ** 
Apomorphine Rot (total)  0.548 ** 0.359 * 0.665 ** 0.476 ** 
Spontaneous Rot (total)  -0.485 ** -0.153  -0.671 ** -0.630 ** 
% Balance Beam -0.425 ** -0.322  -0.408 * -0.653 ** 
% Cylinder -0.516 ** -0.340 * -0.797 ** -0.180  
% Corridor 0.383 ** -0.035  0.568 ** 0.532 ** 
% Staircase 0.016  -0.234  0.213  0.317  
% Stepping Bias 0.400 ** 0.374 * 0.333  0.209  
Gait (stride length left) 0.081  -0.063  0.297  0.151  
Activity Perseverative 0.156  -0.019  0.185  0.252  
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3.4. Discussion 
This study uses 9 different hand tests and drug-induced rotation without initial screening, 
ensuring that groups with a wide range of denervation are able to display group differences 
between lesion placements and dopamine cell loss levels. Since behavioural and 
histopathological differences were found between mice lesioned at different levels of the 
nigrostriatal pathway, this study provides a randomised and blind assessment and comparison 
of the three hemi-parkinsonian models currently used in the literature. The data gathered from 
this investigation has allowed for the fullest behavioural characterisation of 6-OHDA lesioned 
mice to date. In previous studies, no more than four hand tests have been used to quantify 
deficits in mice with near to complete lesions, and only following prior screening with psycho-
stimulant induced rotation. This has the effect of skewing the data, excluding mice with partial 
or poor lesions (Grealish et al., 2010b, Iancu et al., 2005). The differences between previous 
studies to those shown here, the outcome of lesion surgery, behaviour and histological 
correlates are discussed below.  
 
3.4.1. 6-OHDA Lesion Efficiency 
All 6-OHDA lesions produced a marked degeneration of the dopaminergic neurons in the 
midbrain and denervation of TH immuno-positive fibres in the striatum. There were clear 
differences in lesion efficiency between the three target sites of 6-OHDA injection, with the 
Striatal lesion group having the most successfully lesioned mice, the most marked cell loss on 
the ipsilateral side and had the smallest within-group variability. This is in contrast to the MFB 
and SN groups; there were a larger proportion of mice with very small and partial lesions, 
although mice that have died are likely to have near complete lesions, biasing the lesion 
success rate (‘very small’, ‘partial’, and ‘near to complete’ are defined in section 3.3.2.). As 
expected, successful lesions aimed at the MFB were near to complete, extending their 
degeneration in the midbrain, to parts of the VTA and hence ventral striatum, as shown 
previously using this lesion type (Kirik et al., 1998, Grealish et al., 2008a, Francardo et al., 
2011a). Lesions targeted at the SN produced more focal dopaminergic cell depletion, largely 
sparing the VTA and ventral striatum. MFB lesions produced the largest depletion of cell 
bodies in the SNc and VTA, denoting the degradation of fibres in the whole striatum. The 
degree of degeneration in the ventral striatum and VTA was more variable and less severe in 
the other two lesion groups, with dopamine depletion primarily restricted to the SNc and the 
dorsal striatum in the majority of cases. Discussed below are how these unique patterns of 
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denervation, and the different proportion of mice with ‘very small’ and ‘near to complete’ 
lesions in each group, impact on survival and behavioural outcome measures. 
 
3.4.2. Mortality Rate Improvement 
This study also highlights that 6-OHDA lesion efficiency has direct consequences on the 
survival of mice. The surgical and husbandry protocols used previously have led to reported 
death rates of up to 80% of mice, which appears to have resulted in a shift from the use of 
MFB lesions to those of the striatum and SN. This is probably based on the presumption that 
non-specific or bilateral damage is caused during this lesion, which is quite close to the brain 
midline. In particular high mortality rates have been reported with lesions aimed at the MFB 
(Grealish et al., 2010b, Cenci and Lundblad, 2007, Lundblad et al., 2004b). However, 
following a stringent post-surgical care regime, mortality and weight loss in this study were 
minimal, and the survival rate in the MFB lesioned group was greater than 80%, in agreement 
with another recent study (Francardo et al., 2011b). All animals required post-surgical care for 
two weeks, but this was most needed for the MFB lesion group, which is likely to be due to 
both dopaminergic and non-dopaminergic depletion to mesocorticolimbic projections outside 
the nigrostriatal pathway itself. The levels of dopaminergic depletion likely remain the largest 
contributing factor to survival, since MFB lesions typically spare less neurons. There was no 
evidence from any of the lesion types that the bilateral loss of dopaminergic neurons occurred, 
suggesting that this is not the cause of high mortality in other studies. Lesion site along the 
nigrostriatal pathway dictates the approximate latency to death post-surgery, for example 
death on the first few days following the lesion is possible if 6-OHDA is injected directly to 
the SN. Mice are likely to die in the second week after MFB and Striatal lesions as the 
neurotoxin is delayed from reaching the SN by retrograde transport (Alvarez-Fischer et al., 
2008, Marinova-Mutafchieva et al., 2009, Walsh et al., 2011, Blandini et al., 2007a). Low 
mortality rates due to limited drinking and eating may also be linked to limbic functions of the 
ventral striatum, therefore the greater sparing of the VTA in SN and Striatal lesioned groups 
may have contributed to enhanced survival. 
 
3.4.3. Deficits on Behavioural Tests 
Group deficits caused by the lesion on behavioural tests remain one of the most important and 
reliable means to initially screen for adequate dopamine depletion, without pre-selection of 
mice with the biggest lesions. In this study the success of hand tests to determine group 
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deficits in comparison to their unlesioned counterparts depend on the initial site of 6-OHDA 
injection. The cylinder and inverted cage lid tests were only useful in distinguishing Striatal 
lesions, whereas the corridor test was able to detect a group deficit in mice with MFB and 
Striatal lesions. The novel corridor test has been shown to be sensitive to unilateral 6-OHDA 
lesions aimed at the mouse SN (Grealish et al., 2010b), however here no SN group effects 
were observed on this task. These differences most likely result from selection of the 
experimental cohort and their respective overall degree of cell loss. In the previous study, 40 
mice were selected from 122, to represent all subjects of a defined mild, intermediate and 
severe lesion type (Grealish et al., 2010b), where even mice with a mild lesion had a 71% 
reduction of dopaminergic SNc cells. The present study did not remove any mice from the 
lesion cohorts and hence incorporated a wider range of dopamine depletions, most likely 
resulting in the lack of effect of the corridor test in distinguishing SN lesions. The cylinder test 
results presented here are comparable to those seen in the unilateral lesion rat models of PD 
(Lundblad et al., 2004b, Grealish et al., 2010b, Iancu et al., 2005). The lack of deficits in gait, 
was reiterated in another mouse study (Grealish et al., 2010b), and these are in contrast to the 
outcome of this test in unilateral 6-OHDA rat model (Grealish et al., 2008a, Kirik et al., 1998, 
Olsson et al., 1995). Equally, gait analysis has been shown to be sensitive to abnormalities in 
gait of transgenic and lesioned rodents (Brooks et al., 2004b, Carter et al., 1999, Schallert et 
al., 1978), but was not sensitive enough to detect differences in this study. In this study the 
balance beam test detected deficits in MFB and SN groups compared to intact control mice, 
thus indicating that gait for controlled movements may have been impaired, however these 
may partly depend on the lack of co-ordination. In addition, basal locomotor activity did not 
show significant differences between any of the groups, in agreement with the Lundblad et al. 
(2004) study. Locomotor activity was one of the last tests to be carried out and it is possible 
that the lack of movement change was due to spontaneous recovery, as there was reportedly a 
small effect shortly after the lesion in another study (Lundblad et al., 2004b). As an automated 
system was used, behavioural observations used in an open field test were not possible and 
changes in grooming, rearing and time spent on the inside quadrant may have been missed.  
 
Drug-induced rotation remains the most widely used measure of unilateral dopamine 
depletion. However, its use in the mouse has given mixed success to date. In the literature, a 
wide range of doses of amphetamine and apomorphine have been used (amphetamine: 0.25- 
8mg/kg and apomorphine: 0.01- 4mg/kg) (Grealish et al., 2010b, Randall, 1984, Iancu et al., 
2005, Mandel and Randall, 1985, Von Voigtlander and Moore, 1973, Brundin et al., 1986, 
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Torello et al., 1983) with similarly variable outcomes. Amphetamine-induced rotation was the 
most sensitive behavioural measure and was able to identify robust differences in all lesion 
groups. Apomorphine-mediated rotation was a good measure of MFB and Striatal lesions but 
failed to determine dopamine denervation in the SN group. High doses of apomorphine used 
in some studies would have produced strong stereotypic behaviours, slowing movement 
overall and confounding results (Iancu et al., 2005). In this study 0.05 mg/kg apomorphine 
was informative of dopamine cell loss, in all three lesion groups and no stereotypic behaviour 
was observed, although the effect size was small for lesions aimed directly at the SN. In mice 
it is common to give multiple apomorphine injections over a number consecutive days, to 
increase the rotational response prior to the test day (Grealish et al., 2010b). In this present 
study, mice only received a single injection, administered on the day of testing, yet a robust 
turning response was seen. It can therefore be suggested that priming the animals with 
apomorphine is not only unnecessary, but causes long term post-synaptic changes that may 
confound the results from other behavioural tests, and which is likely to render the mice 
unsuitable for use in other experiments, such as those centred around chronic L-DOPA 
treatment (see Chapter 4). Spontaneous rotation in a novel environment was only noted in the 
MFB group. It can be speculated that dopamine is released by anxiety from the novel 
environment causing ipsilateral locomotion. A high degree of dopamine denervation is needed 
to drive this effect, and dopamine release by remaining terminals in SN and Striatal groups is 
enough to overcome the effect of the anxiety-mediated dopamine release on the contralateral 
side. 
 
3.4.3. Correlations between Midbrain Cell Loss and Behavioural Deficits. 
Overall effects by group do not allow for the analysis of how accurate these tests are at 
selecting for various levels of dopamine depletion. Therefore, a correlation analysis was used. 
The most highly correlative tests with behavioural outcome measures, gave a large enough and 
consistent deviation between ‘very small’, ‘partial’ and ‘near to complete’ lesions. 
Behavioural assessment by correlation revealed that drug mediated rotation, spontaneous 
rotation, corridor test, cylinder test, and balance beam were sensitive to dopaminergic 
depletion of the SNc, even when using a partial correlation to exclude potentially confounding 
VTA cell loss. Conversely, there were also a number of tests which were correlated to 
remaining cells of the VTA, however when controlling for remaining SNc cell percentage by 
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partial correlation, the stepping test and the gait analysis were no longer significant, 
suggesting that this effect was at least partially driven by the influence of the SNc.  
 
Interestingly, when you exclude the variance caused by VTA cell loss, the corridor test 
became correlated with remaining SNc cell percentage of this group, whereas performance on 
the cylinder test was no longer significant. These provide an important insight on the 
mechanisms of these hand tests and suggest that there may be a mesolimbic element 
influenced by the ventral striatum in the cylinder test, which might also be detrimental to the 
capacity to retrieve pellets in a linear corridor test. The MFB group deficits were the most 
correlative to cell loss in the SNc, even when controlling for VTA co-correlation. This may 
have resulted from the high degree of intra-group lesion variability and is suggestive that high 
losses of cells in the SNc may be alone enough to cause deficits on these tests regardless of 
VTA damage. Using partial correlation analysis there were no longer influences of the VTA 
on any rotational measure. It suggested that VTA damage of 30% found in our mice were not 
sufficient to alter rotation further than that driven by SNc cell loss, in agreement with the rat 
model (Moore et al., 2001). Interestingly, VTA cell losses of 60% or greater may reduce 
amphetamine hyper-responsiveness and amphetamine-induced rotation (Koob et al., 1981, 
Moore et al., 2001), not seen in this study. The models presented here may therefore reflect the 
patterns of cell loss in late stage PD patients where A10 neurons are largely spared. These 
results demonstrate that the sensitivity of the behavioural tasks to motor deficits varies in 
magnitude and deficits are differentially correlated with cell loss in the SNc and VTA. It can 
be suggested from this data that the use of multiple tests in the assessment of hemi-
parkinsonian mice is important. The best approach may be the use of a drug-induced rotation, 
followed by a small number of behavioural tests, without rotation pre-selection. However, 
tests used will be dependent on lesion type. Further, these studies report the first use of 
spontaneous rotational assessment and the balance beam test for the assessment of mouse 
lesions, thereby validating their use in MFB and MFB/SN lesion groups respectively.  
 
3.4.4. Conclusions 
The typical survival rate of between 95-100% seen in hemi-parkinsonian MFB lesioned rats 
(Torres et al., 2011) is still near impossible to achieve in the mouse, however intensive post-
operative care enabled mortality rates to kept to a minimum ensuring meaningful results and 
compliance with home office rules for this type of procedure. Overall, intra-striatal neurotoxin 
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injections caused clear motor impairments, likely due to the relative hit rate consistency and 
reduced variability of lesions between mice. Targeting the neurotoxin to the SN or MFB was 
more variable, although in successfully lesioned mice the overall level of ipsilateral 
dopaminergic cell loss in the SNc and VTA was greater. This study has allowed for a 
comprehensive evaluation of motor impairments and dopaminergic loss in three 6-OHDA 
models. Deficits in mice can be assessed robustly in hemi-parkinsonian mice to rival threshold 
levels of deficit established in the rat. This was found to be achieved regardless of 6-OHDA 
injection site; although this study demonstrates the need to choose suitable tests specifically 
for each lesion type. Tests indicated in Table 3.3 show those that could be used for groups of 
mice of each type (without excluding mice by any other motor deficit measure), based off both 
group deficit measures and ability to correlate to dopamine loss (Table 3.3).  
 
 
 
 
 
 
 
 
 
 
 
Table 3.3. Summary table of the most sensitive tests that may be used for each lesion type, as 
defined both by group deficit and the correlative capacity of each test to the degree of 
dopamine depletion. Group deficits on behavioural hand tests are indicated in grey, where 
mice with very small (<25%), partial (26 – 89%) and near to complete lesions (>90%) are all 
included. Checked squares indicate the 4 most highly correlative hand tests to cell loss in the 
SNc when controlling for losses in the VTA.  
Hand test/ Group Striatum MFB SN 
Rotarod    
Cage lid    
Amphetamine Rot  xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx 
Apomorphine Rot  xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx 
Spontaneous Rot  xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx 
Balance Beam    
Cylinder    
Corridor xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx 
Staircase    
Stepping     
Gait     
Activity     
106 
 
 
Furthermore, I conclude that drug-mediated rotation, spontaneous rotation, corridor test, 
cylinder test, and balance beam tests are the most reliable and sensitive for indicating the 
degree of dopamine depletion. This detailed optimisation of the 6-OHDA mouse proved 
invaluable in the latter parts of this thesis, where the model enabled new insights into changes 
the molecular biomarkers of L-DOPA function (Chapter 5), and in the transplantation of 
mouse-derived primary foetal dopamine cells that were a pre-requisite for the creation of a 
mouse model of GID (Chapter 8). Prior to these studies however the in-depth characterisation 
of AIMs induced by escalating doses of L-DOPA in the three 6-OHDA lesion models are 
described (Chapter 4). 
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4. Assessment of L-DOPA induced dyskinesia in 
the 6-OHDA-lesioned mouse 
Summary 
The location of the 6-OHDA lesion along the nigrostriatal pathway determines the extent and 
pattern of neuropathology, behavioural phenotypes and responses to the dopamine precursor 
L-DOPA. The objectives of this chapter were to examine the relationship between lesion 
extent and development of LID and to determine if these tasks could be predictive of 
dyskinesia development.  Mice were lesioned with 6-OHDA lesions of the striatum, MFB and 
SN and tested on a variety of motor tasks established for use in rats and mice (discussed fully 
in Chapter 1). The most impaired animals in each lesion group were given L-DOPA in 
progressively increasing doses and assessed for LID at each stage. Many of the motor tests 
correlated with the extent of nigrostriatal dopamine depletion but only rotarod, apomorphine-
induced rotations and locomotor activities were potentially predictive of the development of 
dyskinesia at 6mg/kg and 25mg/kg of L-DOPA. The losses of dopaminergic fibre innervation 
and sparing of serotonergic density in the ventral and dorsal striatum also differed depending 
on lesion location along the nigro-striatial tract and these neuropathological patterns were also 
correlated with LID. In addition, the expression of FosB/∆FosB was differently upregulated in 
the striatum and NAcc regions in dyskinetic mice according to lesion type.  
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4.1 Introduction 
PD patients are commonly treated by the administration of the dopamine receptor agonists and 
with disease progression, the dopamine precursor L-DOPA.  However, administration of L-
DOPA over a prolonged period of time leads to the development of choreic and/or dystonic 
AIMs termed dyskinesia. These behaviours were first modelled in the MPTP-treated primate 
(Jenner et al., 1984) and more recently the 6-OHDA lesioned rat, which has been well 
validated and established as an accurate, more affordable means of assessing the 
dyskinesiogenic potential of L-DOPA (Cenci et al., 1998). In rats, the extent and location of 
the lesion causes variation in the severity and onset of dyskinesia in a dose responsive manner 
and chronic L-DOPA therapy is associated with an increase in prodynorphin within the 
striatum mediated by an upregulation of the FosB/∆FosB transcription factor and other 
immediately early genes (Cao et al., 2010, Lane et al., 2009b, Pavon et al., 2006b, Westin et 
al., 2001, Rodriguez et al., 2001, Doucet et al., 1996). Subsequently, AIMs in both rats and 
mice have been validated and hence can be scored on specifically designed rating scales 
(Cenci and Lundblad, 2007, Winkler et al., 2002b), however in mice LID has not been fully 
validated and the best injection site of 6-OHDA along the nigrostriatal pathway for the 
development and hallmarks of AIMs has not yet been established. The most popular theory of 
LID development is that spared 5-HT neurones in the lesioned hemisphere cause the sporadic 
and unregulated release of dopamine, causing AIMs through uncontrolled post-synaptic 
simulation. Hyperinnervation of 5-HT has been found in rodent and primate models PD 
(Maeda et al., 1994, Gil et al., 2010, Rozas et al., 1998b, Maeda et al., 2003b, Zhou et al., 
1991a), although the extent at which 5-HT fibre innervations contribute to the AIMs is 
unknown and debated, with little research carried out in the mouse model. 
 
Motor and AIMs trends following L-DOPA have not been studied in detail and it remains to 
be seen if patterns established are equal to that of the rat. Prolonged daily L-DOPA treatment 
of 25mg/kg in rats with a full unilateral nigrostriatal lesion, and causes a ‘wearing off’ of the 
duration and increase in magnitude of the rotational response from the second to the third 
week of treatment, not seen in the terminally lesioned group (Papa et al., 1994, Marin et al., 
2004). An increase locomotor sensitisation over time has not yet been reported in mice 
however a dose dependent increase in rotation was seen in Striatal and MFB groups (Lundblad 
et al., 2004a). Here we aim to compare dose dependent rotational differences and overall 
locomotion in lesioned mice in response to L-DOPA.  
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Another important factor to consider is whether histological markers, that have previously 
been linked with LID (levels of: TH, 5-HT and FosB/∆FosB), may be differently correlated 
with AIMs depending on lesion type. Results in this chapter will analyse whether these three 
models allow for varying destruction of 5-HT and TH fibres, and complete or partial 
destruction of the nigrostriatal pathway. Further, these histological were correlated with 
FosB/∆FosB protein expression in post-synaptic cells following L-DOPA, as this has 
previously been correlated to the denervation of TH immuno-reactive fibres in mice and rat 6-
OHDA lesion models (Andersson et al., 1999, Andersson et al., 2003, Francardo et al., 2011b, 
Lundblad et al., 2004b). 
 
The emergence of TH positive cells in the striatum of lesioned animals has triggered much 
interest of late, found in humans, MPTP treated non-human primates and unilateral 6-OHDA 
lesioned mice (Darmopil et al., 2008, Mazloom and Smith, 2006, Tande et al., 2006, 
Francardo et al., 2011b). TH neurones in the striatum were not found to be the result of 
neurogenesis and previous co-localisation studies have pointed towards a phenotypic shift 
from previously exclusive GABAergic cells to dopaminergic like cells (Darmopil et al., 2008, 
Tande et al., 2006). TH cells were found to be expressed 1 week post lesion and appear to be 
maintained by long-term L-DOPA treatment (Darmopil et al., 2008). However, it is still 
unclear how the presence of these cells correlates to dopaminergic cell loss within the SNpc 
and AIM development in response to L-DOPA in each lesion type. 
 
In Chapter 3 it was shown that dopaminergic histological changes post lesion may be 
correlated with behavioural deficits seen on a wide range of hand tests. It remains unclear 
however if motor hand test scores can be used to predict animals which will become the most 
dyskinetic following L-DOPA priming and also whether the criteria, used to determine lesion 
extent, differs from that used to discriminate AIM development. Therefore this chapter 
compares both AIMs initiated at escalating doses of L-DOPA between each lesion group, and 
correlations of dyskinesia scores at 6mg/kg and 25mg/kg of L-DOPA with deficits on 
behavioural hand tests and histological measures. 
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4.2 Experimental design 
The outline of this chapter is indicated in Figure 4.1. 120 adult male mice were used in this 
study. 6-OHDA was injected unilaterally in the SN (n=35), MFB (n=35), and striatum (n=35), 
with a group of intact control animals (n=10). Surgical procedures are detailed in Chapter 2. 
Surviving mice were then subject to an array of motor hand tests, see Chapter 3. In this study, 
10 mice from each lesion group were chosen for dyskinesia assessment, all displayed 
significant contralateral akinesia and motor coordination deficits on the cylinder, apomorphine 
rotation, amphetamine rotation and corridor compared to unlesioned controls. Hence ‘failed’ 
and ‘partially lesioned mice’ (defined in Chapter 2) were likely excluded for the purpose of 
these experiments. All mice were treated daily with L-DOPA and AIMs assessed every 3-4 
days. L-DOPA methyl ester HCl and the peripheral DOPA decarboxylase inhibitor: 
benserazide HCl (Sigma Aldrich) were dissolved in 0.9% saline immediately before use. The 
drugs were injected at the volume of 10ml/kg in a single daily intraperitoneal (i.p.) injection. 
Chronic treatment with L-DOPA was administered for daily for 64 days and consisted of four 
phases with incremental doses: - 
 
• Phase 1 (days 1-13): all groups, at 2 mg/kg of L-DOPAwith 2 mg/kg of benserazide.  
• Phase 2 (days 14-40): all groups, 6mg/kg of L-DOPA with 6mg/kg of benzerazide.  
• Phase 3 (day 41-55): all groups, 12 mg/kg of L-DOPA and 12 mg/kg of benzerazide.  
• Phase 4 (days 56-59): all groups, 25mg/kg of L-DOPA and 12mg/kg of benzerazide*.  
*the SN group continued to received L-dopa for a further 5 days as behaviours had not 
reached a plateau.  
 
Animals were killed using terminal anaesthesia with perfuse fixation 24 hours after the last 
injection and brains harvested for histology.  
 
For statistical analysis behavioural measures in corridor, grip strength, rotarod, balance beam, 
apomorphine rotation, amphetamine rotation, spontaneous rotation, staircase, activity and 
cylinder tests and TH positive cell counts are expressed as a percentage of the intact side. Cell 
bodies were counted under the Lecia light microscope in the VTA and SNpc at the level of the 
medial terminal nucleus of the accessory nucleus of the optic tract interception as described by 
(Dowd and Dunnett, 2004). The dencity of TH- and 5-HT-immunopositive neurons were 
assessed in the ventral and dorsal striatum, from images of every 4th section (taken with Leica 
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DFC420 camera and Lecia application V3.6 software) using the Zeiss imager 22 Fluorescence 
microscope with Axiovision 4 software and on ImageJ software (Version 1.42, National 
Institutes of Health, USA) and TH and 5-HT density levels were normalised to density levels 
of the corpus collosum. SPSS (version 16) was used to deduce statistical significance for all 
correlations and ANOVAs with Dunnett post hoc tests. TH cells within the striatum were 
counted in all sections from a 1 in 6 series through the mouse brain and corrected 
formulaically to deduce cell numbers in whole striatum.   
 
 
 
 
Fig. 4.1. Graphical representation of the experimental design. Motor tests were carried out 
consecutively: Staircase (S), Corridor (C), balance beam (B), spontaneous rotation (S), 
cylinder (Cy), rotarod (R), inverted cage lid (I), locomotor activity (L) amphetamine rotation 
(Am) and apomorphine rotation sessions (Ap). Grey arrow heads indicate the days in which 
dyskinesia was scored. Times are indicated in hours (h), days and weeks (w). 
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4.3 Results 
 
4.3.1. Behavioural deficits in mice with 6-OHDA lesions of the Striatum, MFB or 
SN 
Deficits on motor tests carried out prior to L-DOPA treatment were not significantly different 
between lesion only and L-DOPA treated lesion groups. Compared to non-operated controls, 
there was an overall lesion effect of dopaminergic depletion on behaviour (Table 4.1).  
Lesioned animals showed deficits in the rotarod (F3,69 = 28.76, p <0.001), the balance beam 
(F3,69 = 5.34, p <0.01), inverted cagelid (F3,69 = 2.91, p <0.05), time on balance beam (F3,69 = 
2.92, p <0.05), cylinder (F3,69 = 4.51, p <0.01), staircase (F3,69 = 3.31, p <0.05), corridor (F3,69 = 
3.04, p <0.01), and basal locomotor activity (F3,69 = 3.83, p <0.01). Rotational behaviours also 
demonstrated a clear lesion effect in total apomorphine (F3,69 = 9.18, p <0.001), total 
amphetamine (F3,69 = 4.80, p <0.01) and total spontaneous (F3,69 = 16.33, p <0.001) test 
paradigms. Specific deficits according to lesion type were noted by pair wise comparisons as 
indicated on Table 4.1, where deficits were less pronounced for individual lesion groups.  
113 
 
 
 
Table 4.1. Deficits in mice lesioned at the level of the striatum, MFB or SN compared to 
intact controls on a battery of motor hand tests (mice with failed and partial lesions excluded). 
Significant differences are indicated by p<0.05*, p<0.01** and p<0.001***. Values are 
expressed as means ± SEM. 
 
 
Lesion Type /  
Hand test 
Intact Control Striatum  MFB SN 
Rotarod 
 
131.65 ± 6.08 66.75 ± 5.95*** 45.82 ± 2.89*** 77.15 ± 6.97*** 
Cagelid 
 
215.26 ± 30.85 
 
117.47 ± 11.09* 
 
155.84 ± 17.91 
 
153.09 ± 24.60 
 
Amphetamine 
rot (total) 
26.72 ± 6.84 81.61 ± 6.60*** 
 
87.55 ± 11.88*** 
 
72.34 ± 11.47*** 
 
Apomorphine 
Rot (total) 
2.70 ± 0.39 29.41 ± 4.44*** 
 
59.65 ± 9.43*** 33.10 ± 6.16*** 
Spontaneous 
Rot (total) 
8.20 ± 0.78 
 
12.90 ± 1.45 22.35 ± 2.31*** 8.70 ± 0.76 
 
% Balance  
Beam 
68.62 ± 8.13 
 
73.52 ± 3.07 73.9 ± 3.22* 
 
80.21 ± 3.59 
 
% Cylinder 
 
57.82 ± 2.12 
 
77.18 ± 3.43* 73.41 ± 3.21* 66.37 ± 3.91 
% Corridor 
 
36.69 ± 6.04 
 
18.69 ± 3.42* 
 
16.81 ± 3.07* 
 
27.17 ± 4.41 
 
% Staircase 
 
49.85 ± 2.33 49.61 ± 0.69 52.98 ± 0.76* 46.14 ± 2.41 
Beam time 
 
13.59 ± 2.57 
 
16.79 ± 1.42 
 
20.90 ± 1.16 17.27 ± 1.68 
Activity 
Preseverative 
663.40 ± 27.43 
 
631.70 ± 46.99 469.50 ± 25.70 710.50 ± 80.93 
Activity non-
preseverative 
1320.70 ± 76.13 1382.60 ± 147.61 
 
1137.70 ± 71.45 
 
1429.40 ± 191.03 
 
114 
 
 
 
4.3.2 Histological comparison of mice with 6-OHDA lesions of the Striatum, 
MFB or SN  
Mice were pre-selected from the cohort used in Chapter 1 to have substantial TH cell losses 
based on motor hand tests. Fig. 4.2A-H show representative photomicrographs of TH and 5-
HT neuronal loss present in all lesion groups. Dopamine depletion in the SNc was consistently 
high in all lesioned mice (Fig. 4.2M; F3,69 = 14.80, p<0.001;) compared to intact controls, 
which was also reflected in a substantial reduction in dorsal TH density levels. Overall there 
was also a substantial loss in the percentage of cells remaining in VTA (Fig. 4.2N; F3,69 = 
11.63, p<0.001) and this was reflected in corresponding TH fibre loss in the ventral striatum. 
Mice lesioned at the SN or striatum had a greater sparing of fibres in the ventral striatum than 
those with an MFB lesion, yet a high depletion was seen in all groups (Fig. 4.2P; F3,69 = 13.05, 
p<0.001).  
 
The sparing of 5-HT fibres were highly variable within groups (Fig. 4.2I-L), yet little sparing 
was evident in both the dorsal (Fig. 4.2Q; F3,69 = 3.14, p<0.05) and ventral striatum (Fig. 4.2R; 
F3,69 = 3.15, p<0.05). Specifically, a lack of sparing in dorsal and ventral striatum 5-HT 
density was only seen in the MFB lesioned group (p<0.05), with no difference between lesion 
only and L-DOPA treated lesioned mice. 
 
Fig 4.3 illustrates that the most significant increase in FosB/∆FosB levels was found within 
the dorsal striatum in all lesion groups (A-H) where there was a significant effect of L-DOPA 
treatment (Fig. 4.3I; F2,67 = 23.43, p<0.001) compared to lesion only mice and levels seen in 
the intact control group.  For the dorsal region there was also an effect of lesion type (F3,69 = 
21.04, p<0.001), where the highest FosB/∆FosB expression found in the L-DOPA-treated 
MFB lesioned group compared to SN or striatal lesioned groups receiving the same treatment 
(p<0.001). When assessed in the NAcc core the number of FosB/∆FosB positive cells was 
only significantly increased in the Striatal lesioned group following L-DOPA treatment (Fig. 
4.3J; p<0.05). L-DOPA treatment also increased the number of FosB/∆FosB positive cells 
(F2,67 = 18.69, p<0.001; Fig. 4.3k) within the NAcc shell region, with no overall difference 
between lesion type.  
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Fig. 4.2. Photomicrographs of the SNc in mice, immunostained with TH, in an unlesioned 
control mouse (A) and mice with a 6-OHDA lesion of the Striatum (B), MFB (C) and SN (D) 
(Scale bar 400µm). Photomicrographs are also shown for whole forebrain sections immuno 
stained for TH (E-H) and 5-HT (I-L) on (scale bar 2mm). % TH cell loss from the SNc and 
VTA is shown for the 6-OHDA lesioned, L-DOPA-treated groups compared to the unlesioned 
side (M,N). Optical density was used to measure relative TH and 5-HT expression in the 
dorsal striatum and ventral striatum for each lesion type (O-R). Significant deviations from 
intact control animals and between lesion groups are indicated by p<0.05*, p<0.01** and 
p<0.001***. Values are expressed as means ± SEM. 
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Fig. 4.3. Photomicrographs of sections immuno-stained for FosB/∆FosB on mice with a 6-
OHDA lesion of the striatum, MFB and SN compared to unlesioned controls (scale bar 2mm; 
A-D) and at 5x magnification FosB/∆FosB (E-H), where the scale bar shown is 500µm. The 
number of FosB/∆FosB positive cells within the whole striatum, NAcc core and NAcc shell 
were counted (I-K). Significant differences from intact control animals and between L-DOPA 
treated groups are indicated by p<0.05*, p<0.01** and p<0.001***. Values are expressed as 
means ± SEM.
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4.3.3 L-DOPA-induced AIMs, activity and rotation. 
The analysis of LID in each lesion group was only undertaken in animals with the largest 
behavioural deficits, indicating a near to complete lesion, as rodents with partial lesions are 
not responsive to low dose L-DOPA (Winkler et al., 2002b, Francardo et al., 2011b). In 
general, AIMs in all lesioned mice treated with chronic L-DOPA, increased at each dose over 
the course of L-DOPA administration (F4,108 = 15.42, p<0.001). Moreover, there was a 
difference between the magnitude of the AIMs that were expressed the lesion groups and the 
L-DOPA dose at which AIMs were first exhibited (Group, F2,27 = 14.15, p <0.001; Group x 
Phase, F8,108 = 7.71, p<0.001). Fig. 4.4A-B highlights that the lowest dose of L-DOPA 
(2mg/kg) induced minor AIMs only in the mice with MFB lesions. The MFB lesion group 
continued to express AIMs at progressively higher levels as the L-DOPA dose was increased 
in phase 2 (6mg/kg), phase 3 (12mg/kg) and phase 4 (25 mg/kg), compared to SN and Striatal 
lesion types. In addition, the SN and Striatal groups did not display significant AIMs until 
phase 3 (12mg/kg), but the severity of AIMs then increased further at phase 4 (25mg/kg). 
AIMs in the MFB group were consistently greater than those in the SN and Striatal groups 
throughout all phases (Fig. 4.4B).  
Horizontal L-DOPA induced locomotor activity increased between 2mg/kg and 6mg/kg and 
remained significantly elevated for higher doses (Fig. 4.4 C,D; F4,108= 5.19, p<0.001). There 
was no significant overall effect of lesion type, although there was a significant Group x Phase 
interaction (Fig. 4.4C,D; F8,108 = 3.71, p<0.001). Further, the percentage of animals of the total 
cohort that displayed L-DOPA driven turning behaviour, recorded as an observation in the 
activity cage, gradually increased over the 4 phases (Fig. 4.4E). A dose-dependent increase in 
total net rotations (F1,28 = 4.21, p<0.05) was also noted, between the plateau phases 2 
(6mg/kg) and 4 (25mg/kg). Subsequent post hoc analysis found this trend was only significant 
in the Striatal group (Fig. 4.4F; p<0.05). 
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Fig. 4.4.  AIMs induced by L-DOPA administration, in mice with striatal, nigral or MFB 6-
OHDA lesions scored on the Cenci and Lundblad rating scale each day (A) and averaged for 
each phase (B), where phase 1 = 2(2)mg/kg (days 1-13), phase 2 = 6(6)mg/kg (days 14-40), 
phase 3 = 12(12)mg/kg (days 41-55) and phase 4 = 25(12)mg/kg (days 56-59); brackets 
indicate dose of benzerazide used. Simulateous horizontal locomotor recorded scored each day 
(C) and mean activity are shown (D).  Also displayed are the percentage of mice in each group 
that turned in response L-DOPA treatment by day (E) and net controlateral rotations for each 
lesion type scored at 6mg/kg and 25mg/kg (F). post hoc comparisons from are indicated as 
p<0.01** and p<0.001*** and compared to the MFB group at each phase as p<0.05
† 
Significance found between rotational bias between 6mg/kg and 12mg/kg are annotated as 
p<0.05
†
. Values are expressed as means ± SEM. 
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4.3.4 Correlation of dyskinesia with behavioural hand test scores. 
The severity of AIMs at the end of phases 2 and 4 were correlated with motor defects on a 
select hand tests. Table 4.2 indicates all partial Pearson’s correlation between AIMs and 
behavioural hand test scores, with SNc depletion as a control factor. Contralateral rotation in 
response to L-DOPA correlated with AIMs in all lesioned mice at 6mg/kg (r=0.422, p<0.01) 
and 25mg/kg (r=0.445, p<0.01). Table 4.2 also shows that a greater number of motor deficit 
tests correlate to AIMs induced by 25mg/kg of L-DOPA than 6mg/kg, as AIMs were at 
maximum levels. At 6mg/kg AIMs in all mice were only correlated with total apomorphine 
driven turns (r= 0.305, p<0.05), latency to fall on the rotarod (r= -0.508, p<0.01) and total 
spontaneous turns (r=0.541, p<0.01). In contrast AIMs driven by 25mg/kg were correlated to 
both non- perseverative locomotor activity (r= -0.460, p<0.05) and perseverative locomotor 
activity (r= -0.420, p<0.05) and but were no longer correlated to tests at the lower dose.  
 
When considering each lesion type (Table 4.2) the most consistent correlations with AIMs at 
6mg/kg between groups were found on deficits recorded on the rotarod (Striatum: r= -0.558, 
p<0.05, MFB: r= -0.763, p<0.05; SN: r= -0.784, p<0.01). There were also clear general 
trends in all groups for correlation to apomorphine and amphetamine rotation. Further analysis 
showed that scores on the rotarod remained correlated with AIMs elicited by 2mg/kg (r= -
0.498, p<0.01) but not 12mg/kg or 25mg/kg. In contrast correlations driven by 25mg/kg were 
found with perseverative locomotor activity and non-perseverative locomotor activity, but 
were only noted in MFB and SN lesion groups (p<0.01). Furthermore strong correlations 
between total apomorphine rotations (p<0.001) and rotarod (p<0.05) with AIMs at 25mg/kg 
were only seen in MFB lesioned mice. 
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Table 4.2. Pearson’s correlation coefficients between average AIMs at peak responses to 
6mg/kg and 25mg/kg with L-DOPA induced behaviours and tests of motor function, with 
confounding correlations between AIMs and % of cells remaining in the SNc controlled for.  
Correlation co-effects are indicated for the total L-dopa treated cohort and for each lesion 
type, where p<0.05*,  p<0.01** and p<0.001***. † indicates where correlation coefficient 
could not be deduced as all animals rotating 100% to the contralateral side of the lesion in the 
MFB group. 
Hand 
test/AIMs 
Overall Str MFB SN Overall Str MFB SN 
 6mg/kg 25mg/kg 
 
L-DOPA Rot 
(6mg/kg) 
0.422** 0.882*** -0.200 -0.492 N/A N/A N/A N/A 
L-DOPA Rot 
(25mg/kg) 
N/A N/A N/A N/A 0.445** 0.692* 0.045 0.041 
Rotarod 
 
-0.508** -0.558* -0.763* -0.784** -0.285 -0.440 -0.620* -0.517 
Cagelid 
 
0.001 -0.317 -0.201 -0.519 -0.135 0.122 -0.507 -0.445 
Amphetamine 
rot (total) 
0.140 0.454 0.308 0.339 -0.320 0.194 -0.337 -0.110 
Apomorphine 
Rot (total) 
0.305* 0.389 0.415 0.684* 0.304 -0.268 0.896*** 0.552 
Spontaneous 
Rot (total) 
0.541** 0.039 0.284 0.110 0.350 0.524 0.505 0.208 
Balance Beam 0.066 0.003 
 
0.197 0.309 0.105 -0.183 0.431 0.026 
Cylinder 
 
0.034 0.309 -0.431 -0.707* 0.139 0.567 -0.497 -0.439 
Corridor 
 
-0.182 -0.229 -0.400 -0.367 -0.198 -0.268 -0.324 -0.147 
Staircase 
 
0.156 0.170 -0.267 -0.092 0.154 -0.214 -0.395 -0.357 
Beam time 
 
0.194 0.437 0.114 0.092 0.105 0.026 -0.183 0.431 
Activity 
Preseverative 
-0.298 0.301 -0.310 -0.586 -0.420* -0.260 -0.772** -0.682* 
Activity non-
preseverative 
-0.214 -0.319 -0.241 -0.546 -0.460** -0.182 -0.699* -0.695* 
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4.3.5 Correlating AIMs with histological measures 
AIM scores could be correlated with TH, 5-HT and FosB/∆FosB differently depending on 
dose and lesion type. It can be seen from Table 4.3 that there was a correlation between cell 
loss within the SNc with AIMs score at 25mg/kg (r= -0.533, p<0.01) and the VTA with AIMs 
score at 6mg/kg (Table 4.3; r= -0.596, p<0.01). When looking more closely at individual 
lesion groups AIMs were correlated significantly in the MFB group with respect to cell counts 
within the SNc (r= -0.577, p<0.05) and the SN group with respect to the VTA (r= -0.577, 
p<0.05). Table 4.3 also shows that TH density in the dorsal striatum was correlated with 
AIMs at 6mg/kg (r= -0.341, p<0.05) and at 25mg/kg (r= -0.596, p<0.01). Similar trends in 
density were seen in respect to the ventral striatum at 25mg/kg (r= 0.554, p<0.01) with an 
overall trend at the lower dose.  
 
There was also a weak overall positive correlation with ventral 5-HT density and AIMs (Table 
4.4) at 6mg/kg (r= 0.325, p<0.05) and dorsal density at 25mg/kg (r= 0.343, p<0.05). In 
addition, L-DOPA induced AIMs were moderately correlated to 5-HT density only in the 
MFB group at 6mg/kg, within the ventral striatum (r= 0.616, p<0.05) and dorsal striatum (r= 
0.618, p<0.05). However this trend was lost at high dose L-DOPA and was not found in mice 
with SN or Striatal lesions.  
 
FosB/∆FosB cell counts within the striatum, NAcc core and NAcc shell were correlated to the 
development of AIMs in all three different unilateral lesioned mouse models (Table 4.5). At 
phase 2 (6mg/kg) AIMs and FosB/∆FosB cell counts are only positively correlated in the 
NAcc shell region (r= 0.583, p<0.05).  At 25mg/kg FosB/∆FosB is highly correlative to 
dyskinesia in the striatum (r= 0.754, p<0.01) and NAcc core (r= 0.525, p<0.01) in all mice. 
This striatal FosB/∆FosB upregulation in response to L-DOPA persists in striatum (r= 0.852, 
p<0.01), MFB (r= 0.583, p<0.05) and SN (r=0.713, p<0.05) groups, despite overt differences 
between the severity of AIMs in the three groups at phase 4 (25mg/kg). FosB/∆FosB levels do 
not correlate significantly with AIMs present from 2 or 12mg/kg of L-DOPA although a trend 
can be noted in the latter dose. In addition, a positive correlation was noted between L-DOPA 
induced rotation at 25mg/kg and FosB/∆FosB positive cells in the NAcc shell in MFB 
lesioned mice (r= 0.664, p<0.05). 
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AIMs/TH  TH Cells 
(SN) 
TH Cells 
(VTA) 
TH Density 
(Dorsal) 
TH Density 
(Ventral) 
Overall (6mg/kg) -0.310 -0.521** -0.341* -0.229 
Str (6mg/kg) 0.128 0.102 0.043 -0.172 
MFB (6mg/kg) -0.544 -0.550 -0.416 -0.529 
SN (6mg/kg) -0.379 -0.544 -0.415 -0.529 
Overall (25mg/kg) -0.533** -0.267 -0.596** -0.554** 
Str (25mg/kg) -0.527 -0.55 -0.591* -0.602* 
MFB (25mg/kg) -0.577* -0.452 -0.522 -0.653* 
SN (25mg/kg) -0.548 -0.577* -0.522 -0.563* 
 
Table 4.3. Pearson’s correlations between average integrated AIMs at 6mg/kg and 25mg/kg 
with cell counts within the SNpc and VTA and TH density values within the dorsal and ventral 
striatum of L-DOPA treated mice. Statistically significant correlation co-efficients overall and 
specifically for mice lesioned to the striatum, MFB and SN are indicated by p<0.05* and  
p<0.01**. 
 
 
 
Table 4.4. Pearson’s correlations between integrated AIMs at 6mg/kg and 25mg/kg with 5-HT 
density values in the dorsal and ventral striatum. Statistically significant correlation co-
efficients overall and specifically for mice lesioned to the striatum, MFB and SN are indicated 
by p<0.05* and  p<0.01**. 
 
 
 
AIMs/TH 5-HT Density  
(Cortex) 
5-HT Density  
(Ventral) 
5-HT Density  
(Dorsal) 
Overall (6mg/kg) 0.263 0.325* 0.245 
Str (6mg/kg) 0.226 0.051 0.193 
MFB (6mg/kg) 0.433 0.616* 0.618* 
SN (6mg/kg) 0.980 -0.054 0.168 
Overall (25mg/kg) 0.054 0.127 0.343* 
Str (25mg/kg) 0.450 -0.020 0.042 
MFB (25mg/kg) 0.131 0.432 0.415 
SN (25mg/kg) -0.100 -0.020 0.188 
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Table 4.5. FosB/∆FosB cell counts within NAcc core, NAcc shell and whole striatum 
correlated with total integrated AIM scores in L-DOPA treated mice. Statistically significant 
correlation co-efficents overall and specifically for mice lesioned to the striatum, MFB and SN 
are indicated by p<0.05* and  p<0.01**. 
 
AIMs/ FosB Cells  
(Str) 
FosB Cells  
(NAcc core) 
FosB Cells  
(NAcc shell) 
Overall (6mg/kg) 0.217 0.199 0.316* 
Str (6mg/kg) 0.216 0.390 -0.23 
MFB (6mg/kg) 0.317 0.164 0.583* 
SN (6mg/kg) 0.272 -0.052 0.138 
Overall (25mg/kg) 0.754** 0.525** 0.298 
Str (25mg/kg) 0.852** 0.469 0.195 
MFB (25mg/kg) 0.357 0.733* 0.483 
SN (25mg/kg) 0.713* 0.138 0.418 
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4.3.6 Quantification of TH positive cells in the striatum of 6-OHDA lesioned 
mice 
TH positive cells were identified in the striatum of all lesioned mice (Fig. 4.5A-C).  They 
appear medium sized, displayed apparently aspiny projections (Fig. 4.5G) and were darker in 
appearance in L-DOPA treated groups. TH positive cells were also increased significantly in 
number by L-DOPA treatment compared to lesion only controls (Fig. 4.5D-F). TH 
immunopositve cells in the striatum of lesioned mice also co-expressed GABA (Fig. 4.6), even 
after chronic L-DOPA treatment. The distribution these cells were ubiquitous across the 
lesioned striatum with little observed difference between counts in the dorsal and ventral 
striatum. There was a significant increase of TH cell occurrence by L-DOPA treatment in the 
whole striatum (F1,59 = 12.19, p<0.001) and where dorsal (F1,59 = 14.68, p<0.001), ventral 
(F1,59 = 8.11, p<0.01) regions were considered separately. No differences however were found 
between lesion types. Post hoc analysis has further shown that significant changes were seen 
in the whole striatum in MFB (p<0.001) and SN (p<0.001) lesioned groups, but was not seen 
in mice receiving a Striatal lesion. 
 
The number of TH expressing cells in the whole striatum correlates with the percentage of cell 
loss within the SNc in L-DOPA treated mice receiving either MFB or SN lesions but not non-
L-DOPA treated groups (Fig. 4.5J,K; r= -0.690 and r= -0.811 respectively, where p<0.01 for 
both). AIMs present at phase 4 (25mg/kg) were also correlated to the number of TH positive 
cells in the striatum in all lesioned animals (r= 0.539, p<0.01). With the confounding 
correlations between cell loss in the SNc taken into account and factored into the partial 
correlation, AIM development was only correlated to TH cells in the L-DOPA treated MFB 
group (r= 0.642, p<0.01). 
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Fig. 4.5 Photomicrographs of TH immunopositive cells in the striatum of lesion only controls 
(A, Striatum; B, MFB; C, SN) and L-DOPA treated groups (D, Striatum; E, MFB; F, SN); 
scale bar is 200µm. A high magnification image is shown in (scale bar 50µm; L). TH 
immunopositive cells were quantified in L-DOPA and non-L-DOPA treated groups in the 
dorsal (G), ventral (H) and whole (I) striatal areas. TH immunopositive cells were correlated 
with % cell loss in the SNc of Non-L-DOPA treated (J) and L-DOPA treated lesioned mice 
(K) and total integrated AIMs (25mg/kg; M). Specific values and lesion trends are indicated 
for the Striatal lesion group by circle outlines and dashed lines, the MFB group by filled 
circles and dotted lines and SN group by filled triangles and dashed-dotted lines. Significant 
whole correlation coefficents and increases in TH cell numbers in L-DOPA treated mice are 
labelled as p<0.01** and p<0.001*** Values are expressed as means ± SEM. 
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Fig. 4.6. Photomicrographs of sections immune-stained for TH (A), GABA (B), Hoechst (C) 
and merged (D). Arrow heads indicate cells expressing all markers. Scale bar = 100µm. 
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4.4 Discussion 
The progression of AIMs, locomotion and rotation that manifest from phases 1-4 (6-25mg/kg) 
is reliant on the degree of depletion in the VTA and SNc.  In addition, we find that TH fibre 
depletion, 5-HT fibre depletion and FosB/∆FosB positive cell upregulation in the striatum 
correlate with dyskinesia expression at both 6mg/kg and 25mg/kg of L-DOPA. All selected 
lesioned mice displayed deficits on motor hand tests before the initiation of L-DOPA 
treatment, and a proportion these deficits can correlate both to dyskinesia expression and to 
cell loss in the SNc. A small proportion of the behavioural tests remained predictive of 
subsequent AIM expression, even once allowance is made (by partial correlation analysis) for 
the extent of dopamine cell loss. These data suggest that mice can be preselected for future 
dyskinesia experiments to express severe AIMs following chronic L-DOPA treatment both on 
the basis of cell loss and directly by deficits on motor hand tests. 
 
4.4.1. Histological characterisation of the lesions  
The greatest losses of TH positive neurons in the SNc were seen in Striatal and MFB groups 
with a more moderate depletion in the SN lesion group. Differences in the levels of 5-HT 
depletion and non-nigral dopamine cell losses were also obvious between lesion types. VTA 
dopamine cell loss was the most depleted in the MFB lesion group, with a higher degree of 
sparing produced by Striatal and SN lesions. It can be assumed that the targeting of a lesion on 
a specific nucleus may produce focal denervation with extensive sparing at the nucleus 
periphery. This is in contrast to cases where the toxin is focally injected into a compact fibre 
bundle where the toxin can be transported and hence degeneration spreads along the length of 
the fibre pathway. 
Post lesional 5-HT was not spared in the MFB lesion group and was likely due to the loss of 5-
HT fibres, although this was highly variable between individual mice. This contrasts with the 
only other study to examine 5-HT changes in 6-OHDA lesioned mice, in which no differences 
in whole striatal 5-HT levels were observed following MFB lesion (Francardo et al., 2011b). 
This may be due to procedural differences, the total quantity of 6-OHDA infused in this study 
was less than the one presented here and was administered through a fine glass capillary as 
opposed to a metal cannula. These two factors may have produced less non-specific damage in 
their study, leading to a more selective dopaminergic lesion. Also whole 5-HT levels as 
measured by HPLC are not directly comparable to density as storage capacity may have 
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increased allowing more 5-HT to be stored with fewer fibres. It can be proposed however that 
the 5-HT depletion may not be a disadvantage so long as they are considered, and maybe of 
further use to study dyskinesia in animal models. There is a positive correlative relationship 
between total integrated AIM score and 5-HT density when using dopamine cell loss in the 
SNc as a covariate. Given that in PD there is a significant serotonergic depletion, this may be 
valuable in the study of PD and of particular relevance to the study of L-DOPA mediated 
behaviours. There is growing evidence that in the absence of dopaminergic terminals, 
dopamine is synthesised, stored and released in 5-HT terminals. Although they contain AADC 
so that L-DOPA may be converted, they are unable to regulate the release of dopamine (Arai 
et al., 1995), since they lack the normal feedback mechanisms of autoreceptors. These data 
show that the aberrant pulsatile monoamine release is a major factor in the development of 
LID, in agreement with other studies (Scatton et al., 1983, Carta et al., 2007). This relationship 
warrants further investigation, as 5-HT changes in PD models and their contribution to 
dyskinesia is debated and appears to be dependent upon age at time of lesion, lesion type and 
maybe species (Gil et al., 2010, Maeda et al., 2003a, Rozas et al., 1998a, Zhou et al., 1991b). 
FosB/∆FosB expression was induced significantly in the striatum and NAcc regions in all 
lesioned mice. It is evident that high fosB/∆FosB expression in the NAcc in MFB lesion 
groups is mediated by the lack of TH fibre innervation of this area, a pattern well established 
in the striatal region (Andersson et al., 1999, Andersson et al., 2003, Francardo et al., 2011b, 
Valastro et al., 2007, Westin et al., 2001). The ventral striatal density loss seen in the MFB 
group can be attributed to high levels of neuronal loss in the VTA resulting from optimised 
stereotaxic co-ordinates. Although other studies have not looked specifically in the NAcc, 
striatal FosB/∆FosB expression has previously been found to be highest in MFB lesion mice 
compared to Striatal lesioned groups (Francardo et al., 2011b), also consistent with our 
findings. Dyskinetic mice with SN lesions also have an increase in FosB/∆FosB expression in 
the dorsal striatum which is comparable to the Striatal lesion group, with less expression in the 
ventral striatum owed to sparing of TH fibres in that location. In addition, cocaine-induced 
sensitisation can induce increases of FosB/∆FosB in the NAcc shell (Brenhouse and Stellar, 
2006), analogous to levels shown here, indicating the likely role of L-DOPA in 
supersensitisation specifically in this region.  
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4.4.2. Lesion effects on L-DOPA dyskinesia 
Here we show a comprehensive longitudinal analysis of the dyskinetic responses of mice with 
lesions of the striatum, MFB and SN, through a range of L-DOPA doses. In previous studies, 
AIMs in mice with unilateral MFB or Striatal lesions were triggered by doses in the range of 
6mg/kg and 18-20mg/kg respectively (Lundblad et al., 2002, Lundblad et al., 2004b, 
Francardo et al., 2011b). Those with MFB lesions started to show dyskinesia at 6mg/kg, whilst 
Striatal or SN lesion mice developed AIMs at 12mg/kg, lower than previously found. These 
studies also found a lower severity of AIMs following Striatal and SN lesions in C57/Bl6 mice 
compared to the MFB group even at a 25mg/kg dose of L-DOPA. In this study 6-OHDA 
lesions caused equivalent dopamine cell loss in the SNc in the Striatal group using the same 
strain (Lundblad et al., 2002, Lundblad et al., 2004b), yet cell loss was significantly less 
compared to MFB group, which is likely to be the primary reason why dyskinesia were 
evoked at a lower dose. We report similar striatal lesion extents compared to a recent study 
(Francardo et al., 2011b) with a dose almost twice as high, indicating the difficulty of 
depleting the entire striatum with the chosen 2x1.5µl volume. 
Mice that show few or no AIMs and are termed ‘non-dyskinetic’ (defined as having an 
integrated AIM score of less than 20). The dyskinetic status of lesioned mice is in part due to 
dose: at low doses, some animals only show few AIMs (non-dyskinetic) however long term 
treatment at higher doses increases the severity of AIMs gradually over time until a plateau is 
reached, here AIMs may surpass threshold levels and mice are considered ‘dyskinetic’. 
Following chronic treatment in rats with Striatal and MFB lesions approximately 20-35% of 
the cohort will continue to be classified as ‘non-dyskinetic’ with the moderate dose of 9-
11mg/kg (Winkler et al., 2002b).  In this study we found only 7% of MFB lesion mice were 
non-dyskinetic at 6mg/kg and this is consistent with studies of LID where low levels or the 
absence of non-dyskinetic mice were seen (Lundblad et al., 2004b, Lundblad et al., 2005). 
Conversely, 60% of Striatal lesion mice were non-dyskinetic at 6mg/kg (Francardo et al., 
2011b), while few mice from our cohort had significant AIMs at that dose. The lack of mice 
that could be scored below the dyskinetic threshold at higher doses suggests that AIMs may 
also in part relate to species differences in basal movements and plasticity. Kinetic differences 
in exploratory movement, including the observation that mice have faster grooming 
behaviours could contribute to AIM scores by some investigators. The dose-dependent 
progressive development of AIMs also illustrates that the impact of apomorphine was likely 
minimal and priming was still permitted. 
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Dyskinetic priming and maintenance in mice lesioned directly at the level of the SN was 
observed for the first time in our cohort. AIM expression patterns are highly comparable to the 
striatum group likely due to similar levels of VTA cell loss.  Animals in both groups remain 
largely non-dyskinetic until 12mg/kg and have AIMs of a similar magnitude. Strong L-DOPA 
driven contralateral rotations in the MFB group and correspondingly high horizontal 
locomotor activity are likely caused by the extensive VTA damage. This response is likely to 
manifest in the same manner as amphetamine and apomorphine mediated turning traits (Olds 
et al., 2006), arising from psychostimulant evoked supersensitisation in the NAcc. 
Chronic exposure to L-DOPA pre- and post-synaptic changes, and causing a worsening of 
symptoms (Stocchi, 2006), this is often referred to as a ‘wearing off’ effect approximately two 
weeks after the start of treatment. Some studies have shown that long term L-DOPA treatment 
in hemi-parkinsonian rats causes a shortened rotational response and an increase in magnitude 
from the second to the third week of treatment (Papa et al., 1994, Marin et al., 2004). There is 
speculation that this may be related to high doses or the lesion site as this response is not seen 
in rats following a striatal lesion. In this study we found no evidence of ‘wearing off’ of the 
AIMs or rotational response, regardless of dose. At 6mg/kg it was also found that dyskinetic 
mice have a higher rotational rate compared to non-dyskinetic groups (Francardo et al., 2011b) 
and dose-dependent increases in rotation were also reported in Striatal and MFB mice 
(Lundblad et al., 2004b). In this cohort of mice AIMs can be positively correlated to L-DOPA-
mediated rotation in the Striatum group, suggestive of the previously reported relationship, 
and in contrast no trend was found for the MFB group likely due to the lack of non-dyskinetic 
mice.  
 
4.4.3. Behavioural prediction of susceptibility to dyskinesia 
Dopamine depletion in the SNc correlates with the extent of AIMs present at 6 and 12mg/kg 
irrespective of lesion type. Equally a selection of motor hand tests can be correlated to AIM 
severity at 6mg/kg and 25mg/kg, even when controlling for confounding SNc depletion by 
partial correlations. Therefore tests correlating to AIMs may offer useful predictors of 
dyskinesia even before L-DOPA is given, however the predictability of the motor hand test is 
dependent both on L-DOPA dose and on lesion type. AIMs at 2mg/kg and 6mg/kg are 
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correlated to the rotarod scores prior to L-DOPA dosing but not at higher doses, indicating 
both a ceiling effect from maximal AIM development and the sensitivity of the test to 
distinguish potential dyskinetic mice. At higher doses the correlative nature of AIMs with 
basal horizontal activity measures and apomorphine induced rotations may reflect 
uncontrolled for lesion differences, since this is exclusively found in the MFB group. 
Nevertheless, these tests can be used to predict dyskinesia in specific future experiments using 
bundle lesions. These data suggest that risk factors for LID development may reflect the 
interplay of other neurotransmitter systems, differences in plasticity and other maladaptive 
physiological changes and go beyond dopamine cell loss in the SNc which is currently used as 
the ‘gold standard’ predictor of dyskinesia.  
 
4.4.4. TH expression in striatal neurons 
TH immunopostive cells can be found within the striatum of 6-OHDA lesioned rodents, 
MPTP treated primates and humans with PD (Huot and Parent, 2007, Darmopil et al., 2008, 
Mazloom and Smith, 2006, Tande et al., 2006, Francardo et al., 2011b, Jollivet et al., 2004, 
Mura et al., 2000). In rodent studies the highest number of TH positive cells is typically found 
3-7 days after a 6-OHDA lesion, steadily decreasing from then on (Darmopil et al., 2008), 
with an apparent resurgence upon L-DOPA treatment (Francardo et al., 2011b). The new 
presence of TH cells does not arise from neurogenesis, or from the result of a full phenotypic 
shift, as these cells have been shown to still retain GABA as their primary neurotransmitter 
(Tande et al., 2006). This study also shows that cells retain a GABAergic phenotype even 
following chronic L-DOPA treatment. TH immunoreactive cells were detected ubiquitously in 
the denervated striatum of MFB lesion mice and that further L-DOPA treatment causes an 
increase in the number of these cells. No significant increase was detected in the Striatal lesion 
group and high variability between mice was obvious. Interestingly, the increase in TH cells in 
the SN group is more comparable to that seen in mice with MFB lesions even though other 
parameters shown in this report, including AIM expression, found more similarities between 
the SN and Striatal lesions. This highlights the need for lesion selection to be carefully 
considered, in the light of the anticipated outcomes of the study. 
TH cells residing within the striatum of non-L-DOPA treated mice were not correlated with % 
cell loss within the SNc and this is likely because of the very low number of cells detectable in 
these lesion only groups, while cell loss was highly correlated with TH cells in L-DOPA 
133 
 
treated mice, comparable to previous findings (Francardo et al., 2011b). In a previous mouse 
study, L-DOPA was started 1 week after the Striatal lesion and given over a shorter duration 
(Darmopil et al., 2008). However, TH cell levels and changes were similar to those described 
here, despite a delay of several months between lesion surgery and the start of L-DOPA 
treatment in this present study. Our longitudinal study therefore shows two interesting 
findings; firstly that although TH cell numbers have been reported to decrease from 7 days 
post lesion, those cells still maintain the ability to express TH when prompted by L-DOPA, 
despite a long delay between the lesion and start of treatment. Secondly, high doses and 
prolonged L-DOPA treatment does not cause a further increase in TH cell number, to that 
reported previously. 
 
4.4.5. Conclusions 
AIM expression and locomotor responses caused by L-DOPA are differentially expressed in 
mice lesioned at different locations along the nigrostriatal pathway. This is likely to be the 
result of differences in VTA dopamine losses and 5-HT fibre innervation. Longitudinal L-
DOPA driven responses in mice lesioned to the SN had distinct behavioural and histological 
characteristics compared to mice with MFB and Striatal lesions. In addition, FosB/∆FosB is 
differentially upregulated in the striatum according to lesion type. Furthermore, expression 
patterns of FosB/∆FosB in the NAcc reflect specific ventral dopamine losses, underpinning 
locomotor measures. The emergence of TH positive cells is also enhanced by L-DOPA in all 
three mouse models and is related to cell losses and AIM development. We also find that 
behavioural measures can be used to predict LID distinctly to dopamine cell loss correlates 
and combining both measures would provide a more appropriate selection procedure to study 
LID. Information generated from this chapter has been used to assess the expression of RGS 
following chronic and acute treatment regimes (Chapter 5) and was proved useful for the 
creation of a mouse model of GID (Chapter 8). 
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5. Regulators of G-Protein Signalling as a 
Hallmark of Dyskinesia? 
 
Summary 
RGS genes have previously been shown to be dysregulated by single injections of L-DOPA, 
dopamine agonists/ antagonists and select psychostimulants, and I hypothesise may play a role 
in the priming response to L-DOPA. Unilaterally dopamine depleted mice were primed with 
L-DOPA for 21 days. They displayed AIMs and contralateral rotation in comparison to 
similarly lesioned mice that were given a single injection, in whom AIMs were absent but 
rotation was still initiated. Post-mortem, basal levels of RGS2, RGS4, RGS8 transcripts were 
identified in the striatum and cortex of wild-type mice whereas RGS9-2 was exclusively found 
the striatum. RGS transcripts were found to be differently regulated by acute and chronic 
administration of 10mg/kg L-DOPA, with RGS2 transcripts increased in the striatum (analysed 
by qPCR and density analysis from in situ hybridisation) and RGS4, RGS8 and RGS9-2 
unchanged. RGS2 expression however differed depending on long-term (multiple L-DOPA 
challenges over 21 days) or single L-DOPA challenges. These data were upheld by further 
quantification of the numbers of RGS2 positive cells. RGS2 gene expression was not 
correlated with AIMs and increased RGS2 protein translation. 
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5.1. Introduction 
GPCRs exert intra-cellular signalling consequences, by the activation of specific pathway 
components, caused by the dissociation of Gα and Gβγ subunits, in which regulators of G-
protein singnalling (RGS proteins) are the rate-limiting step.  RGS proteins promote GTP 
hydrolysis of the alpha subunit thereby controlling the rate at which G-proteins can exert post-
receptor signalling mechanisms in a negative feedback mechanism. The ERK pathway, 
dysregulated in L-DOPA-induced dyskinesia, is regulated by GPCRs that stimulate PKA and 
activate CREB mediated transcription of other genes with CRE promoters. RGS proteins have 
the potential to down-regulate a significant number of pathways in the basal ganglia and may 
therefore be future targets for the modulation of LID in PD.  
 
L-DOPA causes functional sensitisation of dopamine receptors and although the exact 
mechanism remains unclear, RGS proteins may play a key role in mediating this response. 
Certainly, RGS9-2, the RGS protein expressed selectively in medium spiny neurons of the 
striatum has been implicated in L-DOPA induced receptor sensitisation as viral-mediated 
over-expression of this gene reduced the severity of AIMs without worsening the beneficial 
effect of L-DOPA (Gold et al., 2007). IEGs and RGS9-2 expression have been considered the 
‘transcriptional hallmarks’ or post-mortem ‘biomarkers’ of post-receptor sensitisation to L-
DOPA and dyskinesia (Cenci et al., 1993, Cenci et al., 1998, Andersson et al., 1999, 
Andersson et al., 2001, Berton et al., 2009, Cao et al., 2010, Pavon et al., 2006a) and, in the 
case of IEGs may actually play a causal role (Andersson et al., 1999).  
 
In intact rodents RGS2, 4, 8 and 9-2 are the most abundant RGS mRNA transcripts in the brain 
(Grafstein-Dunn et al., 2001, Burchett et al., 1999, Burchett et al., 1998, Gold et al., 1997), 
and have distinct regional expression patterns. RGS2 mRNA has been localised to the 
neocortex, piriform cortex, striatum, hippocampus and locus coeruleus in the adult brain 
(Grafstein-Dunn et al., 2001, Taymans et al., 2002). The absence of RGS2 in the GP is 
suggestive of its function in the striatonigral (direct) pathway. RGS4 is also highly expressed 
in the cortex, thalamus and striatum and weakly expressed in the SN, yet RGS8 is ubiquitously 
expressed throughout most of the rodent brain including the striatum and SN, with particular 
density within the Purkinje cells of the cortex (Gold et al., 1997). RGS9-2 is most dense within 
the striatal area, with some expression in the medial hypothalamus (Gold et al., 1997). Specific 
striatal quadrant expression patterns have not been well characterised. 
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In intact animals, RGS gene expression is modulated by pharmacological agents and specific 
dopamine and glutamate receptor agonists and antagonists (Bishop et al., 2002, Burchett et al., 
1999, Burchett et al., 1998, Psifogeorgou et al., 2007, Schwendt et al., 2006, Taymans et al., 
2005a, Taymans et al., 2004, Taymans et al., 2003). Differential changes in RGS levels have 
been shown following selective dopamine denervation by 6-OHDA in the striatum, thought to 
play a part in the post-synaptic compensatory mechanism for the reduction in dopaminergic 
innervation (Geurts et al., 2003). RGS2, RGS5 and RGS8 mRNA transcripts increase and 
RGS9-2 and RGS4 decrease following nigro-striatal dopamine depletion, in comparison to the 
intact control side (Geurts et al., 2003). In contrast, mRNA levels of RGS10 and other RGS 
transcripts that are weakly expressed in the striatum (RGS3, RGS6, RGS7, RGS11 and RGS12) 
were unchanged. Prolonged reserpine treatment which depletes monoamine levels, without 
causing loss of the neuronal projections, causes mRNA levels of RGS2, RGS4, RGS5, RGS8, 
RGS9-2 and RGS10 to decrease (Geurts et al., 2003).  Conversely, Taymans et al. did not 
detect such a change in RGS2 with 6-OHDA injections (Taymans et al., 2005b). RGS9-2 
proteins were found to be markedly decreased in the striatum of MPTP treated mice and 
unilateral 6-OHDA lesioned rats increasingly over 0-6 weeks and RGS4 was upregulated in 
both cases (Yin et al., 2010). Conversely another study has found RGS9-2 protein levels to be 
unchanged by MPTP in primates (Gold et al., 2007), in contrast to findings in PD patients 
(Tekumalla et al., 2001). In humans RGS9-2 was inversely correlated with putamen levels of 
the dopamine transporter, dopamine and dopamine metabolites (Tekumalla et al., 2001). 
Changes in RGS that accompany dopamine denervation in models and humans remain 
unclear, and conflicting results do not provide a clear baseline upon which to measure the 
effect of L-DOPA. 
 
There are few studies that have looked at the role of L-DOPA in modulating RGS expression 
in the dopamine-depleted striatum. In intact animals RGS2 was transiently and rapidly 
upregulated by a single injection of L-DOPA (50mg/kg) after 30 minutes, and this effect 
negated by co-administration with a D1 receptor antagonist, but not with a D2 receptor 
antagonist (Geurts et al., 2002). Interestingly, L-DOPA alone did not change RGS4 expression 
in the intact brain, yet co-treatment with a D1 antagonist caused a significant enhancement in 
RGS4, measured 30 minutes after injection. A large gene expression array analysis showed 
that 50mg/kg of L-DOPA given twice daily for 10 days induced RGS2 upregulation in the 6-
OHDA lesioned brain of dyskinetic rats, but was unchanged by a single injection of the same 
dose 2 hours post injection (El Atifi-Borel et al., 2009). These L-DOPA mediated changes 
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may not be representative of standard doses of L-DOPA used experimentally. In accordance 
with this theory 6mg/kg of L-DOPA given over 21 days increased RGS2, RGS4 and RGS9-2 
transcription in the 6-OHDA lesioned rodent brain, compared to saline treated controls 
(Conference proceedings (ko, 2008). In both the studies using either 50mg/kg or 6mg/kg 
transcript expressions were not compared to AIMs.  
 
This study firstly aims to confirm existing expression patterns of RGS2, RGS4, RGS8 and 
RGS9-2 in the intact mouse using in situ hybridisation, so they may subsequently be used as a 
baseline to look at changes following a 6-OHDA lesion and L-DOPA treatment. This study 
specifically compares RGS transcript levels under single and long-term L-DOPA (10mg/kg) 
treatments, at 1 hour (during the peak of expression of L-DOPA-induced behaviours) and 24 
hours post-injection (where conversion to dopamine is complete and hence there is a complete 
absence of L-DOPA mediated behaviours), in both intact and lesioned striatum, using several 
semi-quantitative techniques. To draw mechanistic conclusions on any changes seen, this 
study also looks at the relative protein levels of RGS, using the same treatment groups.  
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5.2. Experimental Design 
95 adult C57/Bl6 mice were used in this study (outlined in Fig. 5.1 and Table 5.1). 85 of these 
were lesioned unilaterally with 6-OHDA directed at the MFB (methods detailed in Chapter 2). 
76 were had sufficient dopamine depletion indicated by spontaneous rotational assessment 
(confirmed to be useful in selecting mice with an 80% cell loss or more in the SNc in: Chapter 
3). The first group of mice received a single injection of 10mg/kg of L-DOPA with 10mg/kg 
of benzerazide and killed either 1 h post injection (n=15), with a subset killed 24 hours post-
injection (n=14). A second set of mice received 21 days of daily L-DOPA at the same dose 
and killed 1 hour post injection on the last day (n=13), where AIMs were scored in all mice at 
day 20. Another group of dyskinetic mice, also receiving 21 days of treatment, were sacrificed 
24 hours after the last injection on day 22 (n=13). Mice from the long-term L-DOPA treatment 
group were split for biochemical and molecular analysis according to approximately equal 
total net rotation (20 minutes post L-DOPA injection) and total integrated AIM scores. Lesion 
control mice were treated with daily saline injections for 21 days and killed 24 hours after the 
last injection (n=9). Intact control groups were also included from this initial cohort, where 
mice were either subject to 21 days of L-DOPA (n=5) or saline (n=5).  
 
At the end of testing the brains were dissected, snap frozen and sections cut on the cryostat. 
Sections were taken from a 1 in 6 series and stained for TH by immunohistochemistry and 
RGS2 and RGS4 by in situ hybridisation, where density levels were quantified by ImageJ and 
RGS positive cells counted in defined areas of the striatum, detailed in Chapter 2. Rotation 
and AIMs were analysed by either 1-way ANOVA or Students t-test. Differences between 
relative RGS densities and cell counts between groups were determined using 2-way ANOVA 
and Dunnett’s post hoc comparisons. Pearson’s correlations were then compared between 
AIMs and the previously mentioned semi-quantitative measures of RGS. 
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Technique/ Group Saline 
non-Lx  
Saline 
Lx 
L-
DOPA S 
(on) 
L-
DOPA S 
(off) 
L-
DOPA 
LT (on) 
L-
DOPA 
LT (off) 
In situ hybridisation (n) 4 3 9 8 7 7 
qPCR (n) 3 3 3 3 3 3 
Western Blott (n) 3 3 3 3 3 3 
 
Table 5.1 indicates the number of mice (n) used in each experiment group. Abbreviations: 
non-lesioned (non-Lx), lesioned (Lx), single injection (S), after 21 days of L-DOPA: long-
term injection (LT), 1 hour post injection: on L-DOPA (on) 24 hours post injection: off L-
DOPA (off). 
 
 
 
 
 
Fig. 5.1. Time line depicting behavioural assessments in mice and times of tissue collection 
that have contributed to experiments in this chapter.  
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5.3. Results 
 
5.3.1. Localisation of RGS2, RGS4, RGS8 and RGS9-2 in the Rodent Brain.  
The distribution of RGS2, RGS4, RGS8 and RGS9-2 positive cells stained by non-radioactive 
in situ hybridisation, throughout the murine brain at the level of the striatum, is indicated in 
Fig. 5.2 and detailed in Fig. 5.3. These RGS gene transcripts are expressed throughout the 
striatum. In addition, RGS2, RGS4, and RGS8 positive cells can be seen throughout the cortex. 
In-situ hybridisation riboprobes were designed ‘in house’ and therefore much care was taken 
to ensure specific binding, hence control riboprobes with the reverse sequence are sufficient 
negative controls (Fig. 5.3B,F,J,N and Fig. 5.3D,H,L,P). The distribution of RGS8 and RGS9-
2 is ubiquitous across the striatum whereas the density of RGS2 and RGS4 increases from the 
medial-lateral direction, shown in Fig. 5.3A and Fig. 5.3E respectively.  
 
 
 
 
Fig. 5.2. Photomicrographs showing coronal sections through the brain of C57/Bl6 mice after 
in situ hybridisation with riboprobes designed for RGS2 (A), RGS4 (B), RGS8 (C) and RGS9-2 
(D). Scale bar is equal to 2mm. 
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Fig. 5.3. Photomicrographs of the regional expression patterns of RGS2 (A-D), RGS4 (E-H), 
RGS8 (I-L) and RGS9-2 (M-P) positive cells throughout the brain, at the level of the striatum 
in intact mice. Striatal (A, E, I and M) and cortical (C, G, K and O) distributions are presented. 
Anti-sense control sections in adjacent sections are shown for striatal (B, F, J and N) and 
cortical (D, H, L and P) areas. Scale bar equals 1mm. 
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5.3.2. Dyskinesia and Rotational Assessment 
Only mice receiving long term L-DOPA treatment (21 days) displayed AIMs above threshold 
levels (Fig. 5.4A,B), based on defined rating scales (Cenci and Lundblad, 2007, Winkler et al., 
2002b). In mice receiving a single injection of L-DOPA no AIMs were observed. Mice in the 
long-term L-DOPA treatment group were split into three groups for subsequent biochemical 
and molecular experiments, based on equivalent total integrated AIM scores (Fig. 5.4B; F2,23 = 
0.33, p =ns) and total net rotation (Fig. 5.4C; F2,23 = 0.29, p =ns). Mice receiving a single 
injection were split into corresponding groups based only on equivalent total net rotation (Fig. 
5.4D; F2,26 = 0.36, p =ns). Total net contralateral rotation was highest in mice receiving long 
term L-DOPA injections compared to the single treatment (T= 2.26; p<0.05). 
 
F
ig. 5.4. Integrated AIMs in 6-OHDA lesioned mice, timecourse of scores at 20 min intervals 
(A) and totals (B) for mice receiving 21 days of L-DOPA treatment. Total net rotations, scored 
over 20 minutes were recorded in all lesioned mice receiving either a single injection of L-
DOPA (C) or long term treatment (D), for each biochemical analysis groups. Total net 
rotations for all mice in single treatment or long-term groups were also averaged (E). 
Significant differences between groups are annotated by p<0.05*. Values are expressed as 
means ± SEM. 
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5.3.2. Striatal RGS mRNA Expression by qPCR   
There were a small number of relative changes, in the expression of RGS transcripts 
normalised to GAPDH levels, between treatment groups (Fig. 5.5), compared to saline-treated 
intact mice, which were used as a baseline.  Semi-quantitative PCR analysis demonstrated that 
RGS2, RGS4, RGS8 and RGS9-2 mRNA expression was largely unaffected by the lesion, in 
comparison to both the intact side of lesioned mice and unlesioned controls. In the control 
groups there was no difference between (a) L-DOPA/ saline treated intact mice, (b) for either 
acute or chronic treatment groups, (c) between on and off L-DOPA/ saline conditions in intact 
mice or (d) saline treated lesion mice, therefore control groups were pooled by intact or 
lesioned parameters (termed Saline non-lesioned/ Saline lesioned from here in). RGS2 was 
found to increase 6-fold in the lesioned striatum 1 hour after a single L-DOPA injection or 4-
fold after 21 days of L-DOPA treatment (Fig. 5.5A). The expression of RGS2 on the intact 
side was approximately double that of basal levels in an intact controls post L-DOPA 
injection, in single and long-term treatment groups. There was also a smaller increase in the 
expression of RGS2 24 hours post L-DOPA injection, for both single dose and long-term 
groups. There were no relative changes observed in the expression patterns of RGS4, RGS8 
and RGS9-2 (Fig. 5.5B-D). 
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Fig. 5.5. Relative RGS gene expression changes determined by qPCR derived from the ∆∆Ct 
quantification method, normalised to the expression of GAPDH ‘housekeeping’ gene. The 
relative expression of RGS2 (A), RGS4 (B), RGS8 (C) and RGS9-2 (D) in intact and lesioned 
mice treated with saline (Saline non-Lx and Saline Lx respectively), following a single 
injection of L-DOPA in lesioned mice (L-DOPA S on), 24 hours following a single injection 
of L-DOPA in lesioned mice (L-DOPA S off), 1 following 21 days of chronic L-DOPA 
treatment (L-DOPA LT on) and 24 hours following 21 days of chronic L-DOPA treatment (L-
DOPA LT off). Values are expressed as means ± SEM. 
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5.3.3. Regional mRNA Expression of RGS by In situ Hybridisation 
Optical density measurements of the whole striatum were used to measure lesion extent by TH 
presence and as a semi-quantitative measure RGS expression changes (Fig. 5.6.) TH 
immunohistochemistry was performed on adjacent sections to RGS in situ hybridisation and 
dopaminergic fibre loss was evident on the ipsilateral striatum compared to the intact side 
(F1,68= 53.40, p<0.001), and compared to intact control mice (F5,68= 4.92, p<0.01). There was 
an increase in the relative density of RGS2 with L-DOPA treatment, where there were 
significant differences between groups (F5,68= 3.82, p<0.01) and sides (F1,68= 19.14, p<0.001). 
RGS4 expression was increased between intact and lesion sides (F1,68= 4.55, p<0.05) but not 
between groups (F5,68= 0.89, p= ns). Both single injections and long-term L-DOPA triggered 
upregulation of RGS2 on the lesioned striatum, 1 hour post injection (Fig.5.6D), p<0.01 for 
all. Increases of RGS2 were also seen 24 hours after L-DOPA injection in both single and long 
term groups. No change of density levels were noted for either RGS8 (Fig. 5.6F; group: F5,68= 
0.36, p= ns side: F1,68= 2.46, p= ns) or RGS9-2 (Fig. 5.6G; group: F5,68= 1.11, p= ns side: 
F1,68= 1.18, p= ns). 
 
The increased density of RGS2 in the lesioned hemisphere is exclusively seen after L-DOPA 
treatment (Fig. 5.7A-F) and is not seen in intact and lesion only mice, although there was a 
trend for increased density on the intact side of lesioned mice in the long-term treatment 
group. Few RGS2 positive cells could be detected prior to L-DOPA administration by in situ 
hybridisation, however following L-DOPA treatment a greater number of cells could be 
quantified (Fig. 5.7Ai-Fi). 
 
L-DOPA-induced RGS2 upregulation was not uniform across the striatum (Fig. 5.8.). 
Specifically, RGS2 cell increases between lesion and intact sides were found in: the anterior 
medial striatum (Fig. 5.8A; F1,68= 29.99, p<0.001), dorsal medial striatum (Fig. 5.8B; F1,68= 
11.15, p<0.01) and ventral lateral striatum (Fig. 5.8C; F1,68= 21.29, p<0.001). There was no 
change in the number of RGS2 positive cells on lesion and intact sides of the motor cortex 
(Fig. 5.8D; F1,68= 3.98, p=ns), however there was a noticeable increase in RGS2 cells with L-
DOPA treatment between groups (F5,68= 4.92, p<0.01).  Post hoc comparisons show that this 
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was only observed in mice that were chronically treated with L-DOPA and killed during drug 
activity (Intact: p<0.01; Lesion p<0.05).  
 
Fig. 5.6. Lesion extent derived from optical density measurements of TH 
immunohistochemistry (A-C) and relative RGS gene expression changes by L-DOPA, 
determined by optical density measurements of the striatum, following in situ hybridisation 
(D-G). Relative densities of RGS2 (D), RGS4 (E), RGS8 (F) and RGS9-2 (G) in intact and 
lesioned mice treated with saline (Saline non-Lx and Saline Lx respectively), 1 (L-DOPA S 
on) and 24h (L-DOPA S off) following a single injection of L-DOPA in lesioned mice 1(L-
DOPA LT on) and 24h (L-DOPA LT off) following 21 days of chronic L-DOPA treatment 
and 24 hours. Significant differences between intact and lesion sides within a group are 
annotated by p<0.05*, p<0.01** and p<0.001***. Values are expressed as means ± SEM. 
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Fig. 5.7. Representative photomicrographs of RGS2 positive coronal sections, from in situ 
hybridisation, through the dorsal striatim (A-F) and 10x magnification of RGS2 positive cells 
(Ai –Fi), in the ventrolateral striatum of the lesioned side (right). Representative images from 
intact mice treated with saline (A, Ai), 6-OHDA lesioned mice treated with saline (B, Bi), 1 
(C, Ci) and 24 h (D, Di), following acute administration of L-DOPA. 1h (E, Ei) and 24h (F, 
Fi) following 21 days of chronic L-DOPA treatment. Scale bar for images of whole section 
images equals 1mm and for photomicrographs of cells equals 400µm. 
 
148 
 
 
 
Fig. 5.8. RGS2 positive cell counts in an 1mm
2
 area of the anterior medial striatum (A), dorsal 
medial striatum (B), ventral lateral striatum (C) and motor cortex (D) for intact and lesioned 
mice treated with saline (Saline non-Lx and Saline Lx respectively), 1 (L-DOPA S on) or 24 
(L-DOPA S off) following a acute administration of L-DOPA in 6-OHDA lesioned mice, 1 
(L-DOPA LT on) and 24h (L-DOPA LT off) following 21 days of chronic L-DOPA treatment. 
Significant differences between intact and lesion sides are indicated by p<0.05*, p<0.01** 
and p<0.001*** and between intact saline mice in as p<0.05
†
 and p<0.01
††
. Values are 
expressed as means ± SEM.  
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5.3.4. Correlations of RGS Expression with LID and Rotation 
There were few correlations between RGS2 with dyskinesia and rotation (Table 5.1). A 
negative correlation was only found between AIMs and RGS2 expression in the anterior 
medial striatum (r= -0.881, p<0.05) in mice, 24 hours after the final injection of 21 days of L-
DOPA treatment. There was also a negative correlation between total contralateral rotation 
and RGS2 expression in mice reciving the same treatment (r= -0.896, p<0.01), within the 
dorsomedial striatal region. 
 
 
 
 
Table 5.1. Pearson’s correlation co-efficients between total integrated AIMs and total net 
contralateral rotation with the expression of RGS2, quantified through density measurements 
and cell counts from in situ hybridisation. Abbreviations: long-term (LT), short-term (ST), 
abnormal inhibitory movements (AIMs), rotation (Rot), on (on L-DOPA – 1 hour post 
injection) and off (off L-DOPA – 24 hours post L-DOPA). Significance is annotated as 
p<0.05*, p<0.01**. 
 
 
 
5.3.5. Changes in RGS protein Expression 
Levels of RGS2, RGS4, and RGS9-2 did not differ between lesion and intact sides (Fig. 5.9.), 
where samples were normalised appropriately (indicated by standardised levels of β-actin). 
Protein concentrations of RGS2 were increased on both lesion and intact sides, after long-term 
treatment compared to a single injection (Fig. 5.9; T= 3.31, p<0.05), seen at both 1 hour and 
24 hours post injection (groups pooled). No significant differences between RGS4, RGS8, 
Density RGS2 Cell counts  
Whole 
striatum 
Anterior 
medial 
striatum 
Dorsal 
medial 
striatum 
Ventral 
lateral 
striatum 
Motor 
cortex 
AIMs (LT on) 0.655 0.781 0.771 0.708 0.764 
AIMs (LT off) 0.107 -0.881* -0.564 -0.006 -0.143 
Rot (LT on) -0.280 0.431 0.340 0.249 0.660 
Rot (LT off) 0.004 0.089 -0.896** -0.058 0.733 
Rot (ST on) 0.170 -0.028 0.596 0.649 0.034 
Rot (ST off) -0.056 -0.177 0.892 -0.780 -0.744 
Rot (LT + ST on) -0.209 0.353 0.442 -0.458 0.571 
Rot (LT + ST off) -0.023 -0.147 0.199 0.176 0.129 
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RGS9-2 and β-actin were found. 6-OHDA caused a reduction in TH expression on lesioned 
sides compared to intact sides (T= 8.46, p<0.01) (data not shown). 
 
 
 
Fig 5.9. Photomicrographs depicting Western blot analysis of RGS2, RGS4, RGS9-2, TH and 
β-actin. Whole protein lysate concentrations were normalised for all groups and specific 
proteins identified by their respective molecular weights. Abbreviations: Long-term (LT), 
single injection (S), Lesion (Lx), on (on L-DOPA – 1 hour post injection) and off (off L-
DOPA – 24 hours post L-DOPA). Optical density analysis of RGS2 all LT compared to all S 
groups (A). Significance is annotated as p<0.05*. Values are expressed as means ± SEM.  
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5.4. Discussion 
5.4.1 RGS expression is not differently modulated by the 6-OHDA lesion 
There was no effect of 6-OHDA on any of the RGS transcript expression, measured by qPCR 
or in situ hybridisation. This is in contrast with a previous study in which increases of RGS2 
and RGS8 were found in 6-OHDA lesion rats, accompanied by decreases in RGS4 and RGS9-2 
(Geurts et al., 2003). Differences between these two studies may have arisen as a result of the 
surgical techniques applied, as Geurts et al. (2003) inhibited non-specific depletion of 
noradrenergic fibres by the prior administration by desipramine and 6-OHDA toxicity was 
increased by the MAO inhibitor pargyline. Changes in this present study may therefore have 
been masked by the depletion of non-dopaminergic fibres (evident with MFB lesions, shown 
in Chapter 4) or a lower toxicity. This discrepancy may also be due to timing, as previously 
rodents were culled 3 weeks post-lesion (Geurts et al., 2003), in comparison to 7 weeks in this 
study, therefore RGS changes may occur under times of denervation, but are subsequently 
normalised. Accordingly, cell loss in the SN is still ongoing at 21 days after a terminal or 
MFB 6-OHDA injection (Blandini et al., 2007b, Grealish et al., 2008b). There was no effect of 
the lesion on RGS2 expression in another studies (El Atifi-Borel et al., 2009, Taymans et al., 
2005b), where rats were culled 4-7 weeks post lesion, consistent with our findings. These data 
show for the first time that the lack of change in RGS2 in the lesion only condition is also 
shown in the hemi-parkinsonian mouse model, since all previous RGS studies have utilised the 
rat model.   
 
Protein levels of RGS2 are not changed following MPTP administration (mice) or 6-OHDA 
injection (rats) from 1-6 weeks post lesion (Yin et al., 2010), reflecting both the protein and 
gene expression changes of this study. In contrast RGS9-2 was found to be decreased and 
RGS4 increased 6 weeks after 6-OHDA injection (Yin et al., 2010), not shown in this present 
study after 7 weeks. As time courses were comparable and the antibodies were bought from 
the same company, these discrepancies may be due to surgical procedure or species used.  
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5.4.2. Lesion and Intact Differences in RGS2 Expression by L-DOPA 
L-DOPA mediated changes in RGS2 mRNA levels were generally confined to the lesion side. 
This is unusual however since dopamine receptors do not need to be supersensitised in order 
to trigger the transcription of RGS2 within the striatum (Taymans et al., 2004, Taymans et al., 
2003). It can be postulated therefore that the intact system dopamine is better controlled and 
receptors are normosensitive, therefore leading to significantly less transcription. Upregulation 
on the lesioned side supports findings of two other studies where an increase in RGS2 was 
reported two hours post injection (El Atifi-Borel et al., 2009, Geurts et al., 2002). 
Interestingly, this research suggests that dopamine synthesised from its precursor, behaves as a 
partial D1 agonist (increasing RGS2 only on the lesioned side), as opposed to full agonist 
action where equal transcript increases were noted on both sides (Taymans et al., 2004). 
Equally this may be due to the fact that dopamine levels are maintained by intact dopamine 
neurones. In this study however protein changes and qPCR expression changes were found on 
both sides after long-term treatment, although in the latter were much smaller on the intact. 
Therefore even where transcriptional differences between lesion and intact sides were seen, 
long-term L-DOPA causes a normalisation of increased RGS2 protein expression on both 
sides. 
 
5.4.3. RGS2 Dysregulation  
RGS increases were seen both following a single administration of L-DOPA or after 21 days 
exposure. This is in contrast to previous microarray analysis where RGS2 expression, in 
lesioned rats was no longer upregulated after chronic L-DOPA treatment of twice daily 
injections of 50mg/kg (El Atifi-Borel et al., 2009). Discrepancies between studies may be due 
to treatment strategies. This high dose, given twice daily may have caused a reduced duration 
of L-DOPA response and a shift in the peak expression of RGS2. Therefore RGS2 expression 
may have been missed. Certainly, the administration of 25mg/kg of L-DOPA, twice daily 
causes a shortening in the duration of L-DOPA mediated motor effects (Papa et al., 1994).  
 
A high dose of L-DOPA (50mg/kg) was used in two studies to give both a 0.25 fold 
upregulation in RGS2 measured by in situ hybridisation (Geurts et al., 2002) and a 2.4 fold 
increase by microarray analysis (El Atifi-Borel et al., 2009). The data presented here show that 
the approximate level of the mRNA increase (qPCR: 2.5 fold; Density: 0.20 fold; Cell count: 2 
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fold) is sustained despite using a much lower dose of L-DOPA (10mg/kg). Detectable 
transcript changes in RGS2 by either single or long-term L-DOPA injections were not matched 
with protein changes (approximately 0.10 fold). Cells are therefore likely to sustain adequate 
modulation of D1 receptors and other GPCRs by RGS2. However protein increases, seen only 
after long-term L-DOPA treatment, may indicate changes after priming and supersensitsation 
of dopamine receptors. The low level of L-DOPA used in this study is clinically relevant and 
therefore data presented in this chapter may reflect neuropathological, transcriptional and 
protein changes in PD patients receiving long-term treatment. An in-depth characterisation of 
RGS changes in PD patients of different stages and varied LID states is much needed.  
 
RGS2 expression was only increased in the motor cortex after chronic L-DOPA treatment and 
may therefore reflect long-term changes in this region. Interestingly the increases in RGS2 
within the motor cortex were not confined to a single hemisphere. Bilateral changes in cortical 
stimulation have previously been associated with dopamine depletion (Viaro et al., 2011). 
Unilateral 6-OHDA lesions can change the area of stimulation by a given electrode on both 
ipsilateral and contralateral sides (Viaro et al., 2011), reflecting long-term neuroplastic 
changes. Caution must be taken when interpreting the results presented in the present study as 
the bilateral action of L-DOPA on cortical function is currently unknown, thus warranting 
further investigation. 
 
5.4.4. RGS2 Dysregulation ‘Off’ and ‘On’ L-DOPA  
In this study RGS transcript levels were compared 1 h post L-DOPA injection when mice 
were rotating (indicating a near to complete lesion), in single and long-term treatment groups, 
compared to basal levels 24 hours after injection (when all L-DOPA was metabolised). In two 
other studies 30 minute and 2 hour time points were chosen as corresponding ‘on’ groups (El 
Atifi-Borel et al., 2009, Geurts et al., 2003). This is the first study to compare basal levels of 
RGS after L-DOPA treatment in the 6-OHDA lesioned mouse. These data suggest that RGS2 
remains elevated despite the lack of dopamine stimulation 24 hours post injection, however 
qPCR analysis shows that upregulation is much reduced at this later time point. Protein levels 
were also elevated at times on and off L-DOPA. In agreement to this observation RGS2 
remains elevated in the 6-OHDA lesion brain, above baseline levels, for 8 hours after the 
injection of a D1 agonist (Taymans et al., 2004). As RGS2 is increased at times on and off L-
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DOPA, it is unlikely to be related to the expression of AIMs, indicated by few significant 
correlations with either AIMs or rotation.  
 
5.4.5. Methodological Considerations  
There are a number of confounding factors which must be considered when analysing RGS 
proteins. A source of viable antibodies is much needed to explore regional changes of 
dysregulation at the protein level, as it may not be matched to that of the mRNA transcript. 
For example, RGS2 protein and mRNA expressions were in the cortex and striatum of 
untreated rat brains, but not in the SNc where only mRNA transcripts were localised 
(Taymans et al., 2002). Since only non-commercially available RGS antibodies are efficient 
enough to use in immunohistochemistry, specific monoclonal antibody production may give a 
greater insight L-DOPA induced changes throughout the striatum. Nevertheless the 
combination of the three semi-quantatiave methods for RGS analysis presented in this study 
provides a useful and valuable tool to monitor RGS expression. 
 
Further, 2 hours of acute resistance stress in mice can cause an up regulation of 8 RGS genes 
expressed in the mouse brain, where RGS2 was down regulated within the striatum and RGS9-
2 and RGS4 in the prefrontal cortex (Kim et al., 2010). It was therefore important to expose 
control animals to saline injections, avoiding bias induced by stress, although levels of stress 
were much lower in this study.  It is also unlikely that LID induces stress, as the anxiety level 
of rats remains unchanged with AIM expression (Kuan et al., 2008). Therefore this study 
controls for factors in which other studies have not done, providing an good experimental 
design with sufficient controls, that can be used in future studies to monitor other potential 
post-mortem biomarkers of LID. 
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5.4.6. Conclusions 
RGS proteins play a key role in the downstream signalling cascade of GPCRs abundant in the 
striatum, where RGS2 and RGS8 have been linked with the functionality of the D1 receptor 
and RGS4 and RGS9-2 of the D2 receptor (Taymans et al., 2004, Taymans et al., 2003). Seven 
weeks post-lesion RGS were not changed in the striatum at the transcript or protein level, 
indicating usual RGS regulation of GPCRs in post-synaptic cells of the striatum.  RGS2, 
RGS4, RGS8 and RGS9-2 are differently regulated by L-DOPA. Specifically, increased levels 
of RGS2 were found after single injections and long-term L-DOPA treatment, although protein 
increases were only seen in the latter, indicating long-term maladaptive changes in GPCR 
signalling. In addition, RGS2 expression changes were seen at times on L-DOPA (where 
AIMs and/ or rotation were present) and off L-DOPA (where AIMs and rotation were absent); 
hence few correlations between AIM/ rotation and transcript levels were found. RGS2 
expression is therefore inefficient to be used as a post-mortem biomarker or hallmark of LID. 
Chapter 7 will look at basal levels of RGS2 and RGS4 transcripts for their potential to be used 
as a pre- requisite biomarker of GID in rats, following the pharmacological manipulation of 
GID with known modulators of GPCR signalling (Chapter 6). 
 
156 
 
 
6. The Pharmacological Modulation of 
Experimental Graft-Induced Dyskinesia 
 Summary 
Exploring the pharmacology of amphetamine-induced AIMs using compounds with known 
activity in reducing LID may shed some light on the relationship between these two forms of 
treatment-induced dyskinesia in PD. 6-OHDA lesioned rats were primed with L-DOPA for 21 
days, before reciveing transplants of E14 VM derived tissue into the denervated striatum. 
Following neuronal maturation of the graft, animals were challenged with 0.25mg/kg, 
0.5mg/kg, 1.25mg/kg and 2.5mg/kg of methamphetamine, in a randomised Latin square 
paradigm, to elicit dyskinesia and rotational locomotion, which were recorded simultaneously. 
16 rats from the group were selected, with a range of abnormal inhibitory movements (AIMs), 
and given 2.5mg/kg of methamphetamine co-administered with a pharmacological challenge 
at high and low doses: - SCH-22390 (D1 antagonist), raclopride (D2 antagonist), nafadotride 
(D3 anatagonist), naloxone (µ opioid antagonist), WIN55,212-2 (CB1 agonist), yohimbine (α1 
and α2 adrenergic receptor antagonist), CP94253 (5-HT1B agonist), 8-OH-DPAT (5-HT1A 
agonist), amantadine (NMDA antagonist), MK-801 (NMDA antagonist), MTEP (mGluR5 
antagonist) and IEM1460 (AMPA antagonist). Non-dyskinetic animals were used as controls 
throughout. AIMs were decreased with SCH-22390, raclopride, and to a lesser extent 
nafadotride, accompanied by a decrease in net contralateral rotation. Co-administration of 
methamphetamine with amantadine, MTEP and IEM1460 did not alter the AIMs score. 
Interestingly, AIMs in response to MK-801 were increased and a reversal of rotation 
behaviour was observed. The dyskinesia caused by L-DOPA in lesioned models and 
methamphetamine in grafted models is differently modulated by pharmacological agents, 
indicating an alternate mechanism of AIM expression. Furthermore, the dopaminergic, 5-HT 
and glutamate systems are likely to have a fundamental role in the development of GID. This 
is reinforced by findings in chapter 7 in which the graft normalises the lesion and L-DOPA 
driven increase in dopamine receptors. 
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6.1 Introduction 
Restoration of depleted striatal dopamine levels, by the implantation of embryonic tissue 
derived from the VM of human foetuses, has led to the amelioration of the motor symptoms of 
PD in some patients, (Freed et al., 2001, Olanow et al., 2003, Redmond, 2002, Redmond et al., 
1993). A major roadblock in the development of this novel therapy is the occurrence of off-
medication dyskinesia in 15-56% of patients depending on the clinical trial, commonly 
occurring as a combination of hyperkinesia and dystonia (Freed et al., 2003) and (reviewed in 
(Lane and Smith, 2010, Winkler et al., 2005). These spontaneous GID are present in the 
absence of L-DOPA, although unfortunately spontaneous GID cannot be observed following 
grafting into rodent models of PD. However, post-transplanation AIMs can be evoked by the 
administration of methamphetamine (Lane et al., 2006b), which are significantly more 
prevalent in animals that have been primed with L-DOPA before grafting (Lane et al., 2009b). 
2.5mg/kg of methamphetamine may initiate AIMs in some animals and 1.5mg/kg has been 
found to give maximum rotational bias in rats (Lane et al., 2009b, Torres et al., 2008, Torres 
and Dunnett, 2007). The dose relationship of amphetamine in relation to both AIMs and 
locomotion scores has not yet been fully explored in the same cohort.  
 
As the result of the small number of transplanted patients with GID, few pharmacological 
compounds have been trialled with the aim of reducing GID. Currently, amantadine is the only 
clinically available compound that is known to reduce LID with some efficacy (Sawada et al., 
2010, da Silva-Junior et al., 2005, Godwin-Austen et al., 1970), and this may represent an 
avenue that we can exploit to treat GID. Amphetamine-induced AIMs in rats can be reduced 
experimentally in grafted lesioned rodents using D1 and D2 receptor antagonists, indicating the 
necessity of dopamine receptor activity in mediating the response (Lane et al., 2009a, 
Monville et al., 2005).  Furthermore, the 5-HT1A receptor agonist (8-hydroxy-2-(di-n-
propylamino) tetralin (8-OH-DPAT) also show efficacy to reduce AIMs with only a small 
worsening in locomotor score (Lane et al., 2009a), although the exact mechanism of which 
remain unclear. It is not known whether other anti-dyskinetic agents, used for the treatment for 
LID, will have any beneficial effect on the hyperkinesia caused by dopamine cell replacement 
strategies. Here we have selected a range of compounds targeting multiple systems known to 
affect the basal ganglia and motor function. 
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There have been a number of key studies to show the efficiency of both clinically available 
and novel anti-dyskinetic drugs in the 6-OHDA lesioned and L-DOPA treated rat. Dopamine 
antagonists such as haloperidol can reduce LID significantly, but also inhibit locomotor 
activity in lesioned rodents (Johnston et al., 2005, Monville et al., 2005, Lundblad et al., 
2005). Yohimbine and naloxone show some anti-dyskinetic effects in hemi-parkinsonian 
rodents by their α1 agonist and µ-opioid antagonist properties respectively (Dekundy et al., 
2007, Lundblad et al., 2002). Overall locomotion was reduced by yohimbine but remained 
unchanged with naloxone, indicating that the former has a global suppressive effect on 
locomotion. The 5-HT1A receptor agonist 8-OH-DPAT and 5-HT1B receptor agonist CP94253, 
have also shown some efficacy to minimise dyskinesia in rodents and primates (Dekundy et 
al., 2007, Munoz et al., 2008b, Carta et al., 2008d, Carta et al., 2008a), while L-DOPA driven 
locomotion remain largely unimpaired. Cannabinoid agonists targeting CB1 receptors such as 
WIN55,212-2 can also reduce dyskinesia experimentally without effecting the anti-akinetic 
effect of L-DOPA (Morgese et al., 2009). The weak NMDA receptor antagonist amantadine 
has the most promising effect on experimental dyskinesia (Dekundy et al., 2007, Lundblad et 
al., 2002), and has a significant effect in dyskinetic PD patients (Sawada et al., 2010, Wolf et 
al., 2010), although the compound has some anticholinergic properties and causes dopamine 
and NA release (Nastuk et al., 1976), yet does not greatly affect L-DOPA driven locomotion 
(Dekundy et al., 2007, Lundblad et al., 2002). In contrast, the non-competitive NMDA 
receptor antagonist MK-801 reduces dyskinesia, but only at doses that worsen parkinsonism, 
suppressing the beneficial effects of L-DOPA, reflected in reduced rotation in the animal 
model (Paquette et al., 2010). Furthermore, MK-801 has been found to reverse rotation after 
long-term L-DOPA treatment (Engber et al., 1994), possibly through synergistic actions with 
D1 receptor agonism (Fenu et al., 1995). The AMPA-mGluR5 receptor subunit specific 
antagonist 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine (MTEP) is able to reduce the severity of 
LID and lessen contralateral rotations in response to L-DOPA (Dekundy et al., 2006). The 
open-channel blocker of AMPA receptors 1-trimethylammonio-5-(1-adamantane-
methylammoniopentane) dibromide hydrobromide (IEM1460) has shown specific action to 
reduce AIMs without effecting rotarod performance levels seen with L-DOPA treatment 
(Kobylecki et al., 2010). 
 
In the initial part of this study the relationship of AIM score and rotation at escalating doses of 
methamphetamine was analysed. Subsequent experiments presented in this chapter have two 
overall aims, firstly to understand the mechanism of methamphetamine induced AIMs and 
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locomotion in the transplanted model of GID, and secondly to discover the anti-dyskinetic 
potential of compounds designed to target dopaminergic, adrenergic, opioid, cannabinoid, 5-
HT and glutamtergic receptors, known to reduce LID.  
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6.2 Experimental Design 
Sixty female SD rats were lesioned with 6-OHDA using stereotaxic surgery procedures and 
subjected to experiments outlined in Fig. 6.1. All successfully lesioned rats (those rotating 
greater than 7 turns per minute with methamphetamine (2.5mg/kg) were treated with L-DOPA 
(6mg/kg with 6mg/kg of benzerazide in saline) daily for 3 weeks. Rats classified as dyskinetic 
in response to L-DOPA were grafted using dissociated VM from developing E14 SD embryos. 
Rats were classified as dyskinetic if they consistently displayed all categories of AIMs, 
between severity scores 3-4, whereas non-dyskinetic rats exhibited either no or occasional 
AIMs of minimal severity (Winkler et al., 2002b).   Further details of AIM scoring and 
transplantation techniques are detailed in Chapter 2. Transplants were allowed to develop in 
vivo for 16 weeks before a second methamphetamine (2.5mg/kg) test to assess AIMs. 32 
selected rats (N=21 dyskinetic and N=11 non-dyskinetic) were used to determine the dose 
responsive nature of AIMs and rotation, where 0.25, 0.5, 1.25 or 2.5mg/kg methamphetamine 
was administered by i.p injection at twice weekly intervals in a Latin square design. 
Histological analysis of the grafts is outline in Chapter 7. 
 
 
Fig. 6.1. Time line of experimental design to look at the pharmacological modulation of 
methamphetamine induced AIMs in grafted hemi-parkinsonian models of PD.  
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16 rats selected from the cohort used for the above dose response experiment were tested with 
drugs known to modulate LID. In this group rats either exhibit high (N=11 dyskinetic) or 
negligible (N=5 non-dyskinetic) AIM scores. Pharmacological agents and corresponding doses 
were chosen on their proficiency to ameliorate AIMs elicited in response to L-DOPA in the 
hemi-parkinsonian rat model as found in our laboratory (See supplementary Table 2) and as 
reported in the literature (Dekundy et al., 2007, Kobylecki et al., 2010, Lundblad et al., 2002, 
Lundblad et al., 2005, Morgese et al., 2007, Munoz et al., 2009, Munoz et al., 2008b, Rylander 
et al., 2009). SCH23390, raclopride, nafadotride, naloxone, WIN55, 212-2, yohimbine, 
CP94253 8-OH-DPAT, amantadine, MK-801, MTEP and IEM1460 were co-administered 
with 2.5mg/kg of methamphetamine (at doses specified in Table 6.1), twice weekly with 72 
hours or more between sessions. Each drug was given at a high and low dose in a Latin square 
paradigm and the drug completely washed out before the next set of administrations. AIMs 
were scored over 3 hours post-amphetamine injection and rotations measured for 6 hours post 
injection. All drugs doses, primary receptor action, injection time in relation to 
methamphetamine (2.5mg/kg) administration, route and method of dissolving are indicated in 
Table 6.1.  
 
Integrated AIM scores and net rotation were expressed as totals over the whole session and 
temporally in 20 minute and 10 minute time bins respectively. A 1-way ANOVA with 
repeated measures was used for statistical analysis to compare total integrated AIMs between 
dyskinetic rats in response to methamphetamine alone, low dose co-treatment and high dose 
co-treatment. 2-way ANOVAs with Dunnett’s post hoc tests were used to determine the 
difference in total net rotational response between drug administrations, for both dyskinetic 
and non-dyskinetic groups. Since only one dose was used for the AIM assessment using 
yohimbine a paired t-test was used to determine statistical significance. Two sample t-tests 
were used for quantifying dyskinetic and non-dyskinetic differences between rotational scores 
using low dose CP94253. 
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Table 6.1. Table highlighting all pharmacological agents used in combination with 
methamphetamine (2.5mg/kg). Information shown (left to right): - principle receptor action 
site, dosage used in experiment, administration time relative to methamphetamine injection 
(i.p), admimistration route, solution requirements (sol), supplier and reference (ref) for their 
use LID modulation in 6-OHDA lesioned rats. N.B supplier locations are listed in Appendix 
II. 
 
 
 
 
Drug Principle 
Action 
Doses Time 
relative to 
mAmphet 
(mins) 
Route Sol Supplier Ref 
SCH23390 D1 
antagonist 
0.05 and 
0.2 mg/kg 
-20 i.p Saline Sigma (Monville et 
al., 2005) 
Raclopride D2 
antagonist 
0.5 and 2 
mg/kg 
-20 i.p Saline Sigma (Monville et 
al., 2005) 
Nafadotride D3 
antagonist 
0.6 and 
1mg/kg 
-20 s.c Saline Tocris (Monville et 
al., 2005) 
Naloxone κ and δ 
opioid 
antagonist 
4 and 
8mg/kg 
+5 s.c Saline Sigma (Lundblad 
et al., 2002) 
WIN55, 212-2 CB1 
agonist 
1 and 2.5 
mg/kg 
-15 i.p Saline Sigma (Morgese et 
al., 2007) 
Yohimbine α1 and α2 
antagonist 
10mg/kg -30 i.p Water Sigma (Dekundy et 
al., 2007) 
CP94253 5-HT1B 
agonist 
1.5 and 
3mg/kg 
-20 s.c Saline Tocris (Munoz et 
al., 2008b) 
8-OH-DPAT 5-HT1A 
agonist 
0.05 and 
0.1 mg/kg 
-20 s.c Saline Sigma (Munoz et 
al., 2008b) 
Amantadine NMDA 
antagonist 
20 and 40 
mg/kg 
-30 i.p Saline Sigma (Lundblad 
et al., 2005) 
MK-801 NMDA 
antagonist 
0.03 and 
0.3 mg/kg 
-30 i.p Saline Sigma (Paquette et 
al., 2010) 
MTEP mGluR5 
antagonist 
1.25 and 
6.25 
mg/kg 
0 i.p Water Tocris (Rylander et 
al., 2009) 
IEM1460 AMPA 
antagonist 
1 and 3 
mg/kg 
0 i.p Water Tocris (Kobylecki 
et al., 2010). 
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6.3 Results  
6.3.1. Methamphetamine Dose Response  
There was dose dependent effect of methamphetamine on AIMs (F4,120= 22.11, p<0.001) and 
total contralateral rotation (F4,120= 19.33, p<0.001), pair wise comparisons are shown in Fig. 
6.2A and C. Rats classified as dyskinetic exhibited AIMs that were significantly different to 
the non-dyskinetic group (F1,30= 24.95 p<0.001) however rotational scores did not differ  
between dyskinetic and non-dyskinetic groups (F1,30= 0.94, p=ns), although at the highest dose 
there is a trend for an increased turning response in non-dyskinetic animals. The emergence of 
AIMs above threshold levels (scores above 40) on a specific rating scale (Cenci et al., 1998) 
could be seen with 0.5-1.25mg/kg of methamphetamine, however rats were only highly 
dyskinetic when doses of 1.5 or 2.5mg/kg were used. Interestingly the highest change in the 
expression of AIMs in the dyskinetic group was between 1.5mg/kg (85.19 ±14.08) and 
2.5mg/kg (181.71 ±20.13). This is in contrast to the highest recorded rotational bias, which 
was seen at 1.5mg/kg. In addition, the classic ‘two peak’ response to the methamphetamine 
injection was only seen at doses 1.5 and 2.5mg/kg, Fig. 6.2D. 
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Fig. 6.2. The dose response of hemi-parkinsonian grafted rats previously primed with 6mg/kg 
of L-DOPA. Rats were subject to either saline, 0.5mg/kg, 1.25mg/kg, 1.5mg/kg or 2.5mg/kg 
in a randomised Latin square paradigm. Integrated AIMs scores were expressed as totals over 
3 hours (A) and in 20 minute time bins (B), with dyskinetic (white) and non-dyskinetic 
(black). Net contralateral rotations were also analysed as total turns over 6 hours (C) and in 10 
minute time bins over the duration (D). Significant changes in AIMs and rotation from 
0.5mg/kg and saline baselines respectively, are annotated by p<0.05*, p<0.01** and 
p<0.001***. Differences between the scores found for dyskinetic group at 1.5mg/kg and 
2.5mg/kg are also indicated accordingly. Significant dose dependent changes between 
dyskinetic and non-dyskinetic groups are indicated by p<0.05
†
, p<0.01
††
 and p<0.001
†††
. 
Values are expressed as means ± SEM. 
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6.3.2. Dopamine Receptor Antagonism 
The co-administration of the D1 antagonist SCH23390 at the highest dose significantly 
reduced total AIMs by 38% compared to those induced by methamphetamine (2.5mg/kg) 
alone (Fig. 6.3A: F2,22= 6.12, p<0.01). Similarly, a 61% decrease in AIMs was noted using the 
highest dose of the D2 antagonist raclopride (Fig. 6.4A: F2,22= 4.34, p<0.05). Total AIMs 
remained lowest between 20 and 100 minutes in comparison to methamphetamine for both 
SCH23390 and raclopride challenges, shown in Fig. 6.3B and 6.4B respectively. SCH23390 
caused a decrease in contralateral rotation (Fig. 6.3C: F2,28= 4.88, p<0.05), with no difference 
seen in both dyskinetic and non-dyskinetic groups (Fig. 6.3C: F1,14= 0.25, p=ns). Dose 
dependent decreases in rotation occurred at the highest dose of raclopride (Fig. 6.4C: F2,28= 
4.88, p<0.05), with no discrepancy between dyskinetic and non-dyskinetic types (Fig. 6.4C: 
F1,14= 0.57, p=ns). Rotation was decreased at both in the initial and second peak following 
SCH23390 administration, yet with raclopride the effect was predominantly in the second 
peak.  
 
Co-administration with the D3 receptor antagonist nafadotride however did not cause a 
significant reduction in amphetamine-induced AIMs in dyskinetic animals (Fig. 6.5A: F2,22= 
2.20, p=ns), although a trend was noted. There was also no change in the total rotational 
responses (F2,28= 0.24, p=ns) or between dyskinetic and non-dyskinetic groups (F1,14= 0.40, 
p=ns), Fig. 6.5C. 
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Fig. 6.3. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
SCH23390 at a low dose 
(0.05mg/kg) or a high dose 
(0.2mg/kg) (A). Integrated AIMs 
were scored every 20 min for 3 h 
in response to methamphetamine 
and in combination with 
SCH23390 doses (B). Total net 
contralateral rotations were 
recorded with the same doses over 
6 h (C). Rotational asymmetry for 
all animals was recorded over 10 
min intervals for the duration (D). 
Significant differences between 
the combination treatment and 
methamphetamine alone, are 
indicated by p<0.05*, p<0.01** 
Values are expressed as means ± 
SEM..  
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Fig. 6.4. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
Raclopride at a low dose 
(0.5mg/kg) or a high dose (2mg/kg) 
(A). Integrated AIMs were scored 
every 20 min for 3 h in response to 
methamphetamine and in 
combination with Raclopride doses 
(B). Total net contralateral rotation 
was record with the same doses 
over 6 hours (C). Rotational 
asymmetry for all animals was 
recorded over 10 minute intervals 
for the duration (D). Significant 
differences between the 
combination treatment and 
methamphetamine alone, are 
indicated by p<0.05*, p<0.01**. 
Values are expressed as means ± 
SEM.  
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Fig. 6.5. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
Nafadotride at a low dose 
(0.6mg/kg) or a high dose 
(1mg/kg) (A). Integrated AIMs 
were scored every 20 min for 3 h 
in response to methamphetamine 
and in combination with 
Nafadotide doses (B). Total net 
contralateral rotation was 
recorded with the same doses over 
6 h (C). Rotational asymmetry for 
all animals was recorded over 10 
min intervals for the duration (D). 
Values are expressed as means ± 
SEM. 
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6.3.3. Opioid Receptor Antagonism 
The µ-opioid receptor antagonist naloxone did not significantly alter total integrated AIMs in 
response to methamphetamine (Fig. 6.6A: F2,22= 0.36, p=ns). Conversely, there was a small 
suppression of total rotational scores with the highest dose of naloxone (F2,28= 4.11, p<0.05) 
with no difference between dyskinetic and non-dyskinetic groups (F1,14= 0.22, p=ns), Fig. 
6.6C. This bias was most apparent on the second peak of the rotational response, between 70-
160 minutes (Fig. 6.6D). 
 
6.3.4. Cannabinoid Receptor Agonism 
Total integrated AIMs were unchanged (Fig. 6.7A: F2,28= 0.53, p=ns) between treatments. 
Further, the CB1 receptor antagonist WIN55, 212-2 did not alter total net rotations in response 
to methamphetamine (F2,42= 0.04, p=ns), between either dyskinetic and non-dyskinetic groups 
(F1,14= 1.20, p=ns), Fig. 6.7C. Small temporal changes in rotation were apparent using the 
high and low doses of WIN55, 212-2 (Fig. 6.7D). The second methamphetamine-induced peak 
in rotation, usually occurring between 100-130 minutes, was shifted to 160-190 minutes. 
 
6.3.5. Adrenergic Receptor Antagonism 
The α1 and α2-adrenergic receptor antagonist yohimbine was only used at the low dose since 
an adverse reaction was noted. A minority of the grafted rats developed predicted pulmonary 
odema and were observed to be highly anxious. When using the low dose however no change 
in total AIM expression was evident (Fig. 6.8A: T= -0.38, p=ns).  The was no apparent change 
between methamphetamine induced total rotation and that with the addition of yohimbine 
(F1,14= 0.03, p=ns) or between dyskinetic and non-dyskinetic groups (F1,14= 0.31, p=ns), Fig. 
6.8C. Yohimbine altered the contralateral rotation pattern over time (Fig 6.8D), where the 
initial peak usually occurring before the first 10 minutes was postponed until 15 minutes, 
abolishing the second rotational peak. 
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Fig. 6.6. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
Naloxone at a low dose (4mg/kg) 
or a high dose (8mg/kg) (A). 
Integrated AIMs were scored 
every 20 min for 3 h in response 
to methamphetamine and in 
combination with Naloxone 
doses (B). Total net contralateral 
rotation was recorded with the 
same doses over 6 h (C). 
Rotational asymmetry for all 
animals was recorded over 10 
min intervals for the duration 
(D). Values are expressed as 
means ± SEM. 
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Fig. 6.6. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
WIN55, 212-2 at a low dose 
(1mg/kg) or a high dose 
(2.5mg/kg) (A). Integrated AIMs 
were scored every 20 min for 3 h 
in response to methamphetamine 
and in combination with WIN55, 
212-2 doses (B). Total net 
contralateral rotation was record 
with the same doses over 6 h (C). 
Rotational asymmetry for all 
animals was recorded over 10 min 
intervals for the duration (D). 
Values are expressed as means ± 
SEM.  
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Fig. 6.8. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
Yohimbine at a dose of 10mg/kg 
(A). Integrated AIMs were scored 
every 20 min for 3 h in response 
to methamphetamine and in 
combination with Yohimbine 
doses (B). Total net contralateral 
rotation was record with the same 
doses over 6 h (C). Rotational 
asymmetry for all animals was 
recorded over 10 min intervals for 
the duration (D). Values are 
expressed as means ± SEM.  
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6.3.6. 5-HT Receptor Agonism 
The action of the 5-HT1B receptor agonist CP94253 (3mg/kg) caused a significant reduction in 
AIMs compared to methamphetamine alone (Fig. 6.9A: F2,22= 3.46, p<0.05). Primarily 
decreases were observed in the first 100 min of the scoring session (Fig. 6.9B), thereafter 
appearing similar in magnitude to those seen with methamphetamine alone. A dose dependent 
reduction in total AIMs was also seen with the specific 5-HT1A receptor agonist 8-OH-DPAT 
(Fig. 6.10A: F2,22= 5.85, p<0.01). There was no difference between the total rotational 
response to CP94253 and methamphetamine (Fig. 6.9C) compared to methamphetamine alone 
(F2,28= 0.30, p=ns), however there was a difference between dyskinetic and non-dyskinetic 
groups (F1,14= 4.91, p<0.05). Post hoc tests reveal that the latter difference was only evident at 
the low dose (p<0.05). 8-OH-DPAT treatment did not alter total net rotation (F2,28= 0.70, 
p=ns), with no differences between dyskinetic and non-dyskinetic groups (F1,14= 2.64, p=ns) ( 
Fig. 6.10C). Co-administration of CP94263 altered the time course of the rotational response 
with a gradual increase in rotations between 130 and 360 minutes without an identifiable 
second peak in the response, in contrast to the methamphetamine only time course. Dyskinetic 
and non-dyskinetic groups responded differently, where the early rotational responses in non-
dyskinetic rats was suppressed for the early phase of the response (Fig. 6.11; T= -2.60, 
p<0.05) before being normalised (Fig. 6.11; T= -1.48, p=ns). CP94263 treatment also caused 
a small biphasic response in AIM expression (Fig. 6.9B) where dyskinesia is much reduced 
between 20 and 140 minutes and increased above the methamphetamine baseline at 180 
minutes, mirroring the rotational response. 
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Fig. 6.9. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) CP-
94253 at a low dose (1.5mg/kg) or a 
high dose (3mg/kg) (A). Integrated 
AIMs were scored every 20 minutes 
for 3 hours in response to 
methamphetamine and in 
combination with CP-94253 doses 
(B). Total net contralateral rotation 
was record with the same doses over 
6 hours (C). Rotational asymmetry 
for all animals was recorded over 10 
minute intervals for the duration (D). 
Significant differences between the 
combination treatment and 
methamphetamine alone is indicated 
by p<0.05*. Dyskinetic and non-
dyskinetic differences were also 
present, where p<0.05
†
. Values are 
expressed as means ± SEM. 
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Fig. 6.10. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 8-
OH-DPAT at a low dose (1.5mg/kg) 
or a high dose (3mg/kg) (A). 
Integrated AIMs were scored every 
20 minutes for 3 hours in response 
to methamphetamine and in 
combination with 8-OH-DPAT 
doses (B). Total net contralateral 
rotation was record with the same 
doses over 6 hours (C). Rotational 
asymmetry for all animals was 
recorded over 10 minute intervals 
for the duration (D). Significant 
differences between the 
combination treatment and 
methamphetamine alone is indicated 
by p<0.01**. Dyskinetic and non-
dyskinetic differences were also 
present, where p<0.05
†
.Values are 
expressed as means ± SEM. 
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Fig. 6.11. Temporal dyskinetic and non-dyskinetic differences in rotation present when co-
administrating methamphetamine with CP94253 low dose (1.5mg/kg) (A).  Total net 
contralateral rotations are also shown from 0-180 min (B) and 181-360 min (C). Statistical 
significance between groups was deduced by a 2 sampled T-test and annotated as p<0.05*. 
Values are expressed as means ± SEM. 
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6.3.7. Glutamate Receptor Antagonism 
The NMDA receptor antagonist amantadine had no effect on the AIMs response to 
methamphetamine (Fig. 6.12: F2,22= 1.42, p=ns). Conversely, the NMDA receptor antagonist 
MK-801 increased total AIMs (Fig. 6.13A: F2,28= 11.17, p<0.001) at the highest dose, 
resulting from abnormally high dyskinetic responses at 100-140 minutes (Fig 6.13B). When 
the total integrated AIM score is split into sub-components (Fig. 6.14A-D), dyskinesia was 
significantly increased in the forelimbs (F2,22= 3.47, p<0.05) and hindlimbs (F2,22= 3.71, 
p<0.05) of the grafted cohort, with the biggest change recorded the axial form of the 
movement (F2,22= 11.14, p<0.001). No changes in orolingual movements were noted (F2,22= 
0.60, p=ns). The increase in AIMs was mainly the result of increased duration of the response 
in each recording interval (Fig. 6.14E: F2,22= 16.14, p<0.001), although amplitude scores were 
also increased (Fig. 6.14F: F2,22= 3.68, p<0.05).  
 
Total contralateral turns did not differ between groups when treated with amantadine (F1,14= 
3.76, p=ns) or between treatments (F2,22= 0.68, p=ns), shown in Fig. 6.12C. An abnormal 
rotational response was observed with MK-801 co-administration (Fig. 6.13C), where a dose 
dependent reversion in rotation was clear (F2,28= 19.24, p<0.001), with no differences between 
dyskinetic and non-dyskinetic subgroups (F1,14= 0.37, p=ns). Total net rotational scores with 
high dose MK-801 were significantly different to methamphetamine alone (p<0.001) and 
although this was not reiterated at low dose there was a clear absence of the second rotational 
peak, with almost no net rotation in any direction between 70 and 360 minutes (Fig. 6.13D).  
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Fig. 6.12. Total integrated 
AIMs initiated by 
methamphetamine (2.5mg/kg) 
alone and with (+) amantadine 
at a low dose (20mg/kg) or a 
high dose (40mg/kg) (A). 
Integrated AIMs were scored 
every 20 minutes for 3 hours 
in response to 
methamphetamine and in 
combination with amantadine 
doses (B). Total net 
contralateral rotation was 
record with the same doses 
over 6 hours (C). Rotational 
asymmetry for all animals was 
recorded over 10 minute 
intervals for the duration (D). 
Values are expressed as means 
± SEM. 
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Fig. 6.13. Total integrated 
AIMs initiated by 
methamphetamine (2.5mg/kg) 
alone and with (+) MK-801 at a 
low dose (0.03mg/kg) or a high 
dose (0.3mg/kg) (A). Integrated 
AIMs were scored every 20 min 
for 3 h in response to 
methamphetamine and in 
combination with MK-801 
doses (B). Total net 
contralateral rotation was record 
with the same doses over 6 h 
(C). Rotational asymmetry for 
all animals was recorded over 
10 min intervals for the duration 
(D). Significant differences 
between the combination 
treatment and 
methamphetamine alone are 
indicated by p<0.001***. 
Values are expressed as means 
± SEM. 
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Fig. 6.14. The sub-categorisation of AIM score in response to methamphetamine alone 
(2.5mg/kg), with the addition of low dose MK-801 (0.03mg/kg) or high dose MK-801 
(0.3mg/kg). AIM components assessed were forelimb (A), hind limb (B), axial (C), orolingual 
(D), total AIM severity (E) and total AIM amplitude (F). A Tukey post hoc test revealed 
significant differences attest between methamphetamine and with MK-801 treatment at the 
low dose, annotated by p<0.05* and p<0.001***. Differences between high and low doses 
indicated by p<0.05
†
 and p<0.001
†††
. Values are expressed as means ± SEM. 
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The mGlu5 receptor subunit antagonist MTEP used in combination to methamphetamine had 
no effect on the expression of AIMs (Fig. 6.15A: F2,22= 0.66 p=ns). There was a small 
decrease in total number of rotations with administration of the high dose (F2,28= 4.30, p<0.05) 
but no difference between dyskinetic and non-dyskinetic groups (F1,14= 0.44, p=ns), Fig. 
6.14C. The total rotational decrease can be attributed to a specific decrease in the second peak 
of rotational behaviour (Fig 6.15D). 
 
The voltage-dependent open-channel blocker of AMPA receptors, IEM1460, did not affect 
AIMs at either dose (Fig. 6.16A: F2,22= 1.36, p=ns), but reduced total rotations (F2,28= 4.04, 
p<0.05), with no difference between dyskinetic and non-dyskinetic groups (F1,14= 0.66, p=ns), 
Fig 6.16C. At the low dose a small decrease in the second rotational peak was apparent (Fig 
6.16D).  
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Fig. 6.15. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
MTEP at a low dose (1.25mg/kg) 
or a high dose (6.25mg/kg) (A). 
Integrated AIMs were scored 
every 20 minutes for 3 hours in 
response to methamphetamine 
and in combination with MTEP 
doses (B). Total net contralateral 
rotation was record with the 
same doses over 6 hours (C). 
Rotational asymmetry for all 
animals was recorded over 10 
minute intervals for the duration 
(D). Significant differences 
between the combination 
treatment and methamphetamine 
alone are annotated by p<0.05*. 
Values are expressed as means ± 
SEM. 
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Fig. 6.16. Total integrated AIMs 
initiated by methamphetamine 
(2.5mg/kg) alone and with (+) 
IEM-1460 at a low dose 
(1mg/kg) or a high dose (3mg/kg) 
(A). Integrated AIMs were scored 
every 20 minutes for 3 hours in 
response to methamphetamine 
and in combination with IEM-
1460 doses (B). Total net 
contralateral rotation was record 
with the same doses over 6 hours 
(C). Rotational asymmetry for all 
animals was recorded over 10 
minute intervals for the duration 
(D). Values are expressed as 
means ± SEM. 
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6.3.8. Results Summary 
Table 6.2 illustrates the drugs known to reduce LID and their impact on reducing 
amphetamine-induced dyskinesia in the grafted hemi-parkinsonian model. Dopamine and 5-
HT modulating agents did reduce AIMs and altered total and temporal patterns of net 
contralateral rotation. With the exception of MK-801 the NMDA, AMPA and mGlu receptor 
antagonists did not decrease AIMs, yet locomotor activity measured by rotation was 
suppressed at the highest doses. Excluding MK-801, where total integrated AIM changes did 
occur, these were ubiquitous across all subtypes (see supplementary data: Table 1). 
 
 
Table 6.2. A comparison of the pharmacological modulation of LID and methamphetamine 
(2.5mg/kg)-induced GID in unilateral 6-OHDA lesioned rats. Table annotated as: - mildly 
decreased (↓), mildly increased (↑), moderately increased (↑↑), moderately decreased (↓↓), 
greatly increased (↑↑↑), greatly decreased (↓↓↓), unchanged (---), reversion in rotation (†) and 
dyskinetic/ non-dyskinetic group differences (*). 
Drug LID L-
DOPA 
Loco 
Ref mAmphet 
GID 
mAmphet 
Loco 
Ref 
SCH23390 ↓↓↓ ↓↓↓ (Monville et 
al., 2005) 
↓↓↓ ↓↓↓ (Lane et al., 
2009a) 
Raclopride ↓↓↓ ↓↓↓ (Monville et 
al., 2005) 
↓↓↓ ↓↓↓ (Lane et al., 
2009a) 
Nafadotride ↓↓ ↓↓ (Monville et 
al., 2005) 
↓ ---  
Naloxone ↓↓ --- (Lundblad 
et al., 2002) 
--- ↓  
WIN55, 212-2 ↓↓ ---  (Morgese et 
al., 2007) 
--- ---  
Yohimbine ↓↓ ↓↓ (Dekundy et 
al., 2007) 
--- ---  
CP94253 ↓↓ --- (Munoz et 
al., 2008b) 
↓↓ ↓*  
8-OH-DPAT ↓↓ --- (Munoz et 
al., 2008b) 
↓↓ ↓ (Lane et al., 
2009a) 
Amantadine ↓↓ --- (Lundblad 
et al., 2005) 
--- ---  
MK-801 ↓↓ ↓↓ (Paquette et 
al., 2010) 
↑↑ ↓↓↓†  
MTEP ↓↓ --- (Rylander et 
al., 2009) 
--- ↓↓  
IEM1460 ↓↓ --- (Kobylecki 
et al., 2010) 
--- ↓  
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6.4 Discussion 
 
6.4.1. Methamphetamine Dose Response 
The reduction/ reverson in amphetamine-meadiated turning following transplantation have 
long been established (Bjorklund and Stenevi, 1979, Dunnett et al., 1981).  Both stereotypic 
and rotation responses have previously been shown to be dependent upon dose (Lane et al., 
2009b, Torres and Dunnett, 2007), but this is the first data to illustrate the same effect with 
post-transplantation AIMs.  This study also highlights the disparity between AIMs and 
rotational responses, increasing the validity of their assessment as two different parameters of 
post-transplantation activity of the graft. Maximal rotational responses were triggered by 
1.5mg/kg of methamphetamine, whereas the highest AIM scores were recorded at 2.5mg/kg. 
Lower doses (0.5mg/kg and 1.25mg/kg) were sufficient to cause both AIMs and rotational 
bias to equivalent levels that were significantly less than observations at 1.5mg/kg and 
2.5mg/kg. The conflict between the increase in AIMs and decrease in rotation rate may reflect 
the direct competition between these behaviours, since locomotion is limited by the limb/ axial 
dyskinesia and dystonia. However these data suggest that something different underlies this 
difference, since rotation is only slightly higher in the non-dyskinetic group. 
Methamphetamine induces dopamine efflux from the transplant and reduces dopamine influx 
via direct interaction with DAT transporters (reviewed in (Fleckenstein et al., 2007), with the 
efficacy of this mechanism seemingly greatest at 1.5mg/kg. This balance may be shifted at 
2.5mg/kg, favouring reduced and dysregulated dopamine release. Interestingly, the same 
biphasic response and rotational severity is observed in grafted rats that have not been primed 
with L-DOPA (unpublished observations Lane EL, (Steece-Collier et al., 2009, Torres and 
Dunnett, 2007) Thus indicating the super-sensitisation of dopamine receptors doses not 
mediate turning in response to methamphetamine.  
 
6.4.2. Dopamine Receptor Antagonism 
The inhibition of methamphetamine-induced dyskinesia and contralateral turning behaviour by 
D1 and D2 antagonists, SCH-23390 and raclopride respectively, suggests that dopamine 
released from the graft acts on D1 and D2 receptors in the striatum to trigger these behavioural 
responses. These findings by (Lane et al., 2009b) were reproduced here and AIMs score 
reduction, accompanied by a decrease in locomotion, was of equal magnitude to their effect on 
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experimental LID (Johnston et al., 2005, Monville et al., 2005, Lundblad et al., 2005). These 
data also suggest robust turning response and methamphetamine driven GID is not greatly 
modulated by D3 receptors. In contrast both D3 agonism and antagonism are able to reduce 
LID in MPTP treated primates, with the latter also negating the therapeutic benefit of L-
DOPA (Bezard et al., 2003). Since antagonism with nafadotride caused no change in rotational 
asymmetry it is likely that the small reduction in dyskinesia may be explained by the partial D2 
antagonistic properties of the drug.  In addition, other more specific D3 binding compounds 
have no effect on mediating amphetamine-driven ipsilateral rotation after a 6-OHDA lesion, 
where receptors are found to be down-regulated (Robinet and Bardo, 2001).  It is therefore 
unlikely that D3 receptors are further altered post graft. D2 receptors within the graft are likely 
to modulate dopamine release caused by methamphetamine, thus further modulating 
extracellular dopamine levels presynaptically. Levels of D1 and D2 receptors within the 
denervated striatum and transplanted tissue are compared between dyskinetic and non-
dyskinetic groups in Chapter 7.   
 
6.4.3. Opioid Receptor Antagonism 
Naloxone had a small effect of reducing the rotational asymmetry from 75-150 minutes post 
injection, although had no effect on GID. The null effect on AIMs can be explained in part by 
the lack of µ-opioid receptors in dorsomedial regions, as receptors mainly reside within the 
NAcc core and rostral VTA (Soderman and Unterwald, 2008). These results are in contrast to 
its use in the modulation of experimental LID (Dekundy et al., 2007). Rotational changes are 
likely to be post-synaptic and mediated by dopamine receptor intracellular signalling, since D1 
and D2 receptors can be colocalised with µ-opiod receptors and are coupled with adenyl 
cyclise-5, implicated in motor function (de Gortari and Mengod, 2010). In addition, specific µ-
opioid receptor-mediated G-protein activation is significantly enhanced in the basal ganglia 
and cortex of L-DOPA-treated dyskinetic primates (Chen et al., 2005) and therefore naloxone 
may cause an anti-dyskinetic effect by altering opioid specific GPCR intracellular signalling. 
It is currently unknown if specific opioid G-protein mediated signalling is dysregulated or 
normalised in grafted rodent models.  
. 
6.4.4. Cannabinoid Receptor Agonism 
The CB1 receptor antagonist WIN55, 212-2 reduced the rotational response between 25-100 
minutes, without decreasing the expression of methamphetamine induced GID during this or 
any other time point during the observation time. The localisation of CB1 receptors in ventral 
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striatal regions may mediate the locomotor response, preferentially to the abnormal 
movements. This contrasts with the reduction of LID in rats with the same compound 
(Morgese et al., 2007), although this result can be debated, since clinical trials using oral 
cannabis did not improve dyskinetic symptoms (Carroll et al., 2004). The collective action of 
cannabinoid agonists is seemingly unlikely to warrant evaluation as a treatment of GID. The 
lack of effect of CB1 modulation are threefold, since they are unlikely to be found in the graft 
as they have only been localised to striatonigral neurones, are substantially reduced in the 6-
OHDA lesioned brain (Walsh et al., 2010) and unchanged by L-DOPA treatment (Casteels et 
al., 2010). Nevertheless this is an important drug for continued clinical investigation, as there 
is much research in regard to LID and may have some modular and co-modulator roles in 
pharmacological management of GID. 
 
6.4.5. Adrenergic Receptor Antagonism 
Dyskinesia or turning behaviour was not affected by 10mg/kg of yohimbine and proportions 
of the cohort exhibited adverse side effects including pulmonary oedema. Tolerance issues and 
cardiovascular side effects associated with the targeting of the α2 adrenergic receptor have 
been reported following testing in phase II clinical trials for the treatment of LID (Fox et al., 
2008a). The additional antagonist actions on 5-HT1A, 5-HT1B, and D2 have not been excluded 
as mechanisms through which the positive effects of yohimbine on LID may be mediated, 
although do not explain the lack of effect with GID. It is reasonable to assume that a higher 
dose would have negated GID but could not be trialled due to extreme side effects in 
combination with amphetamine administration. The adrenergic antagonistic properties drug to 
cause an inhibition of dopamine release from host terminals should be sufficient to decrease 
turning and dyskinetic behaviour, however the presence of α1 and α2 receptors on dopamine 
neurones on the graft are unknown. 
 
6.4.6. 5-HT Receptor Agonism 
The 5-HT1A receptor agonist (8-OH-DPAT) and the 5-HT1B receptor agonist (CP-94253) 
reduced the total integrated AIM score, largely due to a reduction over the first 80 minutes of 
testing; this reduction in AIMs with 8-OH-DPAT is consistent with previous findings (Lane et 
al., 2009a). 5-HT release is blocked by action at receptors on the dorsal and medial Raphe 
nucleus or on the 5-HT terminals themselves when given 8-OH-DPAT and CP-94253 
respectively. The dual route of these responses has led to the previous finding that combined 
5HT1A and 5HT1B treatment causes a further reduction in L-DOPA induced AIMs (Carta et al., 
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2008a), this could also be applied to the grafted model in future studies. Activation of 
presynaptic 5HT1A receptors on glutamate and 5-HT terminals by CP-94253 causes an 
increase in extracellular 5-HT levels reducing the synaptic release of glutamate and 5-HT and 
controlling dysregulated release. Under these principles AIM reduction is likely to be a 
combined modulation of grafted 5-HT neurones, host 5-HT terminals and corticostriatal 
connections.   
 
CP-94253 did not alter total contralateral rotations but the time course reveals a biphasic 
action, the second peak in rotation being prevented by both doses, with turning remaining 
constant between 225-360 minutes.  CP-94253 acts as a monoamine reuptake inhibitor causing 
the accumulation of 5-HT and dopamine in the brain which may relate to the delayed and 
prolonged increase in rotation in the latter half of the experiment. Interestingly, 5-HT1B 
agonists injected directly into the VTA can enhance methamphetamine-induced 
hyperlocomotion (Papla et al., 2002). Therefore the action of this drug in the VTA may 
contribute to the enhancement of methamphetamine-induced rotation seen toward the end of 
the session and the sustained AIM expression above baseline seen at 180 minutes. 
 
To probe the role of 5-HT in GID, 11CDASB PET scans carried out on 2 of the patients 
grafted in the London/Lund study (Hagell et al., 1999). These revealed high binding of the 5-
HT transporter, and thereby assumed high levels of 5-HT neurons in the grafted putamens 
(Politis et al., 2010). Levels were significantly higher than both neurologically normal controls 
and patients with PD (Politis et al., 2010).  Both patients had GID and were blindly challenged 
with buspirone which reduced the abnormal movements as assessed by a clinician also blind to 
the treatment status.  Although supportive of a role of 5-HT in the GID these data should be 
interpreted with caution as only 2 grafted patients were studied, both of whom had GID, no 
grafted patients without GID were evaluated.  Furthermore, busprione has a notable D2 
receptor antagonist activity which could also be expected to have this effect, assuming 
excessive dopamine release is driving the GID.  The α1, and α2-adrenergic receptor antagonist 
action of buspirone is unlikely to have a direct effect on spontaneous abnormal movements, as 
seen by this study, although it may have a synergistic effect to reduce GID in combination 
with 5-HT agonist and D2 antagonist actions. It is evident that agonist action on 5-HT release 
by the host terminals and 5-HT cells in the graft can modulate GID to a certain extent, but is it 
is unclear whether this is a causative neuro-pathological mechanism, since the relationship 
between grafted 5-HT cells and host fibres with dyskinesia has not fully been explored. 
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Certainly research with the model of amphetamine-induced AIMs has shown no such 
relationship to host or transplant derived 5-HT innervations (Lane et al., 2009a) and although 
the clinical relevance of the rodent model is disputed, grafts with a high proportion of 5-HT 
cells in the transplants were observed in patients without GID (Mendez et al., 2008).  
 
 
6.4.7. Glutamate Receptor Antagonism 
There was no change in AIMs when the NMDA receptor antagonist amantadine was given 
with methamphetamine, equally in the in patients with LID amantadine only has an effect in a 
proportion of patients and efficiency of the drug may ware off after several months (Sawada et 
al., 2010, Wolf et al., 2010).  The drug may act like other NMDA receptor antagonists on LID, 
such that AIMs are only reduced when parkinsonism is increased (Paquette et al., 2010, 
Paquette et al., 2008). Since methamphetamine driven locomotion did not change with 
amantadine perhaps a higher dose than those used in LID would bring about these changes in 
GID. Although clinically available for the treatment of dystonia or LID, this compound is one 
of the least specific and potent NMDA receptor antagonists. Amantadine also acts as a 
dopamine releasing agent, and also has anticholinergic properties (www.accessdata.fda.gov) 
that may be partly responsible for the decrease in LID, yet had these properties fail to effect 
methamphetamine driven AIMs/ rotation. The lack of effect of amantadine could be due to a 
similar competing mechanism since methamphetamine too causes dopamine release in 
addition to replacing dopamine in vesicles and inhibiting dopamine metabolism (reviewed in 
(Fleckenstein et al., 2007).  
Abnormal movements were increased by the highest dose of MK-801, accompanied by a 
reversal in rotation to pre-graft levels. This bizarre turning behaviour may be explained by the 
action MK-801 to increase dopamine in the SN and VTA (Wedzony and Czyrak, 1996, 
Wedzony et al., 1996). In this instance dopamine will have a greater effect on the dopamine 
receptors on the intact side, resulting in an ipsilateral bias. Previously authors have similarly 
reported that high doses of MK-801 are also able to cause a reversal in rotation caused by L-
DOPA or dopamine agonists in lesioned rats (Boldry et al., 1995) and enhance turning where 
dopamine is injected intrastriatally in intact rats (St-Pierre and Bedard, 1995, St-Pierre and 
Bedard, 1994). In intact animals MK-801 causes a down-regulation of RGS2 in the striatum, 
that parallels an enhancement of adenyl cyclase (Taymans et al., 2005a). This is in contrast to 
amphetamine and dopamine mediated upregulation of RGS2 gene expression. RGS2 
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expression reduction could therefore play a causal role in the reversal of rotation seen in our 
animals, as RGS proteins are inhibitory to the cAMP pathway associated with dopamine 
receptors and locomotion. MK-801 given in combination with apomorphine is able to negate 
the priming effect on D2 receptors (Pollack and Strauss, 1999) and can increase the turning 
responses and c-fos expression to D1 agonists (Fenu et al., 1995), highlighting the strong 
functional connection between receptor types. High doses of L-DOPA and MK-801 however 
caused a worsening of scores on simple behavioural tasks assessing asymmetry deficit 
restoration by L-DOPA (Paquette et al., 2010). MK-801 could therefore cause an increase in 
the AIM score due to a lack of balance and co-ordination, therefore resulting in an increased 
parkinsonian phenotype. A loss of balance may also arise because the change in rotation 
occurred yet the lateralised dyskinesia in hind and fore limbs was constant, thus segregating 
the locomotor and dyskinesia mechanisms in the striatum. High axial and hindlimb AIM 
scores may therefore be the result of loss of balance.  
 
MTEP was selected because of its known anti-LID properties in the rodent model (Dekundy et 
al., 2006) and because mGluR5 (Testa et al., 1994), expressed heterogeneously throughout the 
cortex and striatum. The antagonism of mGluR5 however did not cause a decrease in 
amphetamine-induced GID, only a reduction in contralateral rotation. It seems likely that 
MTEP may actually be increasing dyskinesia as a substantial reduction in rotation (an 
indicator of global motor suppression) is often accompanied by a decrease in AIMs. Co-
administration of MTEP in LID states not only causes a reduction in AIMs but also abolishes 
pathological hallmarks of dyskinesia i.e. reversal of L-DOPA-induced up-regulation of PPE 
(Kobylecki et al., 2010). PPE has not yet been studied in relation to amphetamine driven AIMs 
with MTEP, but this aspect warrants further investigation. The lack of effect of MTEP may 
also be due to the absence/ presence of the mGluR5 receptor on grafted cells, which currently 
remains unknown. Nevertheless, the studies presented here indicate a different mechanism of 
amphetamine induced AIMs compared to those triggered by L-DOPA (perhaps through the 
simultaneous function of the graft and super-sensitised striatum), as mGluR5 antagonists 
suppress L-DOPA induced AIMs, yet mGluR1 antagonists have no effect (Dekundy et al., 
2006, Rylander et al., 2010, Mela et al., 2007).   
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IEM 1460 was used to antagonise AMPA receptors without GluR2 subunits (GluR2 is 
expressed largely within the cortex), however had little effect on behaviour in contrast to LID 
where these receptors are critically involved in the initiation and subsequent expression of 
AIMs (Kobylecki et al., 2010). In the same study IEM 1460 was also found to normalise PPE 
and PPD expression in the lateral striatum. IEM 1460 may also be directly affecting the graft 
and the expression of AMPA receptor subunits quantified. GluR2/3 and GluR4 are highly 
expressed on developing dopamine cells 4 weeks post grafting, correlating with behavioural 
recovery, whereas the maturation of GluR1 subunits is prolonged until 12 weeks (Ishida et al., 
2002), yet this later time point is associated with dyskinesia. Therefore GluR1 antagonism 
may be more advantageous in GID.  Overall this indicate that GID is likely the result of graft 
integration, in addition to that of the long-lasting changes triggered by L-DOPA priming, 
requiring different pharmacological treatments compared to LID. 
 
6.4.8. Conclusions 
The dosage of methamphetamine is critically important for the manifestation of severe AIMs 
and locomotion, at 2.5mg/kg dose dyskinetic movements are high, yet strong net contralateral 
rotation is compromised from that seen at 1.5mg/kg. Furthermore, many of the 
pharmacological agents that have shown efficacy to reduce AIMs in humans and animal 
models, as the result of long term L-DOPA therapy, do not appear to reduce amphetamine 
driven dyskinesia in the grafted rodent model. It can therefore be concluded that GID and LID 
are mechanistically distinct and dopamine, 5-HT and glutamate are likely to be the key 
neurotransmitter systems involved in the development of AIMs arising from the dopamine rich 
transplant. It is clear from the literature that little is known about how levels of each receptor 
change following transplantation and whether this procedure can reverse L-DOPA receptor 
states. Therefore it is also unknown whether dyskinetic and non-dyskinetic grafted rats in 
response to methamphetamine have different receptor expression patterns. It is hoped that 
transgenic mice (i.e. specific receptor and functional protein knock-outs) may be used in the 
future to determine the mechanism of GID; however this first requires the creation of a non-
transgenic grafted mouse model of amphetamine-induced AIMs (Chapter 8). Furthermore, a 
greater analysis of the dopamine receptors and associated molecular correlates of 
amphetamine-induced AIMs may also provide clues into the mechanism underlying GID 
(Chapter 7). 
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7. Neural Correlates of Amphetamine Induced 
Dyskinesia in the Grafted Rat Model 
Summary 
Unilateral 6-OHDA lesioned rats were primed with L-DOPA for 21 days, 1 month post 
surgery, before they were transplanted with rat E14 VM tissue in the denervated striatum. 
Dopaminergic grafts were allowed to mature in the absence of L-DOPA treatment for 16 
weeks. Contralateral turning behaviour was elicited in response to 2.5mg/kg of 
methamphetamine in all grafted animals and 60% developed additional AIMs, not seen in 
lesion only rats. These data show that graft size (as determined by 5-HT/ TH cell counts) 
correlates with AIMs, although cell counts of either type do not differ between rats grouped 
into dyskinetic and non-dyskinetic cohorts. D1 and D2 dopamine receptor binding analysed by 
density analysis were found to be upregulated in response to the lesion and normalised 
following transplantation, however receptor expression was not uniform throughout the 
striatum. Cells within the grafted tissue were found to contain mRNA transcripts for both 
RGS2 and RGS4, however the former was the most highly expressed and accordingly was 
correlated with AIMs. It was further found that RGS expression in the grafted tissue does not 
follow that of the adult SNc and VTA, but rather reflects embryonic levels at the time of 
transplantation, or a change induced by graft development in a novel environment. 
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7.1. Introduction 
Transplantation of developing dopaminergic tissue into the dopamine depleted striatum of PD 
patients has lead to improvement of the motor phenotype of some patients (Lindvall et al., 
1989, Madrazo et al., 1988, Freed et al., 1995, Freed et al., 2001, Redmond, 2002, Redmond et 
al., 1993). However this novel technique has been shown to cause dyskinesia that can be 
initiated and sustained off medication (Freed et al., 2001). Although the spontaneous nature of 
this side effect cannot be reproduced in transplanted animal models, AIMs can be initiated by 
the administration of amphetamine in grafted rats (Lane et al., 2009a, Lane et al., 2006b). A 
number of factors have been found to correlate with AIMs in transplanted rats, differing 
according to each individual transplant. Graft placement, L-DOPA pre-treatment and the 
proportions of 5-HT neurones within the graft have been found to modulate the expression of 
AIMs (Carta et al., 2008c, Carlsson et al., 2006b, Lane et al., 2009b), although the latter 
correlate has been disputed (Garcia et al., 2011, Lane et al., 2009a). To date there has been 
little evidence to suggest correlates between the number of transplanted dopamine cells/ size 
of the graft and the expression of amphetamine-induced AIMs (Lane et al., 2009b, Lane et al., 
2006b, Lane et al., 2008). 
 
In addition, dopamine rich transplants also change the expression of dopamine receptors. The 
density analysis of [
3
H] radioligand binding assays show that dopamine depletion causes an 
increase in D1 and D2 receptors in the striatum and following a dopamine rich transplant, there 
is an apparent renormalisation of dopamine receptor levels, although results have been mixed 
and may be dependent on time post-lesion (Dewar et al., 1990, Mileson et al., 1991, Blunt et 
al., 1992, Narang and Wamsley, 1995). Transplantation has also been found to increase [
3
H] 
DAT binding and cause a normalisation of [
3
H] D1 and [
3
H] D2 levels compared to the intact 
side in the striatum and SN (Dawson et al., 1991). Other studies have shown regional 
differences in binding, where a large reduction of [
3
H] D1 and [
3
H] D2 density levels in the 
immediate graft vicinity and a smaller reduction throughout the rostral and caudal striatum 
(Gagnon et al., 1991, Rioux et al., 1991). No further change in D1 and D2 receptor levels are 
observed in L-DOPA treated grafted rats (Rioux et al., 1993). Where no previous lesion 
induced change in [
3
H] D1dencity is seen however [
3
H] D1 levels are reduced compared to 
lesion only controls following transplantation (Savasta et al., 1992).  
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This chapter aims to look at the levels of D1 and D2 dopamine receptors and corresponding 
post-receptor regulators of G-protein signalling (RGS2 and RGS4) within the graft and 
denervated striatum, to find how the transplant alters basal levels with respect to lesion only 
animals. The quantities and correlations of 5-HT/ TH and RGS positive cells in the graft were 
also compared, with the aim of discussing reasons behind observed differences. The ultimate 
goal of this research was to test whether dopamine receptors and RGS transcript expression in 
cells could be used as a new ‘biomarker’ for rats that will become dyskinetic in response to 
amphetamine and/or AIM severity. 
 
7.2. Experimental Design 
47 rats were used for the experiments presented in this chapter. All rats were adult female SD 
rats (Harlan) that had previously received a unilateral 6-OHDA injection to the MFB 
(Outlined in Chapter 2). Four weeks post-lesion rats received 21 consecutive days of L-DOPA 
and benzerazide (10mg/kg each), given by s.c injection. Rats were then transplanted with a 
single cell suspension derived from E14 VM tissue, from time mated SD females (Harlan) and 
the graft left to mature for 16 weeks, in the absence of any treatment. Methamphetamine 
(2.5mg/kg) was then used to induce contralateral turning and AIMs (in transplanted rats), 
given no more than twice per week.   
 
Transplanted rats were separated into two groups, matched on similar AIM scores, to be culled 
either by perfusion from immunohistochemistry (N=16) or a schedule 1 technique so that the 
brains could be snap frozen (N=31) for in situ hybridisation. All rats were sacrificed more than 
48 h after the final methamphetamine injection, where the presence of AIMs was absent. 
Groups were generated from rats that were dyskinetic (perfused: N=11; snap frozen: N=14) 
and non-dyskinetic (perfused: N=5; snap frozen: N=11), with remaining animals serving as 
intact and lesioned controls. Six E14 rat embryo heads, snap frozen immediately following 
dissection, were also used for these experiments. Paraformaldyhyde fixed tissue issue was 
processed for the analysis of TH and 5-HT positive cells and snap frozen tissue to monitor 
basal cell expression of RGS2 and RGS4, following protocols highlighted in Chapter 2. 
Consecutive sections of snap frozen tissue at the level of the striatum were used to determine 
levels of D1 and D2 receptor levels by [
3
H] SCH23390 and [
3
H] Raclopride autoradiography, 
also described in detail in Chapter 2. 
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Student T-tests were used to compare total numbers of TH and 5-HT cells in the grafted tissue 
of dyskinetic and non-dyskinetic rats and Pearson’s analysis were used to measure correlations 
between cell numbers with the expression of AIMs and graft volumes. Dopamine receptor 
levels were measured by density analysis on imageJ (methods outlined in Chapter 2) and a 1-
way ANOVA was used to compare differences between groups. Two-way ANOVAs with 
Dunnett’s post hoc tests were used to compare levels of RGS2 and RGS4 labelled cells in the 
graft vicinity, in defined areas throughout the striatum and in comparison to TH labelled cells.  
  
7.3. Results 
7.3.1. 5-HT and TH Cell Analysis in the Graft  
It is clear from the photomicrographs in Fig. 7.1A-Bi that the E14 VM transplants were rich in 
dopaminergic (TH) and seratonergic (5-HT) cell types. Further stereology analysis confirmed 
that TH and 5-HT cell numbers were directly correlated to the volume of the graft (Fig. 7.1C: 
r= 0.93, p<0.001; Fig. 7.1Ci: r=0.893, p<0.001). On average there was approximately double 
the amount of 5-HT cells compared to TH types. In addition, there was no difference between 
either cell type in dyskinetic and non-dyskinetic groups (Fig. 7.1D: T= 0.74, p=ns; Fig. 7.1Di 
T= 0.76, p=ns). Total integrated AIMs elicited following an injection of 2.5mg/kg 
methamphetamine were correlated to TH (Fig. 7.1E: r= 0.31, p<0.05) and 5-HT (Fig. 7.1Ei: r= 
0.23, p<0.05) labelled cells. However when the percentage of 5-HT cells in the graft were 
considered with respect to total integrated AIM scores (Fig. 7.2), no significant correlation 
was found (Fig. 7.2: r= -0.13, p=ns). 
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Fig. 7.1. Cell analysis of dopaminergic (A-E) and seratoninergic types (Ai- Ei) in transplanted 
hemi-parkinsonian rats. Photomicrographs of transplanted TH (A-B) and 5-HT (Ai-Bi) cell 
types, where scale bar is 1mm (1.6x magnification) and 200µm (10x magnification). The 
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proportion of 5-HT and TH positive cells are directly correlated to graft volumes (C, Ci), 
where significance found by Pearson’s analysis is annotated by p<0.001***. Numbers of TH 
and 5-HT cells were also compared between dyskinetic and non-dyskinetic groups in response 
to 2.5mg/kg of methamphetamine (D, Di) and total integrated AIMs displayed by dyskinetic 
animals were correlated to cell counts (E, Ei), where significance is denoted by p<0.05*. 
Values are expressed as Mean ± SEM. 
 
 
 
 
Fig. 7.2. Correlation between total integrated AIMs and the % of 5-HT labelled cells in the 
graft compared to that of TH (A). No significance was found using Pearson’s correlation 
statistical test. 
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7.3.2. Dopamine Receptor Levels 
D1 and D2 receptor levels were quantified in transplanted rats using [
3
H] SCH23390 and [
3
H] 
Raclopride autoradiography respectively. As shown in Fig. 7.3C-D,H-I a moderate increase in 
dopamine receptor binding was observed in 6-OHDA lesioned rats relative to intact controls. 
D1 receptor binding increases however were unable to reach the 95% level of significance (Fig 
7.3A; F3,27= 0.29, p=ns), whereas D2 receptor levels were significantly increased in the 
lesioned striatum (Fig. 7.3B; F3,27= 3.44, p<0.05). Following the transplant of VM derived 
tissue, receptor levels appear to be normalised, where the density of the striatum is considered 
as a whole. The photomicrographs of transplanted rats reveal that changes in receptor levels 
were not uniform within the denervated striatum (Fig. 7.3E-F, J-K), and transplanted nigral 
cells appear to have a lower density of both D1 and D2 receptors. The highest expression of 
both receptor types could be observed within the lateral region of the striatum. There was a 
significant difference between striatal areas for D1 binding optical densities (Fig. 7.3M; F1,46= 
24.12, p<0.001), with no change between dyskinetic and non-dyskinetic groups (F1,46= 0.22, 
p=ns). The same pattern was noted for D2 receptor binding, where density values were 
significantly decreased in the grafted area compared to the lateral striatum (Fig. 7.3N; F1,46= 
57.84, p<0.001), with no change between dyskinetic and non-dyskinetic groups (F1,46= 0.02, 
p=ns). No significant Group*Area interactions were observed for D1 or D2. 
 
Furthermore, optical density binding values, in the striatum of dyskinetic rats, were not 
correlated to total integrated AIMs scored in response to 2.5mg/kg of amphetamine (D1: r= 
0.09, p=ns; D2:  r= 0.07, p=ns), data not shown. 
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Fig. 7.3 Relative optical density analysis of D1: [
3
H] SCH23390 (A) and D2: [
3
H] Raclopride 
binding (B). Photomicrographs of developed photographic hyperfilms for corresponding [
3
H] 
SCH23390 (C-F) and [
3
H] Raclopride binding (H-K), where scale bar shown as 2mm. Intact 
(C,H), Lesioned (D, I) and Grafted dyskinetic (E,J) and Grafted non-dyskinetic groups (F,K) 
are shown, and [
3
H] Audiographic micro cassettes used for normalisation for corresponding 
dopamine receptor binding compounds are shown (G, L). Differences between the [
3
H] 
SCH23390 (M) and [
3
H] Raclopride (N) density levels within the transplant vicinity and the 
lateral striatum are indicated for dyskinetic and non-dyskinetic rats. Significant differences 
from intact control animals and between graft and host lateral striatal areas, are indicated by 
p<0.05* and p<0.001***. Values are expressed as Mean ± SEM. 
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7.3.3. RGS Transcript Levels 
The photomicrographs in Fig. 7.4 show that the basal levels of RGS2 and RGS4 expression 
differ in the dopamine rich transplant. RGS2 is of high abundance within the vicinity of the 
graft where as RGS4 is of a much lower expression (Fig7.4A-F). The amount of RGS2 and 
RGS4 positive cells residing in the graft was also quantified by stereology in relation to 
numbers of TH positive cells. RGS4 expression was significantly lower compared to that of 
RGS2 and TH (Fig. 7.4G; F2,46= 21.71, p<0.001), yet there was no discernable difference 
between dyskinetic and non-dyskinetic groups (F1,23= 2.38, p=ns), with no Group*Cell marker 
interaction. In accordance, Fig. 7.4H shows that the numbers of TH positive cells residing 
within the graft could be correlated to those expressing RGS2 (r= 6.64, p<0.01) but not RGS4 
(r= 0.06, p=ns). RGS2 positive cells present in the graft of dyskinetic rats in the absence of 
amphetamine, were not correlated to previously scored amphetamine AIMs, even when 
confounding TH cell number-AIM correlations were removed by partial analysis (r= 0.09, 
p=ns), data not shown. Further, there were no correlations between the number of 5-HT cells 
in the grafted tissue and the quantities of either RGS2 (r= 0.12, p=ns) or RGS4 (r= 0.19, p=ns), 
data not shown.  
 
RGS2 and RGS4 were also differently expressed and altered by the transplant in the 
deneravated striatum of transplanted rats, in the absence of methamphetamine, shown in Fig. 
7.5. Fig 7.5A indicates that within a defined area of the anterior medial striatum neither the 
lesion nor transplant were able to alter levels of RGS positive cells from those of unlesioned 
controls (F3,54= 2.07, p=ns) and numbers of cells quantified with each RGS probe were equal 
(F1,54= 3.30, p=ns). In the dorsomedial striatum (Fig. 7.5B) the lesion and transplant were 
unable to alter levels of RGS positive cells seen in unlesioned controls (F3,54= 0.38, p=ns), 
however a small overall decrease in the levels of RGS4 was apparent (F1,54= 4.51, p<0.05). In 
the medial striatum (an area directly over the transplant in grafted dyskinetic and non-
dyskinetic groups) RGS2 expression remained high following a lesion and transplant, whereas 
RGS4 expression was much reduced in transplanted dyskinetic and non-dyskinetic groups (Fig 
7.5C; Group: F3,54= 16.83, p<0.001; Probe: F1,54= 25.96, p<0.001; Group*Probe F3,54= 14.00, 
p<0.001), confirming stereology findings. It is apparent from Fig. 7.5D however that RGS4 
cell counts were lower than those of RGS2 in the ventrolateral striatum, for lesion and grafted 
groups (F1,54= 4.51, p<0.05) and in addition RGS2 positive cells were found to be increased 
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post-lesion and further increased following a dopamine rich transplant, compared to intact 
controls ( F3,54= 2.98, p<0.05). 
 
It was further shown that both RGS2 and RGS4 are present in the adult VTA and SN (Fig. 
7.6A-B), yet RGS4 is absent from the VM of developing E14 embryos, despite the presence of 
RGS2 and TH at this stage (Fig 7.6D-F). 
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Fig. 7.4. Photomicrographs depicting RGS2 (A-B) and RGS4 (D-E) expression by in situ 
hybridisation in the rat E14 VM grafted tissue, with antisense oligonucleotides to respective 
probes used as negative-controls (C,F). Arrows indicate the graft host border. Scale bar = 
1mm (A,D) and scale bar = 200µm (B-C,E-F). Cell counts of RGS2, RGS4 (in situ 
hybridisation) and TH (immunohistochemistry) within the whole graft were quantified using 
stereology for both dyskinetic and non-dyskinetic groups (G) and RGS positive cells were 
then correlated with the amount of TH positive cells (H). Significant differences in the 
expression of TH cell numbers and those of RGS2 and RGS4 are annotated by p<0.001*** 
and p<0.001
+++ 
respectively. Values are expressed as Mean ± SEM. 
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Fig. 7.5. RGS2 and RGS4 positive cell counts from in situ hybridisation were counted in an 
1mm
2
 area of the anterior medial striatum (A), dorsomedial striatum (B), medial striatum (C) 
and ventrolateral striatum (D) for intact, lesioned, and transplanted rats that either displayed 
AIMs above threshold level, in response to 2.5mg/kg of methamphetamine (Dyskinetic), or 
those that did not (Non-dyskinetic). Significant differences between intact striatal cell counts 
are annotated by p<0.05*, p<0.01** and p<0.001*** and between levels of RGS2 and RGS4 
positive cells within a group as p<0.05
+
 and p<0.001
+++
. Values are expressed as means ± 
SEM. 
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Fig. 7.6. Photomicrographs depicting the presence or absense of RGS2 (A, D) and RGS4 (B, 
F) postive cells in the adult (A-B) and developing midbrain of E14 embryos (D,F), by in situ 
hybridisation. The presence of TH at the E14 developmental stage is also shown (E) and 
antisense oligonucliotide probes for RGS2 and RGS4 were used as negative-controls 
throughout (C,G). Scale bar for A-C = 2mm and E-G = 1mm. 
 
7.4. Discussion 
7.4.1. Graft Correlates of GID 
The proportion of 5-HT and TH positive cells within the transplant varied from 20 -90% 
between rats. Data presented here on total cell population analysis revealed that grafts had on 
average approximately double the amount of 5-HT neurones compared to TH, indicative of a 
wide dissection technique. Nevertheless, this 2:1 ratio was classified as within the normal 
range achieved by most investigators in a recent study (Garcia et al., 2011). There were 
positive correlations between the numbers of TH or 5-HT cells in the transplant and total 
integrated AIMs following methamphetamine, which is therefore reflective of previously 
reported graft size- AIM patterns first observed by (Lane et al., 2006b). Since the percentage 
of 5-HT cells in the transplanted tissue were not correlated to AIMs, significant 5-HT cell 
count-AIMs correlations are likely to be the result of graft size difference, as graft volumes are 
also correlated to 5-HT cell counts. Further, there was no difference between the numbers of 
TH or 5-HT cells present in the transplants of dyskinetic and non-dyskinetic groups, adding to 
the increasing body of evidence to suggest that AIM expression, both to L-DOPA and 
methamphetamine, is independent of grafted TH:5-HT cell ratios (Garcia et al., 2011, Lane et 
al., 2009a). Interestingly, TH:5-HT ratios in the 1:10 range are still sufficient to reduce LID 
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(Garcia et al., 2011), indicative of their negligible role in both amphetamine and L-DOPA 
driven AIMs. It is also clear that the weak positive correlations between AIMs and both the 
number of TH and 5-HT positive cells are likely to manifest by the rats which had small grafts 
in comparison to the total cohort, thereby skewing the outcome. Certainly this type of 
relationship exists (Lane et al., 2006) but has a ceiling effect. Once grafts reach a size in 
excess of approximately 2000 dopamine cells AIMs manifest highly in dyskinetic rats 
regardless. 
 
Using autoradiography it can be shown for the first time that D1 and D2 receptor binding 
profiles were not correlated to AIM expression and binding density levels did not differ 
between dyskinetic and non-dyskinetic subtypes. This is unusual as D2 receptors present on 
nigral cells are involved in pre-synaptic regulation of dopamine release to maintain the 
extracellular dopamine concentration (Cragg and Rice, 2004, Venton et al., 2003). Our 
findings may reflect the generally low levels of D2 receptors present within the graft of either 
grafted group, therefore preventing any meaningful correlations. It cannot be ruled out 
however that DAT levels may have differed between dyskinetic and non-dyskinetic grafted 
groups resulting in changes to extracellular dopamine concentrations leading to dyskinesia, 
compared to non-dyskinetic rats receiving methamphetamine treatment, warranting further 
investigation. This theory however is unlikely, as the grafting of dissociated VM tissue from 
DAT KO mice does not lead to spontaneous AIMs and excessive extracellular dopamine, but 
rather a large compensatory reduction in pre-synaptic dopamine release (Jones et al., 1998). 
 
It is unsurprising from the dopamine receptor analysis that the downstream target of the D2 
receptor RGS4 was also of low abundance within the graft and the basal cell expression was 
not associated with methamphetamine driven dyskinesia. However the possibility that the 
RGS4 gene failed to ‘switch on’ in the transplanted tissue cannot be ruled out, as it would in 
the normal development of the SNc neurones. Unlike TH and RGS2, these data show that in 
rat E14 embryos taken from the same litters as used for the transplant, RGS4 is not yet present. 
This suggests that the maturation of the transplanted VM tissue in the adult denervated 
striatum, contributed to the absence of RGS4, as the result of the loss of appropriate 
developmental signals. In contrast low levels of the D1 receptor were not matched by 
associated RGS2 levels, where cell counts of the latter were very high and similar to the 
proportion of TH cells in the transplant. This can be explained however, since A9 dopamine 
cells express G-protein activated inwardly-rectifying potassium (GIRK) channels (Saenz del 
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Burgo et al., 2008) and these are regulated predominantly by RGS2 proteins (Lomazzi et al., 
2008), in addition to their role in the regulation D1 receptors. The equal number of TH and 
RGS2 positive cells in the graft and the positive correlation between their receptive cell counts 
may therefore exist because of the disproportionate presence of the A9 subetype in the grafted 
tissue. In agreement A9 neurones have been found to make up approximately 80% of all rat 
derived TH cells in the graft (personal communication: Marija Fjodovova). Co-labelling 
studies of cell type and RGS may be able to answer some of the questions generated by this 
research, however in the absence of viable RGS antibodies will prove difficult.  
 
7.4.2. Efficiency of Graft to Normalise Lesion and L-DOPA Induced Changes 
L-DOPA has been found to cause a long-lasting increase in dopamine receptor levels and in 
particular the sensitisation of the D1-like receptors. The low levels of D2 receptors within the 
graft are unlikely to be because of the average 2:1 ratio of 5-HT:TH neurones, as the D2 
receptor should also be localised on 5-HT neurones (Aman et al., 2007), but instead is 
reflective of the reinnervation of TH and 5-HT fibres into the denervated striatum. The 
presence of dopamine receptors on the TH and 5-HT fibres should therefore have caused an 
increase in receptor density post-transplantation in dorsomedial and lateral striatal areas, yet a 
decrease in receptor levels was observed in these regions, indicative of a renormalisation of 
post-synaptic receptor levels on MSNs. Similar D1 and D2 renormalisation from pre-graft 
levels was observed previously by use of E14- E15 derived tissue (Gagnon et al., 1991, Rioux 
et al., 1991), reiterating findings in this study. Up-regulations of D1 receptors in the lesioned 
striatum were mild and did not reach statistical levels of significance, which may be due to the 
post-lesion latency, since D1 binding increases were only found between 1-16 weeks post-
lesion (Narang and Wamsley, 1995), a much shorter time period than used in this study. Up-
regulations of D2 receptors were higher in this study than that of Narang and Wamsley (1995), 
likely reflecting the continued trafficking of receptors to the plasma membrane longer than 16 
weeks post-lesion. Therefore the time of transplantation post-lesion may affect the final 
outcome of dopamine receptor levels, and the graft induced changes may too take several 
weeks to manifest.  
 
From previous data presented in this thesis (Chapter 5) it was found that 6-OHDA and L-
DOPA treatment is insufficient to change the basal expression of RGS transcripts in mice. In 
accordance no changes in the number of RGS4 positive cells were found in rats following the 
same protocols, yet RGS2 cells were found to be moderately increased post-lesion. These data 
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show that after a graft the number of RGS2 cells appears to increase further in the lateral 
regions that are likely innervated by transplanted cells. The ventrolateral region is of particular 
interest in relation to LID as it has been implicated in the upregulation of PDyn mRNA, a 
hallmark of dyskinesia (Carlsson et al., 2005, Cenci et al., 1998, Winkler et al., 2002b) and to 
orofacial stereotypes after direct injection of amphetamine into this location (Kelley et al., 
1988), which indicate this area as a highly innervative, causing much intracellular signalling 
and behavioural changes once stimulated. Grafts in close proximity to the ventrolateral region 
have also been found to be involved in both the reduction of LID and the induction of 
methamphetamine induced AIMs (Carlsson et al., 2006b) and thus the upregulation of basal 
RGS2 in the ventrolateral striatum could therefore be triggered by dopamine released from the 
graft and/ or synaptic connections. RGS2 mRNA upregulation may represent a mechanism by 
which intracellular signalling is reduced, as RGS2 is a negative modulator of G-protein 
signalling for D1 receptors. Although basal levels of RGS were not correlated to amphetamine 
driven AIMs, it cannot be ruled out that under the presence of amphetamine this may have 
been the case. 
 
 
7.4.3. Conclusions 
The proportion of 5-HT cells, cell surface expression of D1 and D2 receptors, and quantities of 
RGS2 and RGS4 positive cells, present in the transplant and denervated striatum, did not differ 
between transplanted dyskinetic and non-dyskinetic cohorts and were not correlated to AIMs 
triggered by methamphetamine. In this study, the number of transplanted cells was the only 
determinant of the severity of amphetamine induced AIMs. We observed that the graft was 
able to normalise lesion-induced upregulations of D1 and D2 receptors by a large reduction of 
dopamine receptors in the vicinity of the graft and a moderate reduction in the lateral areas of 
the striatum. RGS2 labelled cells were of high abundance in the graft due its role in A9 
dopamine neurones and 5-HT neurones, whereas RGS4 was of a significantly reduced 
expression either because of its down regulation below threshold levels of detection, or the 
absence of a developmental trigger ‘switching on’ the gene. In addition, basal RGS2 
expression was increased in the ventrolateral areas of the striatum as determined by the 
increased number of cells, perhaps reflecting a negative modulator role in D1 expressing 
MSNs. It can therefore be suggested that D1 and D2 dopamine receptors and their respective 
RGS modulators, do not show potential to be used as new ‘biomarkers’ of GID. New 
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‘biomarkers’ may be found with the use of transgenic mice, however until research covered in 
this thesis (Chapter 8), there has not yet been a wild-type mouse model of GID. 
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8. A Mouse Model of GID 
 
Summary 
AIMs can be initiated by a single injection of methamphetamine (2.5mg/kg) in hemi-
parkinsonian rats. This study explores whether mice of C57/Bl6 and CD1 strains transplanted 
with primary VM derived tissue at day E12 of embryonic development also develop post-
transplantation AIMs. Prior to grafting, mice were primed with L-DOPA for 21 days during 
which time AIMs and rotation were compared between strains. No significant differences 
were apparent between strains with regard to AIMs, however CD1 mice rotated less than C57/ 
Bl6.  Post-transplantation methamphetamine-induced AIMs were seen in approximately 65% 
of the cohort and all limb, trunk and orofacial dyskinetic components were observed and 
scored on a specific dyskinesia rating scale. At this stage there were no differences in AIMs 
and rotational asymmetry between C57/ Bl6 and CD1 strains. Transplants were sufficient in 
size to cause a shift in rotation toward the contralateral direction in a number of animals and 
subsequent histological analysis of the transplanted tissue revealed surviving dopaminergic 
cells, with fibre outgrowth within the lateral motor regions of the striatum. 
210 
 
 
8.1. Introduction 
A number of clinical trials have shown the survival of transplanted dopaminergic cells, their 
functional integration into the host neural tissue and the amelioration of the symptoms of PD 
(Freed et al., 2001, Lindvall et al., 1989, Madrazo et al., 1988, Olanow et al., 2003, Redmond, 
2002, Redmond et al., 1993). The development of abnormal involuntary movements (AIMs) 
6-12 months after the procedure was first noted by Freed et al. (2001) and was found to be 
unrelated to their anti-parkinsonian medication. Subsequently termed graft-induced dyskinesia 
(GID), this issue has been highly damaging to the progress of cell transplantation therapy. 
There has since been a drive to find out the mechanism of GID so that it may be prevented or 
managed whilst maintaining or improving the efficacy of the transplants. In particular there 
has been a search for appropriate animal models of GID for preclinical research into the 
condition. 
 
Embryonic VM grafts transplanted into the denervated striatum of rats following unilateral 6-
OHDA lesions of MFB provide the standard model used to assess the functional efficacy of 
cell replacement in PD (Bjorklund and Stenevi, 1979, Bjorklund et al., 1981, Dunnett et al., 
1981). Quantifiable GID elicited in the absence of any treatment, like the spontaneous 
movements, found in patients, have not been observed in animal models of PD.  In two 
studies, mild spontaneous dyskinesia in transplanted 6-OHDA lesioned rats were reported, 
although the behaviours were transient in expression, sporadic and mild in severity (Vinuela et 
al., 2008, Lane et al., 2006b), therefore lacking the consistency required to be used as a model 
of GID. Thus, post-transplantation AIMs are normally induced in the grafted hemi-
parkinsonian rat model using amphetamine, at a dose where no AIMs or stereotypy are seen in 
lesion-only control groups (Carlsson et al., 2006b, Lane et al., 2006b). Experimental GID is 
not the same as amphetamine-induced stereotypic behaviours and hence is not seen in 
amphetamine-treated lesion-only rats, as described in Chapters 6 and 7. AIMs in grafted rats 
vary in appearance, yet on the whole look phenotypically similar to LID, with dystonic hind 
limb positions, choreic forelimb, chewing and gnawing movements commonly observed, 
mirroring the human form.  
 
Clinical trials have reported reductions in the duration and severity of LIDs in transplanted 
patients and a reduction in the ‘off’ phase (Lindvall et al., 1992). In experimental models, LID 
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is reduced by a graft (Lee et al., 2000) and studies have suggested that transplants may reduce 
the development of abnormal movements when L-DOPA is administered after the graft 
(Steece-Collier et al., 2009).  Therefore, a greater understanding of how graft innervation 
changes both ‘on’ and ‘off’ dyskinesia following transplantation is much needed. Prior to 
transplantation, 6-OHDA lesioned rodents are usually primed with L-DOPA for 3- 4 weeks to 
elicit LID, as described by Winkler et al., (2002), thus causing the long term maladaptive 
changes in the denervated striatum associated with this aberrant behaviour (Cenci and 
Konradi, 2010, Cenci et al., 2009, Picconi et al., 2003, Winkler et al., 2002b, Lane et al., 
2006b). There is a greater tendency for methamphetamine-induced AIMs in animals primed 
for LID, although a proportion of the primed experimental cohort will still not develop 
dyskinesia, termed ‘non-dyskinetic’ (Lane et al., 2009a). It is therefore important to consider 
L-DOPA priming in the creation of a mouse model of GID. Furthermore, L-DOPA priming is 
of fundamental importance to the clinical translation of the model, as the majority of PD 
patients that will undergo transplantation therapy are likely to be on L-DOPA treatment. 
 
A mouse model of GID has not yet been evaluated, due to the lack of optimisation in 
appropriate behavioural tests, poor post-lesion survival rates and the insufficient 
characterisation of LID (addressed in Chapters 3 and 4). Although successful grafting and the 
rotational response to selective psychostimulants has previously been reported in the mouse 
(Thompson et al., 2009, Veng et al., 2002, Zhou et al., 1993, Shimizu et al., 1990, Brundin et 
al., 1989, Shimizu et al., 1988), appropriately sized grafts needed for the assessment of GID 
have been difficult to reproduce. It seems likely therefore that many of these now optimised 
factors needed for model development, can be combined to create a mouse model of GID, 
which should prove invaluable for combined use with transgenic mice and importantly for 
mouse derived cell line transplantation studies.  
 
This chapter will compare LID and GID AIM development in two different mouse strains 
(C57/ Bl6 and CD1). Specifically, methamphetamine and L-DOPA-induced rotation will be 
assessed pre- and post-transplantation and AIMs scored simultaneously for both of these 
agents, over 3 hours post injection. A greater understanding of why only some patients 
develop GID may be gained by comparing dyskinetic and non-dyskinetic groups, therefore 
this study aims to split transplanted mice into these respective groups. Groups will be based on 
methamphetamine-mediated AIMs above and below the defined thresholds used for the rat 
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(Lane et al., 2006b), as recorded on the scoring system for LID in rats and mice (Cenci and 
Lundblad, 2007, Winkler et al., 2002b).  
 
8.2. Experimental Design 
30 adult male CD1 (Harlan) and 30 C57Bl6 (Charles River) mice weighing 25g or more at the 
time of arrival were lesioned with 6-OHDA at the MFB (previous studies in Chapter 4 showed 
this to be the most appropriate lesion site to precipitate LID following L-DOPA). Four weeks 
after the lesion, mice were tested for lesion extent using methamphetamine (2.5mg/kg) 
induced rotation. 26 CD1 and 20 C57/ Bl6 mice were chosen for the final study, based on 
rotation scores of greater than 5 per minute. All mice were then given daily injections of L-
DOPA and benzerazide (10mg/kg each) for 21 days, where a stable AIM plateau was reached. 
L-DOPA-induced AIMs were compared between CD1 (n=15) and C57/ Bl6 (n=14) mice at 
day 21, further exclusions were made on the basis of illness of the animal or AIMs below a 
defined dyskinesia threshold (Cenci and Lundblad, 2007, Winkler et al., 2002b). Seven weeks 
post-lesion the average weight (after the recovery of weight loss in the first 2 weeks, described 
in Chapter 3) of both mouse strains was recorded. CD1 (n=9) and C57/ Bl6 (n=11) lesioned 
mice were then transplanted with E12 tissue from the developing VM of matched strains, the 
remaining mice served as lesioned and L-DOPA primed controls (CD1: n=6; C57/ Bl6: n=3). 
Prior to implantation, tissue was dissociated into crude single cell suspensions and 200,000 
cells transplanted per µl, at two levels in the striatum, as detailed in Chapter 2.  The grafts 
were left to mature for 16 weeks in the absence of any treatment.  
 
Methamphetamine (2.5mg/kg) was used to induce turning and AIMs in mice, where they were 
sub divided into ‘dyskinetic’ (CD1: n=3; C57/ Bl6: n=6) and ‘non-dyskinetic’ (CD1: n=3; 
C57/ Bl6: n=3) groups. All mice were perfusion-fixed with 1.5% paraformaldehyde 72 h after 
the last methamphetamine injection, when AIMs were no longer present. Fixed brains were 
cut, stored and prepared for immunohistochemistry and the numbers of TH positive cells were 
quantified in the grafted tissue using stereological counting protocols. The remaining mice 
(CD1: n=3; C57/ Bl6: n=2) had failed grafts defined by (a) lack of rotational change in 
comparison to pre-graft levels and (b) by very few (<100) surviving cells seen in the graft 
post-mortem. 
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Amphetamine-induced rotation and weight between mouse strains was analysed by Student T-
tests and 2-way ANOVAs with Dunnett’s post hoc comparisons used to compare AIMs (L-
DOPA and methamphetamine) and L-DOPA-induced rotation, between pre and post 
transplantation time points, for each strain. A further T-test was used to compare the numbers 
of transplanted TH cells between strains and a Pearson’s test used to measure the cell number-
AIM correlation. 
 
 
Fig. 8.1. Time line of experiments carried out for Chapter 8, to optimise a mouse model of 
amphetamine driven GID. 
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8.3. Results 
 
8.3.1. Basal weight of CD1 and C57/Bl6 mice 
The two strains of mice were generally different sizes, the C57/ Bl6 strain was approximately 
half the weight of the CD1 strain (T= 27.91, p<0.001***). 
 
 
 
 
Fig. 8.2. The weight of CD1 and C57/ Bl6 mice. Significant differences between strains are 
annotated as p<0.001***. Values are expressed as Mean ± SEM. 
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8.3.2. Amphetamine Mediated Rotation in CD1 and C57/Bl6 mice 
Methamphetamine-treated mice rotated ipsilaterally post-lesion (Fig. 8.3A). At this time point 
the C57/ Bl6 strain had a significantly higher total net rotation score than the CD1 strain (T= 
3.21, p<0.05*). Post-graft rotations were predominantly contralateral in direction (Fig. 8.3B), 
however no difference was found between strains in the same test at 16 weeks after the 
transplant (T= 1.64, p=ns).  
 
 
 
 
 
Fig. 8.3. Total net rotations in response to methamphetamine (2.5mg/kg) in CD1 and C57/ Bl6 
mice 4 weeks after 6-OHDA lesion (A), and 16 weeks post-transplantation (B), scored over 60 
minutes at peak rotation. Significant differences between strains are annotated as p<0.05*. 
Values are expressed as Mean ± SEM. 
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8.3.2. L-DOPA-induced rotation and AIMs in C57/Bl6 and CD1 strains 
L-DOPA-induced rotations were significantly reduced by the presence of a graft (Fig. 8.3A; 
F1,13= 4.70, p<0.05), where p<0.05 for both strains. CD1 mice had a lower rotational response 
to L-DOPA post-graft compared to the C57/Bl6 strain post-graft (Fig. 8.3A; F1,13= 4.98, 
p<0.05), not seen at the pre-graft level. No difference between strains at either the pre-graft or 
post-graft time points, but in both groups total integrated AIMs were signficantly reduced by 
the presence of a graft (Fig 8.3A: F1,13= 14.23, p<0.001, post hoc p<0.05 for C57/ Bl6 and 
p<0.001 for CD1). LID was also reduced post-transplantation for each of the three AIM sub-
types when considered seperately (Fig. 8.3C-E: Hindlimb: F1,13= 10.12, p<0.01; Forelimb: 
F1,13= 9.23, p<0.01; Axial: F1,13= 18.67, p<0.001), but not for the orolingual component (Fig. 
8.3D: F1,13= 2.21, p= ns), post hoc comparisons are indicated on Fig. 8.3. There were also no 
differences between strain for any of the L-DOPA-induced AIM components.  
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Fig. 8.3. LID and L-DOPA induced rotation in hemi-parkinsonian mice. Total net contralateral 
rotations in response to L-DOPA (10mg/kg) in CD1 and C57/ Bl6 mice 7 weeks after 6-
OHDA lesion (Pre-graft) and 16 weeks post-transplantation (Post-graft) (A). Total integrated 
AIMs, scored on defined rating scales (Cenci and Lundblad, 2007, Winkler et al., 2002b), 
were also assessed after at pre-graft and post-graft time points (B). AIMs of each sub-
component were also assessed for the hindlimb (C), forelimb (D), Axial (E) and orolingual (F) 
parameters. Significant differences by 2-way ANOVA and Dunnett’s post hoc test between 
pre-graft and post-graft levels are annotated as p<0.05*, p<0.05* and p<0.001*** and 
between strains as p<0.05
+
. Values are expressed as Mean ± SEM. 
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8.3.2. Amphetamine-Induced AIMs in the Transplanted Mouse 
Methamphetamine (2.5mg/kg)-induced AIMs were not observed in lesion-only control mice 
or those considered non-dyskinetic from either strain (Fig. 8.4).  Methamphetamine induced 
AIMs in 66% of the grafted cohort in both CD1 and C57/ Bl6 strains. Furthermore, neither the 
time course of behaviours over the 3 h post-injection (Fig. 8.4A) or total integrated AIMs 
differed between strains (Fig. 8.4B: F1,21= 0.46, p=ns). Mice which expressed AIMs in 
response to methamphetamine (dyskinetic mice) were significantly higher in comparison to 
lesion only and non-dyskinetic counterparts (defined as mice with no, or minimal AIMs) 
(F2,21= 9.11, p<0.01), where p<0.01 for both strains (Fig. 8.4B). The expression of 
methamphetamine-induced AIMs for each component on the rating scale was also only 
present in the dyskinetic group (Table 8.1: axial: F2,21= 6.66, p<0.01; orolingual: F2,21= 4.31, 
p<0.05; forelimb: F2,21= 7.04, p<0.01; hindlimb: F2,21= 8.21, p<0.01). No difference found 
between strains for any of the AIM components or Time-point*Strain interactions. Fig. 8.5 is a 
pictorial representation AIM component seen in all dyskinetic mice.  
 
Post-mortem analysis of the brains of dyskinetic animals revealed high numbers of TH 
positive cells in transplants within the denervated striatum (Fig. 8.6.), which were equivalent 
between CD1 and C57/ Bl6 strains (F1,13= 0.31, p=ns) and between dyskinetic and non-
dyskinetic groups (F1,13= 1.01, p=ns). From the 400,000 cells transplanted approximately 3% 
of these were surviving dopaminergic neurones, based on calculations previously used for the 
approximate percentage of dopamine neurones per VM (Castilho et al., 2000). There was a 
moderate positive correlation between cell counts in the grafted tissue of dyskinetic mice and 
AIMs, however a statistical level of significance was not reached (Fig. 8.6D; r= 0.52, p=ns). 
In addition there were no correlations found between TH cell counts and either pre-graft LID 
(r= 0.12, p=ns) or post-graft LID (r= 0.24, p=ns) (data not shown). There were also no 
correlations found between pre- and post graft LID and methamphetamine-induced AIMs 
(data not shown). 
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Fig. 8.4. AIMs triggered by 2.5mg/kg of methamphetamine the unilateral 6-OHDA lesioned 
mouse, 16 weeks after the transplantation of E12 VM tissue. AIMs were observed over 180 
minutes post injection (A) and total integrated AIMs (B) are shown for lesioned controls that 
have been L-DOPA primed (Lx) and transplanted CD1 and C57/ Bl6 mouse strains that were 
either non-dyskinetic (ND) or dyskinetic (D), based off the rating scale described by (Cenci 
and Lundblad, 2007, Winkler et al., 2002b). Significant differences are annotated as 
p<0.01**. Values are expressed as Mean ± SEM. 
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Fig. 8.5. AIMs induced by 2.5mg/kg of methamphetamine the unilateral 6-OHDA lesioned 
mouse, 16 weeks after the transplantation of E12 VM tissue. AIMs were observed for all four 
dyskinesia components (Axial, orolingual, forelimb and hindlimb) based an existing rating 
scale (Cenci and Lundblad, 2007, Winkler et al., 2002b). 
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Table 8.1. Axial, orolingual, forelimb and hindlimb AIM components initiated by 2.5mg/kg of methamphetamine, based off the rating scale 
described by (Cenci and Lundblad, 2007, Winkler et al., 2002b). Significant differences are annotated as p<0.05*, p<0.01** and p<0.001***. 
Values are expressed as Mean ± SEM. 
 
 
 
 
 
 
 
 
 
 Pre-transplantation 
 
Post-transplantation (Non- 
Dyskinetic group) 
Post-transplantation (Dyskinetic group) 
 CD1 C57/ Bl6 CD1 C57/ Bl6 CD1 C57/ Bl6 
Axial 4.89 ± 0.88 5.73 ± 0.26 6.89 ± 1.23 7.03 ± 2.21 45.33 ± 11.78** 32.31 ± 7.63** 
Orolingual 0.11 ± 0.01 0.11 ± 0.01 2.11 ± 0.01 * 1.66 ± 2.15 2.33 ± 0.88* 3.17 ± 1.11* 
Forelimb 2.12 ± 1.25 3.45 ± 1.78 6.40 ± 7.02 8.45 ± 3.78 35.00 ± 12.00*** 28.00 ± 5.09** 
Hindlimb 1.25 ± 0.31 1.04 ± 0.10 9.91 ± 6.76 5.04 ± 9.03 32.33 ± 10.73** 29.50 ± 5.84** 
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Fig. 8.6. Photomicrographs depicting representative dopaminergic grafts in mice (A-B), where 
the scale bar on the low magnification picture is 1mm and on high magnification image are 
200µm. The total number of cells in the graft were quantified in CD1 and C57/ Bl6 strains, 
from dyskinetic and non-dyskinetic groups (C), and correlated to total integrated AIMs scored 
following 2.5mg/kg of methamphetamine (D). White circles = CD1 mice (n=3) and black 
circles = C57/ Bl6 mice (n=6). Values are expressed as Mean ± SEM. 
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8.4. Discussion 
 
8.4.1 Optimisation of the Mouse GID model  
The optimisation of the GID mouse model is dependent on two factors, firstly the survival of a 
sufficient number of transplanted TH positive cells, and secondly the ability of the mouse to 
undertake all of the procedures necessary to generate the rat GID model i.e. survival, sufficient 
lesioning, L-DOPA priming and AIMs triggered by 2.5mg/kg of methamphetamine.  
 
The experiments presented here provide evidence that TH cells from E12 VM tissue can be 
transplanted successfully into the striatum of the unilateral 6-OHDA lesioned mouse model, 
with approximately 3% of transplanted cells surviving and expressing TH. The percentage of 
dopaminergic cells that survive in most other mouse studies using this transplantation model 
has largely not been quantified/ estimated (Brundin et al., 1986, Low et al., 1987, Shimizu et 
al., 1988, Shimizu et al., 1990, Witt and Triarhou, 1995), with recent quantified 
transplantation studies using rat as the host even though donor tissue is derived from mice 
(Grealish et al., 2010a), therefore comparisons are difficult. A recent study has shown that 
mouse cells transplanted into the mouse SNc can survive and project to partially reinnervate 
the denervated striatum (Thompson et al., 2009). The TH cells transplanted in Thompson et al. 
were GFP labelled under the TH promoter and approximately 10% of TH/GFP-positive cells 
survived. As the GFP tag enabled a very fine and controlled dissection of the VM, few 5-HT 
neurones would be expected to be present. However the proportion of dopamine cells in the 
graft, generated by a normal dissection technique (as used in this study) is approximately 33-
66%, with the remaining neurons largely made up of 5-HT neurones (Garcia et al., 2011). 
Thus in this experiment the total surviving neurones are likely more than the 3% dopamine 
cell component (as 5-HT neurones were not taken into account), making total cell comparisons 
to Thompson et al. (2009) inaccurate.  
 
The number surviving dopaminergic neurons following rat-rat transplants varies hugely 
between reported studies (Abrous et al., 1993, Arbuthnott et al., 1985, Carlsson et al., 2009, 
Carlsson et al., 2006b, Dawson et al., 1991, Dunnett et al., 1983b, Ishida et al., 1990, Lane et 
al., 2008, Lane et al., 2009b, Lane et al., 2006b, Rioux et al., 1993, Steece-Collier et al., 2003, 
Torres and Dunnett, 2007).  This may relate to simple experimental criteria such as the 
224 
 
number of cells transplanted or the dilution of cells in the transplantation media.  The 
appropriate concentration of cells may be difficult to achieve, as dilution of the cells to a 
certain point is necessary for practical reasons, but too dilute and the loss of cell-cell contacts 
may have a detrimental effect on survival and functional recovery. The numbers of rat derived 
dopaminergic neurons in transplanted rats relate to the extent of functional recovery, with 
small grafts (Mean: 280 ± 63) that are unable to reduce ipsilateral turning and large grafts 
(Mean: 17,403 ± 1229) that cause robust contralateral turning (Lane et al., 2006b). In 
accordance, the numbers of grafted TH positive neurons in the C57/ Bl6 and CD1 mice of this 
study (Mean: 976 ± 116) give rise to less pronounced contralateral turning, likely due to a 
lower cell number than those seen in defined large rat grafts. When comparing mouse and rat 
studies, it is also important to consider embryonic age as this can affect the levels of survival 
in the rat (Torres et al., 2008, Torres et al., 2007), where E12 is favoured over E14. Based on 
the Carnegie stage equivalence, E12 mouse is the same developmental stage as E13.5 rat, and 
is therefore relatively comparable to rat E14. This may offer another explanation as to why 
grafts were smaller than that seen in the rat.  
 
The reduction in LID following a graft has also been reported previously in the rat (Carlsson et 
al., 2006b, Garcia et al., 2011, Lane et al., 2006b, Steece-Collier et al., 2009) and was found to 
be dependent on the number of cells transplanted and L-DOPA priming, rather than total 
numbers of dopamine neurones. There was an approximate 30% reduction in total integrated 
AIMs in this study, providing further evidence that transplanted cells are acting as a constant 
source of dopamine and either handling the dopamine derived from L-DOPA in a less 
pulsatile, more controlled manner and/or normalising the sensitivity of the post-synaptic 
receptors. The modest reduction in LID in the mice reported here and the lack of correlation 
between AIMs (pre or post-graft) with number of cells in the graft is likely the result of small 
graft sizes and the low numbers of mice used. These variables, may also explain why there 
was a lack of correlation between amphetamine-mediated AIMs and L-DOPA mediated AIMs 
(pre or post-graft), and why the former was so variable between mice. It has also been reported 
that novel L-DOPA driven stereotypic behaviours can develop following transplantation 
(Steece-Collier et al., 2003); possibly reflecting incomplete reinnervation of the striatum. 
These behaviours, forepaw tapping and forelimb facial stereotypies, were not seen in this 
study.  It is unlikely that these moderate sized grafts were able to reinnervate the whole 
striatum, therefore these previous findings may be species specific, or may arise by different 
means. 
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The lesion technique and robust LID expression in mice at the pre-graft stage and a reduction 
of LID post-graft are critical characteristics in the development of an efficient model of GID. 
These factors have been addressed in this study and in Chapters 3 and 4. The present 
experiment shows that the final factor needed for the generation of the model, which is the 
trigger by 2.5mg/kg of amphetamine, was able to generate AIMs which are comparable to 
those described previously for the rat (Lane et al., 2006b). As with the rat, methamphetamine-
induced AIMs, in this study, were generally less severe and more stereotyped compared to 
LID. In agreement with Lane et al., amphetamine-mediated AIMs in transplanted mice were 
positively correlated to the number of cells in the graft, yet in this study significance was not 
reached. Importantly, these data show the survival of dopaminergic cells and subsequent 
amphetamine triggered AIMs in the host striatum of both CD1 and C57/Bl6 strains, despite 
dramatically different weights and small discrepancies between amphetamine-mediated 
rotations at the pre-graft stage. 
 
8.4.2 Future directions 
The current data show that a mouse model of GID can be established and that AIMs can be 
correlated to graft size, however there are a number of avenues in which this model can be 
used to assess GID mechanisms and/ or reiterate other rat model findings. As with the rat, the 
influence on host and donor 5-HT innervations, graft placement, influence of previous L-
DOPA treatment and other biochemical markers can be analysed to emphasis findings across 
species. In addition, this model may provide a useful tool for the analysis of GID in transgenic 
mice and for allografts of mouse derived cell lines, such as those with genetic cell type 
specific markers, without the need for immunosuppression. There is still some controversy 
over the distribution of dopaminergic neurons from different sources, ie A9 and A10 derived 
populations (reviewed in (Stromberg et al., 2010). This may be resolved by the use of labelled 
cell populations derived from transgenic mice, which will be more easily identified and 
tracked. Given the limited survival and functionality of stem cells lines when transplanted, the 
use of embryonic VM is still critical to the study of transplantation, as a greater understanding 
on the precise roles of these cell populations may be key to the function of stem cell grafts, 
without inducing dyskinetic side effects. 
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8.4.3 Conclusions 
Overall this study demonstrated that grafts in CD1 and C57/ Bl6 are sufficient in size to cause 
functional improvements on amphetamine and L-DOPA-induced rotation, and reduce LID 
from levels seen prior to transplantation. Methamphetamine is able to trigger AIMs that are 
not seen in lesion only mice, thus providing a mouse model of GID that can be used alongside 
the already established rat model. As with the rat, a proportion of grafted cohort does not 
develop amphetamine triggered dyskinesia and in animals where significant AIMs occur these 
were correlated to the number of TH positive cells within the graft. Furthermore, this model 
may have a number of applications in the future to study the mechanisms of GID, where either 
CD1 or C57/ Bl6 strains are needed. 
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9. General Discussion 
 
9.1. Animal Models of LID and GID- Pre-Clinical Efficiency. 
The major goal in the generation of models of L-DOPA or dopamine-rich graft-induced AIMs 
is a similarity to PD-related dyskinesia, both in terms of phenotype (‘face validity’) and 
underlying mechanism (‘construct validity’). The ultimate test for models of dyskinesia is 
their ability to accurately permit the translation of any therapeutic effect of new treatments to 
the patient (‘predictive validity’), and this may only be the case if the underlying mechanisms 
are the same. In the case of GID, once an underlying mechanism has been established, it will 
be important to identify the efficiency of anti-dyskinetic treatments in models, using a 
combination of behavioural assessments and biochemical markers or ‘biomarkers’.  
 
9.1.1 Dyskinetic Phenotype 
In both models, AIMs are considered to be phenotypically similar to dyskinesia, showing all 
of the involuntary movement subcomponents seen in the patients. Although unilateral 6-
OHDA lesioned mice are useful in practical and financial terms, MPTP treated primates can 
be lesioned bilaterally, show bilateral movements in response to L-DOPA, and off medication 
they have profound akinesia, more closely mimicking late stage PD (Jenner et al., 1984). 
However the use of unilateral 6-OHDA lesioned rodents, including the mice described in this 
thesis are benifical because of lateralised impairments and hence are of great benefit to pre-
clinical science. The unilateral nature of this model means that it does not give rise to 
debilitating akinesia, although milder motor impairments are present, which has led to a 
behavioural deficit baseline which is well defined in rats, less so in mice. The the 6-OHDA 
mouse model is being continuously optimised and is likely, in the future, likely to come to be 
used as frequently as the ‘gold standard’ rat model, as highlighted in Chapter 3. A major 
advantage of using the unilateral 6-OHDA lesion rodent model is that rotational asymmetry 
can be assessed simultaneously to LID, providing a means of measuring general locomotion. 
Amphetamine-induced AIMs in the transplanted rat model are also phenotypically similar to 
the clinical form (reviewed in (Lane and Smith, 2010). Further, in Chapter 8 it was shown 
that GID can also be modelled in two different strains of mouse, to the same extent as 
previously reported the rat (Lane et al., 2006b), therefore providing a new and valuable tool 
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for pre-clinical investigation. The testing of a new treatment for LID often follows a 
hierarchical pre-clinical system: invertebrates > rodents > primates > humans. This 
hierarchical system however will not stand up for the testing of therapeutic approaches to 
GID, as spontaneous AIMs have not been reproduced in primates and therefore research may 
be need to be fast tracked from rodents to phase I clinical trials. As a solution, amphetamine-
mediated AIMs might be used to model GID in the primate, however the usefulness as a 
representation of spontaneous GIDs in patients would be disputed. 
 
9.1.2 Underlying mechanisms of Dyskinesia 
The mechanisms of LID in rodents share characteristics of LID seen in the human conditon. 
This seems to be the case in all aspects of the condition, including electrophysiological 
changes of the direct and indirect signalling pathways and the post-synaptic intracellular 
signalling dysregulation of FosB (Picconi et al., 2003, Westin et al., 2001, Tekumalla et al., 
2001, Morgante et al., 2006). FosB/ ∆FosB is now an established biomarker of dyskinesia in 
the rodent model having been shown to be expressed in patient samples also (Tekumalla et al., 
2001) and hence it was used in Chapter 4 to show that the upregulation of this IEG in the 6-
OHDA mouse reflects a similar profile of change to that previously reported in the rat 
(Andersson et al., 1999), with the extent of expression dependent on the lesion location along 
the nigrostriatal path and correlated with extent of dyskinesia. The magnitude of AIMs was 
highest in the MFB group for all L-DOPA doses and FosB/∆FosB expression was 2-fold 
higher at 25mg/kg, allowing for a robust phenotype that could be easily scored by the 
investigator. Therefore despite the mouse model being one of the hardest to implement in 
terms of survival and success rate, it is extremely useful for the study dyskinesia. In addition, 
the MFB lesion group was the only one of the three to show loss of the 5-HT terminals. 
Although 5-HT loss was likely the result of non-specific uptake of toxin and/or mechanical 
damage, this is not necessarily detrimental to the model, as 5-HT losses are also seen in 
patients (Kish et al., 2008). In Chapter 4 it was shown that fibre innervation patterns are 
positively correlated to dyskinesia, not previously found in the mouse, supporting the notion 
of dysregulated dopamine release from 5-HT neurons may contribute to LID in humans as it is 
noted across species.  
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Although cell type analysis has proven to be an interesting avenue for GID research, it is of 
fundamental importance to test all possible causes of GID in the pre-clinical models, see Fig. 
9.1.  
 
 
 
 
Figure 9.1. Factors of the transplantation process that may alter the outcome of GID. The 
same factors can also be considered for the functional integration of the transplant and can be 
broadly divided into three broad categories (Lane and Smith, 2010). 
 
 
The pharmacological screen of compounds, known to reduced LID, in the transplanted rat 
model of amphetamine-induced dyskinesia (Chapter 6), has led to some unusual observations 
with regard to the glutamatergic system. Specifically that amantadine commonly used for the 
treatment of LID was ineffective at treating GID, and MK-801, a drug with similar 
mechanistic action, increased AIMs and reversed rotation. Research into this system however 
is limited and may represent a new avenue of investigation to uncover the mechanism of GID. 
The glutamatergic system is also linked to long-term electrophysiological changes and 
plasticity; these too have yet to be examined in either humans or animal models of GID, in 
contrast to LID where there is currently a major research focus. Importantly, rat models of 
LID also show the same long-term plasticity seen in the human, where an inability to reverse 
LTP is seen only when AIMs above threshold levels manifest (Morgante et al., 2006, Picconi 
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et al., 2003, Picconi et al., 2008). Such research is therefore overdue in amphetamine-driven 
transplanted rodent models of GID. 
 
The wealth of preclinical investigation into LID suggests that rodent models of this 
debilitating side effect are closer to human form than models of GID are to the human form. 
However, there are a number of limitations of using LID models to investigate new treatments. 
The most profound is the translation of pharmacological agent co-treatments from rodents to 
humans. Many of the compounds targeting 5-HT, cannabinoid, adrenergic and glutamatergic 
systems that cause a significant decrease in L-DOPA induced AIMs in mouse and rat models 
(Dekundy et al., 2007, Lundblad et al., 2002, Lundblad et al., 2005, Fox et al., 2008b) have 
failed to do so when progressed to the stage of a clinical trial (Rascol et al., 1994, Wolf et al., 
2010, Fox et al., 2008b, Manson et al., 2000, Carroll et al., 2004). It is unclear whether this 
was purely a failure of the model-patient translation, poor clinical trial design, or the result of 
a lower experimental number, resulting in statistical insignificance. Pre-clinical 
pharmacological treatment studies of amphetamine-initiated GID in rodent models, may be 
more effective for ruling out drugs prior to human testing, since the majority of compounds 
(used at the same doses as those for LID) were unable to alter AIMs (Chapter 6). 
Furthermore, other agents such as 5-HT1A and 5-HT1B agonists decrease AIMs in these 
animals and amantadine was insufficient to significantly reduce AIMs, all of which is 
consistent with findings in patient with GID, reported in (Lane et al., 2010).  
 
9.1.3 Dyskinesia Biomarkers 
In contrast to LID, biological markers of AIMs following an amphetamine injection in 
transplanted rodents have not been well established. An increase in c-fos and a decrease of 
FosB/ ∆FosB was found in the grafted model. However, correlations between these 
biomarkers and AIMs were not established (Lane et al., 2009b). Biological changes resulting 
from GID may be difficult to find in rodent models, since it is hard to distinguish between the 
positive effects of the graft, improved motor function and the negative effects of 
amphetamine-induced AIMs. One key issue is that there is no access to pathological 
specimens from patients with GID so understanding how and if these markers are relevant in 
GID has not been possible. 5-HT innervation of the graft and the denervated striatum is 
receiving much interest of late. In recent studies, the imaging of two patients with off 
medication GID showed 5-HT hyperinnervation and AIMs were subsequently suppressed by 
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pharmacological manipulation of 5-HT receptors (Politis et al., 2011b, Politis et al., 2010). 
Considering the data presented in Chapter 7 and those from other studies (Garcia et al., 2011, 
Lane et al., 2009a) it seems unlikely that the proportions of 5-HT neurons within the graft 
and/or levels of striatal 5-HT innervation have a causative role in rodent models of GID or the 
alleviation of LID post-graft. The suitability of the model in this regard has proved to be 
accurate, as no GID was found in an ongoing foetal tissue clinical trial, despite variable 
numbers of 5-HT neurons in each of the 6 patients (Mendez et al., 2008). Nevertheless, 5-HT 
receptor agonism may provide a useful means to treat individuals, as shown by (Politis et al., 
2010) and reiterated in the GID model, using compounds with greater specificity (Chapter 6). 
Further investigation is warranted, as 5-HT drugs currently licensed for patient use also have 
D2 antagonistic properties, and may therefore lead to the suppression of GID by other means.  
 
Some biochemical fingerprints of LID are recognised (sensitisation of D1 receptors, the ERK 
pathway and IEG expression), yet the search for biochemical changes related to LID continues 
in order to better understand the mechanisms of dysregulation. Distinguishing between 
sensitised (chronic L-DOPA treatment) and non-sensitised (single L-DOPA injection) post 
synaptic mechanisms is one approach, as many animals are not ‘primed’ to develop AIMs 
with a single injection but may develop AIMs with chronic adminstration. In Chapter 5 it was 
shown that RGS2 mRNA transcripts were up-regulated in response to L-DOPA, but could not 
distinguish between long and short-term treatment. RGS2 is therefore a biomarker for general 
L-DOPA action and does not permanently change basal levels within cells. Dysregulation of 
RGS2 results from immediate D1 receptor stimulation and may therefore be in part a 
compensatory mechanism, to hinder the priming response to L-DOPA by reducing the 
signalling transmission rate. Further basal levels of RGS2 or RGS4 did not differ between 
dyskinetic and non-dyskinetic transplanted rodents, thereby ruling these out as important basal 
biomarkers of GID. However, whether or not the change in RGS expression occurring after 
amphetamine injection would differ depending on AIM expression should not be overlooked 
at this stage. The search for hallmarks of GID thus far, including those presented in this thesis, 
are based on the screening of markers known in LID, yet it is unclear whether this is the best 
strategy. To some effect, the same sensitised post-synaptic response must be dysregulated in 
GID, as priming increases the severity of amphetamine triggered AIMs (Lane et al., 2009b), 
however IEG indicators of LID were not correlated to amphetamine driven AIMs (Lane et al., 
2009b). Therefore further investigation of the differences between LID and GID, both in 
animal models and in the patients, will be invaluable to future of this research field. The 
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candidates for efficient biomarkers for use in rodent models of GID depend on data derived 
from clinical observations and the tissue of transplanted patients at post-mortem, of which 
there is little.  
 
9.2. The Future of L-DOPA and Transplantation Strategies. 
The future of both L-DOPA and transplantation strategies for the treatment of PD depends on 
their ability, separately or in combination, to treat or prevent major side effects (such as 
dyskinesia), their cost effectiveness, and their long-term efficacy relative to other treatments. 
 
9.2.1 Dopamine Replacement 
L-DOPA remains the single most important treatment for PD, readily accessible to a wide 
range of the population. Yet problems of dyskinesia, the drugs short half-life and non-motor 
symptoms are debilitating enough for the continued search for a new treatment (either for the 
prevention of PD or dyskinesia) and in an adjacent line of research, the possibility of a cure. 
Just as fundamental to the disease from a global perspective however is the availability of L-
DOPA to all, where drug companies should be encouraged to reduce costs when selling to 
developing countries. L-DOPA therapy would be a viable long-term therapy if dyskinesia 
could be easily managed (although this would still not control non-motor symptoms). Novel 
pharmacological interventions for LID are much needed as most clinically available 
compounds do not sufficiently reduce AIMs and others only do so at doses that suppress 
overall locomotion in rodent models. The suppression of dyskinesia by modulation of the post-
synaptic signalling cascade, using viral-mediated gene transfer of TH and co-factor 
synthesizing enzyme guanosine-5'-triphosphate cyclohydrolase-1, to increase dopamine 
synthesis may be an emerging alternative for delivering dopamine directly to the brain. The 
results of the phase I clinical trial have not yet been divulged, however the pre-clinical data is 
promising (Kirik et al., 2002). Another dopamine replacement strategy has been assessed in 
PD patients, where encapsulated retinal pigmented epithelial cells were implanted, for their 
hypothesised ability to produce L-DOPA. However, there were no differences in motor 
outcome compared to sham-operated controls (Gross et al., 2011). Thus, it would seem that ‘in 
brain’ dopamine delivery therapeutics are difficult to achieve, and are subject to factors 
including dopamine quantity, turnover and difficulty in reaching the whole of the target area. 
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Furthermore, these interventions do not detract from the requirement of invasive surgery and 
the comparative ease and availability of L-DOPA therapy.  
 
Small molecule pharmacological interventions might represent a further emerging avenue for 
L-DOPA co-treatments. Novel small molecules may give the highly specific actions 
unattainable by current pharmacotherapy, as many standard compounds are derived or 
synthesised from natural derivatives. High throughput screening of randomly synthesised 
small molecules, or of ones that have been designed from specific pathways, has lead to the 
discovery of modulators capable of interfering with specific protein-protein interactions 
(Blazer et al., 2011, Blazer et al., 2010, Fry, 2006). This approach may be advantageous either 
as a replacement for L-DOPA as a treatment in PD or in the screen for an L-DOPA co-
treatment to control dyskinesia, as the current regulation of the sensitised ERK pathway by 
dopamine receptor modulation, or indirectly via the action of other receptors on the same 
membrane, has a global cell affect. Thus, problems arise from the balance of receptor 
occupancy and specificity to gain a therapeutic effect on LID, without suppressing general 
locomotion. For example RGS2 was found to be dysregulated by low dose L-DOPA (Chapter 
5), which can be controlled by readily available dopamine and glutamate agonists/ antagonists 
(Taymans et al., 2005a, Taymans et al., 2004), however dopamine and glutamate antagonists 
only suppress AIMs at doses that suppress general movement. Therefore very specific targets 
at the site of the RGS-Gα subunit interaction may provide a more powerful means of LID 
control. Recently, small molecules that interact with RGS4 at the Gα binding site have been 
synthesised (Blazer et al., 2010, Blazer et al., 2011). One disadvantage of this approach is that 
they cause irreversible changes, however they often pass through the BBB and into cells 
readily (Chambers et al., 2011). Research of these compounds in PD models has so far only 
been looked at from a neuroprotection perspective (Chambers et al., 2011). 
 
9.2.2. Cell Therapies 
In the western world, reconstruction of the basal ganglia circuitry remains the ultimate goal in 
the treatment of PD and seems a realistic possibility in the future as only a few cell types are 
needed for reconstruction and with the procedure already proving beneficial in some patients 
(Freed et al., 1990, Freed et al., 2001, Freeman et al., 1995, Lindvall et al., 1992, Mendez et 
al., 1996, Olanow et al., 2003). Certainly the survival and function of transplanted dopamine 
neurons in PD patients after 14 years is possible (Mendez et al., 2008), and this would warrant 
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considering transplantation as a viable PD treatment if this level of function could be made 
more reliable and without risk or side effect. The forthcoming TransEUro trials will utilise 
lessons learnt from past transplantation studies and is testing the hypothesis that 
transplantation can be rendered more reliable, by utilising recent pre-clinical refinements, 
rigorous trail design, and the recruitment of younger patients. The future of cell therapies may 
be seen as under threat however after the observation of Lewy body pathology found within 
grafted cells (Kordower et al., 2008) and the emergence of GID in some patients (Freed et al., 
2001). Other issues to be considered are the contribution of immune responses to transplant 
efficiency and patient welfare when under immunosuppression. Although successful treatment 
without any of these complications is the ultimate goal in transplantation, from an ulilatarian 
perspective some of these issues may not hinder the momentum of this therapeutic strategy, by 
judgement of the cost-benefit ratio.  A hitherto more important issue to be resloved is its 
unrelaiablity. 
 
The use of stem cell (SC) replacement in PD is dependent on the resolution of both scientific 
and political difficulties. Although primary tissue from surgical termination is generally 
regarded as safe, it is not standardised, not matched on allotype and will be extremely difficult 
to implement logistically for use as a mainstream therapy. Rather, findings from studies using 
primary fetal tissues, provide both the stimulus for, and are likely pave the way for, new SC 
therapeutics. The primary cell strategy cannot be ruled out altogether, as more mainstream 
medical terminations that could be utilised, as tissue derived by this means is just as viable 
(Kelly et al., 2011). In addition, there are important issues that need to be resolved by pre-
clinical investigation before the first SC clinical trial can be implemented, such as the 
prevention of graft overgrowth, improper localisation of transplanted cells by migration, 
development of GID and obtaining large enough yields of dopamine neurons to have a 
meaningful outcome. In the case of the former, this is likely to be overcome by new 
biotechnologies that will allow for the programmed suicide of tumerogenic and excessively 
proliferative cells (reviewed in (Kiuru et al., 2009). It would be difficult however for 
governmental bodies to grant approval to genetically modified SCs. Resolution of the poor cell 
yield is likely to take longer and more pre-clinical research is needed. Furthermore the 
occurrence of GID may not be found until first trials. Further, preliminary work has also 
shown that SC grafts can be monitored in vivo by PET and MRI scans (Jackson et al., 2009), 
which have proved invaluable to primary cell transplantation trials clinical trials (Markham et 
al., 1994, Piccini et al., 2005). These key technical issues will influence the start date for the 
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first SC clinical trials, however the question of whether key issues have been explored enough 
lies within ethical committees. 
 
In some regards, issues governing the initiation and patient selection for the first SC 
transplants at clinical trial should be considered independently to benchmarks previously 
established for primary tissue grafts. The International Society for Stem Cell Research 
(ISSCR) was set up for the translation of pre-clinical SC research to the clinic and 
incorporates expertise specific to each of its main foci, which include voluntary informed 
consent, patient monitoring, potential adverse events, medical intervention and social justice 
(Hyun et al., 2008), with much initial decision making from ethical committees (Hyun, 2010). 
There is a recent drive to answer the fundamental question of whether or not to start clinical 
trials with SCs using different ethical models, for example a utilitarian approach may disallow 
SC therapy on the grounds of safety and cost, however a more rights-based deontological 
argument would favour this treatment (Hug and Hermeren, 2011). If however, by using these 
tools, it is decided to be most appropriate to resolve all problems before conducting the first 
human trials, would we in fact be denying the basic human right of the patient to receive 
treatment after knowing all the risks. Moreover, if legitimate academic medicine restricts 
access to such options, desperate patients are likely to search elsewhere, often to less reputable 
commercially-driven sources, contributing to the growth of SC tourism?  
 
9.3. Is there a Single Treatment for Parkinson’s Disease? 
There are now a variety of treatments available for PD, as well as some novel therapeutics 
discussed above that may be licensed in the forthcoming years. The viability of each as a PD 
treatment involves a combination of interacting factors, including cost and effectiveness.  
 
The most important treatment strategies for most patients for quick diagnosis are formulated 
by scrupulous management of the motor symptoms by pharmacology, well-informed general 
practitioners and access to specialist PD nurses. There is still much work required to ensure 
patients get the best management of the disease and PD specialist nurses are currently scarce 
in the U.K. For example, in the Cardiff and Vale area there is currently only 1 nurse to every 
850 patients (www.cardiffandvaleuhb.wales.nhs.uk). Using dopamine agonists and careful 
control of L-DOPA doses, it is possible to treat akinetic symptoms to delay the onset of 
dyskinesia development (Watts et al., 2010). Further research on small molecule 
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pharmacotherapy may alleviate parkinsonian symptoms or dyskinesia in the future, thus 
providing a cost effective and low risk strategy for many.  
 
DBS is also currently available on the NHS, but access is restricted (the so called ‘postcode 
lottery’) since economic costs of this treatment are high and certain levels of expertise are 
needed both to perform the surgery and to monitor and maintain the implant devices. There is 
evidence that when comparing the predicted cost of PD patient care over a lifetime and in 
comparison to other diseases, a single DBS procedure costing £20,000 - £30,000 was 
approved by UK National Institute for Health and Clinical Excellence (NICE) (Shan et al., 
2011), and subsequently this benefit-cost ratio is being calculated for the use of DBS in other 
countries. Since DBS is subject to the review of each patient and still does not treat non-motor 
symptoms, this will not be a strategy suitable for the majority of the PD population. Moreover, 
DBS is not without risk, and there have been several reports where DBS can induce dyskinesia 
as a side effect in patients, reported in a meta-analysis of clinical trials (Groiss et al., 2009) 
and also noted in the forelimb animal models that have received DBS (Quintana A, 2010).  
 
Ultimately the reconstruction of the dopaminergic circuit is probably the preferred future 
strategy for the treatment of PD as this may be able to counteract some of the motor and non-
motor pathological changes, without the need for further intervention. Transplantation 
strategies may only be rivalled by that of the protection of existing midbrain dopaminergic 
neurons, using neurotrophic factors or viral mediated gene transfer. Appropriate diffusion 
strategies for these agents have recently been optimised and treatments have been found to be 
safe in phase I trials (Gasmi et al., 2007, Herzog et al., 2007, Slevin et al., 2007). Although the 
support of diseased cells may be beneficial, the ultimate goal in neuroprotection is to stop 
disease progression. However, the major limitation of neuroprotective options at present is that 
viable targets for this strategy have not yet been identified, let alone clinically validated, even 
though there are number of early stage pre-clinical studies screening for intracellular pathway 
dysregulation. The recent modelling of PD in rodents through AAV-mediated over-expression 
of human mutant α- synuclein has highlighted pathological trafficking deficits that if 
prevented may be able stop denervation in the midbrain (Chung et al., 2009). Although pre-
clinical neuroprotection studies are alluding to successful translation to patients, motor 
symptoms (and hence diagnosis) do not occur until a large proportion of dopamine neurons 
die. Intervention at this point would perhaps spare remaining cells and hinder disease 
progression, but would not lead to circuitry reconstruction that is possible with transplantation.  
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9.4. Final Summary 
Research undertaken for this thesis has addressed some of the issues that need to be resolved 
in pre-clinical PD research: the continued optimisation of 6-OHDA lesion mouse models, their 
use to recapitulate LID, the search for new biomarkers of L-DOPA function, the screen for 
compounds that may suppress GID, the search for neuro-pathological correlates of GID and 
the creation of an amphetamine-driven mouse model of GID. Continued research into each of 
these aspects and others, will be needed to fully understand the mechanisms of LID, GID and 
graft integration and function, in the hope for an effective treatment for PD and/or its 
debilitating side effects. Although L-DOPA and transplantation are the focus of the 
experiments presented here, a ‘one size fits all’ approach to the treatment of PD may never be 
found, as symptomatic treatment depends on the specific patient problems and stringent 
observation by the clinician. Although findings using animal models are of fundamental 
importance to the translation of PD research to the clinic, we should always use lessons learnt 
from patient trials to feedback into pre-clinical science. 
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11. Supplementary Data 
 
 
 
 
 
 
 
 
Drug Dose 
(mg/kg) 
Duration HLi Li Ax OL 
mAmphet 2.5 51.27 ± 5.09 23.90 ± 3.09 25.72 ± 3.47 31.36 ± 6.17 2.18 ± 0.33 
SCH23390 0.05  
0.2  
31.72 ± 3.76* 
15.63 ± 2.39*** 
16.72 ± 3.59* 
5.54 ± 2.14** 
18.00 ± 3.97* 
6.00 ± 1.83** 
22.73 ± 5.32 
13.18 ± 2.01** 
1.09 ± 0.62 
2.36 ± 0.86 
Raclopride 0.5  
2  
33.45 ± 3.55* 
32.00 ± 2.08** 
18.18 ± 2.53* 
14.81 ± 1.89* 
18.27 ± 3.10* 
14.09 ± 1.56** 
21.63 ± 3.51 
18.90 ± 2.20** 
0.45 ± 0.20* 
0.72 ± 0.23* 
Nafadotride 0.6  
1 
36.45 ± 1.84 
35.63 ± 1.47 
24.63 ± 3.24 
16.63 ± 1.72* 
24.18 ± 2.66 
18.18 ± 1.83* 
35.81 ± 2.76 
23.36 ± 1.58 
0.81 ± 0.22 
1.45 ± 0.31 
Naloxone 4 
8  
48.45 ± 3.65 
44.72 ± 3.77 
27.36 ± 5.14 
29.18 ± 3.44 
27.54 ± 4.83 
27.63 ± 3.02 
32.27 ± 2.58 
35.90 ± 7.23 
3.30 ± 0.70 
2.50 ± 1.00 
WIN55, 212-2 1 
2.5  
48.73 ± 3.32 
41.82 ± 3.91 
31.36 ± 3.02 
31.27 ± 4.04 
30.27 ± 3.01 
29.55 ± 3.65 
31.90 ± 4.72 
32.00 ± 4.21 
1.45 ± 0.67 
1.72 ± 0.58 
CP94253 1.5 
3 
43.63 ± 3.11 
49.27 ± 3.97 
26.45 ± 2.93 
20.90 ± 3.13 
25.00 ± 2.54 
20.73 ± 2.90 
24.81 ± 2.32 
7.45 ± 1.76*** 
3.36 ± 0.81 
7.00 ± 1.97** 
8-OH-DPAT 0.05  
0.1  
50.45 ± 4.74 
33.09 ± 4.03** 
19.54 ± 3.32 
11.54 ± 2.75** 
19.00 ± 3.25 
11.45 ± 2.45** 
12.45 ± 2.01** 
13.27 ± 1.78** 
5.81 ± 1.63* 
0.45 ± 0.15* 
Amantadine 20  
40  
53.18 ± 4.13 
41.27 ± 2.29 
25.27 ± 3.00 
19.18 ± 2.67 
25.00 ± 2.97 
19.45 ± 2.12 
26.54 ± 5.32 
25.81 ± 2.53 
1.54 ± 0.47 
0.63 ± 0.20 
MTEP 1.25  
6.25  
48.45 ± 4.91 
43.63 ± 3.04 
23.36 ± 2.13 
28.45 ± 2.57 
22.18 ± 2.25 
27.90 ± 2.21 
22.00 ± 2.89 
25.27 ± 4.57 
3.09 ± 0.91 
1.45 ± 0.54 
IEM1460 1  
3  
61.36 ± 5.18 
48.73 ± 2.91 
34.45 ± 4.29 
27.72 ± 2.62 
32.54 ± 4.00 
26.45 ± 2.10 
32.90 ± 4.26 
30.09 ± 5.23 
3.27 ± 1.38 
4.18 ± 2.00 
 
Table 1. Breakdown of AIMs caused by 2.5mg/kg of methamphetamine, in grafted hemi-Parkinsonian rats treated with various 
pharmacological agents, into dyskinetic sub-components. Abbreviations: Hindlimb (HLi), Forelimb (Li), Axial (Ax) and 
Orolingual (OL). Stars indicate a significant differences between the combination treatments and methamphetamine alone, where 
p<0.05*, p<0.01**, p<0.001***. Values are expressed as means ± SEM. 
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Table 2. Total integrated AIMs and total net rotation caused by L-DOPA alone and co-
administration with anti-dyskinetic agents. Data was taken in a latten square design by PhD 
student Ludivine Breger (BRG and Welsh School of Pharmacy). Stars indicate a significant 
differences between the combination treatments and L-DOPA alone, where p<0.05*, 
p<0.01**. Values are expressed as means ± SEM. 
 
a
 Brackets indicate dose of benzerazide. 
 
Drug Dose 
(mg/kg) 
Dyskinesia Rotation 
L-DOPA 
SCH23390 
12 (15)a 
0.2  
127.86 ± 9.65 
69.29 ± 5.27** 
2349.20 ± 269.73 
1234.48 ± 277.03** 
Raclopride 2 90.86 ± 7.31** 1781.38 ± 234.12* 
Amantadine  40 95.86 ± 10.21** 3078.14 ± 375.56* 
L-DOPA 
MTEP 
12 (15)a 
6.25 
134.46 ± 5.04 
108.40 ± 6.76** 
2106.80 ± 322.88 
1436.55 ± 218.77** 
Naloxone  8  115.00 ± 7.11* 1902.63 ± 339.02* 
L-DOPA 
8-OH-DPAT 
CP94253 
12 (15)a 
0.1 
3  
138.12 ± 4.80 
101.87 ± 3.44** 
107.12 ± 7.57** 
1978.43 ±246.57 
1905.31 ±225.90* 
2519.70 ±314.06* 
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12. Appendix 
Appendix (I) – Primer Design 
 
A) Insitu hybridisation primers 
- Optimised for: - 
o Primer length 20b +/- 2 
o Primer Tm 60oC +/- 5 
o Primer GC% 50 +/- 5 
o Product length 300-800b 
o Specificy: Mus musculus and Rattus norvegicus 
 
1) RGS2 
  Left primer        5’ –ATGCTACATGAGACAGGGAGACC– 3’ 
  Right primer       3’ –AACGGACACTGGTTCTACAGCAC– 5’ 
  PRODUCT SIZE: 451bp 
 
2) RGS4 
  Left primer        5’ –TCCTTAAAGGGTGTCAGGTGAGC– 3’ 
  Right primer       3’ –TCTCAAACATCCATCTCCAGACC– 5’ 
  PRODUCT SIZE: 443bp 
 
3) RGS8 
  Left primer        5’ –CCTTCCCTGGATCTTCAGCTACC– 3’ 
  Right primer       3’ –TCAGGAAGGATGGCTGTGAAGTC– 5’ 
  PRODUCT SIZE: 599bp 
 
4) RGS9 
  Left primer        5’ –CCACAG TGAAGTCTTCGGTGTCC– 3’ 
  Right primer       3’ –ATGTCCACGGTGTTGGCTGCTTC– 5’ 
  PRODUCT SIZE: 674bp 
 
  
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
B) Mus musculus QPCR primers 
- Optimised for: - 
o Primer length 20b +/- 2 
o Primer Tm 60oC +/- 0.5 
o Primer GC% 50 +/- 5 
o Product length 75-125b 
 
1) RGS2 
  Left primer        5’ –ACGAAAACCCCAAGTTTCCT– 3’ 
  Right primer       3’ –CCTGCATTTAGTGCAAGCAA– 5’ 
  PRODUCT SIZE: 110bp 
 
2) RGS4 
  Left primer        5’ –ACTGCTTAGGTGAGGGCAGA– 3’ 
  Right primer       3’ –TGACATTCTTGAGGGGAAGG– 5’ 
  PRODUCT SIZE: 93bp 
 
3) RGS8 
  Left primer        5’ –TTCGAAAGGACGCCAATATC– 3’ 
     Right primer       3’ –GTCAAGGCTCTGGAAACAGC– 5’ 
     PRODUCT SIZE: 122bp 
 
4) RGS9 
  Left primer        5’ –ACAGACCCACAAACCTCCTG– 3’ 
  Right primer       3’ –GTCATGTGGCTTGTCACCAC– 5’ 
  PRODUCT SIZE: 125bp 
 
5) GAPDH 
  Left primer        5’ –TCTCCACACCTATGGTGCAA– 3’ 
     RIGHT PRIMER   3’ –CAAGAAACAGGGGAGCTGAG– 5’ 
     PRODUCT SIZE: 106bp 
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Appendix (II) – Suppliers 
 
Company Location (Headquaters in U.K) 
Ambion Cambridge 
Animal Care Limited York 
Bioehringer Berkshire 
Bioline London 
Bio-Rad Bath 
Bright Cambridge 
Chemicon U.S.A 
Charles River Wilmington 
Chapion photochemistry U.S.A 
Dako Cambridge 
Difco Surrey 
Fisher Scientific Leicestershire 
Harlan Loughborough 
Immunostar Inc U.S.A 
Invitrogen Paisley 
KOPF U.S.A 
Promerga Southampton 
QIAGEN Crawley 
Roche Welwyn 
Sandon Scientific Middlesex 
Santa Cruz U.S.A 
Sero-Wel Birmingham 
Sigma Poole, Dorset 
Thermoscientific Leicester 
Med Associates St Albans 
New England Biolabs Herts 
U.V.P Cambridge 
Vector Laboratories Peterborough 
VWR Sussex 
Xograph Gloucester 
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Appendix (III) - Solutions 
 
TRIS buffered Saline (stock) 
48g TRIS base (Sigma) 
36g Sodium Chloride (Sigma) 
1000mls Distilled Water 
pH 7.4 
 
TRIS buffered Saline (working solution) 
1:4 dilution of stock with distilled water 
TWEEN (0.2%) (Sigma) 
pH 7.4 
 
Phosphate buffered saline 
90g di-sodium hydrogen orthophosphate (Bhd) 
45g Sodium Chloride (Sigma) 
5000mls Distilled water 
pH 7.3 
 
Paraformaldehyde solution (20%) 
90g Di-Sodium hydrogen phosphate (Bhd) 
45g Sodium Chloride (Sigma) 
Paraformaldyhyde (20%) 
3300mls Distilled water 
pH 7.3 
 
Sucrose solution (25%) 
25g sucrose (Fisher Scentific) 
100mls phosphate buffered saline (Sigma) 
 
10x AP buffer (stock) 
121.1g Tris-base (Sigma) 
58.4g Sodium Chloride (Sigma) 
8000mls Distilled Water 
pH 9.5 
 
1x AP buffer (working solution) 
1:10 dilution with distilled (DEPC treated) water 
 
Magnesium chloride 
203.3g MgCl2 x 6H2O (Fisher Scientific) 
10000mls Distilled Water 
 
10x TE (stock) 
12.1g Tris-base (Sigma) 
vi 
 
3.27g EDTA (Sigma) 
10000mls Distilled water 
 
1x TE (working solution) 
1:10 dilution in distilled (DEPC treated) water 
 
20x PBS (stock) 
160g Sodium Chloride (Sigma) 
4g Pottasium Chloride (Sigma) 
28.84g Na2HPO4 x 2H2O (Sigma) 
4.1.4g KH2PO4 x H2O (Sigma) 
10000mls Distilled water 
pH 7.4 
1ml DEPC (Sigma) 
 
1x PBS (working solution) 
1:20 dilution in distilled (DEPC treated) water  
 
1x T-PBS (working solution) 
1:20 dilution in distilled water 
TWEEN (0.2%) (Sigma) 
 
20x SSC (stock) 
175g Sodium Chloride (Sigma) 
88.3g Tri-sodium citrate dehydrate (Sigma) 
10000mls Distilled water 
pH 7 
1ml DEPC 
 
5x SSC (working solution) 
1:4 dilution in distilled (DEPC treated) water 
 
2x SSC (working solution) 
1:10 dilution in distilled (DEPC treated) water 
 
0.2x SSC (working solution) 
1:100 dilution in distilled (DEPC treated) water 
 
50x Denhart Solution 
1g Ficoll (Sigma) 
1g Bovine serum albumin (non acetylated) (Sigma) 
1g Polyvinylpyrrolidone (Sigma) 
100mls Distilled water 
Heated 50oC 
 
 
10x TBS-T 
100mls Tris-HCl (Sigma) 
87.7g Sodium Chloride (Sigma) 
100mls TWEEN (Sigma) 
vii 
 
10000mls Distilled water 
 
Prehybridisation/hybridisation buffer 
5mls Formamide (50%) (Cal Biochem) 
2.5mls 5x SSC 
1ml Denhardts 
250u l Total yeast RNA (250u/ml) (Roche) 
500ul herring Sperm (500u/ml) (Roche)  
 
5x TBE  (Running buffer)  
54g Tris- base (Sigma) 
27.5g Boric acid (Fisher) 
20mls EDTA (0.5m) (Sigma) 
 
TXTBS 
250ml 1xTBS 
500ul Triton X-100 (Sigma) 
pH 7.4 
 
ABC solution 
5ul A (DAKO) 
5ul B (DAKO) 
1ml 1% serum in 1xTBS 
 
Quench 
10ml Methanol (Fisher Scientific) 
10ml Hydrogen peroxide (VWR Prolabo BHD) 
80ml Distilled water 
 
TNS 
6g Trisma base (Sigma) 
1000ml Distilled water 
pH 7.4 
 
2x LB Laemmli loading buffer with 2-mercaptoethanol 
5 ml (1M) or 4 ml (1.25 M)  Tris-HCl    
10ml Glycerol              
20ml SDS             
1ml Bromophenol blue (0.2 %)                   
100µl per 7 ml 2-mercaptoethanol (200 mM)                          
pH 6.8  
 
10x Transfer Buffer (stock solution) 
30.3g Tris base (250 mM) 
117.5g Glycine (1.5 M) 
1000ml Distilled water 
pH  8.5  
 
1x Transfer Buffer (working solution) 
1:10 dilution in distilled (DEPC treated) water  
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Stacking Gel 
1.0ml Acrylamide/BisAcylamide solution                    
620µl Tris-Base (1.25M) 
50µl SDS                              
50µl APS 
3.3ml Distilled water 
pH 6.8 
 
Resolving Gel 
5.33ml Acrylamide/BisAcylamide solution                    
2.5ml Tris-Base (1.25M) 
100µl SDS                              
100µl APS 
1.97ml Distilled water 
pH 8.8                                            
                                            
Radio-Ligand Binding Buffer 1 
6.075g Tris-HCl (50mM)  
7.012g NaCl (120mM)  
0.373g KCl  (5mM)   
0.36g CaCl2 (2.5mM)  
0.230g MgCl2 (1mM)  
pH 7.4  
 
Radio-Ligand Binding Buffer 2 
6.075 g Tris-HCl (50mM)  
7.012 g NaCl (120mM)  
1000ml Distilled water 
pH 7.4 
 
